β1-adrenoceptor blockade treatment of right ventricular dysfunction caused by pulmonary hypertension by Fowler, Ewan Douglas
β1-adrenoceptor blockade treatment of 
right ventricular dysfunction caused by 
pulmonary hypertension 
 
Ewan Douglas Fowler BSc, MRes 
 
 
 
 
Submitted in accordance with the requirements for the degree of 
Doctor of Philosophy 
 
 
 
 
University of Leeds 
Faculty of Biological Sciences 
School of Biomedical Sciences 
Multidisciplinary Cardiovascular Research Centre 
 
 
 
 
October, 2015 
  
  
ii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The candidate confirms that the work submitted is his/her own, except where work 
which has formed part of jointly authored publications has been included. The 
contribution of the candidate and the other authors to this work has been explicitly 
indicated below. The candidate confirms that appropriate credit has been given within 
the thesis where reference has been made to the work of others. 
 
 
 
This copy had been supplied on the understanding that it is copyright material and that 
no quotation from the thesis may be published without proper acknowledgement. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2015 University of Leeds and Ewan D Fowler   
  
iii 
 
Acknowledgements 
 
I am most grateful to my supervisor, Prof Ed White, with whom I have thoroughly 
enjoyed working during my 4 years at Leeds.  I am incredibly appreciative of your 
excellent guidance and willingness to allowing me the academic freedom to pursue my 
own interests.  I‘m extremely grateful for the opportunities you afforded me including 
Amsterdam, New Zealand and the US. 
 
Thanks to my co-supervisor Prof Derek Steele for your insight and opinions on my 
results and hypotheses over the years.  Dr Sarah Calaghan who was so welcoming 
when I arrived at Leeds, I hope we can work together on more projects in the future.  
Prof John Colyer for invaluable scientific discussions and his opinions on my work, and 
also great conversations at the pub.  Dr Rachel Stones made a vital contribution to this 
project with your expertise in molecular biology.  Dr Mark Drinkhill who performed all 
the in vivo pressure-volume measurements, including many that didn‘t make it into this 
thesis.  Prof Stuart Egginton and Dr David Hauton for their role in developing and 
implementing the oxygen modelling software, and in particular to Dr Hauton for 
discussions on this topic and histology advice.  Thanks to Prof Chris Peers and Dr 
John Boyle for allowing me time on the oxygraph recorders and for discussion of the 
results. 
 
Thanks to Prof Ger Stienen for allowing me to spend six weeks in his lab in Amsterdam 
performing the stretch experiments and to Dr Rob Wüst for helping organise my visit 
(and for letting me crash on his sofa when the money ran out!).  I am particularly 
grateful to Dr Michiel Helmes who taught me the difficult cell stretching technique and 
also for excellent scientific discussions.  ‗Dank je wel!‘ to Vasco Sequeira and everyone 
at the VU who made me feel so welcome and introduced me to kroketten, bitterballen 
and Brouwerij 't IJ. 
 
I‘m also incredibly privileged to have worked with such great friends as David, Ruth, 
Emma, Sabine and Matt.  David you have been most influential in shaping my outlook 
on science and beyond through our often heated discussions.  Ruth you‘ve kept me 
balanced on a knife edge between athleticism and full blown beer belly through our 
early morning bike rides, afternoons of coffee and cake, and evenings in the 
Faversham – I dread to think what will happen when I leave!  Emma, Sie gewesen sind 
eine Freude, neben sitzen und ich wünschen könnte nicht für eine besser Nachbarn!  
Sabine it‘s been great to have someone to go to UNOD and Subdub with – next time it 
  
iv 
 
will be OBF in France!  Matt you taught me loads in the lab and were always up for a 
much needed pint after work in the early days – sorry to be leaving just as you return to 
Leeds! 
 
Most importantly I thank my family: Mum, Dad, Lindsay, Lauren and Laura.  Mum and 
Dad for their unwavering support and encouragement throughout my many years of 
higher education.  Linny and Lauren for helping me keep one foot in Glasgow and not 
cocooned away as I‘d no doubt otherwise be.  And finally Laura, who knows better than 
anyone exactly what the last 4 years have involved and what this means to me – thank 
you all for being so supportive. 
 
 
  
  
v 
 
Author publications 
Research papers 
 
Work directly attributable to the author and presented in this thesis has featured in 
joint-author publications which are listed below.  An echocardiographic estimate of 
ventricle wall stress calculated using data in Chapter 3 was included in Benoist et al. 
(2014).  Passive ventricle stretch in isolated hearts was included in Sequeira et al. 
(2015) and is included as Appendix B.  I contributed to Natali et al. (2015) in part by 
helping with and maintaining the monocrotaline heart failure model.  Figures from 
Chapter 6 were included in Fowler et al. (2015) as Figures 3&8.  Co-authors 
contributed to these publications by performing and planning experiments and by 
revising manuscripts. 
 
Benoist D, Stones R, Benson AP, Fowler ED, Drinkhill MJ, Hardy MEL, Saint DA, 
Cazorla O, Bernus O & White E. (2014) Systems approach to the study of stretch and 
arrhythmias in right ventricular failure induced in rats by monocrotaline. Progress in 
Biophysics and Molecular Biology, 115, 162-172. 
 
Sequeira V, Najafi A, McConnell M, Fowler ED, Bollen IAE, Wüst RCI, dos Remedios 
C, Helmes M, White E, Stienen GJM, Tardiff J, Kuster DWD & van der Velden J. (2015) 
Synergistic role of ADP and Ca2+ in diastolic myocardial stiffness. Journal of 
Physiology, 593(17), 3899-916. 
 
Natali, AJ, Fowler ED, Calaghan SC & White E. (2015) Voluntary exercise delays heart 
failure onset in rats with pulmonary artery hypertension. American Journal of 
Physiology – Heart and Circulatory Physiology, 309, 421-4. 
 
Fowler ED, Benoist D, Drinkhill MJ, Stones R, Helmes M, Wüst RCI, Stienen GJM, 
Steele DS & White E. (2015). Decreased creatine kinase is linked to diastolic 
dysfunction in rats with right heart failure induced by pulmonary artery hypertension. 
Journal of Molecular and Cellular Cardiology 86, 1-8. 
 
  
  
vi 
 
Published abstracts 
 
Fowler ED, Stones R, Steele DS & White E. (2013). Reduced expression of creatine 
kinase and diastolic dysfunction in failing rat ventricular myocytes 37th Congress of 
IUPS (Birmingham, UK) Proc 37th IUPS, PCB057. 
 
Norman R, Hardy M, Fowler ED, White E & Calaghan S. (2013). Remodelling of the 
caveolar domain in right ventricular failure in rats. 37th Congress of IUPS (Birmingham, 
UK) Proc 37th IUPS, PCB044. 
 
Fowler ED, Stones R, Benoist D, Drinkhill MJ & White E. (2014). Reduced expression 
of creatine kinase in rat failing right ventricle causes diastolic dysfunction in ventricular 
myocytes. J Muscle Res Cell Motil 35, 90. 
 
Fowler ED, Drinkhill M, Steele D & White E. (2014). Passive stiffness in the failing right 
ventricle: contribution of collagen and creatine kinase. Proc Physiol Soc 31 
 
Fowler ED, Drinkhill MJ, Wust RC, Helmes M, Stienen GJM, Steele DS & White E. 
(2015). Workloop Contractions in Isolated Cardiac Myocytes Reflect in vivo Pressure-
Volume Dysfunction in Rat Right Heart Failure. Biophysical journal 108, 294a. 
 
Fowler ED, Norman R, Steer E, Pervolaraki E, Stones R, Drinkhill M, Calaghan SC, 
Steele DS & White E. (2015). The β1 adrenergic receptor blocker metoprolol improves 
survival and partially restores Ca2+ handling abnormalities in rat pulmonary artery 
hypertension. Proc Physiol Soc 34, C03. 
 
Norman R, Fowler ED, Stones R, White E & Calaghan S. (2015). Reverse-remodelling 
of cardiac β-adrenergic responsiveness in metoprolol-treated pulmonary hypertensive 
rats. Proc Physiol Soc 34, PC019. 
 
 
  
  
vii 
 
Communications 
 
Oral 
 
Reduced expression of creatine kinase in rat failing right ventricle causes diastolic 
dysfunction in ventricular myocytes.  May 2013.  The 42nd European Muscle 
Conference, Amsterdam, The Netherlands. 
 
Diastolic dysfunction in rat pulmonary arterial hypertension studied at the cellular, 
whole organ and in vivo level.  September 2014.  Early Career Research Conference in 
Cardiovascular and Diabetes Research.  Leeds, UK. 
 
Workloop contractions in isolated cardiac myocytes reflect in vivo pressure-volume 
dysfunction in rat right heart failure.  November 2014.  Alternative Muscle Club, Leeds, 
UK. Oral communication prize 
 
β1-adrenergic receptor block improves survival and Ca
2+ handling in right ventricle 
failure.  March 2015.  Multidisciplinary Cardiovascular Research Centre Annual 
Retreat, Derwent water, UK. 
 
The β1 adrenergic receptor blocker metoprolol improves survival and partially rescues 
Ca2+ handling abnormalities in right ventricle failure.  April 2015.  Northern 
Cardiovascular Research Group Meeting, Newcastle, UK. 
 
The β1 adrenergic receptor blocker metoprolol improves survival and partially restores 
Ca2+ handling abnormalities in rat pulmonary artery hypertension.  July 2015.  The 
Physiological Society Annual Meeting, Cardiff, UK. Oral communication prize 
 
Improved survival and Ca2+ handling in rat pulmonary arterial hypertension following β1 
adrenergic blockade.  September 2015.  Alternative Muscle Club, Canterbury, UK. 
 
Posters 
 
The 37th Congress of IUPS, Birmingham, UK.  July 2013.   
Multidisciplinary Cardiovascular Research Centre Retreat.  Leeds, UK.  March 2014. 
Northern Cardiovascular Research Group meeting, Manchester, UK.  April 2014. 
The Physiological Society Annual Meeting, London, UK.  July 2014.   
The Biophysical Society Annual Meeting, Baltimore, MA.  February 2015.  
  
viii 
 
Abstract 
 
Failure of the right ventricle (or ventricular) (RV) is the leading cause of death in 
patients with pulmonary arterial hypertension (PAH), however no treatments 
specifically target the failing RV.  β1-adrenoceptor blockers (β-blockers, BB) reduce 
mortality in left heart failure but current clinical guidelines caution against their use in 
PAH.  Recent studies suggest β-blockers may be beneficial in PAH however the 
mechanisms remain unknown.  The present study sought to establish whether the β1-
blocker metoprolol (10 mg/kg/day) improved survival and function in a rat model of 
PAH induced by monocrotaline (60 mg/kg, MCT), and to elucidate the mechanisms 
responsible. 
 
Daily metoprolol or placebo was administered 15 days post-monocrotaline injection.  
PAH resulted in severe RV hypertrophy, dysfunction and heart failure by median day 
23 in placebo treated rats (FAIL), whereas metoprolol extended the median survival to 
day 31 (MCT+BB).  RV function measured by echocardiography and catheterisation 
was severely impaired in FAIL, but was partially restored in MCT+BB on day 23±1.  
Metoprolol appeared to act primarily on the myocardium and not the vasculature. 
 
Contractile abnormalities in isolated FAIL RV cardiomyocytes included increased cell 
volume, negative force and Ca2+ transient response to faster pacing, increased 
stiffness to stretch and shorter resting sarcomere length.  Reduced creatine kinase 
activity was found in FAIL; creatine kinase inhibition reproduced characteristics of FAIL 
in healthy cells, whereas exogeneous creatine kinase reversed the shorter sarcomere 
length in FAIL cells.  Contractile and Ca2+ handling properties of MCT+BB cells were 
partially or fully restored relative to healthy cells.  Capillary density was reduced in FAIL 
and partially restored in MCT+BB; computer modelling indicated fewer areas of 
hypoxia in MCT+BB RV.  Assessment of FAIL RV mitochondria revealed reduced 
creatine-coupled respiration but no other detectable defects.  
 
Metoprolol improved survival, Ca2+-handling, contractility, oxygen delivery and diastolic 
properties of PAH rats.  β-blockers represent a novel myocardium-specific therapy to 
target the failing RV in PAH.  
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Chapter 1  General introduction 
1.1 General introduction 
The most recent statistics from the British Heart Foundation reveal diseases of the 
cardiovascular system affected 1.6 million people in the UK in 2012/13, at an estimated 
cost to the NHS in excess of £8.5 billion per annum (Bhatnagar et al., 2015).  Of these 
patients, 3.9% were afflicted by diseases of the pulmonary circulation or right heart, 
such as pulmonary arterial hypertension (PAH), chronic obstructive pulmonary disease 
and pulmonary thromboembolism, often leading to right heart failure.  Heart failure can 
be defined as the pathological inability of the heart to supply the body‘s demand for 
oxygen, or to do so at the expense of increased filling pressure.  Patients are usually 
graded according to their functional capacity using the New York Heart Association 
Functional Classification, which defines heart failure along a spectrum from no 
limitation to physical activity, to severe symptoms of heart failure even at rest which are 
exacerbated by even light activity.  The impairment of mobility has a profoundly 
negative impact on quality of life and without early diagnosis and treatment early 
mortality is inevitable (McKee et al., 1971). 
 
Progress in diagnosing and treating heart failure has benefitted patient survival and 
quality of life immensely, however the majority of new treatments have been for left 
heart failure and comparatively little is known regarding the specific nature of right 
ventricular (RV) failure.  RV failure is the leading cause of death in patients with PAH 
(Delcroix & Naeije, 2010) and poor RV function is an important risk factor in left heart 
failure (Kjaergaard et al., 2007; Szwejkowski et al., 2012).  Despite the clinical 
importance no treatments are currently available which specifically target the failing 
RV, leading some to propose trialling existing drugs used in left heart failure as ‗novel‘ 
treatments for RV failure (Handoko et al., 2010).  One such class of drug gaining 
interest are β-adrenoceptor blockers (β-blockers) which have been a mainstay of 
therapy in left heart failure for several decades as they offer long-term benefits to 
morbidity and mortality (Waagstein et al., 1989; Waagstein et al., 1993; Poole-Wilson 
et al., 2003), but are currently contraindicated in PAH (Provencher et al., 2006b; Galiè 
et al., 2015b).  Recent clinical (Thenappan et al., 2014; Bandyopadhyay et al., 2015) 
and preclinical studies (Bogaard et al., 2010; de Man et al., 2011; Perros et al., 2015) 
have found no deleterious effects of β-blockers in PAH and actually reported 
improvements in survival and RV function, although the mechanisms responsible are 
still unclear.  Therefore the purpose of this study was first to establish whether β-
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blockers improved survival and RV function in a rat model of PAH, and secondly to 
identify the mechanisms responsible for RV dysfunction and subsequent rescue with β-
blockers.  
 
1.2 Structure and function of the heart 
1.2.1 Anatomy 
The heart is located in the chest immediately posterior to the sternum.  The free end of 
the heart points down and towards the left whereas the base containing the great 
arteries and veins is at the top at the level of the third costal cartilage.  The superficial 
anatomy of the heart consists of two thin-walled atria separated by an interatrial 
septum sitting on top of two thicker walled muscular ventricles (Martini, 2006).  The 
atria and ventricles are divided into a right and left side and the 4 chambers of the heart 
are enclosed by serous membranes which adhere to the epicardial surface of the heart 
and secrete pericardial fluid which acts as a lubricant reducing friction during 
contraction.  These membranes and fluids are enclosed by the fibrous pericardium 
which stabilizes and constrains the heart. 
 
The function of the right and left atria is broadly similar, in that they both receive blood 
returning from the systemic and pulmonary circulation, respectively, and deliver it to the 
ventricles.  They are thin walled allowing them to cope with sudden changes in venous 
return.  The superior and inferior vena cava supply deoxygenated blood from the 
systemic circulation to the right atrium whereas two right and two left pulmonary veins 
supply oxygenated blood returning from the pulmonary circulation to the left atrium.  
The right atrium is further supplied by the cardiac veins which return blood via the 
coronary sinus inferior to the superior vena cava.  The right and left atrium are divided 
from the ventricles by the fibrous tricuspid and mitral valves, respectively. 
 
The ventricles are more muscular than the atria and the LV is approximately 6 times 
the mass of the RV (Lorenz et al., 1999).  The shortening and thickening of muscle 
fibres in the walls of the ventricles reduces the chamber volume forcing blood out 
during ejection. 
 
1.2.2 Left ventricle and systemic circulation 
The geometry of the LV is that of an ellipsoidal thick walled chamber.  LV diastolic 
pressure is typically around 8 mmHg and rises to around 130 mmHg in healthy 
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individuals (Sengupta et al., 2008).  Two thick papillary muscles anchor the chordae 
tendinae to the two flaps of the mitral valve which prevents backflow of blood into the 
atrium during systole. 
 
Ventricular myocytes in the LV are predominantly arranged parallel to the surrounding 
cells forming fibres which arrange into a helix with a prevailing orientation which can be 
described in terms of its angle.  In the LV the fibre angle changes counter clockwise 
from around -60° in the subepicardium, to circumferential in the midmyocardium, to 
+90°  in the subendocardium (Jiang et al., 2004).  When the heart contracts during 
systole the apex is pulled towards the base while simultaneously sheets of fibres slide 
past each other in a ‗wringing‘ motion due to muscle fibre orientation which thickens the 
ventricle wall reducing the chamber lumen further and efficiently ejecting blood (Hales 
et al., 2012).   
 
The systemic circulation is a high resistance circuit (around 1100 dyne.s.cm-5) with 
typical systolic and diastolic pressures around 120 mmHg and 80 mmHg, respectively 
(Stamler et al., 1994).  These pressures are necessary to allow blood to be delivered 
against gravity and to the most distal parts of the body.   
 
1.2.3 Right ventricle and pulmonary circulation 
The RV pumps blood through the short and normally low resistance pulmonary 
circulation (around 50 dyne.s.cm-5) which is the site of gas exchange (Stamler et al., 
1994).  The RV can be described anatomically in terms of its inlet through the tricuspid 
valve with its associated chordae tendinae and three papillary muscles, the highly 
trabeculated RV free wall, and the smooth infundibulum of the outflow tract region.  
Viewed in cross section the RV is a crescent shaped thin walled chamber contiguous 
with the interventricular septum at its anterior and posterior aspects.  The 
interventricular septum normally bulges convex into the RV chamber reflecting the 
transseptal pressure gradient (Portman et al., 1987).  A longitudinal section through the 
4 chambers reveals the RV to be triangular with papillary muscles attaching to the 
chordae tendinae ready to contract and resist retrograde flow during RV contraction.  
The pressure required to perfuse the pulmonary circulation is much lower than the 
systemic circulation and the RV has approximately one sixth of the muscle mass but a 
larger end diastolic volume than the LV (75 vs 66 mL per body surface area (m2) in 
humans), however as the two chambers are connected in series the stroke volume is 
generally equal (Lorenz et al., 1999).  The systolic RV pressures in healthy individuals 
  
4 
 
is typically around 25 mmHg whereas diastolic pressure is around 4 mmHg (Chemla et 
al., 2002). 
 
RV contraction begins with the papillary muscles followed by the inflow region and 
ends with contraction of the infundibulum which produces a sustained ejection of blood 
even as RV pressure is rapidly falling, possibly due to the momentum of blood and the 
low pulmonary artery (PA) diastolic pressure (Dell'Italia, 1991).  Contraction occurs 
predominantly through longitudinal shortening and movement of the tricuspid annulus 
relative to the apex of the heart, with comparatively less concentric movement of the 
RV free wall compared to the LV.  Ejection is further assisted by the LV pulling on the 
RV at the points of attachment to the interventricular septum (Starr et al., 1943). 
 
Under normal circumstances the RV ejects blood into a highly compliant and 
distensible pulmonary arterial system.  Pulmonary artery systolic and diastolic blood 
pressures are typically around 18-25 and 8-12 mmHg respectively, though these can 
transiently rise for instance at the onset of exercise before additional vessels are 
recruited by vasodilation. 
 
1.2.3.1 Examining cardiac function in vivo 
Echocardiography and ventricular pressure-volume measurements using conductance 
catheters are two major techniques used in the characterisation of in vivo cardiac 
function. 
 
Echocardiography 
Echocardiography is a widely used tool to examine cardiac function in vivo as it is non-
invasive and carries minimal risk, reveals a great deal of information which can be 
extracted fairly rapidly, and is low cost so can be repeatedly performed.  Consequently 
it is an ideal technique for monitoring the progression of heart failure and the efficacy of 
treatments allowing interventions to be adjusted if necessary.   
 
In echocardiography an ultrasound signal is generated by passing an alternating 
current through piezoelectric crystals in the head of a transceiver which deform 
depending on the polarity (Feigenbaum, 2004).  Similarly, when returning sound waves 
strike the crystals they generate an electric current which is recorded by the 
transceiver.  The transceiver alternates between transmitting (usually around 1% of the 
time) and recording (99% of the time).  When the transceiver is placed against the body 
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sound travels through the tissue, generally in straight lines until it encounters an 
interface with a tissue of different acoustic properties.  When this happens some of the 
wave is reflected back to the transceiver at the incident angle while the rest is refracted 
and continues to propagate through the tissue or is absorbed.  The velocity of sound 
through a medium depends on its density, as sound travels more quickly through 
denser objects, but in most soft tissue in the body the velocity is a fairly constant 1540 
m/s.  Thus the presence of a reflected wave identifies the boundaries of different 
tissues, while the delay between the outgoing and returning wave is determined by the 
distance between the object and the transceiver.  This information is processed online 
by the ultrasound machine and displayed as a two-dimensional representation of the 
underlying tissue. 
 
It is also possible to detect blood flow through vessels using a kind of 
echocardiography which capitalises on the shift in wavelength which occurs when 
sound travels through a medium moving towards or away from the observer, in the so 
called Doppler shift.  A classic example of this is the siren of an ambulance travelling 
towards an observer sounds higher pitched due to the waves being compressed, 
whereas when the ambulance drives in the opposite direction the waves are stretched 
and sound lower pitched (a description of how velocity can be mathematically deduced 
from the Doppler shift is given in Section 2.3.2).  Doppler echocardiography can be 
performed with one set of continually transmitting crystals and a second set of 
receiving crystals, however this cannot discriminate where the returning signal comes 
from.  The great advancement in clinical Doppler echocardiography was the advent of 
'pulsed mode' Doppler which allows the measurement of velocity and depth by 
alternately transmitting and receiving and adjusting the duty cycle to restrict the 
recording to a set depth. 
 
There are limitations to what can be studied using echocardiography.  For instance, 
certain tissues such as bone which is very dense and the lungs which contain a lot of 
air, transmit sound poorly and therefore almost all of the sound is reflected.  This may 
restrict access to deeper tissues (e.g. the ribs and lungs can limit the view of the heart) 
and may necessitate the use of alternative viewing windows such as transoesophageal 
echocardiography.  A wave can reflect off an object whose thickness is at least one 
quarter of its wavelength, thus the ability to resolve small objects requires high wave 
frequencies typically in the MHz range (Feigenbaum, 2004).  This means low frequency 
waves penetrate deep into tissue but have poor resolution, whereas high frequency 
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waves give greater detail but have little penetration because the signal is reflected by 
more objects.  The orientation of tissue relative to the wave also affects the quality of 
image as wave reflections from boundaries at 90° to the transceiver produce the 
greatest reflections, whereas those parallel to the wave produce minimal reflections.  
This has implications in the heart with its round chambers where typically the anterior 
and posterior walls can be visualised but the lateral walls can suffer from image 
dropout. 
 
Cardiac pressure-volume loops 
The cardiac cycle can be conceptualized as consisting of four phases of changing 
pressure and volume, depicted as a loop (Figure 1.1).  Phase 1, isovolumic contraction, 
consists of a rise in ventricular pressure due to contraction of the ventricle at the onset 
of systole without a change in volume due to closure of the aortic or PA valves.  Phase 
2 occurs between aortic or PA valve opening and closing and therefore represents the 
ejection of blood under quasi-isotonic conditions.  The transition to Phase 3 
corresponds to end systole when ejection stops, the valves close and pressure 
declines under isovolumic conditions.  Phase 4 begins with mitral or tricuspid valve 
opening and represents ventricle refilling with blood due to passive and active filling 
during diastole.  The effect of inotropic or lusitropic factors such as altered filling 
pressures, vascular resistance, or catecholamines on the ventricle and vasculature can 
easily be visualised as a change in the shape of the PV loop.  PV loops allow a greater 
insight into ventricle contractility as they permit load-independent parameters of 
contractility to be calculated which are not affected by heart rate or vascular resistance 
(Figure 1.2) (Champion et al., 2009; Naeije & Manes, 2014). 
 
RV and LV PV loops differ in their normal shape which reflects differences in arterial 
diastolic pressure (afterload) and isovolumic contraction and relaxation times (Burkhoff 
et al., 1987).  The LV exhibits a pronounced isovolumic contraction Phase 1 due to the 
time it takes for ventricular pressure to exceed arterial afterload, similarly there is a 
long isovolumic relaxation as ventricular pressure falls after aortic valve closure.  In 
contrast the RV PV loop is normally triangular due to the smaller difference between 
ventricular diastolic pressure and afterload (Redington et al., 1988) (Figure 1.1), 
although pathological changes due to pressure or volume overload can reduce the 
differences as both ventricles develop pronounced isovolumic contraction and 
relaxation phases (Redington et al., 1990).  For this reason some parameters 
commonly used to describe LV function such as the highly load-dependent dP/dtmax are 
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Figure 1.1 Cardiac pressure-volume loops 
A Human LV PV loop showing the four phases of contraction: 1) isovolumic contraction, 2) ejection, 3) isovolumic relaxation, and 4) refilling.  B 
Healthy RV PV loop with no discernible isovolumic contraction and relaxation and low systolic pressure.  C RV PV loop from a patient with pulmonary 
stenosis showing a more rectangular loop with high systolic pressure.  Figure adapted from Redington et al. (1990)  
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Figure 1.2 Ventriculo-arterial coupling measured by pressure-volume analysis 
A Diagram of pressure-volume (PV) measurements during progressive preload reduction.  Arterial elastance (Ea) reflects the relationship between 
stroke volume and systolic pressure. B RV PV loops in compensated and decompensated PAH.  Ea steepens in late PAH due to continued vascular 
remodelling, however ESPVR decreases as RV contractility progressively worsens.  Consequently, ventriculo-arterial coupling is initially preserved 
(ESPVR ≈ Ea) but then declines (ESPVR < Ea) .  Figure adapted from Champion et al. (2009).  
A B
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of questionable value in the RV, as the short isovolumic contraction time leads to low 
values of dP/dtmax which can increase even in a severely compromised RV as the 
afterload and therefore isovolumic contraction time increases (Gleason & Braunwald, 
1962). 
 
1.2.4 Electrical conduction 
Cardiomyocytes in the heart are electrically connected and function as a syncytium, 
meaning every cell should depolarize during every heartbeat, however the order in 
which they depolarize is critical to ensure the ventricles fill and eject blood efficiently; 
uncontrolled activation can rapidly lead to pump failure and death.  To this end a 
specialised conduction system in the heart carries the depolarization wavefront to 
regions of the heart at different rates and ensures a synchronized contraction.   
 
The heart generates its own electrical impulse originating in specialized pacemaker 
cells which display intrinsic automaticity and set a basal heart rate of around 100 beats 
per minute in humans, though at rest this is reduced by parasympathetic nervous 
activity to 60-80 beats per minute.  Pacemaker cells are situated in the sinoatrial node 
(SAN) which is located near the inflow of the superior vena cava into the right atrium 
and automaticity of SAN cells is critical to their function.  Automaticity is shared with 
other cells such as atrioventricular (AV) node cells, however as the firing rate of SAN 
cells is faster than AV node cells they normally determine the minimum heart rate.  
SAN cells undergo spontaneous diastolic depolarization under the control of a 
‗membrane clock‘ regulated by channels which carry inward currents and reduce 
outward repolarizing currents, and also possibly through an independent mechanism of 
spontaneous Ca2+ release from the sarcoplasmic reticulum (‗calcium clock‘) which 
generates inward current through Ca2+ efflux from the cell (Honjo et al., 2003; Monfredi 
et al., 2013). 
 
The action potential (AP) wavefront spreads from the SAN to the AV node though 
internodal pathways and during the process spreads to activate atrial cardiomyocytes.  
At this point the activity is confined to the atria due to the fibrous atrioventricular valves 
which do not conduct.  The AV node sits near the coronary sinus in the right atrium and 
connects with specialized conducting fibres in the interventricular septum called the 
bundle of His which divides to separately supply the RV and LV.  The AV node slows 
the propagation of the AP into the ventricles allowing time for the atria to contract and 
fill the ventricles with blood.  The right and left bundle branches travel towards the 
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apex, then turn and divide to supply the papillary muscles and Purkinje fibres.  The 
papillary muscles contract first due to direct innervation by the bundle branches, 
applying tension to the AV valves preventing retrograde blood flow into the atria during 
ventricular contraction.  Purkinje fibres then activate the remaining myocardium starting 
from the endocardium and apex and travelling towards the epicardium and base of the 
heart. 
 
The action potential (AP) propagates between cardiomyocytes through intercellular 
coupling at the ends of cells (Veeraraghavan et al., 2014).  Gap junctions form from 
hemi-channels of hexamers of connexin proteins (Cx43 being the primary cardiac 
isoform) expressed in opposing membranes at the intercalated disk.  These pores 
connect the cytosol of neighbouring cells as a syncytium allowing electrotonic diffusion 
of Na+ ions during an AP (Söhl & Willecke, 2004).  This organisation results in 
anisotropic conduction through the myocardium which is faster parallel than transverse 
to muscle fibres (Kanai & Salama, 1995). 
 
1.2.5 Coronary blood supply 
The coronary circulation begins with a right and left coronary artery originating at the 
aortic sinuses at the base of the ascending aorta.  The right coronary artery supplies 
most of the RV and right atrium except the posterior wall and inferoseptal region which 
are supplied by the left anterior descending artery.  The left coronary artery supplies 
the LV, interventricular septum and left atrium.  Gas and solute exchange between the 
blood and myocardium occurs via capillaries which generally run parallel to muscle 
fibres.  Blood is collected from the capillary bed in venules which feed into the cardiac 
veins which either return blood to the right atrium via the coronary sinus or drain 
directly into the RV via the Thebesian system of small veins (von Ludinghausen, 2003).  
 
The RV and LV differ in their normal coronary perfusion, as the LV experiences phasic 
perfusion mainly during diastole due to compression of vessels resulting from the high 
intramural stress generated during systole whereas the RV with its smaller muscle 
mass experiences more continual flow throughout systole and diastole.  Elevated RV 
pressures in PAH stops RV coronary flow during systole resulting in perfusion mainly 
during diastole (Lowensohn et al., 1976).   
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1.2.6 Extracellular matrix 
The extracellular matrix (ECM) is the acellular component of tissues consisting of 
proteins such as collagens, fibronectin, glycoproteins and proteases.  It serves as a 
scaffold to interconnect cells and distribute the mechanical forces generated by the 
heart during contraction and diastolic filling (Souders et al., 2009).  Frank and Langer 
(1974) showed using electron microscopy that collagen constituted 4% of the 
extracellular matrix.  Collagen forms triple helical strands comprised of (X-Y-Glycine)n 
repeating units, where X and Y are predominantly proline and 4-hydroxyproline (Bella 
et al., 1994).  The predominant collagen isoform in the rodent heart is Type I which 
forms large well organised fibre strands which are stiff and resist stretching (Ishikawa 
et al., 1992a).  Type III collagen is the other main cardiac isoform which forms a fine 
reticular network surrounding cells and is more compliant. 
 
A significant proportion of the ECM is synthesized by fibroblasts which comprise 55-
70% of all cells in the adult LV (Zak, 1974; Nag, 1980; Banerjee et al., 2007).  
Fibroblasts also secrete protease enzymes (matrix metalloproteinases; MMPs) which 
degrade the ECM allowing fibrous scars to form around injured tissue such as a 
myocardial infarction (MI).  The secretion and activation of MMPs occurs in response to 
growth factor and cytokine signalling through interleukins and tumour necrosis factor 
(TNF)-α and is important in facilitating the remodelling process. 
 
1.2.7 Cardiomyocyte structure 
Ventricular cardiomyocytes are generally rectangular ellipsoids in shape with a long 
axis of 100-150 µm and short axis of 15-25 µm.  A plasma membrane (sarcolemma) 
encloses the cell which is relatively impermeable to ions and charged molecules except 
through specific channels and ion transporters expressed on the cell surface allowing 
the establishment of an electrochemical gradient of ions.  The sarcolemma of 
ventricular myocytes is highly invaginated and forms tubules (t-tubules) which travel 
deep inside the cell which have a distinct ion channel composition to the surface 
sarcolemma.  Atrial myocytes contain a sparser tubule network (Dibb et al., 2013).  At 
the ends of cardiomyocytes are specialized regions called the intercalated disks which 
form end-to-end connections which couple cells both mechanically and electrically.  
Immediately below the sarcolemma is a dense population of mitochondria which power 
the energy-dependent processes of ion exchange and contraction and occupy around 
30% of total cell volume.  Adult cardiomyocytes are typically binucleate and terminally 
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differentiated.  The remaining ~70% of cardiomyocyte volume is occupied by an 
interdigitating array of myofilament proteins which contain the contractile elements 
necessary for cell shortening; certain cell types specialized for generating or 
conducting electrical waves are nearly devoid of this contractile apparatus.  An internal 
Ca2+ store (sarcoplasmic reticulum) encircles the myofilaments and forms close 
connections with t-tubules.  A dense cytoskeleton permeates throughout cells forming 
connections between membranes and internal structures giving structural support, as 
well as acting as a scaffold for cytosolic protein binding and trafficking. 
 
1.2.8 Myofilament structure 
The sarcomere is the fundamental unit of muscle contraction and is composed of 
interdigitating arrays of actin and myosin filaments which give rise to the striated 
appearance of cardiac muscle under a light microscope.  The Z-lines demarcate the 
boundaries of the sarcomere and are maintained by α-actinin which forms connections 
between thin filaments and has both a structural and signaling role (Bers, 2001).  The 
Z-disk is important in maintaining the interfilament spacing of myocytes which is critical 
to crossbridge formation.  When viewed in cross-section, muscle cells appear as a 
hexagonal lattice with the globular heads of central thick filaments projecting out 
towards thin actin filaments at a regular distance of around 43 nm at resting length 
(Figure 1.3) (Konhilas et al., 2002).  The terminal Z-disk also contains signaling 
complexes such as desmosomes and fascia adherens which anchor the intracellular 
myofilaments and cytoskeleton to the sarcolemma and extracellular matrix and are 
involved in the activation of transcription factors in response to mechanical stress. 
 
The actin thin filament is composed of repeating units of globular actin which forms a 
double stranded filamentous actin polymer.  One end of the actin thin filament anchors 
to the Z-disk while the other end extends about 1 μm towards the centre of the 
sarcomere.  Tropomyosin is another doubled stranded helix which binds in the groove 
of the actin filament and extends for about 7 actin monomers.  The troponin (Tn) 
complex comprising the tropomyosin binding TnT, Ca2+ binding TnC, and inhibitory 
subunit TnI, binds to tropomyosin and regulates its position within the actin groove.  
 
The myosin thick filament is held halfway between Z-lines and contains the proteins 
responsible for shortening the sarcomere during contraction.  The thick filament 
extends perpendicular to the M-line for 0.8 μm in each direction and is composed of 
around 300 myosin heavy chains (MHC).  Each MHC is composed of an α-helical tail 
  
13 
 
about 130 nm in length and a globular head containing the ATP and actin binding 
domains.  Myosin can be proteolytically divided into most of the tail region (light 
meromyosin) and the remaining tail and head region (heavy mereomyosin).  Heavy 
meremyosin can further be digested into an S1 region containing the flexible neck and 
globular head, and an S2 region which contains the remaining α-helical tail.  Point 
mutations in either the S1 or S2 region are strongly associated with cardiomyopathies 
(Colegrave & Peckham, 2014).  Each MHC also has an essential and a regulatory light 
chain associated with its S1 region which confer stability and influence crossbridge 
cycling kinetics when phosphorylated.  In the centre of the A-band is the M-line which 
contains no myosin heads but does contain proteins such as myomesin which anchor 
myosin, titin and creatine kinase (Auerbach et al., 1999). 
 
Titin is the largest protein in the body (3-3.3 MDa) spanning the half sarcomere from Z-
disk to M-line by more than 1 µm when a cell is stretched.  It is a bidirectional spring 
which determines the slack sarcomere length in unloaded cardiomyocytes by exerting 
a passive force when cells are stretched and a restoring force when cells are shortened 
(King et al., 2011) and is thought to be the main determinant of passive stiffness in the 
healthy myocardium at physiological sarcomere lengths (Wu et al., 2000; Chung & 
Granzier, 2011).  The extensible region of titin occurs in the I-band of the sarcomere 
and consists of three regions: 1) a PEVK (proline, glutamate, valine, lysine) rich region 
2) a highly folded Ig repetition domain and 3) a cardiac isoform-specific N2B or N2BA 
element.  The N2BA isoform of titin contains a longer PEVK region (600-800 residues) 
and is therefore more compliant and has a higher molecular mass than the shorter 
stiffer N2B isoform (163 residues).  The spring elements unfold according to their 
entropic state (Ig domains unfold first, followed by the PEVK and N2B/N2BA domains) 
then refold when the cell shortens (Watanabe et al., 2002; Nedrud et al., 2011).  Titin-
based stiffness depends on isoform expression and post-translational modification of 
residues in the spring elements by phosphorylation and oxidation (Borbély et al., 2009; 
Grutzner et al., 2009; Hidalgo et al., 2013).  A restoring force is generated by titin when 
sarcomeres shorten below ~1.97 µm which is important during the early phase of 
diastole as it returns the cell to its resting length (King et al., 2011).  Titin may also 
have a signalling role in response to stretch as it binds to proteins such as telethonin in 
the Z-disk, thought to be important in t-tubule stability, and also contains a  
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Figure 1.3 Myofilament lattice spacing 
Thin actin filaments (A) are arranged in a hexagonal array surrounding thick myosin 
filaments (M). Axial stretch of a cardiomyocyte leads to a decrease in lattice spacing.  
Redrawn from Shiels & White (2008). 
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serine/threonine kinase domain which is activated by stretch (Puchner et al., 2008; 
Candasamy et al., 2014). 
 
A dense cytoskeleton composed of filaments of actin and tubulin monomers facilitate 
trafficking of proteins around the cell and provides structural support to cardiomyocytes 
(Rogers & Gelfand, 2000; Nishimura et al., 2005).  Other roles include internalization of 
receptors on the cell membrane (Limas & Limas, 1990), remodelling cell membrane 
morphology (Zhang et al., 2014), stretch induced reactive oxygen species production 
(Prosser et al., 2011) and modulation of energy metabolism (Maldonado et al., 2010). 
 
1.3 Energy metabolism in the heart 
1.3.1 Mitochondria: structure and function 
Mitochondria are essential subcellular organelles found in the vast majority of cell types 
in the body which harness the energy liberated by the oxidation of substrates to 
generate ATP which powers energy-demanding cellular processes.  There are 10000 
to 20000 mitochondria in every cardiomyocyte which account for 30% of total cell 
volume (Williams et al., 2015).  Two populations of mitochondria are found in 
cardiomyocytes either in the immediate subsarcolemma (SSM) or between rows of 
myofilaments (interfibrillar mitochondria; IFM) (Figure 1.4).  IFM are thought to normally 
exhibit higher maximal oxidative capacity (Palmer et al., 1977), although this may 
change in a diseased state (Rosca et al., 2008; Vazquez et al., 2015).  In addition 
transmural variation in mitochondrial function is thought to occur which may also be 
differentially affected by disease (Sharov et al., 2000; MacDonald et al., 2011). 
 
The function of muscle mitochondria is assisted by their highly organised structure 
consisting of an outer membrane (MOM) separated from an inner membrane (MIM) by 
the intermembrane space (Scheffler, 2008).  The MIM contains lipid soluble respiratory 
complexes and is highly folded to increase surface area.  Enclosed by the MIM is the 
matrix which contains water soluble enzymes of the tri-carboxylic acid (TCA) cycle and 
enzymes responsible for β-oxidation of fatty acids (Figure 1.5).  In the adult heart 60-
90% of energy is supplied by fatty acid oxidation, while most of the remaining 10-30% 
comes from glucose oxidation (Neely & Morgan, 1974); a small proportion of energy 
can come from glycolysis but normally the heart is a net consumer of lactate and not a 
producer.  Glycolysis in the cytosol produces pyruvate which is converted to acetyl-
CoA in the matrix under the control of pyruvate dehydrogenase.  Acetyl-CoA is also 
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produced through β-oxidation of fatty acids in the matrix (Tzagoloff, 1982).  The first 
step of the TCA cycle is catalyzed by the enzyme citrate synthase which reacts acetyl-
CoA with the four carbon oxaloacetate forming citric acid.  Through a series of seven 
reactions the two carbons from acetyl-CoA are oxidized to reduce NAD+ forming a pool 
of NADH and produce CO2 as a waste product.  The other high energy intermediate 
formed during the TCA cycle is FADH2 which is produced from FAD
+ during the 
oxidation of succinate to fumarate by the enzyme succinate dehydrogenase which is a 
component of Complex II of the electron transport system (Complex II) and the only 
membrane bound enzyme of the TCA cycle.   
 
1.3.2 Electron transport system 
The electron transport system uses NADH and FADH2 produced by the TCA cycle as a 
source of electrons to power the pumping of H+ ions across the MIM to generate a 
large membrane potential (-180 mV).  The controlled dissipation of this membrane 
potential through influx of H+ drives the final complex of the respiratory system (F1F0-
ATP synthase) which synthesises ATP from ADP.  This process is facilitated by the 
presence of four respiratory complexes which facilitate electron transport and proton 
pumping, and the fifth ATP synthase (Scheffler, 2008). 
 
In Complex I (NADH dehydrogenase) NADH is oxidised to NAD+ with the transfer of 
two electrons to the lipid soluble carrier Coenzyme Q (CoQ) forming CoQH2 and in the 
process four H+ are exported into the intermembrane space (Tzagoloff, 1982).  
Complex II (succinate dehydrogenase) catalyses the oxidation of succinate to fumarate 
producing FADH2 which is immediately oxidized to FAD
+ with the transfer of electrons 
to CoQ but no pumping of H+ occurs at this step.  Thus CI and CII share a common 
pathway for electron flow via CoQ, or the ‗Q-junction‘, which converge into Complex III 
(cytochrome c reductase).  Complex III transfers electrons from CoQH2 to the water 
soluble carrier cytochrome c (cyt c) with the transport of a further four H+ across the 
MIM.  The final respiratory complex to establish the H+ gradient is cytochrome c 
oxidase (complex IV) which transfers 4 electrons from cyt c to molecular O2 producing 
water.  The final complex in the ETS is also the ATP generating step which utilises the 
electrochemical gradient established by the preceding steps to drive the catalytic 
subunit of the F1F0 ATP synthase which phosphorylates low energy ADP to the high 
energy ATP. 
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Figure 1.4 Subcellular distribution of mitochondria 
Electron micrograph image of mouse LV imaged at ×10,000.  Mitochondria are located in the immediate subsarcolemma (SSM) and interspersed 
between myofilaments (IFM).  Bar shows 0.5 µm.  Figure adapted from Hollander et al. 2014. 
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Figure 1.5 Electron transport system 
Schematic diagram of production of electron donors in the TCA cycle and sources of electron flow into the electron transport system.  ATP produced 
by mitochondria is immediately used by CK-mt to generate PCr which diffuses into the cytosol via VDAC.  Ca2+ released during systole activates 
Ca2+-dependent dehydrogenases (red boxes).  Leak of H+ across the MIM decreases mitochondrial efficiency. Rotenone and antimycin A block 
electron transport through complex I and III, respectively.  PDH, pyruvate dehydrogenase; CS, citrate synthase; A, aconitase; ICDH, isocitrate 
dehydrogenase; KDH, α-ketoglutarate dehydrogenase; SCS, succinyl-CoA synthetase; SDH, succinate dehydrogenase; F, fumarase; MDH, malate 
dehydrogenase; MCU, mitochondrial Ca2+ uniporter. Figure adapted from Kilbaugh et al. (2015) and Williams et al. (2015). 
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1.3.3 Regulation of mitochondrial respiration 
Mitochondria respond to changing energy requirements by increasing or decreasing 
the ATP synthesis in response to feedback from factors such as the availability of 
adenylates and ions such as Ca2+.  The addition of ADP to isolated mitochondria in the 
presence of substrates immediately increases respiration through a process of 
phosphate acceptor control (Chance & Williams, 1955).  The large ADP and ATP 
molecules are impermeable to the mitochondrial outer membrane (MOM) and therefore 
enter and leave mitochondria through the voltage dependent anion channel (VDAC).  
VDAC is a 19 stranded β-barrel with an effective pore size of 14 Å (Ujwal et al., 2008).  
VDAC is perhaps a misnomer, as even in the voltage dependent closed state VDAC is 
still permeable to cations such as Ca2+, however the pore size and therefore 
permeability of VDAC to adenylates is reduced in intact cells by the binding of 
negatively charged free tubulin to the pore channel (Rostovtseva et al., 2008; 
Maldonado et al., 2010). 
 
The adenine nucleotide translocase (ANT) situated in the inner mitochondrial 
membrane exchanges ATP produced in the matrix for ADP in the intermembrane 
space.  The activity of the ANT and therefore the stimulation of respiration is greatly 
facilitated by its functional coupling to octameric mitochondrial creatine kinase (CK-mt) 
(Bessman & Fonyo, 1966).  CK-mt rapidly hydrolyses ATP and transfers Pi to the small 
molecule creatine producing phosphocreatine (PCr) which easily diffuses through 
VDAC into the cytosol (Guzun et al., 2009), while the product ADP is immediately 
transported back into the matrix via the ANT in exchange for further ATP.  This 
mechanism permits a small pool of adenylates to be retained and continually cycled 
without needing to enter the bulk cytosol.  
 
The cytosolic concentration of ATP and ADP measured using 31P-NMR changes little in 
the heart during abrupt increases in work, suggesting they are not the main stimulus for 
increased respiration during periods of demand (Balaban et al., 1986).  In contrast, 
Ca2+ enters and leaves mitochondria on a beat by beat basis through VDAC then into 
the matrix via the Ca2+ uniporter (Lu et al., 2013).  This activates Ca2+-sensitive 
pyruvate, α-ketoglutarate and isocitrate dehydrogenases of the TCA cycle thus 
stimulating mitochondrial respiration (Figure 1.5) (McCormack et al., 1990).  Ca2+ entry 
occurs on the same time scale as the systolic Ca2+ transient but removal from the 
matrix happens over a longer time due to exchange of Ca2+ and Na+ (and Li+) via the 
mitochondrial NCX; the stoichiometry of mitochondrial Ca2+ and Na+ exchange remains 
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to be demonstrated conclusively (Boyman et al., 2013; Lu et al., 2013).  The difference 
in entry and exit kinetics means mitochondrial Ca2+ can accumulate when heart rate is 
high and therefore modulate energy production according to demand.   
 
Electron transfer is normally tightly coupled to ATP synthesis through one-electron 
reduction of carrier proteins down the electrochemical gradient with greater than 98% 
of electrons resulting in the reduction of molecular O2 to water.  However some 
respiration occurs due to leak of H+ across the MIM via endogenously expressed 
uncoupling proteins or the ANT, or slippage of electrons from electron carriers.  
Dedicated uncoupling proteins are expressed in some tissues such as the brown fat of 
infants and allow the translocation of H+ directly across the MIM which uncouples 
electron transport from ATP production for the purpose of generating heat.  Leak of 
electrons can occur if CI or CIII are inhibited or impaired by disease resulting in direct 
reduction of O2 to the superoxide radical (Turrens & Boveris, 1980; Ide et al., 1999). 
 
1.3.4 Creatine kinase system 
The rapid and reversible formation of ATP or PCr through the creatine kinase (CK) 
reaction was discovered by Lohmann (1934) and was initially considered as a temporal 
energy buffer during periods of high energy turnover.  The discovery of the 
mitochondrial isoform (CK-mt) and its ability to exert acceptor control over respiration 
spurred on the development of the ‗phosphocreatine energy-shuttle‘ hypothesis 
(Jacobs et al., 1964; Bessman & Fonyo, 1966).  This hypothesis postulates the 
reversible CK reaction allows the transport of high energy phosphates around the cell 
in the form of small easily diffusible PCr while simultaneously removing lower energy 
ADP and its inhibitory effect on ATPases.  The compartmentation of adenylates and 
preferential ability of PCr over solely ATP to sustain muscle contraction has since been 
thoroughly demonstrated (Ventura-Clapier et al., 1987a; Kaasik et al., 2001; Kuum et 
al., 2009; Birkedal et al., 2014). 
 
Cardiomyocytes contain a mixture of 4 CK isoenzymes which all catalyze the reversible 
reaction with equal activity: 
 
                            
 
CK-mt accounts for 20-30% of total CK activity and is found exclusively in the 
intermembrane space of mitochondria as an octamer or dimer functionally coupled to 
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the ANT through binding with cardiolipin (Khuchua et al., 1998).  Cytosolic isoforms 
consist either of 86 kDa homodimers of muscle (CK-M) or brain isoforms (CK-B), or 
heterodimers (CK-MB).  CK-M is the most abundant isoform in adult cardiomyocytes 
accounting for around 70% of total CK (Younes et al., 1985).  CK-MB and CK-B 
constitute a small proportion of total activity in healthy adult cardiomyocytes, though 
during early development and in disease their absolute and relative abundance 
increases (Ingwall, 1984). 
 
The dense myofilament lattice, t-tubule and SR networks represent a significant barrier 
to diffusion of adenylates through cardiomyocytes (Sokolova et al., 2009), therefore the 
much smaller molecule PCr forms an energy shuttle between sites of ATP production 
and utilisation through the colocalisation of CK with ATPases.  This ensures a high 
ATP/ADP ratio in the vicinity of ATPases and prevents product inhibition by ADP.  
Around 10-30% of CK-M is bound to myomesin in the M-line of sarcomeres where it is 
functionally coupled to myosin (Ventura-Clapier et al., 1987a; Hornemann et al., 2003).  
CK-M is also functionally coupled to SERCA (Kuum et al., 2009) and at the 
sarcolemma to the Na+/K+ ATPase (Grosse et al., 1980) and ATP-sensitive IKATP 
channels (Crawford et al., 2002).  CK-B loosely associates with the I-band of 
myofilaments in complexes of glycolytic enzymes (Kraft et al., 2000).  The targeting of 
different CK isoforms to the M-band or glycolytic complexes is thought to occur 
exclusively through the affinity of their N-terminal domain to their respective binding 
partners (Stolz & Wallimann, 1998) 
 
1.4 Excitation-contraction coupling 
Excitation-contraction (EC) coupling in ventricular myocytes is the process through 
which a change in the membrane potential of the sarcolemma leads to a small influx of 
Ca2+ to the cell which leads to a larger release of Ca2+ from the sarcoplasmic reticulum 
(SR) activating myofilament proteins resulting in the generation of force or shortening.  
Cytosolic Ca2+ is returned to resting levels by efflux from the cell or sequestering into 
the SR which causes dissociation of actin-myosin crossbridges and muscle relaxation 
(Figure 1.6) (Bers, 2002). 
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Figure 1.6 Cardiac excitation-contraction coupling 
Ca2+ transport pathways activated in response to electrical activation.  Inset shows the different time course of the action potential, Ca2+ transient, and 
contraction in a rabbit ventricular myocyte at 37°C.  Figure from Bers (2002).  
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1.4.1 Ventricular action potential 
At rest Na+ and K+ ions are pumped across the sarcolemma generating a membrane 
potential (Em) between the inside of the cell membrane which is negatively charged and 
the outside which is positively charged.  The ventricular AP arises due to the opening 
and closing of channels in the sarcolemma which allow the passage of ions carrying an 
electric current.  The AP morphology varies depending on species, cell type and region 
of the heart (both base-apex and transmural) due to differential expression of ion 
channels (Akar & Rosenbaum, 2003), and has an important role in determining the 
refractory period which coordinates contraction across the heart (Schram et al., 2002).  
The AP can be divided into 5 phases whose morphology is shaped by the presence 
and conductance of different ion channels which can activate and inactivate depending 
on voltage, time and ions present (Nerbonne & Kass, 2005).  A model of an idealised 
human ventricular AP is illustrated in Figure 1.7. 
 
During diastole Em is in a hyperpolarized resting state (Phase 4) maintained between -
90 to -70 mV by the inwardly rectifying potassium current (IK1) (Dhamoon & Jalife, 
2005).  The channels which carry IK1 (Kir 2.1) activate at Em negative of -40 mV and 
carry an outward current making the cytosolic side of the membrane more negative up 
to the point at which Em equals the reversal potential of potassium (Ek, around -80 mV).  
IK1 carries an inward current at membrane potentials more negative than EK, thus 
stabilizing the resting membrane potential.  During depolarization IK1 is inhibited by 
Ca2+ and Mg2+ ions and polyamides (Nerbonne & Kass, 2005) thus reducing the 
repolarizing effect and allowing the membrane potential to rapidly rise. 
 
The rapid upstroke of the action potential occurs during Phase 0.  An initial rise in Em to 
around -70 mV due to the electrical coupling to neighbouring cells via gap junctions 
triggers the opening of voltage-gated sodium channels (primarily Nav 1.5) carrying the 
inward INa current which further depolarizes the membrane to around +40 mV.  The 
rapid onset of INa is followed by an equally rapid decrease in INa due to voltage- and 
time-dependent closure of channels which allows repolarisation to begin. 
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Figure 1.7 Ventricular cardiomyocyte action potential 
Time course of inward (downward deflections) and outward (positive deflections) 
currents which are active during the human ventricular action potential (top).  Not 
shown is INCX, which carries outward current early during the action potential then 
reverses and carries inward current as Ca2+ is removed from then cell.  Rat ventricular 
action potentials are shorter and more triangular due to IKr and IKs being low or absent.  
Figure from Nerbonne and Kass (2005).  
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The initial repolarisation of the cell during Phase 1 occurs due to inactivation of INa with 
simultaneous activation of the transient outward potassium current (Ito).  Ito is carried by 
three channels with similar rapid activation kinetics but have different time-dependent 
inactivation kinetics.  Kv 4.2 and 4.3 channels inactivate rapidly and carry the Ito,fast 
current, whereas Kv 1.4 channels deactivate slowly and carry the Ito,slow current (Apkon 
& Nerbonne, 1991).  During this time Em approaches 0 mV which is the peak of the ICa 
activation curve, allowing influx of Ca2+ to the cell. 
 
In human ventricular action potentials Phase 2 is typified by a pronounced plateau 
following early repolarisation representing the opposing influences of inward current 
generated by entry of Ca2+ to the cell (ICa) through voltage dependent long lasting 
calcium channels (Cav 1.2) and repolarising influence of delayed K channels.  ICa 
begins to activate at around -30 mV and reaches its peak around 0 mV.  The 
inactivation of ICa occurs through voltage, Ca
2+ and time-dependent mechanisms 
(Benitah et al., 2010).  A fast (IKr) and slowly activating (IKs) repolarising outward K 
current begin to activate during Phase 2 (Sanguinetti & Jurkiewicz, 1990).  IKr 
inactivates rapidly, shows inward rectification, and recovers quickly from inactivation, 
whereas IKs shows outward rectification and does not inactivate.  Rabbits have a similar 
AP morphology to humans, however small rodents such as rats and mice have a very 
short Phase 2 due to species differences in ion channel densities (Nerbonne, 2000). 
 
Final repolarisation to the resting membrane potential during Phase 3 is achieved by 
the voltage-, time- and Ca2+-dependent inactivation of ICa and the remaining current 
generated by IKr and IKs which repolarises the cell. 
 
1.4.1 Transverse-axial tubule system 
A dense tubule network formed by invaginations of the sarcolemma occurring primarily 
at the Z-line of sarcomeres is present in adult ventricular myocytes from most 
mammalian species and in some other cell types including skeletal myocytes and atrial 
myocytes of large animals (Dibb et al., 2013).  T-tubules are approximately 200 nm in 
diameter and make up around 1% of the total cell volume (Page et al., 1971) but due to 
their large surface area account for 25-30% of total cell membrane (Kawai et al., 1999; 
Bryant et al., 2015).  They project radially into the interior of the cell at the Z-lines of 
sarcomeres giving rise to the name ‗transverse‘ tubule (t-tubule), where they co-
localize with the junctional SR forming a functional unit called a dyad.  Cav 1.2 
channels are expressed at a 3- to 9-fold greater abundance in t-tubules compared to 
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the surface sarcolemma (Kawai et al., 1999; Bryant et al., 2015), thus placing them 
immediately opposite the junctional SR which is densely populated with ryanodine 
receptors (RYR2).  This arrangement facilitates the primary role of t-tubules in ensuring 
uniform Ca2+ entry throughout the cell which potentiates SR release and ensures a 
rapid upstroke of the systolic Ca2+ transient. 
 
The close apposition (12-15 nm) with the terminal cisternae of the SR arises due to 
stabilization by scaffolding proteins such as junctophilin-2 (JP2) which forms a 
microdomain called the dyadic cleft in which ion concentrations change rapidly and of 
greater magnitude than in the bulk cytosol (Dries et al., 2013).  This activates Ca2+ 
dependent protein kinases in the dyadic cleft which can phosphorylate RYR2 
sensitizing it to further Ca2+ release (Maier & Bers, 2007).  Other ion channels and 
receptors highly expressed in t-tubules compared to the surface sarcolemma include 
NCX and the sarcolemmal Ca2+ ATPase (Scriven et al., 2000; Yang et al., 2002; Chase 
& Orchard, 2011), whereas others such as Nav 1.5 appear to be more evenly 
distributed throughout the sarcolemma (Yang et al., 2002).  β2 adrenoceptors are also 
primarily localised to t-tubules by the scaffolding protein caveolin-3, resulting in a 
compartmented cAMP response to selective stimulation β2-AR (Nikolaev et al., 2010). 
 
The structural integrity and localisation of ion channels and receptors to t-tubules is 
maintained by scaffolding proteins thought to include bridging integrator-1 (BIN-1) (also 
called amphiphysin II), JP2, caveolin-3 and telethonin (t-cap).  BIN-1 has a positively 
charged concave surface with a high affinity for phospholipid membranes (Peter et al., 
2004).  Expression of BIN-1 in cell types normally devoid of membrane invaginations is 
sufficient to induce tubule formation, whereas knockdown of BIN-1 in cardiomyocytes 
reduces overall tubule density suggesting it has an important role in the formation of 
membrane invaginations (Hong et al., 2014).  JP2 tethers the sarcolemma to the 
junctional SR maintaining the 12-15 nm cleft through its 8 lipophillic N-terminus 
domains which associate with the t-tubule sarcolemma, α-helical domain spanning the 
dyadic cleft, and C-terminus transmembrane domain embedded into the SR 
(Takeshima et al., 2000).  Knockdown of JP2 in mice reduces the proportion of 
transverse but not longitudinal tubules, suggesting it is important in maintaining the 
dyads (Chen et al., 2013).  T-tubule formation may also be helped by the association of 
caveolin-3, highly expressed in cholesterol-rich rafts in the sarcolemma, with α-actinin 
found in the Z-disk of sarcomeres (Parton et al., 1997; Ueda et al., 2004). 
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A smaller network of axial (or longitudinal) tubules spanning between half and one full 
sarcomere (1-2 µm) form connections between the sarcolemma and longitudinal SR 
with the generic name ‗couplons‘.  Their role in EC coupling in health has received less 
attention than the more prolific t-tubule network, however up to 20% of RYR2 may be 
associated with axial tubules in the form of couplons and the association between 
sarcolemma and SR is indistinguishable from that of dyads suggesting they may also 
play a role in EC coupling (Asghari et al., 2009).   
 
1.4.2 Calcium-induced calcium release 
Ca2+-induced Ca2+-release (CICR) in cardiac muscle was described by Fabiato and 
Fabiato (1975) in a series of seminal papers as the process through which a small 
amount of Ca2+ activates RYR2 Ca2+ release channels on the SR thus amplifying the 
signal and raising cytosolic Ca2+ from around 100 nM at rest to ~1 µM at the peak of 
the Ca2+ transient.  The fundamental units of Ca2+ release were shown by Cheng et al. 
(1993) to be Ca2+ sparks.  The spatial and temporal summation of around 10000 Ca2+ 
sparks produces the systolic Ca2+ transient (Cheng et al., 1993; Shang et al., 2014). 
 
RYR2 are arranged in quatrefoil clusters of Ca2+ release units (CRU) in cardiac muscle 
consisting of around 14 RyR per CRU primarily located at the junctional SR, with a 
smaller proportion of CRU on the longitudinal SR (Chen-Izu et al., 2006; Soeller et al., 
2007; Baddeley et al., 2009; Soeller & Baddeley, 2013).  Interactions within CRU 
confer stability and allow coupled gating of the channels, making the whole unit open 
and close in unison.  Ca2+ is thought to activate RYR2 by first binding to a low affinity 
site with a fast association constant  (Fabiato, 1985).  Termination of Ca2+ release 
occurs due to inactivation of ICa and Ca
2+ dependent inactivation of RYR2 as well as 
depletion of junctional SR stores (Bers et al., 1990).  At high cytosolic Ca2+ 
concentrations a high affinity inactivation site on RYR2 with a slow association 
becomes occupied thus inactivating the channel and giving rise to a refractory period 
which prevents uncontrolled self-activation (Fabiato, 1985).  SR depletion of Ca2+ may 
also contribute to the refractory period between Ca2+ release events (Sham et al., 
1998). 
 
Under normal circumstances Ca2+ sparks also occur in the absence of an action 
potential through the stochastic opening of RYR2 (Cheng et al., 1993).  Factors which 
destabilize CRU such as increased SR load, RYR2 sensitization by phosphorylation or 
oxidation, dissociation of accessory proteins, and increased cytosolic Ca2+ tend to 
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increase spark frequency (Loughrey et al., 2004; Zima & Blatter, 2006; Zima et al., 
2010; Bovo et al., 2011).  Ca2+ spark diffusion is limited due to rapid reuptake by 
SERCA in the junctional SR meaning they normally fail to activate CRU on adjacent 
sarcomeres across the ~2 µm gap between Z-disks.  However if this does happen an 
iterative saltatory process of CICR occurs resulting in a Ca2+ wave which propagates 
along the cell at around 70 µm/s  (Lukyanenko & Györke, 1999).   
 
1.4.3 Myofilament activation 
Muscle shortening occurs due to the cycling of myosin heads in the thick filament which 
bind to actin thin filaments causing a conformational change in myosin which pulls actin 
along the filament before detaching ready to repeat the cycle; in striated muscle this 
process is mostly regulated at the level of the thin filament (Figure 1.8) (de Tombe, 
2003; Kobayashi et al., 2008).  In diastole TnI binds to actin and sterically hinders 
crossbridge formation and the first step of myofilament activation involves Ca2+ 
relieving this inhibition through inducing a conformational change in the tropomyosin 
complex.  Ca2+ binding to the N terminus of TnC causes a conformational shift which 
exposes a previously hidden hydrophobic region of the protein which is attracted to and 
binds TnI.  This destabilizes TnI causing it to switch binding from actin to TnC which 
further stabilizes Ca2+ binding to TnC.  The release of actin by TnI results in 
tropomyosin shifting deeper into the groove of the actin filament and changes from a 
blocked state to a closed state.  This is relayed through tropomyosin causing the 
complex to shift deeper within the groove of the actin helix thus exposing further actin 
binding sites on the thin filament.  A 5-10 amino acid overlap between the carboxy and 
amino ends of tropomyosin imparts a stiffness which means neighbouring tropomyosin 
also shift deeper into the actin groove cooperatively activating further myosin binding.  
Strongly bound myosin further activates the thin filament by maintaining tropomyosin in 
the open state and promoting the TnC-TnI interaction even in the absence of Ca2+ (Li et 
al., 2014).  Phosphorylation by protein kinases of troponins and regulatory proteins 
such as myosin binding protein-C on the thick filament influences myofilament Ca2+ 
sensitivity and therefore force and kinetics of contraction (Kooij et al., 2010; Walker et 
al., 2011a). 
 
The S1 region of MHC contains the ATP binding pocket which hydrolyses ATP.  
Inorganic phosphate (Pi) is released upon actin binding causing the myosin head to 
rotate, thus translating the two filaments past each other during the powerstroke.  For 
the cycle to continue ADP must dissociate (the rate limiting step in the crossbridge 
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cycle) to allow more ATP to bind, which releases actin from myosin.  ATP is hydrolysed 
to ADP and Pi which remain bound to myosin, causing the head to straighten having 
moved along the actin filament by 5-10 nm.  The steps involved, as proposed by 
Goldman and Brenner (1987) are illustrated in Figure 1.9. 
 
1.4.4 Mechanical function 
The Frank-Starling law of the heart as it is now know, was established through the work 
of Otto Frank (1865-1944) and Ernest H. Starling (1866-1927) who working 
independently built on the work of those at Carl Ludwig‘s Physiological Institute in 
Leipzig in describing the process by which an increase in end-diastolic volume 
immediately increases the force of contraction to maintain stroke volume  (Zimmer, 
2002).  The same effect can be seen in isolated muscle cells and tissue as an inverted 
U-shape isometric length-tension relationship as described by Grimm and Whitehorn 
(1968), which reaches a maximum at sarcomere lengths (SL) between 2-2.2 µm. 
 
The shape of the SL-tension relationship was initially attributed to the degree of actin 
and myosin overlap affecting the availability of crossbridge binding (Gordon et al., 
1966).  Overlap increases as sarcomeres are stretched from slack length but then 
decreases beyond the optimal length due to reduced overlap and fewer attached 
crossbridges.  Conversely force is impaired at short SL due to collision of actin 
filaments below 2 µm, while further shortening below 1.6 µm causes myosin to collide 
with the Z-disk greatly reducing the force generating ability.  This explains much of the 
Frank-Starling mechanism, however cannot fully account for why force continues to 
increase in cardiac muscle stretched from SL 2.0 to 2.2 µm when the number of 
available crossbridges does not change, therefore further contributory mechanisms are 
likely. 
 
An increase in Ca2+ sensitivity is widely recognised to contribute to the increased force 
produced at longer SL, however the precise mechanisms through which this occurs are 
not entirely understood (Shiels & White, 2008).  Acute stretch of intact cardiomyocytes 
increases the developed force without an increase in the systolic Ca2+ transient (Allen 
& Kurihara, 1982; White et al., 1993; Yasuda et al., 2003), in fact the peak of the Ca2+ 
transient measured using a fluorescent dye may actually be reduced and the rate of 
decay slowed during stretch.  Conversely, unloaded shortening increases the peak of 
the Ca2+ transient (Janssen & de Tombe, 1997).  This indicates loading increases TnC 
affinity for Ca2+ and therefore retains it for longer during the contraction.  This causes 
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the rate of tension decay to be slower at longer sarcomere lengths (de Tombe, 2003; Li 
et al., 2014). 
 
An ongoing focus has been on the mechanisms which regulate cooperative activation 
of the thin filament.  This occurs when strongly bound crossbridges shift the 
tropomyosin complex deeper into the groove of the actin filament and into the open 
state thus exposing and increasing the affinity of further actin binding sites in a process 
of positive feedback (de Tombe, 2003).  Kurihara et al. (1990) showed Ca2+ was 
released from the myofilaments of ferret papillary muscles injected with aequorin when 
quickly shortened, whereas when the muscles were incubated with 2,3-BDM this effect 
was absent, indicating the length-dependent increased affinity of TnC requires strong 
myosin attachment.  This could be due to allosteric feedback from tropomyosin causing 
greater excursion of the hydrophobic TnI binding patch of TnC thus increasing the TnC-
TnI interaction, as was shown by Li et al. (2014) using a FRET tagged TnC N-terminal. 
 
Crossbridge attachment is a stochastic process therefore decreasing the interfilament 
spacing increases the likelihood of actin-myosin interaction.  Stretching cardiac muscle 
from SL 1.9 to 2.3 µm decreases muscle width by around 13% which compresses the 
myofilament lattice spacing (Figure 1.3) (Fukuda et al., 2000).  Decreasing lattice 
spacing using Dextran beads in chemically permeabilized cardiomyocytes increases 
Ca2+ sensitivity at short SL (Fuchs & Wang, 1996).  Titin may reduce interfilament 
spacing during stretch through its association with the Z-disk, as rats expressing a 
giant N2BA-G titin isoform have reduced length-dependent activation (Patel et al., 
2012).  However not all studies support interfilament spacing as a primary cause of 
length-dependent activation as Konhilas et al. (2002) found a poor correlation between 
Ca2+ sensitivity and lattice spacing caused by stretch and osmotic compression.  
 
Even unloaded cells must shorten against an internal load and a viscous component 
thought to be due to the cytoskeleton (Zile et al., 1999).  An elastic element due to the 
giant protein titin acts as a brake at end systole and exerts a restoring force returning 
the cell to resting length (Helmes et al., 1996).  Titin may also be involved in the 
process of 'shortening deactivation' in which Ca2+ sensitivity is reduced at short SL by 
exerting a radial strain on the Z-disk increasing myofilament lattice spacing. 
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Figure 1.8 Regulation of crossbridge formation 
Schematic representation of myofilaments in diastole (top) and systole (bottom).  In the 
absence of Ca2+ tropomyosin inhibits crossbridge formation.  Ca2+ binding to TnC 
during systole causes a conformational change in the inhibitory TnI leading to 
movement of tropomyosin deeper into the actin helix and exposure of the thin filament 
to the actin binding site on myosin heads.  Energy stored from the hydrolysis of ATP in 
the myosin neck region is used to generate force or shortening.  Figure adapted from 
de Tombe (2003).  
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A•M A•M•ATP A•M•ADP•Pi A•M•ADP* A•M•ADP A•M
MM•ADPM•ADP*M•ADP•PiM•ATPM
ATP Pi ADP
ATP Pi ADP
Figure 1.9 Steps of the crossbridge cycle 
Model of the steps of the crossbridge cycle.  The main order of the cycle is indicated by thick black arrows, although each step is possible.  M, myosin; 
A, actin.  Figure redrawn from Bers (2003).  
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The aforementioned mechanisms of length-dependent activation responsible for the 
Frank-Starling mechanism have all been acute (within one activation cycle) effects, 
however a slow force response to stretch also occurs.  The Anrep effect is an increase 
in the force of contraction due to elevated afterload lasting more than a few minutes 
causing an increase in the end-systolic volume.  The effect is mediated by an increase 
in the systolic Ca2+ transient amplitude and can be blocked by inhibiting stretch-
activated channels permeable to Na+ and/or Ca2+ with streptomycin, inhibiting 
angiotensin and endothelin receptors, preventing Na+/H+ exchange across the 
sarcolemma, or by blocking NCX (Cingolani et al., 2003; Calaghan & White, 2004; 
Luers et al., 2005; Kockskämper et al., 2008).  Thus the slow force response seems to 
be due to intracellular accumulation of Ca2+ via reverse mode NCX and increased 
myofilament sensitivity, secondary to intracellular accumulation of Na+ via stretch-
activated channels and Na+/H+ exchanger. 
 
The mechanical properties of cardiomyocytes have primarily been elucidated through 
isometric or loaded contractions in chemically skinned cells and unloaded cell 
shortening, however neither of these can reproduce the forces experienced during the 
cardiac cycle.  Early attempts at stretching electrically-excitable cells were 
cumbersome or unreliable, for instance embedding cells in gel matrices, trapped 
between coverglass slides, or using suction micropipettes (Garnier, 1994).  A 
breakthrough came from the laboratory of Didier Garnier in the 1990s with the use of 
compliant carbon fibres which could stick to cell membranes by electrostatic forces and 
allowed the force of auxotonic contractions to be measured from the displacement of 
the fibre (Le Guennec et al., 1990; White et al., 1993). 
 
The first physiological workloop style contractions in isolated cardiomyocytes were 
conducted by Yasuda et al. (2001) and Nishimura et al. (2004) using feedforward 
control of a piezo motor to clamp carbon fibre bending either by stretching or 
shortening the cell, however these were limited by the relatively low force needed for 
the cell to detach (~ 5.7 µN).  This problem has been aided recently by the 
development of a biological glue consisting of extracellular matrix proteins, which 
enhances the attachment between cell and fibre allowing greater stretch and larger 
forces to be measured (Prosser et al., 2011).  Further recent advances include fast 
high resolution optical force transducers based on atomic force microscopy technology 
which are essentially isometric (Helmes et al.; Tasche et al., 1999). 
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1.4.5 Cytosolic Ca2+ removal 
The termination of ICa and cessation of Ca
2+ release from the SR starts the process of 
removal of Ca2+ from the cytosol and cell relaxation.  The primary Ca2+ removal 
pathways are SERCA and the sarcolemma NCX; the plasma membrane Ca2+ ATPase 
(PMCA) and mitochondrial Ca2+ uniporter also have a small contribution to Ca2+ 
removal.   
 
The SR is the intracellular Ca2+ store in myocytes and encircles the myofilaments 
occupying around 5% of total cell volume (Page et al., 1971).  The SR can be divided 
morphologically into a junctional region, which contains most of the CRU and a 
substantial amount of SERCA, and the longitudinal SR which also contains SERCA but 
minimal RYR2.  The junctional SR forms close connections with t-tubules and is the 
source of the vast majority of Ca2+ released during an action potential.  The SR is 
refilled by SERCA which hydrolyses one ATP molecule to power the pumping of two 
Ca2+ ions into the SR against an approximately 1000 fold concentration gradient (~100 
nM in cytosol, 100 µM in SR) (Vangheluwe et al., 2003).  Of all ATPases, SERCA 
requires the greatest free energy of ATP hydrolysis to function normally (Tian et al., 
1998).  Inside the SR calsequestrin chelates free Ca2+ greatly reducing the 
concentration gradient and free energy requirement of SERCA.  SERCA activity is 
controlled by its endogenous inhibitor phospholamban (PLB) which is incorporated into 
the SR membrane.  PLB binds to and inhibits SERCA when unphosphorylated but 
relieves its inhibition when phosphorylated at Ser16 by PKA or Thr17 by CaMKII 
(Mattiazzi et al., 2005).  SR Ca2+ release is highly dependent on SR content, therefore 
factors which increase SR content tend to increase the systolic Ca2+ transient and 
developed force (Shannon et al., 2000). 
 
NCX is the main Ca2+ efflux pathway and is distributed primarily in the t-tubules (Despa 
et al., 2003; Chase & Orchard, 2011; Bovo et al., 2014).  NCX in forward mode utilizes 
the electrochemical gradient to pump 1 Ca2+ ion out of the cell in exchange for 3 Na+ 
ions into the cell, thus slightly depolarizing the cell.  NCX is energetically less efficient 
than SERCA as only one Ca2+ ion is removed from the cytosol per ATP (indirectly via 
the Na+/K+ ATPase).  A fast heart rate or pacing rate in myocytes increases intracellular 
Na+ reducing forward-mode NCX and resulting in cytosolic accumulation of Ca2+ which 
is sequestered in the SR (Harrison & Boyett, 1995).  This increases total SR content 
and is primarily responsible for the positive force-frequency relationship in most 
mammals (Endoh, 2004).  NCX flux can also reverse depending on membrane 
  
35 
 
potential and the concentration of ions across the membrane, for instance a small 
amount of Ca2+ enters the cell via reverse-mode NCX during the early action potential, 
and NCX is responsible for the transient inward current generated by spontaneous 
Ca2+ release (Berlin et al., 1989; Grantham & Cannell, 1996).   
  
The PMCA is located exclusively in the t-tubules of cardiomyocytes and transports 1 
Ca2+ per ATP hydrolysed (Chase & Orchard, 2011).  It is slow and therefore contributes 
little to Ca2+ removal under normal circumstances.  It maximally removes Ca2+ from the 
cytosol by <1 µM/s, in comparison to SERCA (200 µM/s) and NCX (30 µM/s).  A small 
amount (~1%) of the systolic Ca2+ transient is also taken into the mitochondrial matrix 
through the Ca2+ uniporter on the MIM (Lu et al., 2013).  Mitochondrial Ca2+ is slowly 
released back into the cytosol via the mitochondrial NCX. 
 
The relative contribution of each pathway to Ca2+ removal in rat ventricular myocytes is 
around 90% SERCA, 7-9% NCX and <2% slow pathways, whereas in rabbit and 
humans the proportional contribution of NCX is greater (70% SERCA, 28% NCX and 
<2% slow pathways) (Negretti et al., 1993; Bassani et al., 1994).  This means species 
such as rabbit tend to deplete their SR stores when left unstimulated, whereas species 
with high SERCA activity such as mice and rats tend to accumulate SR Ca2+ at rest 
(Bassani & Bers, 1994; Bers et al., 1998; Hobai & O‘Rourke, 2001).  
 
1.4.6 Adrenergic system 
The β-adrenergic system is one of the main neural/hormone-regulated mechanisms 
through which the heart increases cardiac output during periods of demand, such as 
during exercise.  Noradenaline is released from sympathetic nerves which directly 
innervate the myocardium and adrenaline is released into circulation from the adrenal 
glands on the kidneys in response to decreased output from baroreceptors in the aortic 
arch and carotid arteries activated by stretch.  Agonist binding to β-adrenoceptors 
(βAR) on the cell membrane initiates a cascade of intracellular signalling events which 
mediate the chronotropic (increased heart rate), inotropic (increased force of 
contraction) and lusitropic (faster relaxation) response. 
 
βAR exist in an equilibrium between active (R*) and inactive (R) forms.  The presence 
of an agonist stabilizes the receptor in its active conformation increasing downstream 
signalling events, however even in the absence of agonist, intrinsic receptor activity 
contributes to a basal level of cAMP within cardiomyocytes.  This constitutive receptor 
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activity is important for maintaining a basal level of phosphorylation of key intracellular 
targets, including PLB and myofilament proteins such as MyBP-C and TnI, which are 
important for normal systolic and diastolic function (Gresham & Stelzer, 2015).  Neutral 
antagonists compete with agonists for binding thus preventing the stabilization of the 
receptor in its active conformation.  Reverse agonists possess a further ability to 
reduce the intrinsic activity of receptors by stabilizing them in the inactive R 
conformation  (Bond et al., 1995).  Metoprolol, but not carvedilol, exhibits reverse 
agonist properties and as such may be superior at preventing βAR desensitization by 
preventing receptor phosphorylation.  Some β-blockers such as carvedilol are also 
partial agonists, meaning they can stabilize the receptor in its R* conformation, but do 
so less well than a full agonist.  This property of carvedilol means it may actually 
contribute to receptor desensitization through recruitment of β-arrestins targeting the 
receptor for internalization (Wisler et al., 2007).  Likewise, carvedilol failed to increase 
or even decreased β1AR expression in ventricular samples from human heart failure, 
whereas chronic metoprolol treatment resulted in increased β1AR density, (Gilbert et 
al., 1996; Böhm et al., 1998).  Increased β1AR sensitivity is potentially dangerous if 
patient adherence to β-blockers is poor or if treatment is suddenly withdrawn as this 
can lead to a rebound hypersensitivity, as shown by increased heart rate, susceptibility 
to arrhythmias and angina (Ross et al., 1981; Morimoto et al., 1999). 
 
There are three isoforms (β1, β2 & β3) which are all members of the G-protein coupled 
receptor (GPCR) family.  The predominant cardiac isoform responsible for enhancing 
cardiac output and also the receptor most strongly implicated in adverse remodelling in 
heart failure is the β1AR (Bristow, 2000). 
 
1.4.6.1 β1-adrenoceptor signalling 
The β1AR shares with all GPCRs a conserved 7 transmembrane α-helical domain and 
an intracellular domain which binds heterotrimeric guanine-nucleotide binding 
regulatory proteins (G proteins) (Rockman et al., 2002).  Upon agonist binding the 
receptor undergoes a conformational change causing GDP bound to stimulatory Gαs to 
be replaced by GTP which dissociates the different G proteins into the subunits Gαs and 
Gβγ which bind to and regulate the activity of effector enzymes including adenylyl 
cyclase (AC).  Different isoforms of AC are expressed throughout the body, of which 
AC5 and AC6 are the predominant isoforms in cardiomyocytes (Vatner et al., 2013).  
Gαs binding causes dissociation of the AC regulatory subunit, increasing its enzymatic 
activity, and the production of the intracellular second messenger molecule cyclic AMP 
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(cAMP) from ATP.  β1AR stimulation leads to a cell-wide increase in cAMP which binds 
the regulatory subunit of protein kinase A (PKA) activating the enzyme to 
phosphorylate serine or threonine residues on proteins (Gorelik et al., 2013).  
Phosphorylation of proteins is an important post-translational regulatory modification 
allowing fine control over cell function in seconds.  β1AR stimulation in sinoatrial node 
cells leads to phosphorylation of Ca2+ cycling and membrane channels increasing the 
firing frequency of the cells, therefore increasing heart rate (Lakatta et al., 2010; Liao et 
al., 2010).  The archetypal inotropic effect of PKA activation in ventricular myocytes is 
mediated through phosphorylation of the L-type Ca2+ channel at Ser1928 and Ser1700 
(Lemke et al., 2008; Fuller et al., 2010), RYR2 at Ser2808 and Ser2030 (Xiao et al., 2006), 
and PLB at Ser16 (Sande et al., 2002), which increases Ca2+ entry to the cell and 
uptake into the SR thus increasing the systolic Ca2+ transient amplitude and contraction 
(Weiss et al., 2013).  Phosphorylation of TnI reduces the affinity of TnC for Ca2+ which 
decreases myofilament sensitivity, which combined with faster Ca2+ removal via 
SERCA causes the cell to relax more quickly (Kentish et al., 2001). 
 
Compartmentation of cAMP means PKA preferentially targets proteins within a 
signalling domain thus preventing phosphorylation of every possible target every time 
β1AR are activated.  This is achieved in part through co-localization of AC and PKA to 
their targets via scaffolding proteins and by degradation of cAMP by 
phosphodiesterases (PDEs) (Steinberg & Brunton, 2001).  PKA can bind to scaffolding 
proteins such as A kinase anchoring protein (AKAP) and caveolin-3 which also bind 
other proteins such as the L-type Ca2+ channel, allowing preferential phosphorylation of 
these targets (Bryant et al., 2014).  In cardiac myocytes the major constituent PDE 
isoforms are PDE3 and PDE4 whereas in vascular smooth muscle cells PDE5 is the 
major isoform (Omori & Kotera, 2007).  PDEs are expressed in discrete subcellular 
locations, for instance in lipid rafts in the cell membrane and bound to the cytoskeleton 
in the cytosol, limiting the spread of the cAMP signal.   
 
1.4.6.2 β2-adrenoceptors 
β2AR are expressed at a much lower level than β1AR in the myocardium with a relative 
ratio of approximately 20:80 in rat and human (Bristow, 2000; Leineweber et al., 2003).  
β2AR are three times more prevalent in the vasculature and bronchioles than β1AR and 
mediate smooth muscle cell relaxation (O'Donnell & Wanstall, 1981).  In 
cardiomyocytes under resting conditions β2AR are located predominantly in t-tubules 
where they are targeted to caveolae through association with caveolin-3, whereas 
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β1AR are distributed evenly throughout the sarcolemma (Rybin et al., 2000; Nikolaev et 
al., 2010).  β2AR stimulation normally has little lusitropic effect on cardiomyocytes as 
the cAMP signal is highly localized to the t-tubule.  This is sufficient to promote L-type 
Ca2+ channel phosphorylation which increases the amplitude of the Ca2+ transient 
(Kuschel et al., 1999).  Uncoupling β2AR from the t-tubules by disrupting caveolae with 
the cholesterol-scavenging methyl-β-cyclodextrin switches the cAMP response from a 
local to a global signal similar to β1 stimulation (MacDougall et al., 2012). 
 
As well as Gαs, β2AR can also couple to the inhibitory Gαi protein following 
phosphorylation by PKA or GRK2 at high concentrations of agonist which activates 
protein phosphatase 1 and inhibits PKA thus limiting the global response to adrenergic 
stimulation (Liu et al., 2009).  This endows β2AR with cardioprotective properties 
against apoptosis during catecholamine stimulation (Communal et al., 1999). 
 
1.4.6.3 β3-adrenoceptors 
The β3AR is expressed at low levels in human heart, it is thought to mediate a negative 
inotropic response to catecholamine stimulation associated with nitric oxide (NO) 
production coupled to Gαi activation (Gauthier et al., 1996; Gauthier et al., 1998).  This 
is mediated by protein kinase G phosphorylation of L-type Ca2+ channel (Méry et al., 
1991; Schröder et al., 2003), TnI (Shah et al., 1994), and activation of PDE2 which 
enhances cAMP degradation (Méry et al., 1993). 
 
1.4.6.4 α-adrenoceptors 
α1 receptors are also present in cardiomyocytes, however the proportion of αAR is only 
around 10% that of βAR in humans and rodents (Rockman et al., 2002).  The primary 
isoforms expressed in ventricular myocytes are α1A and α1B which couple with Gαq.  
Unusually and in contrast to βAR, up to 80% of α1AR are expressed on the nuclear 
membrane (Wright et al., 2008).  Their activation leads to diacyl glycerol and IP3 
release which in conjunction with Ca2+ activates protein kinase C (PKC) to 
phosphorylate targets such as the myosin light chain which increases Ca2+ sensitivity 
(Andersen et al., 2002).  α1AR are also expressed in the pulmonary vasculature where 
they mediate vasconstriction via PKC mediated Ca2+ entry to smooth muscle cells, 
however this is normally antagonized by activation of β1 and β2 receptors which 
increase levels of cAMP and Ca2+ uptake into the SR. 
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PKC is a potent stimulus for hypertrophy and therefore α1ARs are generally considered 
to contribute to pathological remodelling in heart failure, however there is evidence 
α1AR activation may actually be cardioprotective in heart failure.  Clinical trials of α1AR 
blockers to treat hypertension have been stopped early due to a doubling of the risk of 
mortality, possibly due to preventing the inotropic effects of α1AR activation (Furberg et 
al., 2001).  There is substantial heterogeneity in the response to α1AR stimulation 
between cells from different regions of a ventricle, or between RV and LV cells, with 
some showing a positive and others a negative inotropic response.  Healthy mouse RV 
cells tend to exhibit a negative response compared to LV cells (68 vs 36%) which is 
mediated by Ca2+ handling alterations (Chu et al., 2013).  Interestingly, this overall 
negative response of RV cells was switched to a positive response in a mouse model 
of RV failure, suggesting α1AR may play different roles in health and disease (Cowley 
et al., 2015). 
 
1.4.6.5 Autoinhibition and desensitization 
β-AR undergo desensitization which reduces receptor activity temporarily, or can cause 
internalization of the receptor and degradation reducing the responsiveness to future 
stimulation.  Non-agonist specific desensitization occurs within seconds and results 
from phosphorylation of β-AR by PKA (Gardner et al., 2004).  When receptors are 
occupied with agonists a further process of homologous desensitization can occur 
through phosphorylation by G-protein coupled receptor kinases (GRKs).  There are 6 
members of the GRK family, of which GRK2 is most highly expressed in the 
myocardium (Sato et al., 2015).  Phosphorylation by GRKs increases the affinity of β-
AR to binding by β-arrestin proteins which uncouple the receptor from its G-proteins 
and thus prevent signalling.  β-arrestins also act as scaffolds for further proteins such 
as clathrin which target the receptor for endocytosis (Zhang et al., 1997).  Internalized 
receptors either undergo dephosphorylation in the acidic vesicles to be recycled to the 
surface membrane or are degraded (Marchese & Trejo, 2013).  Long term 
desensitization occurs through decreased transcription or degradation of β-AR mRNA 
and increased degradation of internalized receptors. 
 
1.5 Heart failure 
1.5.1 Structural remodelling 
Cardiomyocytes are terminally differentiated cells which cannot proliferate in adulthood 
and therefore must adapt to the increased mechanical stress of heart failure by 
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remodelling their geometry to maintain ventriculo-arterial coupling.  Loading conditions 
are partly responsible for orchestrating the remodelling process by promoting 
lengthening or widening the cells depending on whether the ventricle is pressure or 
volume overloaded (Tamura et al., 1998).  Pressure overload is thought to increase 
myocyte cross-sectional area which helps normalize systolic wall stress, whereas 
volume overload leads to myocyte elongation which initially maintains stroke volume; 
however remodelling cannot continue indefinitely and if the underlying pathology is not 
extirpated pump failure will eventually result (Grossman et al., 1975; Gerdes & 
Capasso, 1995).  For instance,  in spontaneously hypertensive rats at 5 months of age 
cardiomyocyte volume increases primarily due to increased cross sectional area, 
however during the transition to dilated systolic heart failure over 12-24 months 
myocyte growth is primarily driven by the addition of sarcomeres in series (Gerdes et 
al., 1996; McCrossan et al., 2004).  Similar patterns of remodelling also occur in 
myocardial infarction and dilated cardiomyopathies (Gerdes et al., 1992; Tamura et al., 
1998).  Catecholamines are also a potent stimulus for hypertrophy as overexpressing 
β1AR in mice or continually infusing isoprenaline into rats leads to concentric LV 
hypertrophy (Engelhardt et al., 1999; McMartin & Summers, 1999).  Similarly the 
hypertrophy associated with chronic β-AR activation in heart failure can be ameliorated 
with β-blockers (Bogaard et al., 2010), or reduced by knocking out β1 and β2AR 
(Kiriazis et al., 2008). 
 
As the heart undergoes hypertrophy the diffusion distance between the cores of muscle 
fibres and capillaries increases.  This could lead to a mismatch between O2 supply and 
demand and the development of hypoxic and inexcitable regions of myocardium unable 
to contribute to contraction.  Cardiomyocyte hypertrophy without an increase in 
capillary angiogenesis will reduced the capillary density (CD) of a tissue and thus 
increase the area supplied by each capillary.  An excellent example of this was 
reported by Roberts and Wearn (1941) who showed CD decreased in hypertrophied LV 
from donated human hearts.  In the early compensated stages of heart failure CD may 
be preserved by an increase in capillary number through angiogenesis in response to 
signalling factors such as VEGF and HIF-1α produced by hypoxic tissue (Shipley et al., 
1937; Sano et al., 2007; Sutendra et al., 2013), however in decompensated RV failure 
VEGF expression decreases which may result in capillary rarefaction (Kobayashi et al., 
1994; Bogaard et al., 2010).  The resultant tissue hypoxia is thought to promote 
apoptosis which has been reported in the failing RV in the rat monocrotaline (MCT) 
model of PAH (Campian et al., 2009).  The primary enzyme responsible for proteolysis 
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in apoptosis is caspase-3 which is produced as a 37 kDa full length protein and 
undergoes cleavage into the 17-19 kDa active ‗executioner‘ isoenzyme by caspase 9 
(Nicholson et al., 1995), and both caspase 3 and 9 are increased in the failing RV of rat 
PAH (Mouchaers et al., 2009; Okumura et al., 2015).  If apoptosis occurs the entire 
stress of contraction is distributed between fewer cardiomyocytes which respond by 
increasing cross-sectional area thus fuelling the viscous cycle.  Myocardial fibrosis 
replaces lost cardiomyocytes and maintains the structural integrity of the heart 
(Cingolani et al., 2004), however excessive fibrosis is frequently reported in failing 
human RV and LV (Chaturvedi et al., 2010; Rain et al., 2013) and in animal models of 
RV failure (Mouchaers et al., 2009) which may impair pump function by reducing 
diastolic filling.  Collagen also decreases the diffusion of O2 in the interstitial space and 
thus may reduce oxygenation of muscle fibres (Sabbah et al., 1995). 
 
1.5.2 Metabolic derangement 
Failing human and animal hearts have reduced PCr/ATP ratio which is associated with 
worse prognosis leading to the suggestion the heart is energy starved (Neubauer et al., 
1997; Ingwall & Weiss, 2004; Bottomley et al., 2013).  Mitochondrial mass has been 
found to increase during the early compensated phase of LV failure in rat (Kindo et al., 
2012) but then return to normal or decrease at more advanced stages of disease (De 
Sousa et al., 2002), whereas in failing human hearts mitochondrial mass is usually 
preserved (Rosca et al., 2008; Stride et al., 2013) although occasionally small 
reductions have been reported (Lemieux et al., 2011a).  Reduced expression of the 
master activator of mitochondrial protein synthesis, PGC-1α, may be responsible as 
this was shown to decrease in rat LV and RV failure coinciding with reduced 
mitochondrial mass and CK-mt expression (Garnier et al., 2003; Enache et al., 2013).  
Maximal respiration is often decreased in animal models of LV failure (De Sousa et al., 
2002; Kindo et al., 2012) and was found to progressively decrease over time in RV 
failure (Daicho et al., 2009).  This finding has also been reported in failing human 
myocardium in some (Sharov et al., 2000; Lemieux et al., 2011a; Stride et al., 2013) 
but not all studies (Cordero-Reyes et al. (2014).  The source of dysfunction is often 
attributed to decreased Complex I driven respiration, possibly due to decreased 
expression of Complex I proteins (Stride et al., 2013), however this could also be due 
to damage to Complex I in the absence of altered expression (Kuznetsov et al., 2004).  
Some studies have also reported decreased Complex II activity in human LV failure 
(Stride et al., 2013) or even increased activity in RV failure in rats (Redout et al., 2007).  
Decreased Complex I could result in a functional block the ETS leading to increased 
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ROS production (Ide et al., 1999).  Overexpression of CK-M in mice with transverse 
aortic constriction improves survival and function (Gupta et al., 2012) and the 
contractility of the myocardium following ischaemia (Akki et al., 2012) whereas absence 
of a functioning CK system greatly reduces the ability of rats to survive myocardial 
infarction (93% mortality vs 46% mortality with a functioning CK system) (Lorentzon et 
al., 2007).  
 
A shift from primarily fatty acid oxidation in health towards a greater reliance on 
glucose utilization also occurs in human and experimental models of heart failure and 
PAH (Oikawa et al., 2005; Piao et al., 2010).  Carbohydrate oxidation yields more ATP 
per mole O2 suggesting substrate use by mitochondria may adapt to optimize the 
efficiency of ATP production.  Increased glycolysis and glycolytic enzyme expression is 
also frequently reported in failing hearts which may indicate the mitochondria are 
hypoxic (Champion et al., 2009; Balestra et al., 2015). 
 
1.5.3 β-adrenergic signalling 
Chronic reliance on the β adrenergic system to augment contractility in LV failure leads 
to desensitization of β1-ARs in part due to receptor phosphorylation by PKA and GRK2 
(recently reviewed by Sato et al. (2015)) and also due to increased GRK2 and β-
arrestin expression which promotes receptor internalisation and degradation (Luttrell & 
Lefkowitz, 2002).  Reduced β1AR mRNA and protein have been reported in the RV of 
human and animal models of PAH along with reduced stimulatory Gαs subunit and 
adenylyl cyclase expression (Seyfarth et al., 2000; Piao et al., 2012).  Loss of 
constitutive βAR activity may impair normal contractile function by causing 
hypophosphorylation of, for instance, Ca2+ handling proteins.  Furthermore, these 
changes in βAR signalling will blunt the responsiveness to catecholamines and reduce 
the contractile reserve of the myocardium when challenged by an acute stress, for 
instance exercise.  This loss of βAR-mediated inotropy was found in human failing RV 
and LV muscle samples and trabeculae and in RV muscle samples from animals 
models of PAH in response to isoprenaline (Holubarsch et al., 1996; Quaile et al., 
2007; Milani-Nejad et al., 2015).  This may explain the apparent paradox between the 
detrimental effects of chronic β-adrenergic activation and the beneficial effects of β-
blockers which could increase β-AR signalling by preserving β1AR density, i.e., by 
preventing chronic excessive cAMP production βAR density and sensitivity is 
preserved, thus maintaining a basal level of cAMP for normal cell function while 
ensuring a dynamic response range is available during acute periods of high demand.   
  
43 
 
 
Hypophosphorylation of TnI increases myofilament Ca2+ sensitivity and impairs 
diastolic relaxation and has been reported in rat RV failure (Lamberts et al., 2007a; de 
Man et al., 2011).  However other studies have instead found Ca2+ sensitivity 
decreases in skinned RV cells from rat PAH induced by pulmonary artery banding (Fan 
et al., 1997) or remains the same in MCT (Benoist et al., 2014) and in human PAH 
compared to donor hearts (Rain et al., 2013).  Differences in disease severity or 
sample preparation may account for these discrepancies. 
 
Slower Ca2+ uptake into the SR has been reported in failing MCT RV cells which may 
be due to decreased expression of SERCA and reduced phosphorylation of PLB at 
Ser16 (Xie et al., 2012; Benoist et al., 2014), as Reilly et al. (2001) found transfecting 
failing cells with adenoviral constructs of SERCA2a restored the rate of Ca2+ uptake.  
Decreased SR content has been reported in human LV failure (Pieske et al., 1999) and 
also in MCT RV cells and PAB feline models of PAH which would be expected to 
decrease the Ca2+ transient amplitude (Quaile et al., 2007; Xie et al., 2012).  The Ca2+ 
transient amplitude has also been found elevated during the development of RV and 
LV failure suggesting Ca2+ handling changes during the natural progression of disease 
(Mørk et al., 2007; Benoist et al., 2012). 
 
In mammals, a heart-rate dependent increase in contractility is one of the mechanisms 
which ensures adequate delivery of blood to the body during periods of increased 
metabolic demand.  In healthy rat ventricular myocytes the relationship between twitch 
force and contraction rate is triphasic: initially large at low pacing frequencies 0.2-1 Hz 
due to diastolic Ca2+ loading of the SR, then lower around 1-2 Hz, then increasing up to 
7 Hz, before decreasing beyond 7 Hz  (Kassiri et al., 2000).  This overall positive 
response to pacing can switch to a negative force-frequency in human LV failure 
(Holubarsch et al., 1996; Brixius et al., 2001) and animal models of RV failure 
secondary to PAH (Lamberts et al., 2007a; Quaile et al., 2007).  This is likely due to 
detrimental alterations in Ca2+ handling which impair systolic Ca2+ release.  Reduced 
SERCA activity could impair Ca2+ reuptake and deplete the SR in a rate-dependent 
manner which would both reduce the amplitude of the systolic contraction and lead to 
accumulation of diastolic Ca2+ which would impair diastolic relaxation.  Increased 
refractoriness of RYR2 Ca2+ release could reduce the amplitude of the systolic Ca2+ 
transient at faster pacing despite maintained SR Ca2+ content due to 
hypophosphorylation of RYR2 (Maier et al., 2000; Poláková et al., 2015).   
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A progressive loss of t-tubules occurs in ventricular myocytes during the transition from 
compensated hypertrophy to decompensated heart failure which strongly correlates 
with deterioration of cardiac function (Wei et al., 2010).  Expression of the t-tubule 
scaffolding proteins JP2 and BIN-1 are notably decreased in advanced experimental 
RV failure (Wei et al., 2010; Xie et al., 2012) and human LV failure (Hong et al., 2012).  
This results in a slowing of Ca2+ release in MCT RV cells and a loss of spatial 
synchrony in LV cells from chronically ischaemic pig myocardium (Heinzel et al., 2008; 
Xie et al., 2012), which would delay and reduce the force of contraction (Ferrantini et 
al., 2014).  A slight reduction in Ca2+ release synchrony was seen in human LV 
cardiomyocytes from chronic ischaemia, although there was relatively little t-tubule 
disruption observed in this study possibly due to humans having a less dense t-tubule 
network compared to rats and mice (Louch et al., 2004).  Cav 1.2 expression and ICa 
density are usually not changed in heart failure as might be expected given the loss of 
t-tubules (Lee et al., 1997), suggesting there may be redistribution of channels from t-
tubules to the surface sarcolemma or enhanced activity of existing channels, as was 
recently reported in a rat model of myocardial infarction (Bryant et al., 2015).  JP2 and 
BIN-1 act as scaffolding proteins for Cav 1.2 therefore their loss during heart failure may 
influence the redistribution of ICa from the t-tubules to the surface sarcolemma (Hong et 
al., 2010; Bennett et al., 2015). 
 
The most consistent electrophysiological finding in failing hearts is a prolongation of the 
action potential at low pacing rates (Janse, 2004), however in failing human, rabbit and 
rat myocardium a decrease in the cycle length leads to a sharp fall in AP duration 
(Vermeulen et al., 1994; Benoist et al., 2012).  This steep AP duration restitution may 
be a trigger for the initiation of alternating long and short APs which can degenerate 
into ventricular fibrillation (Rosenbaum et al., 1994).  Reduced Ito is thought to play a 
major role in delaying repolarization in failing RV cells from MCT rats and may be due 
to reduced mRNA expression of the subunits which compose the channel (Benoist et 
al., 2011).  The role of Ito in humans and other large mammals may be less important 
due to the longer Phase 2 (Kääb et al., 1996), however reduced Ito could slow 
repolarization during Phase 1 and thereby reduce ICa and thus the amplitude of the 
Ca2+ transient (Tomaselli & Marbán, 1999; Workman et al., 2003).  Reduced IK1 in 
failing hearts may also destabilize the resting membrane potential and make failing 
hearts more prone to delayed after depolarizations by transient inward currents 
generated by NCX (Kääb et al., 1996; Benoist et al., 2011). 
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Increased diastolic SR Ca2+ leak in the form of sparks and waves is thought to trigger 
arrhythmias in heart failure.  Ca2+ waves propagate through pairs of isolated cells 
(Eisner et al., 2012), in trabeculae (Miura et al., 1993) and in Langendorff-perfused rat 
hearts (Minamikawa et al., 1997; Kaneko et al., 2000) and have been shown to trigger 
ectopic APs (Fujiwara et al., 2008) and could contribute to the emergence of sustained 
ventricular fibrillation following burst pacing (Benoist et al., 2011).  Likely causes of 
increased Ca2+ leak in heart failure include increased SR content, phosphorylation and 
oxidation of RYR2, and dissociation of FKBP12.6 from RyR2.  The emphasis placed on 
each of these mechanisms seems to vary depending on the laboratory and some 
results are conflicting.  RYR2 has been found to be hyperphosphorylated by PKA and 
CaMKII in human failing hearts, possibly due to decreased RYR2-bound protein 
phosphatase 1 and 2 or increased β-AR activation.  This caused dissociation of 
FKBP12.6 which could destabilize RYR2 (Marx et al., 2000; Respress et al., 2012).  
However PKA phosphorylation does not necessarily lead to FKBP12.6 dissociation 
(Xiao et al., 2004), and FKBP12.6 dissociation is not always required for increased 
Ca2+ leak (Eschenhagen, 2010).  Disulphide formation between thiol residues in RYR2 
was reported to increase leak in cardiomyocytes isolated from a canine tachypacing 
model, which was reversed following acute incubation of cells with a reducing agent, 
indicating ROS-induced leak from the SR may further impair diastolic Ca2+ handling 
(Terentyev et al., 2008). 
 
1.6 Pulmonary arterial hypertension 
1.6.1 Epidemiology 
Pulmonary hypertension is a condition in which the normally low pressure, high 
compliance pulmonary circulation becomes increasingly resistant to blood flow 
requiring higher pulmonary artery systolic pressures to maintain adequate perfusion of 
the lungs.  The clinical definition of pulmonary hypertension is a resting mean PA 
pressure ≥25 mmHg, compared to the normal range of 11-17 mmHg (Galiè et al., 
2015b).  The clinical manifestation of PAH consists primarily of exercise intolerance, 
dyspnoea and systemic congestion due to raised right atrial filling pressure (Vonk-
Noordegraaf et al., 2013).  Patients with pulmonary hypertension are currently 
classified into one of 5 groups depending the apparent etiology of disease: 1) idiopathic 
pulmonary arterial hypertension (PAH) 2) pulmonary hypertension secondary to left 
heart failure 3) pulmonary hypertension secondary to lung disease 4) pulmonary 
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hypertension due to chronic thromboembolism 5) pulmonary hypertension due to 
undefined or multifarious reasons (Simonneau et al., 2009).  
 
Group 2 pulmonary hypertension is the most common form as nearly all patients with 
LV failure will have some degree of pulmonary hypertension, defined as a mean PA 
pressure ≥25 mmHg with a pulmonary capillary wedge pressure (PCWP) >15 mmHg 
(an indicator of increased left atrial pressure) (Guazzi & Borlaug, 2012; Hoeper et al., 
2013).  The raised PCWP is what separates Group 2 from Group 1, as in PAH patients 
the left atrial pressure is normal but the precapillary arterial pressure is elevated.  
Group 3 PAH includes patients with connective tissue disease such as scleroderma as 
well as chronic obstructive pulmonary disease (COPD).  In these patients alveolar 
hypoxia is detected by the pulmonary vasculature which constricts to divert blood to 
better ventilated regions of the lung.  Ascent to altitude also causes pulmonary 
hypertension through the same mechanism although this is transient and reverses 
upon returning to lower altitudes.   
 
Group 1 consists of patients with pulmonary arterial hypertension (PAH) (formerly 
called primary or idiopathic PAH).  This is a relatively rare condition affecting between 5 
and 50 people per 1 million adults (Humbert et al., 2010; Ling et al., 2012), in 
comparison the annual incidence of LV failure is around 1400-2300 per 1 million adults 
(McKee et al., 1971).  PAH affects more women than men, with estimates ranging 
between 1.7 and 4.1 females affected per male (Humbert et al., 2010; Ling et al., 
2012).  This may be due to prevalent cases of PAH as women survive with the 
condition for significantly longer than men; in the UK, females make up 70% of incident 
cases of PAH (Jacobs et al., 2014).  Survival in PAH is extremely poor and left 
untreated the 1, 3 and 5 year survival in patients is 68%, 48% and 34%, respectively 
(D'Alonzo et al., 1991).  This is worse than the survival of patients with prevalent LV 
failure found in the Framingham study (79%, 55%, 38% at 1, 3, 5 years) (McKee et al., 
1971).  Treatment with the most effective current PAH therapies modestly improves 
survival to 83% and 58% at 1 and 3 years respectively (Humbert et al., 2010). 
 
1.6.2 Vascular remodelling in pulmonary arterial hypertension 
Narrowing of the pulmonary arterioles due to vasoconstriction, hypertrophy and 
proliferation of smooth muscle cells increases pulmonary vascular resistance over time 
(Humbert et al., 2004; Haddad et al., 2008a).  Excessive smooth muscle cell 
remodelling can eventually lead to fully muscularized vessels in which flow is 
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completely obstructed.  Disorganized proliferation of monoclonal populations of 
endothelial cells creates plexiform lesions in patients with severe PAH (Stacher et al., 
2012) and occurs in some preclinical hypoxic models of PAH (Gomez-Arroyo et al., 
2011).  Plexiform lesions seem to precede concentric luminal obliteration and while 
their direct haemodynamic effect is not known their presence may reflect a serious 
underlying fault in the endothelium.  The causes of this can be multifactorial and can 
arise from one or a combination of genetic, neurohormonal, inflammatory, and acquired 
alterations to the pulmonary arterioles (Humbert et al., 2004). 
 
Vasoconstriction is thought to influence the early stages of PAH and has been related 
to impaired production of vasodilators such as nitric oxide (NO) and prostacyclin.  NO 
is produced in endothelial cells from L-arginine via the action of endothelial NO 
synthase (eNOS).  Activation of soluble guanylyl cyclase (sGC) by NO results in the 
production of cGMP from GTP which activates PKG resulting in downstream 
phosphorylation of Ca2+ handling proteins which decrease cytosolic Ca2+.  NO 
mediated vasodilation is reduced in pulmonary arteries of PAH patients due to 
decreased expression and activity of NO synthase, increased cGMP degradation by 
PDE5, and increased ROS which degrades NO reducing its bioavailability (Giaid & 
Saleh, 1995; Friebe & Koesling, 2003; Landmesser et al., 2003). 
 
The prostacyclin pathway is another potent stimulus for vasodilation of the pulmonary 
and systemic vasculature.  Prostacyclin is primarily produced in vascular endothelial 
cells from arachidonic acid by the enzyme cyclooxygenase (Brock et al., 1999).  Upon 
release from endothelial cells it binds to prostacyclin receptors which are a type of 
GPCR on vascular smooth muscle cells resulting in the activation of PKA and 
increased Ca2+ removal from the cytosol.  Expression of prostacyclin synthase is 
reduced in the endothelial cells of PAH patients which coincides with reduced 
circulating levels of prostacyclin metabolites (Humbert et al., 2004). 
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Figure 1.10 Progression of PAH and RV failure 
The healthy RV pumps blood into compliant pulmonary arteries at low pressure.  
Dysfunctional pulmonary arteries are stiffer with a narrower lumen which increases 
resistance to blood flow.  This is compensated for by RV hypertrophy to maintain 
cardiac output with raised systolic pressures.  The RV eventually fails to cope with the 
worsening resistance and dilates into a low cardiac output state.  Figure adapted from 
Champion et al. (2009). 
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Concomitant with reduced vasodilation is a rise in vasoactive peptides which induce 
constriction such as endothelin-1 (ET-1).  ET-1 is a peptide produced by the vascular 
endothelium in response to diverse stimuli including angiotensin II, ROS and shear 
stress.  ET-1 release from endothelial cells in the proximity of vascular smooth muscle 
cells binds to ETA or ETB receptors coupled to Gαq causing PKC activation and Ca
2+ 
release from the SR (Wagner-Mann & Sturek, 1991).  ET-1 and its receptors are 
upregulated in the vasculature of the MCT rat model and human PAH (Price et al., 
2012). 
 
High circulating levels of noradrenaline have been reported in PAH patients which 
could initiate remodelling in the pulmonary vasculature through activation of α1AR 
causing vasoconstriction and hypertrophy of smooth muscle cells through PKC.  This is 
normally antagonized by β1 and β2AR however chronic activation of βAR leads to 
receptor internalization and downregulation (Faber et al., 2006a).  Mutations in the 
bone morphogenetic protein receptor 2 (BMPR2) gene which causes a truncation in the 
protein have been identified in 10-30% of patients with idiopathic PAH (Deng et al., 
2000), and BMPR2 protein is also decreased in PAH patients without mutations 
(Atkinson et al., 2002).  BMPs are part of the transforming growth factor-β1 family of 
proteins and inhibit pulmonary artery derived smooth muscle cell proliferation, therefore 
reduced signalling through this pathway could contribute to the concentric obliteration 
of arterioles (Yang et al., 2005).   
 
1.6.3 Right ventricle failure 
Most research on remodelling in heart failure has been conducted in the LV and while 
there are certainly correlates with RV failure a direct extrapolation cannot be assumed 
due to the different normal physiology of the two chambers as well as the distinct 
embryological origin of the constituent cells (Haddad et al., 2008b).  A 2006 report from 
the US National Heart, Lung and Blood Institute recognized that experiments 
specifically on the failing RV were needed (Voelkel et al., 2006).  The thin-walled and 
highly compliant RV which supplies the pulmonary circulation responds poorly to 
increased afterload and SV suffers as a consequence (Abel & Waldhaus, 1967).  The 
response of the RV to chronically elevated afterload is to undergo a complex process 
of structural, excitation-contraction coupling, and metabolic remodelling which are 
initially compensatory but ultimately become pathological (Figure 1.10).  These 
changes are promoted partly through mechanical stresses experienced by 
cardiomyocytes but also through increasing reliance on catecholamines to provide the 
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inotropic support needed to maintain ventriculo-arterial coupling (Handoko et al., 2010; 
Naeije & Manes, 2014). 
 
It was initially thought the RV was merely a passive receptacle of blood as the heart 
can function normally for a short time without a working RV when unstressed (Starr et 
al., 1943), however RV function becomes critical when load is increased (Lowensohn 
et al., 1976).  Accordingly, RV failure is the leading cause of death in PAH patients 
(Delcroix & Naeije, 2010), and is also a key determinant of survival in LV failure 
(Kjaergaard et al., 2007; Szwejkowski et al., 2012; Ghio et al., 2013).  For instance, 
increased RV end-diastolic diameter and decreased ejection fraction measured using 
echocardiography are associated with significantly worse survival in patients with PAH 
and chronic LV failure (Ghio et al., 2010; Ghio et al., 2011; Ghio et al., 2013).  Similarly, 
Rain et al. (2013) found that in PAH patients decreased RV diastolic compliance was 
closely associated with markers of disease severity (exercise capacity and stroke 
volume) which are associated with worse survival (van de Veerdonk et al., 2011).  
Therefore there is great interest in identifying the cellular causes of RV dysfunction and 
failure and possible therapies which prevent or reverse these changes. 
 
1.7 Therapies for pulmonary arterial hypertension 
There is currently no cure for PAH except a lung or heart-lung transplant which 
immediately lowers vascular resistance removing the excess load on the heart and 
allows RV structure and function to return to normal (Katz et al., 1996; Perrin et al., 
2015).  This is clearly not an option in most patients due to scarcity of donor organs 
and recipient compatibility, therefore most patients receive one or a combination of 
drugs which target the vasculature and aim to improve vasodilation and reduce the 
afterload on the RV (Figure 1.11) (Perrin et al., 2015).  Currently approved specific 
therapies include prostanoids, endothelin (ET) receptor antagonists and 
phosphodiesterase-5 (PDE-5) inhibitors which target three separate pathways to 
induce vasodilation or prevent vasoconstriction.  Treatment with any one of these 
therapies reduces the risk of mortality by around 40%, but there is little difference in 
efficacy between treatments (Galiè et al., 2009), and combination therapy with two or 
all three treatments does not consistently improve morbidity or mortality beyond that 
achieved by monotherapy (Ghofrani et al., 2003; McLaughlin et al., 2014; Sitbon et al., 
2014).  Patients who respond positively to treatment and show decreased vascular 
resistance may still deteriorate and RV function seems to be a more important 
determinant of outcome (van de Veerdonk et al., 2011).  New drugs have come on the 
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market in recent years however these have all been refinements of existing drugs 
which act on the same three pathways; with this in mind it is clear more therapeutic 
options are needed if progress is to be made in the treatment of PAH patients.  The 
clear prognostic relevance of RV function and lack of therapies which target the RV in 
PAH has led to calls for further research into therapies which target the failing RV 
(Naeije, 2010); β-blockers in particular have garnered interest due to their beneficial 
effect in slowing maladaptive remodelling and reducing mortality in LV failure (Handoko 
et al., 2010; Andersen et al., 2015). 
 
1.7.1 General therapies 
Ca2+ channel blockers reduce the entry of Ca2+ into smooth muscle cells in the 
pulmonary arterioles causing vasodilation.  Some studies have found the Ca2+ channel 
blockers diltiazem and nifedipine improve function in a subset of patients who are 
responsive to other vasodilating therapies (Sitbon et al., 2005; Montani et al., 2010), 
however no long term randomized controlled trials have demonstrated a survival 
benefit to Ca2+ channel blockers and bradycardia and systemic hypotension can occur 
as side effects.  Anti-coagulants may be prescribed due to the increased risk of thrombi 
forming in inactive patients, particularly those receiving prostacyclins via an indwelling 
cannula.  Diuretics may relieve some symptoms of systemic congestion and peripheral 
oedema, however large studies have not consistently found a survival benefit resulting 
from such therapy.  No large scale randomized controlled trials have investigated the 
effect of exercise in PAH, unlike LV failure where moderate or intense exercise is safe 
and actively encouraged (Rognmo et al., 2012).  Small studies have found 
improvements in fatigue severity in PAH patients undergoing 10 weeks of low intensity 
exercise (Weinstein et al., 2013) and a recent preclinical study found improved survival 
in MCT rats given access to running wheels (Natali et al., 2015), and exercise has 
recently become encouraged within symptom limits (Galiè et al., 2015b). 
 
1.7.2 Prostacyclin analogues 
Prostacyclin analogues bind directly to prostacyclin receptors initiating vasodilation of 
the pulmonary and systemic vascular beds.  Intravenous infusion of epoprostenol, a 
synthetic mimetic of prostacylin, was shown to lower pulmonary arterial pressure in 
patients with PAH in a randomized control trial over 18 months (Rubin et al., 1990), and 
became the first FDA-approved therapy for PAH in 1995.  Tachyphylaxis is reported to
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Figure 1.11 Vasodilating therapies in PAH 
Drugs targeting the endothelin, nitric oxide and prostacyclin pathways are the only 
treatments shown to improve survival in human PAH.  Figure from Humbert et al. 
(2014) 
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occur with epoprostenol due to internalization of the prostacyclin receptor, requiring up-
titration of dose, however this may also reflect clinical worsening of PAH.  Prostacyclins 
have a short half-life of 3-5 min and therefore require continual intravenous infusion via 
an indwelling cannula which carries the risk of catheter-related sepsis.  For these 
reasons long-term intravenous prostacyclin therapy is usually not possible.  The most 
recently available drug for PAH is selexipag, approved by the FDA in 2015, and is the 
first effective oral prostacyclin analogue.  In a Phase III clinical trial selexipag reduced 
mortality in PAH patients receiving either ET antagonist or PDE-5 inhibitors by 40% 
(McLaughlin et al., 2015). 
  
1.7.3 Endothelin antagonists 
The ET receptor anatagonist bosentan (non-selective ETA and ETB) was approved for 
use in PAH in 2001 and later ambrisentan (selective ETA) in 2007.  Treatment with 
bosentan for up to 12 weeks prevented clinical worsening and improved exercise 
capacity in patients with PAH (Rubin et al., 2002).  Bosentan is metabolized by 
CYP3A4 and is also an inducer of this enzyme, therefore certain other drugs may 
become ineffective if given in combination. 
 
1.7.4 Nitric oxide pathway 
PDE5 is highly expressed in the pulmonary vasculature of PAH patients and degrades 
cGMP thus reducing the vasodilating effect of NO.  There are two PDE5 inhibitors 
currently approved for use in PAH: tadalafil (approved in 2003) and sildenafil (approved 
in 2007).  PDE5 inhibitors prevent the degradation of cGMP thus increasing PKG 
activity and vasodilation.  Sildenafil and tadalafil produce a similar reduction in 
mortality, although some patients do not respond to treatment due to a lack of 
endogeneous NO production (Giaid & Saleh, 1995; Galiè et al., 2009).  Certain 
beneficial effects of sildenafil have been attributed to a direct effect on the RV 
myocardium, however chronic sildenafil exacerbated hypertrophy in a rat model of PAH 
with a fixed afterload, suggesting the survival benefits are primarily due to the afterload 
lowering effect (Andersen et al., 2008).  The major route for both sildenafil and tadalafil 
metabolism is oxidation via CYP3A4.  A new class of sGC activators has recently been 
developed as an alternative to PDE5 inhibitors which bypasses the need for NO 
synthesis and promotes cGMP production rather than preventing its degradation.  
Riociguat was granted FDA approval in 2013 and a randomized controlled trial of over 
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400 PAH patients found improvements in haemodynamics, exercise capacity and time 
to clinical worsening (Ghofrani et al., 2013). 
 
1.7.5 β-adrenoceptor blockers? 
There is substantial clinical evidence of over-activation of the sympathetic axis in 
patients with PAH, including: increased circulating levels of noradrenaline, decreased 
heart rate variability, decreased RV β1AR expression (see Kurzyna and Torbicki 
(2007), Maron and Leopold (2015) and references therein).  In addition the degree of 
sympathetic activation in patients correlates with the severity of haemodynamic 
compromise (Nootens et al., 1995).  Similar findings have been reported in preclinical 
models of PAH which have further shown increased GRK2 expression (Piao et al., 
2012), decreased basal levels of cAMP (Seyfarth et al., 2000) and decreased inotropic 
response to β1-AR agonists (Vescovo et al., 1989).  Given the obvious parallels with 
chronic adrenergic activity in LV failure it is surprising β-blockers have not been the 
subject of large clinical trials in PAH patients.  The most recent European Society of 
Cardiology guidelines for the treatment of PAH go as far as to state β-blockers are not 
recommended in PAH unless required to treat comorbidities (Galiè et al., 2015b). 
 
This hesitance to use β-blockers in PAH is often justified on the basis of a highly cited 
study by Provencher et al. (2006b) showing improved exercise capacity 2 months after 
withdrawal of propranolol from 10 PAH patients with portopulmonary hypertension.  
However this finding was likely influenced by an acute inotropic effect of withdrawal of 
β-blockers and the use of a non-selective β1/β2 blocker which may have aggravated 
pulmonary vasoconstriction.  A case study by Peacock and Ross (2010) describing a 
patient with portopulmonary hypertension who developed severe systemic hypotension 
when administered metoprolol is also a source of anxiety, however this extreme 
response was most likely due to inhibition of metoprolol breakdown by other 
medications.  The most compelling argument against β-blockers in PAH is the relatively 
high load-dependence of RV SV, meaning cardiac output in PAH patients is highly 
dependent on heart rate (Abel & Waldhaus, 1967; Groepenhoff et al., 2010), and 
therefore negative chronotropic effects could lead to ventriculo-arterial uncoupling as 
was reported in an animal study (Brimioulle et al., 2003).  It is worth noting this same 
argument was first made against using β-blockers to treat LV failure, as contemporary 
thinking was that inotropic support was needed to treat heart failure, however ultimately 
this proved to increase mortality (Packer et al., 1984; Packer, 1993).  It took 25 years 
from the development of propranolol by Sir James Black in 1964 to the first 
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demonstrated long-term survival benefit from chronic metoprolol in LV failure (Black et 
al., 1964; Waagstein et al., 1989); what is currently unknown is the long term effect of 
chronic β-blocker treatment in PAH as no clinical trials have tested this.   
 
Despite the two aforementioned reports there is growing interest in the therapeutic 
potential of β-blockers in PAH.  Recent retrospective analyses of PAH patients 
receiving β-blockers for co-morbidities have revealed no clinical worsening compared 
to patients without β-blockers (So et al., 2012; Thenappan et al., 2014; Bandyopadhyay 
et al., 2015), however these matched but non-randomised cohort studies were not 
designed to answer the question of whether β-blockers are beneficial in PAH.  
Evidence of beneficial effects comes from a small number of preclinical investigations 
showing improvements in RV function and survival in rats with PAH (Bogaard et al., 
2010; de Man et al., 2011; Perros et al., 2015).  On this basis further study into the 
mechanisms underlying the putative benefits of β-blockers in PAH is warranted. 
 
Metoprolol (1-[4-(2-methoxyethyl)phenoxy]-3-(propan-2-ylamino)propan-2-ol) is a 
competitive β1-selective adrenergic receptor blocker which lacks sympathomimetic  
properties and is an inverse agonist (Maack et al., 2000) (Figure 1.12).  It was first 
synthesized by the para-substitution of phenoxy-hydroxypropylamines (Brandstrom et 
al., 1976).  In cats it was shown to be cardioselective as it caused a negative 
chronotropic response to isoprenaline infusion but did not inhibit isoprenaline-induced 
systemic vasodilation or bronchial smooth muscle relaxation (Åblad et al., 1973).  In 
humans metoprolol exhibits β1AR selectivity at low doses but spills over into β2AR 
block at higher doses (Zebrack et al., 2009).  Non-specific block of β2AR may be 
ameliorated by the use of controlled-release metoprolol succinate rather than the 
rapidly available metoprolol tartrate (Kendall et al., 1990).  A target dose of 200 mg per 
day, as used by the Metoprolol CR/XL Randomised Intervention Trial in Congestive 
Heart Failure (MERIT-HF) study, is currently recommended in left heart failure, 
although the actual dose achieved in that study was only 159 mg per day (Hjalmarson 
et al., 2000; López-Sendó et al., 2004).  A subgroup analysis of MERIT-HF revealed 
some patients were more sensitive and achieved an equivalent heart rate reduction 
and survival benefit from a lower mean dose of 76 mg per day, compared to patients 
who tolerated a high dose (mean 192 mg per day); this may be due to genetic 
polymorphisms encoding the CYP2D6 enzyme affecting the rate of drug clearance 
from blood plasma (Wikstrand et al., 2002; Wojtczak et al., 2014). 
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Figure 1.12 Structure of β-receptor agonist, isoprenaline, and antagonist, 
metoprolol 
The isopropyl amine group of isoprenaline and metoprolol confers specificity to β-
receptors.  Isoprenaline structure from Sigma-Aldrich 
(http://www.sigmaaldrich.com/catalog/product/sigma/i5627) and metoprolol structure 
from DrugBank (http://www.drugbank.ca/drugs/DB00264) Accessed 09/12/2015.  
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The ability of metoprolol to significantly improve survival and function in left heart failure 
(Hjalmarson et al., 2000), increase expression of β1AR (Gilbert et al., 1996), improve 
Ca2+ handling irregularities (Chen et al., 2012) and avoid broncho- and vasoconstriction 
in the pulmonary vasculature which could occur with non-selective β-blockers (Åblad et 
al., 1973) makes it an ideal β-blocker for trial in PAH.  Metoprolol is unlikely to affect 
vascular resistance therefore any functional gains should occur by directly increasing 
RV contractility.  Furthermore, metoprolol is the most widely prescribed β-blocker 
therefore if found beneficial in PAH these results will have the immediacy of translation 
into clinical trials. 
 
1.8 Preclinical models of pulmonary arterial hypertension 
Animal models of cardiovascular disease can never fully replicate all aspects of the 
human condition, however different models may lend themselves more to particular 
aspects of a disease and all have provided invaluable insight into the processes and 
pathways underpinning pathological remodelling. 
 
1.8.1 Pulmonary artery banding 
Pulmonary artery banding (PAB) involves the surgical placement of a ligature or metal 
clip around the pulmonary trunk which increases the afterload experienced by the RV 
but which leaves the pulmonary vasculature distal to the clip unaffected.  As the 
afterload is fixed this is an ideal model for studying direct effects of drugs on the RV in 
numerous species including mice, rats, cats, dogs and bovines.  With the exception of 
immediate mortality following surgery, PAB generally results in a compensated RV 
hypertrophy without significant mortality (Faber et al., 2006b; Borgdorff et al., 2013).  
This may occur due to the sudden, proximal occlusion of the pulmonary artery which 
also tends to be better tolerated in humans, for instance in the case of pulmonary 
thromboembolism.  Alternatively PAB can be performed on young animals such that as 
the animal grows there is progressive constriction of the pulmonary artery (Bogaard et 
al., 2009).  This also results in a compensated hypertrophy which might reflect the 
adaptive capacity of the RV to overload early in life, such as in the case of congenital 
heart defects which are generally less detrimental than acquired PAH.  Downsides to 
this model include the highly invasive procedure and microsurgical expertise required. 
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1.8.2 Chronic hypoxia 
Hypoxic or hypobaric chambers have been used to simulate high altitude hypoxic 
vasoconstriction in rats and calves which results in mild PAH (Meyrick & Reid, 1980; 
Walker et al., 2011b).  A more severe phenotype can be induced by injecting the VEGF 
inhibitor Su-5416 prior to the start of hypoxia (SuHx).  VEGF promotes survival in 
endothelial cells during hypoxia, however blocking VEGF selects for a population of 
apoptosis-resistant proliferating endothelial cells.  This results in obstructive vascular 
remodelling and is one of the few models of PAH which produces plexiform lesions.  
Severe PAH results which progresses to RV failure and death in some but not all 
animals after 8 weeks or longer (Taraseviciene-Stewart et al., 2001).  The similarities 
between vascular remodelling in SuHx and human PAH make it an ideal model to 
study the role of the pulmonary vasculature in PAH. 
 
1.8.3 Monocrotaline 
Monocrotaline (MCT) is a pyrrolizidine alkaloid isolated from the seeds of the Crotalaria 
spectabilis plant and is commonly used as a model of progressive PAH in rats.  MCT is 
typically injected in its inactive form intraperitoneally into 200-250 g rats at a dose 
corresponding to 60-80 mg/kg which is sufficient to induce PAH, RV hypertrophy and 
overt right heart failure within 3-4 weeks (Lamberts et al., 2007a; de Man et al., 2011).  
Lower doses of 30-40 mg/kg result in a compensated hypertrophy without overt heart 
failure and have been used to study the long term effects of PAH on the RV and LV 
(Benoist et al., 2012; Ruiter et al., 2013).  Higher doses of 80-300 mg/kg have also 
been used but may cause acute lung injury, interstitial pulmonary fibrosis and hepatic 
veno-oclusive disease (Copple et al., 2003).  In the liver MCT is oxidized by mixed 
function cytochromes P450 CYP3A4 to the short-lived reactive MCT pyrrole compound 
(Mattocks et al., 1990; Kasahara et al., 1997); induction of these enzymes increases 
the production of MCT pyrrole (Reid et al., 1998).  The active MCT pyrrole enters the 
venous circulation then is pumped by the RV into the pulmonary vasculature.  MCT 
damages the endothelial cells of pulmonary arterioles in its first pass through the 
pulmonary vascular bed resulting in apoptosis, although the exact mechanism through 
which this occurs is not yet clear.  This damage to the endothelium impairs barrier 
function allowing infiltration of macrophages and initiates a cascade of proliferation and 
remodelling of the underlying smooth muscle cells eventually resulting in lung fibrosis 
(Pleština & Stoner, 1972; Pan et al., 1993; Sahara et al., 2007).  Loss of endothelial 
NO synthase, release of proliferative growth factors and inhibition of BMPRII through 
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loss of caveolae have been observed in endothelial cells exposed to MCT which 
initiates a process of smooth muscle cell proliferation, constriction and hypertrophy 
(Ramos et al., 2007; Huang et al., 2010).  Due to its short half-life the systemic 
circulation is not directly affected by MCT and total peripheral resistance is unchanged 
(Correia-Pinto et al., 2009).  It has been suggested that MCT also damages the hepatic 
veins causing fibrotic occlusion and hepatic congestion, however this appears to occur 
at very late stages of the disease (Roth et al., 1981; Gomez-Arroyo et al., 2012); 
furthermore the reduction in liver weight of rats treated with a low dose of 40 mg/kg 
MCT is reversible beyond 4 weeks, arguing against hepatic veno-occlusion as the 
cause of death in rats (Ruiter et al., 2013).  MCT causes more severe PAH in male rats 
compared to female rats, therefore male rats are typically used to study RV failure.  
Ovariectomised female rats injected with MCT develop similar pulmonary artery 
pressures and RV hypertrophy as male rats, whereas infusion of metabolites of 
estrogen is protective against vascular remodelling in male MCT rats (Tofovic et al., 
2005; Yuan et al., 2013).  The protective effect of estrogen against PAH may be 
through elevating levels of antioxidant enzymes in the pulmonary vasculature (Bal et 
al., 2013). 
 
1.9 Study aims 
This study aims to test the hypothesis that β1-AR blockade is beneficial to survival and 
RV function in the rat MCT model of PAH.  The MCT model was chosen as it is a well-
characterised model of RV failure which consistently recapitulates many of the 
pathological changes reported in human RV failure and does so within a relatively short 
period of time, while reducing animal suffering due to its minimally invasive nature.  
The β1 AR blocker metoprolol was chosen because the detrimental effects of 
noradrenaline are primarily mediated through the β1 signalling pathway; it has been 
proven to significantly reduce mortality in LV failure (Waagstein et al., 1993; 
Hjalmarson et al., 2000) as effectively as more expensive non-selective β-blockers 
(Tang et al., 2003; Fröhlich et al., 2015) and its effects show greater selectivity for the 
myocardium than the pulmonary vasculature.  The specific aims and hypotheses to be 
tested were: 
 
I. To establish a chronic metoprolol treatment regime which improves survival in 
established rat MCT PAH. 
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II. Using in vivo techniques, characterise the function and remodelling of the RV in 
PAH compared to healthy rats, and test whether these were improved by 
metoprolol treatment. 
 
III. To test whether altered energy metabolism was a source of contractile 
dysfunction in the failing RV and if so, whether this was improved by metoprolol. 
 
IV. To test whether metoprolol restores dysfunctional excitation-contraction 
coupling in failing RV cardiomyocytes. 
 
V. To test whether a shorter sarcomere length increase the likelihood of Ca2+ 
waves occurring. 
 
There has been little investigation into the mechanisms underlying the salutary effect of 
β-blockers in PAH; the work contained in this thesis aims to address this gap in 
knowledge and comes during a resurgence of interest in β-blockers as a potential 
therapy (Andersen et al., 2015; Bandyopadhyay et al., 2015; Bristow & Quaife, 2015; 
Perros et al., 2015).   
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Chapter 2  Methods 
2.1 Monocrotaline model of pulmonary artery hypertension 
Monocrotaline (MCT; Sigma, UK) was prepared fresh on the day of injection by 
dissolving 68 mg MCT in a small volume of 1 M HCl with 140 mM NaCl, pH was 
adjusted to 7.4 with 5 N NaOH, the final concentration of MCT was 20 mg.mL-1. 
Male Wistar rats bred at the University of Leeds weighing 200 ± 20 g were given an 
intraperitoneal injection of 60 mg/kg MCT to induce PAH, or an equivalent volume of 
140 mM saline for control (CON) rats.  Milli-Q grade water was used for all 
experiments.  Rats were housed three per cage at 20-22°C in 50% humidity on a 12 h 
light/dark cycle with ad libitum access to food and drinking water.  Rats were weighed 
and checked for signs of heart failure twice per week from the day of MCT injection 
(day 0) then daily from day 21 onwards.  FAIL rats were killed upon showing symptoms 
of heart failure such as cachexia (10 g in one day or 20 g over several days), lethargy, 
dyspnoea, cold extremities or piloerection.  Experiments in CON rats were performed 
on temporally equivalent days.  Experiments were conducted in accordance with the 
Animals (Scientific Procedures) Act (1986) and local ethical approval. 
 
2.2 Chronic treatment with metoprolol 
The goal of this work was to establish a β-blocker treatment regime therefore we first 
attempted to replicate the treatment regime of Bogaard et al. (2010) but for reasons 
described in Appendix A a de novo regime had to be devised; the results from this first 
attempt are presented in Appendix A.  Rats were trained to drink a placebo solution 
containing 20% (v/v) Ribena and 10% (w/v) sucrose (placebo) voluntarily from a 1 mL 
syringe starting several days after MCT or saline injection.  Chronic treatment with 
metoprolol tartrate (10 mg/kg/day; Santa Cruz Biotechnology, TX) was initiated 15 days 
after MCT injection (MCT+BB and FAIL+BB groups), when PAH and hypertrophy are 
already established (Lee et al., 1997; Jones et al., 2002).  Metoprolol was dissolved in 
placebo at a concentration of 1.25 mg/mL, which was found to be the highest 
concentration rats would willingly consume without displaying an aversion to taste 
(Figure 2.1).  Dosing was administered within 2 h prior to the start of the dark cycle.  
Daily dose volume was around 2.5 mL and adherence was calculated from any 
remaining unconsumed solution in the syringe.  The target dose was well adhered to by 
all rats, however 3/9 FAIL+BB rats reduced their consumption in the days leading up
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Figure 2.1 Drug treatment by voluntary syringe feeding 
Rats were trained to voluntarily drink from a 1 mL syringe containing placebo solution, 
or placebo plus metoprolol (1.25 mg/mL).  The volume was adjusted daily to achieve a 
target dose of 10 mg metoprolol/kg body weight/day.  Rats were fed within the 2 h 
preceding the start of the dark (active) cycle.  
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to failure.  Metoprolol and placebo solutions were prepared fresh every 2 days and 
covered in aluminium foil to prevent photoinactivation of metoprolol. 
 
2.3 In vivo characterisation of right ventricle function 
2.3.1 Anaesthesia 
Rats were anaesthetised in a Perspex chamber ventilated with 5% isoflurane (IsoFlo, 
Abbott Laboratories, IL) mixed with medical O2.  Anaesthesia was confirmed by the 
lack of pedal-withdrawal reflex in response to a toe-pinch.  Rats were transferred to a 
heated platform and secured in a supine position with pieces of autoclave tape over the 
paws.  Anaesthesia was maintained under ~1.5% isoflurane and adjusted according to 
breathing frequency.  The chest was shaved with electric clippers and depilatory cream 
applied to remove remaining hair.  For recovery experiments, rats were allowed to 
awaken on the heating pad while breathing medical O2.   
 
2.3.2 Echocardiography 
Serial non-invasive transthoracic echocardiography was performed on anaesthetised 
rats using a Vivid7 ultrasound (GE Healthcare, WI) with a curvilinear 11.5 MHz 10s 
probe (GE Healthcare, WI).  Ultrasound gel (Cardiacare, Essex, UK) was generously 
applied to the shaved chest, taking care to avoid air bubbles.  The probe was lightly 
pressed against the chest and oriented to view the heart in transverse cross-section.  
Geometry of the RV and LV were measured using brightness (B-) and motion (M-) 
modes taken from the parasternal short axis (PSAX) view at the level of the LV 
papillary muscles.  Imaging depth was set to 2 cm with a data recording rate of 100 Hz.  
Care was taken to avoid reflections and shadows in the viewing window due to the 
lungs and ribs. 
 
Two-dimensional B-mode and one-dimensional M-mode measurements were taken 
when chamber area or diameter was greatest in diastole and smallest during systole.  
RV and LV areas were measured in B-mode by tracing the endocardium of the 
ventricles.  The LV endocardial perimeter was measured to calculate the LV circularity 
index (LVSCI), which is an indicator of the mechanical interaction between the RV and 
LV across the septum and reflects the trans-septal pressure gradient (Portman et al., 
1987).  The LVSCI quantifies how circular the LV is during systole as a percentage, 
100% being a perfect circle, and is calculated by: 
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Figure 2.2 Echocardiography measurement modes 
A 2D B-mode images were used to calculate chamber areas (white dashed line).  B Wall thickness (white line, flat caps) and chamber diameter 
(white line, arrow caps) were measured in M-mode.  C The PA blood flow was measured 1-2 mm from the pulmonary valve leaflets, parallel to the 
direction of blood flow (white arrow).  D Blood flow through the PA was measured using Doppler ultrasound.  PA acceleration time (PAAT) was 
measured from the onset of flow to peak forward velocity.  Velocity-time integral was measured from the start to the end of systolic blood flow.  
A B
PAATVTI
100 ms
100 ms
C D
1mm
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LV
RV LV
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Where LVAs = LV end-systolic area and C = LV chamber perimeter at end-systole.  M-
mode images were constructed by stacking the pixel values along a line bisecting the 
heart through the RV, septum and LV as a function of time.  Wall thickness, chamber 
diameter and pulmonary artery diameter (PAD) were measured in M-mode. 
 
Pulmonary artery (PA) blood flow was measured using Doppler ultrasound taken from 
the PSAX view near the base of the heart at the level of the pulmonary arch (Figure 
2.2).  The Doppler effect is a shift in wave frequency occurring when a wave passes 
through a medium moving relative to the observer.  This property of sound is utilised in 
pulsed-mode Doppler echocardiography to measure blood flow through arteries and 
across the heart valves by alternating the transducer crystal between transmitting and 
recording signals.  The shift in frequency of the returning wave is processed online 
using a fast Fourier transform and converted to flow velocity by solving the Doppler 
equation (Lewis et al., 1984): 
 
  
       
          
 
 
Where V = blood velocity (m/s), ΔF = frequency shift,  Vm = the speed of sound in the 
medium (approximately 1540 m/s in tissue and blood), F0 = emitting frequency of the 
transducer (11.5 MHz), θ = angle of incidence between sound waves and direction of 
blood flow.  When θ<20° it has minimal influence on the calculated velocity 
(Feigenbaum, 2004); images were acquired from a region of the PA with maximal 
laminar flow, therefore no angle correction was applied and θ was assumed to be 0° 
(Cos (0) = 1).  The B-mode image screen rate is reduced to 6 Hz during Doppler 
ultrasound to allow correct positioning of the transducer.  Data were recorded from a 1 
mm sample volume placed 1-2 mm from the PA valve leaflets.   
 
Pulmonary artery acceleration time (PAAT) was measured from the onset to the peak 
of systolic flow.  The PA velocity-time integral (VTI) was measured from the start to the 
end of systolic flow.  Cardiac output was calculated by multiplying stroke volume (SV) 
by heart rate.  RV SV was calculated from the VTI and PAD, assuming a circular PA 
cross-sectional area: 
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The cardiac index was calculated as the ratio of cardiac output to body surface area 
(BSA).  BSA was predicted according to Meeh‘s formula, where k is an empirically 
derived constant (9.83) and W is body weight in grams  (Gouma et al., 2012): 
 
             
 
   
 
Each echocardiography examination was assigned a unique identifier consisting of a 
computer-generated 5-digit random number, allowing image analysis to be performed 
blinded to the group and time point of the rat.  Each parameter was measured offline 
from a total of 9 cardiac cycles from 3 separate video files and the mean value 
calculated and used for subsequent statistical analyses. 
 
2.3.3 Right heart catheterisation 
In some cases following the ultrasound scan an experienced investigator (Dr Mark J 
Drinkhill) performed terminal right heart catheterisation to measure in vivo RV 
haemodynamics in anaesthetised and mechanically ventilated rats.  Body temperature 
was maintained using a heating lamp positioned above the rat.  Pressure was 
calibrated before the start of the experiment using a mercury manometer.  The chest 
was opened with a medial sternotomy and the heart exposed.  The RV free wall was 
pierced with a needle close to the apex and a Millar pressure-volume catheter (SPR-
869, Millar Instruments, TX) inserted transmurally into the RV chamber and secured in 
place with suture thread.  Load-independent parameters of contractile function were 
obtained by transient occlusion of the ascending vena cava.  The end-diastolic and 
end-systolic pressure-volume relationships were fitted with a linear regression to 
calculate the slope.  Pulmonary vascular resistance (PVR) was calculated according to 
the following equation, assuming a constant LV diastolic pressure of 8 mmHg (as found 
by Correia-Pinto et al. (2009) in up to 6 weeks post injection of 60 mg/kg MCT in rats).  
PVR was expressed in Wood units (mmHg.min.mL-1): 
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Time-varying volume, V(t), was calculated from the time-varying conductance, G(t), 
measured between two outer and two inner ring electrodes separated by a fixed 
distance, L, and the resistance of blood, ρ, measured after the experiment in a cuvette 
(P/N 910-1048, Millar Instruments, TX) filled with a known volume of fresh heparinized 
blood.  Uncorrected volume was thus given by: 
 
               
 
The myocardium and lungs also conduct electricity, therefore volumes were corrected 
by subtracting non-blood sources of conduction, termed parallel conductance (GP) 
(Baan et al., 1984).  GP was calculated by infusing a 20 µL bolus of hypertonic saline 
into the left jugular vein to increase the conductivity of the blood without altering 
ventricle volume or the properties of the surrounding tissue.  During the period of saline 
infusion the apparent end-diastolic volume (VED) is plotted against end-systolic volume 
(VEs) and fitted with a linear regression.  GP is found by solving the equation of this line 
to find the point of intersection with the line of equivalence (VED
 = VES).  The point of 
intersection represents conductance due to non-blood sources.  Thus, blood volume 
corrected for parallel conductance becomes: 
 
                    
 
An additional factor, α, may be incorporated to account for the fact volumes measured 
by conductance catheter generally underestimate true volumes due to the apical and 
basal volumes not being measured and inhomogeneity of the electrical field due to the 
use of point-source electrodes (Cardozo et al., 2003).  α can be calculated from the 
ratio of stroke volume measured by an independent method such as thermodilution, to 
stroke volume measured by conductance catheter.  The resulting absolute corrected 
ventricle volume would therefore be: 
 
                     
 
Correcting for α is of greater importance in animals with larger hearts due to the greater 
distance between catheter electrodes, whereas in small hearts such as those of rats 
and mice, α is thought to be less problematic and therefore was assumed to be equal 
to 1 (Pacher et al., 2008). 
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2.4 Histology 
Rats were killed by the approved UK Home Office Schedule 1 method of cranial 
stunning and cervical dislocation.  The diaphragm was cut along the ribcage and a 
bilateral incision made towards the head to expose the heart.  The sternum was 
retracted and the heart removed by cutting the main blood vessels above the base of 
the heart.  The heart was immediately placed in 4 °C isolation solution (I.S.), 
containing, in mM: 130 NaCl, 5.4 KCl, 0.4 NaH2PO4, 5 HEPES, 10 glucose, 10 
creatine, 20 taurine, 1.4 MgCl2, pH 7.4 with 5N NaOH.  Fat was trimmed from around 
the atrium, the heart weighed then cannulated via the aorta on a Langendorff 
apparatus.  The time from opening the ribcage to cannulating the aorta was usually 
less than 1 min.  The heart was perfused retrograde at a constant flow of 7 mL/min with 
I.S. containing 100 μM EGTA to arrest the heart in diastole and clear the coronary 
circulation of blood. 
   
The heart was cut down from the cannula and dissected into a base, mid and apex 
portion in ice-cold EGTA I.S. using a safety razor blade.  The mid RV free wall was 
dissected free and divided into two equal pieces following the long axis of the heart.  
One of these pieces, along with the RV free wall from the base and apex, was frozen 
for subsequent biochemical analysis, the remaining piece of RV mid free wall was 
frozen for histology.  The RV was pinned to a 20 mm diameter cork specimen disk and 
maintained in a vertical orientation against a piece of liver also pinned to the cork 
(Figure 2.3).  The sample was covered in a layer of OCT (optimal cutting temperature; 
VWR, Lutterworth, UK) then the whole sample inverted and frozen in isopentane, 
precooled by liquid N2.  The LV was processed in a similar manner, however only the 
mid LV free wall was used, due to there being no clear boundary between LV and 
septum at the apex.  Samples were tightly wrapped in PVC film and stored in airtight 
plastic bags at -80 °C. 
 
Samples were warmed to -20°C in a cryostat (CM1900, Leica, Milton Keynes, UK) and 
10 μm thick sections were cut orthogonal to the long axis of the tissue using a 
microtome.  Sections were transferred to poly-L-lysine coated microscope slides 
(Polysine Microscope Adhesion Slides, VWR, Lutterworth, UK) marked with a 5-digit 
computer-generated random number unique to each heart, which allowed image 
acquisition and analysis to be performed blinded to the origin of the sample. 
 
  
69 
 
2.4.1 Measurement of fibrosis 
Sirius Red is a large, linear (length ~46 Å), anionic dye with six sulphonic acid groups 
which preferentially bind basic side group amino acids in collagen (Figure 2.4) 
(Junqueira et al., 1979).  The parallel alignment of the dye to the collagen fibres causes 
strong birefringence under polarized light, making polarised light microscopy an ideal 
detection method (Whittaker et al., 1994).  Alternatively, co-staining the myocardium 
yellow with picric acid provides contrast against the red-stained collagen, allowing the 
area of fibrosis to be quantified using standard light microscopy and colour thresholding 
image analysis. 
 
Slides were immersed for 1 h in 4% formaldehyde in phosphate-buffered saline (PBS) 
containing, in mM: 137 NaCl, 2.7 KCl, 9.6 Na2PO4, 1.5 KH2PO4, pH 7.4 with HCl, then 
rinsed twice in PBS for 5 min and air dried and stored at 4°C until use.  Slides were 
permeabilised in 0.1% Triton X-100 in water for 25 min.  A saturated picric acid solution 
was made by dissolving 6.5 g picric acid crystals in 500 mL water; saturation was 
confirmed by the presence of picric acid crystals after 24 h.  A 0.1% picrosirius solution 
was made by dissolving 0.5 g Direct Red 80 (Sigma-Aldrich, Poole, UK) in 500 mL 
saturated picric acid, pH 2.15 with HCl.  Slides were stained in picrosirius dye for 90 
min then excess stain was removed by immersion in 0.01 M HCl for 10 min.  Slides 
were dehydrated by washes in 50, 70, 90 and 100% EtOH for 2 min each.  Slides were 
cleared in Histoclear (National Diagnostics, Atlanta, GA) to prevent air bubbles forming 
within the tissue when non-aqueous mounting media was applied.  A drop of DPX 
(distyrene, plasticiser (butyl, pfthalate, styrene), xylene; Sigma, UK) mounting media 
was applied to each section and a glass coverslip carefully applied, avoiding air 
bubbles.  Slides were left to cure at 22±1°C and stored at 4°C in the dark until imaging. 
 
Slides were imaged on a Nikon Eclipse E600 light microscope with a Nikon Plan Fluor 
20X objective.  Three separate 0.15 mm2 areas of the sample were imaged at a 
resolution of 2560x1920 pixels using a camera (MicroPublisher 5.0, QImaging, Surrey, 
Canada) attached to the side port of the microscope.  Only areas cut in good cross-
section were used.  Distances were calibrated using a micrometer graticule (Graticules 
Ltd, Kent, UK).  Red collagen staining was identified using a colour thresholding 
algorithm in ImageJ (National Institute of Health, Bethesda, MA).  The threshold was 
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Figure 2.3 Preparation of tissue for biochemical and histological analyses 
Hearts were dissected into a base, mid and apical portion.  The basal, apical and half 
of the RV mid free wall was frozen for biochemical analysis.  The remaining half was 
frozen for histology.  The RV was pinned against a piece of liver to maintain the correct 
orientation during freezing in liquid N2-precooled isopentane.  
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A
B
Figure 2.4 Structure of collagen triple helix and Sirius Red dye 
A Collagen fibrils form linear strands of triple helices consisting of repeating units of 
proline, hydroxyproline and glycine amino acids.  Separate strands of collagen are 
coloured in red, green and blue.  Structure from  Protein Data Bank entry: 1CAG (Bella 
et al. (1994)) B The linear structure of Sirius Red dye binds to basic amino acids in 
collagen and enhances its birefringence.  Chemical structure of Direct Red 80 from 
http://www.sigmaaldrich.com  
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optimised for each section to account for possible variation in staining intensity but was 
kept constant for both ventricles of a particular heart.  For each ventricle, the mean % 
area fibrosis of the 3 areas was calculated and used for statistical analysis. 
 
2.4.2 Capillary density 
Plant lectins are proteins which bind sugar residues including N-acetylglucosamine 
found in the glycocalyx of capillaries and cardiomyocytes.  Sections were fixed in 
acetone on ice for 5 min then allowed to air dry and stored at -80°C until use.  Slides 
were incubated in the dark for 1 h with fluorescein-conjugated lectin from Griffonia 
simplicifolia (Vector Laboratories, CA), at a final concentration of 10 µg/mL in PBS.  
Slides were rinsed in 3 washes of PBS then mounted in an anti-fade mounting medium 
(Vectashield, Vector Laboratories, CA) diluted 1:8 in PBS, sealed with a coverslip and 
stored in the dark until imaging (within 24 h).  Slides were imaged using 
epifluorescence on a Nikon Eclipse E600 microscope with a Nikon Plan Fluor 20X 
objective.  A 0.15 mm2 area (~200-400 capillaries per field) was imaged at a resolution 
of 2560x1920 pixels using a camera (MicroPublisher 5.0, QImaging, Surrey, Canada) 
attached to the side port of the microscope.  An LED lightsource provided excitation 
light which was filtered through a 487±10 nm bandpass filter and fluorescence 
collected through a 533±20 nm longpass filter.  Only areas cut in good transverse 
cross-section were imaged. 
 
2.4.2.1 Modelling myocardial PO2 
Capillaries were identified by eye by an observer blinded to the sample origin.  Muscle 
fibres were counted following Gundersen‘s unbiased counting rule.  Capillary 
distribution was converted to a binary image and processed using a finite element 
model implemented in the MatLab computing environment (The MathWorks Inc., 
Natick, MA) (described in detail in Al-Shammari et al. (2012) and (2014)).  Capillary 
supply area was calculated using Voronoi polygons, in which points within the polygon 
lie closer to a central capillary than any other capillary.  This avoids the complication of 
the inability to tesselate circles which would occur if Krogh and Erlang‘s cylindrical 
model was used (Krogh, 1919).  Tissue O2 flux (MVO2) can be assumed to be 
proportional to tissue O2 according to Fick‘s principal, so long as tissue PO2 is above a 
critical value (generally approximated as 0.5-1 mmHg (Goldman, 2008)).  All 
biophysical parameters (except MVO2max) were obtained from published literature 
following the recommendation of Beard et al. (2003) and are presented in Table 2.1. 
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Table 2.1 Tissue PO2 model parameters 
Capillary radius 2 µm
Capillary PO2 40 mmHg
Tissue PO2 (half max Mb saturation) 2.39 mmHg
Tissue PO2 at half max MVO2 0.5 mmHg
Tissue O2 solubility 4.42 x 10
-5
 mL O2 / mL • mmHg
Free O2 diffusivity in tissue 1.45 x 10
-5
 cm
2
/s
Free Mb diffusivity in tissue 2.2 x 10
-7
 cm
2
/s
Michaelis-Menten tissue VO2max 3.81 µL O2 / mL • s
Mb concentration in tissue 2.878 Mb µL / mL
Capillary mass transfer coefficient 0.00086
Mb, myoglobin; MVO2, myocardial oxygen uptake
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2.5 Isolated myocyte studies 
Single cardiomyocytes were first successfully isolated nearly 40 years ago and since 
then have enabled properties of the heart to be studied without the confounding 
influence of electrical connections, complex geometry, non-cardiomyocyte cells and 
proteins and circulating hormonal factors (of course, all of these could equally be 
described as limitations) (Powell & Twist, 1976).  
 
2.5.1 Ventricular myocyte isolation 
Rats were killed by the approved UK Home Office Schedule 1 method and hearts 
removed and cannulated on a Langendorff perfusion system as described above.  The 
heart was perfused retrograde at a constant flow of 7 mL/min/g with I.S. containing 750 
μM Ca2+ until the coronary circulation cleared of blood and spontaneous sinus rhythm 
was re-established.  Perfusion was switched to I.S. containing 100 μM EGTA for 4 min 
to arrest the heart in diastole.  The heart was then perfused with 40 mL I.S. containing 
50 μM Ca2+, 1 mg/mL collagenase Type II (activity 270 U/mg, Worthington Biochemical, 
New Jersey, USA) and 0.1 mg/mL protease (Type XIV, Sigma, UK).  Enzyme solution 
was collected and recirculated for a total digestion time of 7 min (Figure 2.5). 
 
The heart was cut down from the cannula, reweighed and the enzyme solution 
collected for subsequent steps of the protocol.  The RV, LV and septum were carefully 
dissected and weighed.  The RV and LV were coarsely minced with scissors then 
placed in separate conical flasks with 4 mL enzyme solution.  The tissue was gently 
agitated in a water bath at 37 °C for 4 min using a rotary shaker to liberate isolated 
cardiomyocytes.  The tissue and enzyme solution was strained through 200 μm2 nylon 
mesh and the enzyme solution centrifuged at 50 x g for 40 seconds.  The supernatant 
was removed and the cell pellet resuspended in 750 μM Ca2+ I.S.  The tissue was 
returned to the conical flasks with fresh enzyme solution and the shaking/centrifuge 
process repeated 3-4 times.  If the heart was not properly perfused or went hypoxic 
(indicated by no increase in heart weight following perfusion) cells were not used.  
Cells were stored for up to 8 h at room temperature in experimental Tyrode solution 
containing, in mM: 137 NaCl, 5.4 KCl, 0.33 NaH2PO4, 0.5 MgCl2, 5 HEPES, 5.6 
glucose, 1 CaCl2,  pH 7.4 with 5N NaOH.  In some experiments [Ca
2+] was raised to 1.8 
mM or lowered to 0.75 mM depending on the nature of the experiment. 
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PUMP
water jacket 
in
water jacket 
out
enzyme 
recirculation 
line
Collecting 
reservoir
750 µM Ca2+ I.S. 0.1 mM EGTA I.S. Enzyme I.S.
Bubble trap
Three-way tap
Figure 2.5 Langendorff perfusion apparatus 
Hearts were secured via the aorta to a metal cannula with suture thread and perfused 
at 7 mL/min/g initially in 750 µM Ca2+ Isolation Solution (I.S.) to clear remaining blood 
from the coronary circulation.  The solution was then switched to 0.1 mM EGTA I.S. for 
4 min to arrest the heart.  The heart was then digested for 7 min in enzyme I.S. 
Solutions were continuously bubbled with 100% O2 and warmed to 37°C using glass 
water-jacketed reservoirs and a heating coil.  A bubble trap prevented air entering the 
coronary circulation.  
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2.6 Simultaneous recording of contraction and cytosolic Ca2+ in myocytes 
2.6.1 Unloaded shortening 
A drop of cells was placed in the perfusion chamber on the stage of an inverted 
microscope (Eclipse TE300, Nikon, Japan) and viewed under a 40x objective (Nikon, 
Japan).  Bulk flow through the bath was by gravity-fed reservoirs.  Local perfusion of a 
single cell was achieved using an 8-channel pipette (MPRE8, Cell MicroControls, 
Norfolk, VA).  Bulk and local perfusion temperature were controlled independently 
using a TC2bip bipolar temperature controller (Cell MicroControls, Norfolk, VA).  To 
minimise the effect of a temperature gradient between the chamber inflow and outflow, 
bulk flow rate was adjusted to maintain a central region of the bath at 37±0.5°C.  
Contractions were recorded during electrical field stimulation delivered by two platinum 
electrodes placed at the sides of the bath.  Pacing frequency was controlled between 
1-7 Hz with a pulse duration of 5 ms using an analogue stimulator (SD9, Grass 
Instruments, Warwick, RI). 
 
Rod-shaped, quiescent cells with clear striations were used for experiments.  A video 
image of cells was acquired using a video camera (MyoCam-S, IonOptix, Milton, MA) 
mounted to the side port of the microscope and displayed on a computer monitor.  Data 
were recorded at 250 Hz.  Cell length and width were measured using a ruler overlaid 
on the computer monitor and calibrated with a micrometer graticule (Graticules Ltd, 
Kent, UK).  Cell volume (pL) was estimated from cell length and width, assuming an 
elliptical geometry with 54% of the volume of a rectangular parallelepiped defined by 
length x width x depth, as found by (Satoh et al., 1996).  According to Natali et al. 
(2002), cell width is proportional to cell depth (W:D) in a ratio of 1.44±0.03.  Therefore: 
 
                                         
     
   
                       
 
Which can be solved to: 
                  
                        
              
 
 
The mean sarcomere length was calculated online using the SarcLen algorithm in 
IonWizard software (IonOptix, Milton, MA).  The algorithm is based on a Fast Fourier 
transform of a region of the cell with alternating light and dark striations resulting from 
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the I- and A-bands.  The inverse of the dominant spatial frequency was automatically 
calculated and displayed as the mean sarcomere length in μm. 
 
2.6.2 Ca2+ fluorescence imaging with Fura-4F 
The development of intracellular indicators sensitive to Ca2+ and other ions was 
pioneered by Roger Tsien and collaborators  (Tsien, 1981).  Ratiometric Ca2+ indicators 
such as Fura, developed from the Ca2+ buffer BAPTA (1,2-bis(o-aminophenoxy)ethane-
N,N,N',N'-tetraacetic acid), avoid problems of variable dye loading.  Attachment of an 
acetoxymethyl (AM) ester to the dye moiety allows it to pass through the cell 
membrane without the need to microinject the dye salt.  Once inside the cell, 
intracellular esterases cleave the –AM group, trapping the dye within the cell. 
 
Changes in cytosolic Ca2+ were followed using the cell permeant, –AM form of the 
ratiometric Ca2+ indicator Fura-4F (Fura-4F-AM, Invitrogen, UK).  Fura-4F is derived by 
a single fluorine substituent on the BAPTA moiety of Fura-2, which reduces its Ca2+ 
binding affinity (Kd of Fura-4F 0.77 μM versus Fura-2 0.14 μM).  Fura-4F was chosen 
over the more commonly used Fura-2 to reduce the Ca2+ buffering effect on 
contraction. 
 
Fura-4F-AM was dissolved in DMSO to produce a 1 mM stock solution and stored 
frozen at -20°C.  Cells were incubated with 2 μM Fura-4F-AM for 20 min at room 
temperature on a rocker and protected from light to prevent photobleaching.  Cells 
were resuspended in fresh Tyrode and allowed to de-esterify for 30 min before being 
used for experiments. 
 
A red filter was placed in the path of the microscope light source and experiments were 
conducted in the dark allowing the cell to be visualised while minimising 
photobleaching and fluorescence interference.  This allowed simultaneous shortening 
and Ca2+ fluorescence measurements.  A cell was centred in the field of view and a 
rectangular light excluding diaphragm adjusted to fit around the cell boundary.  A 
monochromator (Optoscan, Cairn Research, Kent, UK) alternately illuminated cells with 
10 ms pulses of 340±10 and 380±10 nm light.  The excitation light source was a 150 W 
Xenon arc lamp [Cairn Research, Kent, UK).  Returning light was directed through a 
dichroic mirror which separated light >600 nm towards the video camera for cell 
viewing and light <600 nm was passed through a 510 ± 20 nm bandpass filter into a 
photomultiplier tube and measured by a spectrophotometer integrated into the 
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Figure 2.6 Simultaneous sarcomere length and Ca2+ monitoring 
Sarcomere length in isolated cardiomyocytes was calculated online using 
IonWizard software (bottom).  Intracellular Ca2+ was monitored using the cell 
permeant Ca2+ indicator Fura-4F-AM (top).  The ratio of fluorescence collected 
at 510 nm during alternate excitation at 340 and 380 nm was used to follow 
changes in intracellular Ca2+.  A red filter placed in front of the light source 
minimized photobleaching while allowing simultaneous monitoring of sarcomere 
length and Fura-4 fluorescence.  
1  s
0 .1 0  r .u .
1 .9 0
F u ra  4  ra t io
S a rc o m e re  le n g th  (m ) 1 .8 0
1 .7 0
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monochromator unit.  The resulting fluorescence collected at 510 nm in response to 
340/380 nm excitation light was converted to a digital signal and output to IonWizard to 
automatically calculate and record the ratio at 200 Hz. 
 
2.6.3 Sarcoplasmic reticulum Ca2+ content estimation 
Caffeine opens the RyR2 in cardiac myocytes and as such, sarcoplasmic reticulum 
(SR) Ca2+ content can be estimated by the amplitude of the caffeine-evoked Ca2+ 
transient (Varro et al., 1993).  Cells loaded with Fura-4F were locally perfused with 1 
mM Ca2+ Tyrode solution heated to 37°C using an 8-channel MPRE8 (Cell 
MicroControls,  Norfolk, VA).  Cells were paced at 5 Hz for 1 min then stimulation was 
stopped and the solution quickly switched to 1 mM Ca2+ Tyrode containing caffeine (20 
mM). 
 
The relative contribution of different Ca2+ removal pathways can be determined by the 
rate of Ca2+ decay during the systolic or caffeine-evoked Ca2+ transient (Negretti et al., 
1993).  Single exponential functions were fitted to the systolic and caffeine-evoked Ca2+ 
decay (Figure 2.7).  The rate of the caffeine-evoked Ca2+ decay (KCAFFEINE) is a 
measure of SERCA-independent Ca2+ removal pathways (primarily NCX and the 
sarcolemmal Ca2+ ATPase).  The rate of Ca2+ removal through SERCA (KSERCA) is 
calculated as the difference in rate of decay between the systolic (KSYSTOLIC) and 
caffeine-evoked Ca2+ transient. 
 
2.6.4 Myofilament Ca2+ sensitivity in intact cells 
During recovery from contraction cytosolic Ca2+ and relengthening are thought to reach 
a ‗dynamic equilibrium‘ (Spurgeon et al., 1992).  This is apparent in phase-plane loops 
of cytosolic Ca2+ versus sarcomere length, as a linear change in Ca2+ and length near 
end diastole.  The slope of this relationship is therefore an index of myofilament Ca2+ 
sensitivity in intact cells.  Cells loaded with Fura-4F-AM (2 µM) were electrically paced 
at 1 Hz at 37°C and Fura-4 ratio and sarcomere shortening recorded.  The Fura-4 
record was interpolated to account for the different data acquisition rates of Fura-4 ratio 
and sarcomere length (200 vs 250 Hz).  Instantaneous Fura-4 ratio was plotted against 
sarcomere length and the slope of the relationship near end diastole was calculated by 
linear regression. 
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Figure 2.7 SR Ca2+ content analysis 
A Example of Fura-4 recording for estimation of SR Ca2+ content.  Cells were 
electrically paced to elicit systolic  Ca2+ transients, then pacing was stopped and 
caffeine (20 mM) rapidly applied.  B Expanded time view of a systolic and caffeine 
transient. SR Ca2+ content was estimated as the amplitude of the caffeine-evoked Ca2+ 
transient.  Contributions from SERCA and non-SERCA Ca2+ removal pathways were 
calculated from the rate of systolic (left) and caffeine-evoked (right) Ca2+ transient 
decay.  SERCA activity was calculated as the difference in the rate of decay of the 
systolic minus caffeine-evoked Ca2+ transient (KSERCA = KSYSTOLIC – KCAFFEINE) (red lines).  
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2.7 Force measurement in intact myocytes 
Force measurements in single cardiomyocytes were performed at the Vrijie 
Universiteit, Amsterdam.  The force of electrically paced contractions was measured in 
isolated myocytes subjected to stretch in 1.8 mM Ca2+ Tyrode.  A cell bath was made 
from a milled block of aluminium encircled by a 30 MΩ resistance wire connected to an 
mTCII-HT100 digital temperature controller (Cell MicroControls, Norfolk, VA) which 
maintained the solution temperature at 37±0.1°C.  The bath coverglass was coated in 
poly-HEMA (2-hydroxyethyl methacrylate; Sigma, Poole, UK) to prevent firm cell 
attachment to the chamber.  A piezo motor and force transducer were mounted on an 
optical-grade railing system allowing coarse positioning.  Fine positioning was 
performed using motorized micromanipulators (MX7500, Siskiyou, OR) with push-
button controllers (MC1000e, Siskiyou, OR).  Cell length was adjusted using a 
command signal generated by IonWizard which was output to a Nano-Drive 1 controller 
(Mad City Labs, Madison, WI) driving a piezoelectric motor (Mad City Labs, Madison, 
WI).  Video acquisition and online measurement of cell and sarcomere length were 
performed using the same equipment described in Section 2.6.1.  Cells were 
electrically paced between 1-7 Hz with a MyoPacer (IonOptix, Milton, MA) controlled 
using IonWizard software.   
 
2.7.1 MyoTak coating 
Stiff glass fibres 30 µm in diameter were attached to the piezo motor and force probe 
with a small drop of beeswax and angled slightly downwards to prevent the force 
transducer or piezo contacting the bottom of the cell bath.  The glass fibre tips were 
precoated in a suspension of 1 µm in diameter alumina silica aggregate in water 
(Buehler, Lake Bluff, IL).  The precoat suspension was vortexed for 10 s then a 10 μL 
drop was pipetted onto a spare coverslip.  Tips of the glass fibres were viewed under a 
20x objective and dipped in the droplet for several seconds then withdrawn, leaving a 
thin coating.  The process was repeated until the tips were covered in an even layer of 
precoat, then the coating was allowed to harden in air for 20 min. 
 
MyoTak is a biological glue primarily consisting of cell membrane and extracellular 
matrix proteins in Dulbecco‘s Modified Eagle Medium (Sigma-Aldrich).  It consists of 
soluble collagen IV (BD Biosciences, Franklin Lakes, NJ), laminin, entactin, heparin 
sulfate proteoglycan, gentamicin, and Alexa Fluor-647 conjugated to bovine serum 
albumin (Invitrogen, Carlsbad, CA) (Prosser et al., 2011).  20 μL aliquots of MyoTak 
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were stored at -80°C.  Soluble collagen IV rapidly polymerises at room temperature, 
therefore on the day of experiments an aliquot of MyoTak was thawed and kept on ice 
at all times.  Pipette tips were also cooled on ice prior to use.  Unused MyoTak was 
refrozen and used on subsequent days. 
 
The tips of the glass fibres were viewed under a 40x objective and repeatedly moved in 
and out of a 1 μL drop of MyoTak pipetted onto a coverslip until a visible bead of glue 
could be seen covering the tip.  The fibres were then quickly submerged in the cell bath 
to prevent drying.  MyoTak was carefully removed from the glass fibres at the end of 
each experiment using a fine tipped Number 2 paintbrush (van Gogh Museum, 
Amsterdam, The Netherlands) dipped in 6 M glacial acetic acid. 
 
2.7.2 Force measurements 
A drop of cells was placed in the bath of an inverted microscope.  MyoTak coated glass 
fibres were lowered onto the ends of a cell one at a time, pressing down until the 
membrane bulged slightly.  Cells were then paced for 1 min at 4 Hz which is thought to 
improve the strength of attachment by increasing the cell surface attachment area 
(Iribe et al., 2007).  The cell was lifted off the coverslip when recording force or 
unloaded shortening.  In some experiments the unloaded shortening-frequency 
relationship was first measured in cells attached to a single glass fibre, then the second 
fibre was attached and the isometric force-frequency relationship was measured in the 
same cell. 
 
2.7.3 Interferometer force transducer 
A high sensitivity (<10 nN resolution) optical force transducer (OptiForce, IonOptix, 
Milton, MA) (frequency response >3.3 kHz) was used to measure the force of 
contracting myocytes.  Force is calculated from the change in path length of laser light 
guided along a single-mode optical fibre and directed against a gold-plated cantilever 
on the force probe.  Some light is reflected at the interface between the tip of the 
optical fibre and the Tyrode solution, while the rest reflects off the cantilever and re-
enters the optical fibre where a sensor measures the intensity of the returning light.  If 
the two returning beams are in phase the intensity increases, whereas if they are out of 
phase the intensity decreases.  Hence light intensity can be used to calculate the path 
length between the fibre and cantilever.  Contracting myocytes cause a small deflection 
in the cantilever (<1 μm) which is of a known compliance (24.1 N/m), meaning the force 
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Figure 2.8 Intact cell stretch 
Cells were attached to stiff glass fibres coated in MyoTak.  Loaded and unloaded 
contractions were measured from the same cells by first attaching a single fibre and 
measuring cell shortening, then attaching a second fibre and measuring isometric 
force.  Stretching the cell lead to an increase in end systolic force (red arrow) and end 
diastolic force (blue arrow).  
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applied to the cantilever can be calculated from the spring constant multiplied by the 
cantilever deflection. 
 
2.8 Laser scanning confocal microscopy 
Confocal microscopy comprises three fundamental components: 1) a laser providing 
excitation light which can be scanned across the X and Y axes 2) a confocal pinhole 
aperture which restricts light passage to a narrow focal plane 3) a photomultiplier to 
detect the emitted fluorescence.  Adjustment of the focal plane allows an additional Z 
axis to be recorded. 
 
2.8.1 di-8-ANEPPS staining of cell membrane 
T-tubules are invaginations of the sarcolemma occurring at the Z-disk of muscle cells 
and are prominent in mammalian ventricular myocytes.  The lipophilic potentiometric 
dye di-8-ANEPPS binds to the polarized sarcolemma allowing visualisation of the T-
tubule network.  A 1 mM stock solution of di-8-ANEPPS was prepared in DMSO and 
stored at -20°C.  Cells were incubated with 5 μM di-8-ANEPPS for 10 min at room 
temperature and protected from light, then resuspended in fresh Tyrode and used 
immediately.  Cells were scanned at 188 lines per second in XY imaging mode using a 
488 nm sapphire laser.  Emitted fluorescence was directed through a 560 nm long pass 
filter and collected with a PMT. 
 
2.8.1.1 T-tubule analysis 
Images were rotated until t-tubules aligned with a grid displayed onscreen.  A thin 
rectangular area approximately the length of the cell was selected close to the level of 
the nuclei avoiding the surface membrane and a pixel intensity profile was generated 
using ImageJ.  The mean pixel intensity values were imported into Origin and a Fast-
Fourier Transform performed.  A Gaussian best fit curve was fitted to the power 
spectrum in the frequency domain and used to calculate the amplitude of the first 
harmonic frequency (Figure 2.9) (Wei et al., 2010).  Orientation of tubules was 
assessed by first subtracting background to enhance contrast, applying median filtering 
to smooth the images, using automated thresholding to produce a binary image, then 
skeletonizing images and using the Directionality plugin in ImageJ (Figure 2.10) 
(Wagner et al., 2012).  Tubules oriented 90±5° to the long axis of the cell were 
considered transverse, while those at 0±5° to the long axis of the cell were considered 
longitudinal tubules. 
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Figure 2.9 T-tubule regularity 
The regularity of T-tubule spacing was analysed using a Fast-Fourier transform of the pixel intensity profile of a region across the long axis 
of the cell.  A The image was rotated to maximise the orientation of T-tubules perpendicular to a rectangular region of interest across the 
length of a cell (white box).  A fast-Fourier transform was applied to the pixel intensity profile (B) of the region of interest to find the power of 
the dominant spatial frequency.  C A Gaussian curve (red line) was fitted to the first harmonic of the fast-Fourier transformed data in the 
Frequency domain.  The amplitude of the curve (black arrow) indicates the regularity (or Power, in arbitrary units) of T-tubule spacing.  
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Figure 2.10 Analysis of tubule directionality 
The proportion of tubules in the transverse and longitudinal orientation was determined in skeletonized images of di-8-ANEPPS stained cells imaged 
on a confocal microscope.  A An area inside the cell was selected (excluding the surface sarcolemma) (upper panel) and converted to a binary image 
(lower panel) by pixel value thresholding.  B A histogram of tubule angles was plotted and the proportion of tubules from 85-95° (transverse) and 175-
185° (longitudinal) was counted.  
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2.8.2 Linescan Ca2+ imaging with Fluo-4 
The spatiotemporal characteristics of Ca2+ release were measured in cells loaded with 
the non-ratiometric Ca2+ indicator Fluo-4-AM, using line scanning confocal microscopy.  
In line scan mode a mirror repeatedly scans the laser across the same line in a cell and 
the pixel values are stacked as a function of time.  This allows discrete events such as 
Ca2+ sparks and regional variation in the timecourse of Ca2+ release to be visualised, 
which is not possible using epifluorescence. 
 
A 1 mM stock solution of Fluo-4-AM (Invitrogen, UK) was made in DMSO and stored at 
-20°C.  Cells were incubated with 6 μM Fluo-4-AM for 20 min at 22±1°C on a rocker 
and protected from light to prevent photobleaching.  Cells were re-suspended in fresh 
Tyrode and allowed to de-esterify for 45 min at 4°C before being used for experiments.  
A drop of cells was placed in the bath of an inverted confocal microscope and 
continually perfused with 750 µM Ca2+ Tyrode at 22±1°C.  Cells were electrically paced 
at 0.5 Hz with a 5 ms pulse duration (S48, Grass Instruments, Warwick, RI) using a 
pair of platinum electrodes.  A 488 nm sapphire laser repeatedly scanned across a line 
in the focal plane of the long axis of a cell at 188 lines per second.  Fluorescence was 
passed through a 520±20 bandpass filter and recorded using a PMT. 
 
2.8.2.1 Ca2+ release dyssynchrony 
The uniformity of Ca2+ release was quantified using the coefficient of variation of 
fluorescence at the beginning of a Ca2+ transient, termed the Dyssynchrony Index.  A 
pixel intensity profile was measured across the length of a cell using confocal line scan 
images of Fluo-4-AM (6 µM) loaded cells electrically paced at 0.5 Hz.  Regions of 
delayed Ca2+ release increased the variability (standard deviation) of pixel intensities.  
Dyssynchrony Index was calculated by dividing the standard deviation by the mean 
fluorescence multiplied by 100 to express as a percentage (Figure 2.11).  The standard 
deviation of the time to half maximum Ca2+ (measured line-by-line across the length of 
the cell using pClamp 10 (Molecular Devices, CA)) was used as an additional measure 
of heterogeneity in Ca2+ release (Caldwell et al., 2014).   
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Figure 2.11 Quantification of Ca2+ release spatial and temporal synchrony 
The spatial synchrony of Ca2+ release was measured in confocal linescan images 
during electrical pacing at 0.5 Hz.  A A pixel intensity profile was measured at the 
onset of a systolic Ca2+ transient (black dashed line).  B The standard deviation (gray 
shaded area) was divided by the mean (black dashed line) and multiplied by 100 to 
give the coefficient of variation (%).  The coefficient of variation value (―dyssynchrony 
index‖) increases with greater variation in the time to Ca2+ release across the cell.  
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2.9 High-resolution respirometry 
2.9.1 Equipment 
Mitochondrial respiration experiments were performed in an Oxygraph-2k (Oroboros 
Instruments, Innsbruck, Austria).  Two 2 mL glass chambers housed a Clark-type 
polarographic O2 sensor and PVDF-coated stirrer bar set to 700 rpm.  Both chambers 
were heated by a single Peltier heating block to 37±0.002°C.  PVDF stoppers fitted with 
Viton O-rings were lowered to seal the chamber from the atmosphere; care was taken 
to ensure no bubbles were present when the stoppers were fully lowered.  An injection 
port through the centre of the stopper allowed serial addition of substances to the 
chamber using a 5 or 25 μL Hamilton syringe (Figure 2.12).  O2 concentration was 
maintained between 200 and 400 μM by raising the stopper and injecting a few 
millilitres of 100% O2 with a 25 mL syringe (Pesta & Gnaiger, 2012); preliminary 
experiments showed respiration was not inhibited until the chamber O2 concentration 
fell below 50 µM. 
 
Clark-type electrodes were first developed by Leland Clark in 1954 (Severinghaus & 
Astrup, 1986) and consist of a gold or platinum cathode and Ag-AgCl anode in a KCl 
reservoir separated from the sample solution by a thin (~25 μm) fluorinated ethylene-
propylene copolymer membrane which is highly permeable to O2.  A constant potential 
(0.8 V) is applied which reduces O2 at the cathode by the following reaction: 
 
                     
 
The resulting current is directly proportional to the O2 partial pressure in the 
experimental medium.  Oxygen flux was corrected to account for this net consumption 
of O2 by the O2 sensor.  The O2 sensor was calibrated between two points: 1) a daily 
calibration was carried out in room air equilibrated respiration medium 2) a reference 
zero PO2 calibration point was obtained by titrating 100 μL of sodium dithionite (10 mM) 
to fully deplete dissolved O2 concentration to zero.  The same reference zero PO2 
calibration value was used for all experiments.  O2 concentration and O2 flux (the first 
derivative of the O2 concentration slope) were recorded every 2 s and analysed using 
DatLab 5.2 software (Oroboros Instruments, Innsbruck, Austria).  O2 flux was allowed 
to stabilise after substrate or inhibitor addition before subsequent additions. 
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Figure 2.12 Measurement of mitochondrial respiration in an oxygraph chamber 
Mitochodrial respiration was measured at 37°C in saponin permeabilised cells in the 
glass chamber of an Oxygraph 2K respirometer.  Cells were suspended in a 
mitochondrial respiration medium (MiR05) and were continually stirred by a PVDF 
stirrer. A PVDF stopper sealed the chamber from atmospheric O2, while an injection 
port allowed the addition of substances during an experiment.  A polarographic O2 
sensor recorded O2  concentration in the chamber every 2 s.  
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2.9.2 Myocyte permeabilization 
Some aspects of mitochondrial function can be measured in intact tissue and cells, 
however certain substrates can only access the mitochondrial outer membrane if the 
sarcolemma is first selectively permeabilised with digitonin or saponin.  Saponins have 
a steroid hydrophobic core which binds cholesterol and forms pores in the sarcolemma 
but leaves the mitochondrial and sarcoplasmic reticulum membranes relatively intact.  
This selectivity is due to the molar ratio of cholesterol to phospholipid being about 0.5 
in the sarcolemma but only 0.1 in the sarcoplasmic reticulum and 0.07 in the 
mitochondrial outer membrane (Korn, 1969). 
 
The density of isolated myocytes in solution was measured by pipetting 2 μL of cell 
suspension onto a microscope slide and counting cells under a microscope using a 20x 
objective.  Five replicate counts were made, the highest and lowest values were 
excluded and the remaining 3 counts were averaged to give the mean cell density.  
The volume of cell suspension added to each chamber was calculated according to cell 
density to use a constant number of cells (5000 cells/mL for SUIT protocol, 10000 
cells/mL for ADP titration protocol [see Section 2.9.3 and 2.9.4 for details]).  Cells in 
Tyrode solution were centrifuged and re-suspended in two changes of Mitochondrial 
Respiration Medium 05 (MiR05), containing (in mM): 110 D-sucrose, 60 K-lactobionate, 
20 HEPES, 20 taurine, 10 KH2PO4, 3 MgCl2.6 H2O, 0.5 EGTA, 1 mg/mL BSA, pH 7.1 
with 5N KOH.  The appropriate volume of cells was added to each oxygraph chamber 
to give a final volume of 2.1 mL in MiR05, then the chamber was sealed.  Saponin from 
Quillaja bark (Sigma, UK) was injected into the chamber at a final concentration of 25 
µg/mL, from a 25 mg/mL stock in water. 
   
2.9.3 Substrate-uncoupler-inhibitor titration (SUIT) protocol 
Serial addition of substrates feeding into complex I or II followed by selective inhibition 
of respiratory complexes allows individual complex activities to be determined in a 
functionally relevant manner.  Each substrate or inhibitor was added sequentially after 
respiration has stabilized.  FCCP, rotenone and Antimycin A were dissolved in EtOH, 
all other substances were dissolved in Milli-Q water.  The following were added to the 
oxygraphy chamber in this order at these final concentrations (Lemieux et al., 2011b): 
 
 Saponin (25 μg/mL) selectively permeabilizes the cell membrane making the 
mitochondria accessible to exogenous substrates. 
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 Glutamate (10 mM), malate (0.5 mM), and pyruvate (5 mM) were added to 
stimulate dehydrogenases yielding NADH as a source of electrons feeding into 
complex I in the absence of oxidative phosphorylation due to lack of adenylates 
(respiratory State 2). 
 ADP (2.5 mM) was added to maximally activate complex I supported oxidative 
phosphorylation (respiratory State 3). 
 Cytochrome c (10 μM) does not cross the mitochondrial outer membrane and 
was added to test mitochondrial integrity.  An increase in respiration <15% 
following cytochrome c addition indicated viable mitochondria (Wüst et al., 
2012). 
 Succinate (10 mM) was added to maximally activate succinate dehydrogenase 
production of FADH2 and thereby convergent complex I+II electron flow into 
complex III. 
 Carbonyl cyanide p-trifluoro-methoxyphenyl hydrazone (FCCP) was titrated in 
0.5 μM steps; FCCP is a protonophore which increases O2 flux if the 
phosphorylation system limits oxidative phosphorylation capacity.  In rat cardiac 
muscle the phosphorylation system is not limiting therefore the ratio of 
uncoupled:maximal respiration is ≤ 1, therefore only a single FCCP titration was 
added. 
 The complex I inhibitor rotenone (0.5 μM) was added to measure complex II 
activity in the absence of convergent complex I+II respiration. 
 The complex III inhibitor Antimycin A (2.5 μM) was added to inhibit cytochrome 
c reductase in complex III measure residual oxygen consumption in the 
absence of electron transport. 
 N,N,N',N'-Tetramethyl-p-phenylenediamine dihydrochloride (TMPD) (0.5 mM) 
was added as an artificial substrate for cytochrome c oxidase which has been 
shown to correlate well with mitochondrial mass (Larsen et al., 2012).  
Ascorbate (2 mM) was added to maintain TMPD in a reduced state and prevent 
uncontrolled autooxidation.  A chemical background correction for TMPD 
autooxidation was applied. 
 
2.9.4 ADP titration 
ADP and ATP diffuses across the mitochondrial outer membrane through the voltage-
dependent anion channel (VDAC).  Coupling of mitochondrial CK (CK-mt) in the 
mitochondrial intermembrane space with the ATP/ADP translocase increases the 
sensitivity of mitochondrial respiration to cytosolic ADP by catalysing the transfer of 
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phosphate from ATP to Cr, producing PCr and ADP which can re-enter the 
mitochondrial matrix.  Sequential titrations of ADP allow MOM permeability to be 
functionally assessed; addition of Cr to the medium further tests the ability of CK-mt to 
stimulate respiration. 
 
Cells were added to both oxygraph chambers according to the methods described in 
Section 2.9.3; in one of the chambers MiR05 was supplemented with 25 mM creatine 
monohydrate (Sigma, UK).  Glutamate (10 mM) and malate (0.5 mM) were added as 
reducing equivalents.  ADP was titrated to give the cumulative concentrations (in mM): 
0.05, 0.1, 0.2, 0.3, 0.4, 0.6, 0.8 and 1.0. 
 
The ADP-stimulated respiration was normalised between 0% (glutamate+malate in the 
absence of ADP) and 100% (respiration in 1 mM ADP) (Kaasik et al., 1999).  The 
Michaelis-Menten equation was fitted to the data to determine the apparent Km of 
mitochondria for ADP in the presence or absence of Cr. 
 
2.10 Biochemical analyses 
2.10.1 Tissue preparation and protein determination 
Frozen ventricle samples were thawed on ice, weighed and coarsely minced in a 
volume of homogenization buffer (HZ buffer) corresponding to 100 mg tissue/mL HZ 
buffer.  HZ buffer contained, in mM: 5 HEPES, 1 EDTA, 5 MgCl2, 0.1% Triton-X100 
(Brown et al., 1989).  Protease inhibitors (cOmplete™ Protease Inhibitor Cocktail, 
Roche, Bazel, Switzerland) and phosphatase inhibitors (Halt™ Phosphatase Inhibitor 
Cocktail, Thermo Scientific, Waltham, MA) were added to HZ buffer immediately prior 
to use.  Tissue was homogenized on ice at 30,000 rpm for 4x20 s pulses using a 
handheld homogenizer (T10, Ika-Werke, Germany).  Enzyme assays and CK isoform 
separation were performed on the crude homogenate (i.e. without centrifugation) and 
activity expressed as international units (IU) per mg protein.  An aliquot was centrifuged 
at 12000 g and the supernatant used for determination of protein concentration. 
 
2.10.2 Bicinchoninic acid (BCA) assay 
Protein concentration was determined according to the method of Smith et al. (1985) 
using the Pierce™ BCA Protein Assay Kit (Thermo Scientific, Waltham, MA).  In an 
alkaline environment divalent Cu2+ is reduced to monovalent Cu+ in the presence of 
peptide bonds, which occur equally with amino acids, turning purple in colour absorbing 
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maximally at 540 nm.  Bicinchoninic acid (BCA) reacts with Cu+ forming a deeper 
purple which makes the shift in absorbance greater (maximally absorbs at 562 nm) and 
hence improves the sensitivity of the reaction.  The reaction was performed in 96 well 
plates (Nunc™, Thermo Scientific, Waltham, MA).  Bovine serum albumin (BSA) was 
used as a protein standard and pipetted into wells in duplicate to give a final protein 
concentration between 0-50 µg/mL.  3 or 4 dilutions of each sample was made ranging 
from 1:2 to 1:20 and pipetted into wells in triplicate.  The reaction was started by adding 
BCA and copper(II) sulfate in a 50:1 ratio to each well to a final volume of 200 µL.  The 
plate was incubated at 37°C for 30 min then the optical density of each well was 
recorded at 562 nm in a spectrophotometer (Varioscan Flash, Thermo Scientific, 
Waltham, MA). 
 
2.10.3 Creatine kinase activity 
CK activity was determined spectrophotometrically from the production of NADPH 
according to the Rosalki assay (Rosalki, 1967): 
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NADPH absorbs UV light maximally at 340 nm whereas NADP does not.  β-
mercaptoethanol (1 mM) was added to each sample prior to CK assay.  CK activity 
assays were performed by medical technicians at Leeds General Infirmary, Leeds, UK. 
  
2.10.4 Citrate synthase assay 
Samples were prepared according to the methods described in Section 2.10.3.  Citrate 
synthase catalyses the reaction of acetyl-CoA with oxaloacetate in the tricarboxylic acid 
cycle, forming citrate and regenerating coenzyme A [Equation 1].  It is only found in 
mitochondria and therefore has been used as a marker of mitochondrial mass (Larsen 
et al., 2012).  Citrate synthase activity was measured using a colorimetric assay, 
according to the method of Srere (1969): 
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Figure 2.13 Citrate synthase assay 
Example of a citrate synthase activity assay.  The formation of TNB from CoA-SH and 
DTNB causes an increase in absorbance at 412 nm (OD412).  Reaction velocity was 
calculated between 0-30 s during which time the change in absorbance was linear. 
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CoA-SH chemically reacts irreversibly with 5,5‘-dithiobis-(2-nitrobenzoate) (DTNB) 
forming 5-thio-2-nitrobenzoate (TNB) which strongly absorbs light at 412 nm.  Thus the 
change in absorbance at 412 nm is proportional to citrate synthase activity. 
 
The assay was performed in triplicate in clear round-bottom 96-well plates in a 
spectrophotometer.  Homogenized samples were added to the reaction buffer 
containing, in mM: 150 Tris, 10 acetyl-CoA, 1 DTNB, pH 7.0 with HCl.  The assay was 
followed at 30°C for 60 s to measure baseline levels of thiol and acetylase activity, then 
oxaloacetate (0.5 mM) was dispensed into each well via an automated injection pipette 
to start the citrate synthase reaction.  The change in absorbance was followed for 60 s 
and enzyme activity calculated during a 30 s period when reaction velocity was linear 
(Figure 2.13).  The saturation of DTNB and oxaloacetate was confirmed by the lack of 
change in reaction rate when further DTNB or oxaloacetate was added. 
 
2.11 Statistics 
Statistical analyses were performed in SigmaStat 3.5 (Systat Software, San Jose, CA) 
and Prism 6 (Graphpad, La Jolla, CA).  Tests for normal distribution were performed in 
Prism 6.  Parametric statistical tests were performed where data followed a normal 
distribution, otherwise depending on the skewedness it was transformed (by log10 or 
squared), and normality was re-tested.  Parametric statistical tests were used on 
transformed data which passed tests for normality.  In cases where data still did not 
pass tests for normality, equivalent non-parametric statistical tests were used on the 
original data.  For reasons of clarity and consistency, all data are presented as 
mean±SEM, even when tests were performed on non-parametric or transformed data. 
 
When two unrelated groups were compared (e.g. CON vs FAIL), an unpaired t-test was 
used.  When three or more unrelated groups were compared (e.g. CON vs MCT+BB vs 
FAIL) a one-way ANOVA was used.  When more than one measurement was taken 
from the same subject a paired t-test or one-way repeated measures ANOVA was 
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used.  When multiple measurements were made from different groups (e.g. contraction 
at different pacing frequencies in CON vs MCT+BB vs FAIL) a two-way repeated 
measures ANOVA was used.  PINTERACTION values are given in some cases where there 
was a significant main effect of a variable (e.g. pacing frequency).  Categorical events 
(e.g. number of cells with and without Ca2+ waves in CON vs MCT+BB vs FAIL) were 
compared using Fisher‘s Exact test.  Survival curves were compared using a Mantel-
Cox (log rank) test.  A post hoc Bonferroni correction was used where multiple 
comparisons were made. 
 
P<0.05 was considered significant.  The following conventions are used to illustrate 
significant differences on figures: *P<0.05, **P<0.01, ***<P<0.001 vs CON, †P<0.05, 
††P<0.01,  †††P<0.001 vs FAIL.  Required sample sizes were calculated a priori using 
preliminary data or published results from the scientific literature.  Number of rats, 
hearts or cells used in each experiment are provided in the figure legends. 
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Chapter 3  Therapeutic potential of β-blockers in pulmonary 
arterial hypertension 
3.1 Introduction 
The therapeutic goal of currently approved PAH drug therapies is to increase 
pulmonary vasodilation thereby reducing afterload and the mechanical load on the 
heart which slows remodelling and delays, but does not prevent, RV failure (Delcroix & 
Naeije, 2010).  Despite RV failure being the leading cause of death in PAH patients it is 
not currently a target for drug treatment, which has led to calls for novel RV-specific 
therapies for this disease (Handoko et al., 2010). 
 
β-blockers are a mainstay of therapy in left heart failure due to their positive effects on 
morbidity and mortality following long-term treatment (Waagstein et al., 1989), however 
they are contraindicated in PAH due to concern that acute cardiodepressive effects 
may lead to catastrophic RV pump failure (Provencher et al., 2006a; Peacock & Ross, 
2010).  Indeed, the most recent European Society of Cardiology and European 
Respiratory Society guidelines for the treatment of PAH state: ―No convincing data are 
available on the usefulness and safety of angiotensin-converting enzyme inhibitors, 
angiotensin II receptor antagonists, beta-blockers or ivabradine in patients with PAH 
(Galiè et al., 2015b)‖.  However, recent retrospective analyses have shown no 
increased risk of morbidity or mortality in PAH patients receiving β-blockers to control 
co-morbidities such as high blood pressure, left heart failure and coronary artery 
disease (So et al., 2012; Thenappan et al., 2014; Bandyopadhyay et al., 2015).  
Furthermore, recent preclinical studies have demonstrated improvements in survival 
and RV function in rats with PAH treated with β-blockers (Bogaard et al., 2010; de Man 
et al., 2011), raising questions as to whether β-blockers are in fact detrimental to PAH, 
or might the long-term benefits of chronic treatment outweigh the short term negative 
inotropic effect. 
 
This chapter describes the effect of chronic treatment with a β1-specific AR blocker in 
rats with PAH.  Metoprolol significantly improved the survival of MCT rats compared to 
placebo treatment.  In vivo assessment of RV function using echocardiography and 
pressure-volume analysis showed metoprolol slowed the rate of RV functional 
deterioration without preventing PAH or regressing elevated pulmonary vascular 
resistance.  This suggests β-blockers are a potential cardiac-specific therapy for the 
treatment of PAH. 
  
99 
 
 
3.2 Methods 
Rats were injected with saline (CON) as control or 60 mg/kg monocrotaline (MCT) to 
induce PAH.  A sugar placebo solution (CON and FAIL) or 10 mg/kg/day metoprolol 
(MCT+BB and FAIL+BB) was administered daily by voluntary syringe feeding from day 
15 onwards.  All rats underwent a transthoracic echocardiography examination on day 
15 prior to their first dose of placebo or metoprolol.  Echocardiography and terminal 
pressure-volume analyses were performed according to the methods described in 
Chapter 2.  MCT+BB and FAIL+BB rats received identical treatment except that 
MCT+BB rats were taken on the median survival day of FAIL rats, whereas FAIL+BB 
rats were taken on the day heart failure symptoms developed (as described in Section 
2.1). 
 
A second echo examination and terminal cardiac catheterisation was performed: 1) on 
CON rats on the median survival day of FAIL rats (±1 day); 2) on MCT+BB rats on the 
median survival day of FAIL rats (±1 day); 3) on FAIL rats on the day heart failure 
symptoms developed; or 4) on FAIL+BB rats on the day heart failure symptoms 
developed.   
 
Appendix A details a further group of rats given a higher dose of 150 mg/kg/day 
metoprolol by inclusion in the drinking water in an attempt to replicate the study by 
Bogaard et al. (2010).  Despite extensive time and effort devoted to reproducing this 
study, no survival or functional benefit was found using this higher dose compared to 
placebo.  A comprehensive echocardiographic and pressure-volume characterisation of 
these rats and possible reasons for the discrepancy between our study and that of 
Bogaard et al. (2010) is provided. 
 
3.2.1 Validation of echocardiography 
Echocardiography had not previously been performed within the Cardiac Research 
Group at the University of Leeds in rats.  Therefore during the establishment of this 
technique the validity and reproducibility of measurements was characterised.  
Pulmonary artery acceleration time (PAAT) and stroke volume estimated using 
echocardiography were compared against their equivalents measured invasively by 
conductance catheter, and RV diastolic wall thickness was compared to the RV:LV+S 
ratio measured post-mortem (Figure 3.1). 
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There was a significant negative linear correlation between RV systolic pressure and 
PAAT, following the relationship: Pressure (mmHg) = 117.2-1.828[PAAT] (r2 = 0.58, 
P<0.001).  The slope of this relationship has been used as a non-invasive predictor of 
pulmonary artery systolic pressure in rats and humans (Jones et al., 2002; Urboniene 
et al., 2010).  There was also a significant negative correlation between RV systolic 
pressure and PAAT/ET however the relationship was worse than PAAT alone (r2 = 
0.29) (P<0.05).  There was a positive association between RV diastolic wall thickness 
and RV:LV+S ratio (r2 = 0.43) (P<0.001).  Stroke volume predicted by echo tended to 
increase with that measured by catheter (r2=0.16, P=0.10), however this was highly 
significantly different to the line of equivalence (y=x) (P<0.001). 
 
The reproducibility of blinded measurements was verified by repeating the analysis of a 
Doppler, M-mode and B-mode parameter following a gap of at least 8 months.  There 
was a good correlation between the first and second measurement of PAAT (r2 = 0.84), 
RV diastolic wall thickness (r2 = 0.55), and RV diastolic area (r2 = 0.82) (Figure 3.2).  
None of the slopes of these relationships significantly differed from the line of 
equivalence indicating that in our hands echocardiography is a reproducible method of 
monitoring the progression of PAH in rats. 
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Figure 3.1 Correlation between echocardiography and independent biometric indices 
A PAAT negatively correlated with RV systolic pressure measured during cardiac catheterisation. B RV wall thickness measured in M-mode 
increased with RV hypertrophy index C Stroke volume predicted from the Doppler flow tended to increase with conductance catheter 
measured stroke volume, however the relationship was significantly different from the line of equivalence (P<0.001).  
  
102 
 
PAAT RV wall thickness RV area
M e a s u re  1  (m m )
M
e
a
s
u
re
 2
 (
m
m
)
0 .0 0 .5 1 .0 1 .5 2 .0
0 .0
0 .5
1 .0
1 .5
2 .0
r
2
 =  0 .5 5
M e a s u re  1  (c m
2
)
M
e
a
s
u
re
 2
 (
c
m
2
)
0 .0 0 .2 0 .4 0 .6
0 .0
0 .2
0 .4
0 .6
r
2
 =  0 .8 2
M e a s u re  1  (m s )
M
e
a
s
u
re
 2
 (
m
s
)
0 2 0 4 0 6 0
0
2 0
4 0
6 0
r
2
 =  0 .7 5
A B C
Figure 3.2 Reproducibility of echocardiographic measures 
The reproducibility of Doppler, M-mode and B-mode measurements was verified by repeating the analysis under blinded conditions.  (A) 
PAAT, (B) RV diastolic wall thickness and (C) RV diastolic area all showed a high degree of reproducibility as the slopes of Measure 1 vs 
Measure 2 (thick line) did not differ from the line of equivalence (y=x) (thin line) (PAAT P=0.17, RV wall thickness P=0.40 , RV area 
P=0.30).  
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3.3 Results 
3.3.1 Survival and growth curve 
Between days 0 and 15 (i.e. before the start of treatment or placebo) CON rats gained 
on average 5.6±0.3 g.day-1, whereas MCT treated rats gained weight at a significantly 
slower rate (FAIL+BB 4.1±0.4 g.day-1, P<0.01 vs CON; FAIL 4.1±0.2 g.day-1, P<0.05 vs 
CON).  Rats continued to gain weight during the treatment period (i.e. from day 15 
onwards) however a loss of body weight occurred around day 21 in FAIL rats which 
indicated the onset of heart failure (see Section 2.1 for definitions).  Weight gain in 
FAIL+BB rats tended to plateau around day 25 after which there was a loss of body 
weight over several days (Figure 3.3).  On the day the humane endpoint was reached 
FAIL+BB rats lost on average 11.0±1.2 g and FAIL rats lost 8.7±1.1 g versus the 
previous day (not significantly different vs FAIL+BB).  The final bodyweight of FAIL+BB 
(273±7 g) and FAIL rats (260±3 g) was significantly less than CON rats (CON 306±8g; 
P<0.001).  The time taken to reach the humane endpoint was significantly increased 
from median day 23 in FAIL rats (N=12) to day 31 in FAIL+BB rats (N=15) (P=0.0019).  
This represents a 35% increase in longevity in metoprolol treated MCT rats compared 
to placebo. 
 
3.3.2 Anatomical characteristics 
The organs most affected by PAH were removed and weighed at the end of the 
pressure-volume experiment in CON, MCT+BB, FAIL+BB and FAIL rats.  Data were 
expressed either as absolute values, normalized to bodyweight (BW) to account for the 
slower rate of growth and weight loss of MCT treated groups, or as the ratio of RV to 
LV+interventricular septum (LV+S).  The hearts of MCT treated rats tended to be larger 
than those of CON rats.  In absolute terms the hearts of MCT treated rats were 
between 7-26% heavier than CON, however there were no statistical differences 
between groups (Figure 3.4).  However, when expressed relative to bodyweight the 
hearts of all MCT treated rats were significantly heavier than CON by between 28-33%.  
The RV of MCT treated rats was 81-120% heavier compared to CON rats, and 
expressed relative to bodyweight there was a greater than twofold increase in the 
RV:BW ratio.  In contrast there were no significant differences in LV+S weight between 
MCT treated and CON rats, although the LV+S of MCT+BB rats was significantly 
heavier than FAIL rats.  The increased LV+S weight in MCT+BB rats may have been 
due to the greater body weight, as there were no differences in LV+S:BW ratio 
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Figure 3.3 Growth and survival curve 
Two groups of MCT rats treated with either 10 mg/kg/day metoprolol (FAIL+BB) or 
placebo (FAIL) starting on day 15 were allowed to progress to heart failure to establish 
survival curves  A FAIL and FAIL+BB rats gained weight at a slower rate than CON 
rats then lost weight in the days preceeding the onset of heart failure. Data were fitted 
with a third-order polynomial curve; shaded areas represent 95% confidence intervals.  
B The median survival time of placebo treated FAIL rats was day 23, whereas in 
FAIL+BB rats the survival time was significantly increased to day 31.  No CON rats 
died during this period.  Mortality events were recorded as such if the symptom-limited 
humane endpoint was reached or the rat died unexpectedly. N= 11 CON, 15 FAIL+BB, 
12 FAIL. **P=0.0019 FAIL vs FAIL+BB.  
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Figure 3.4 Post-mortem organ and ventricle weights 
Rats were killed either on the day heart failure symptoms presented (for FAIL and 
FAIL+BB rats) or on the median survival day of FAIL rats (for CON and MCT+BB rats).  
Organs were removed and weighed and the heart dissected into RV and 
LV+interventricular septum (LV+S).  Data are shown as absolute values (A&B), 
expressed relative to body weight (C&D), or normalized to LV+S weight. N=10 CON, 5 
MCT+BB, 12 FAIL+BB, 12 FAIL rats.  *P<0.05, **P<0.01, ***P<0.001 vs CON; †P<0.05 
vs FAIL; aP<0.01 vs FAIL+BB.  
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between groups.  Thus cardiac hypertrophy in MCT treated rats was mainly restricted 
to the RV, as shown by the RV:LV+S ratio (Figure 3.4).  In CON rats the RV was 24% 
of the weight of the LV+S, whereas in FAIL rats the RV was 51% of the weight of the 
LV+S.  The RV:LV+S ratio was 9-11% lower in metoprolol compared to placebo treated 
rats at the median and failing stage, but this was not statistically significant. 
 
Lung congestion (reflective of elevated pulmonary artery pressure) was apparent in all 
MCT-treated groups, indicated by greater lung weight and lung:BW ratio (Figure 3.4).  
The liver weight and liver:BW ratio was not significantly different between groups, 
however owing to their lower bodyweight the liver:BW ratio tended to increase in MCT 
treated groups. 
 
3.3.3 Serial monitoring of PAH progression using echocardiography 
Echocardiography was performed on day 15 post-MCT injection and again on either 
the median survival day of FAIL rats or the day heart failure symptoms developed.  
Trends were emerging of early signs of hypertrophy and hypertension in MCT+BB and 
FAIL rats compared to CON although these were generally not statistically significant 
by day 15.  There were no significant differences in Doppler measurements between 
groups on day 15, with the one exception of peak pulmonary artery ejection velocity 
which was reduced in MCT+BB compared to CON rats (Table 3.1).  Systolic pressure 
was predicted from pulmonary artery acceleration time (PAAT) using an empirically 
derived formula (Section 3.2.1).  Estimated systolic pressure was increased by 12% in 
the MCT+BB group and by 29% in the FAIL group, indicating pulmonary hypertension 
was established by day 15, however the difference between groups was not statistically 
significant.  A trend towards chamber dilation was beginning in MCT treated rats, as 
the RV systolic chamber area measured in B-mode was significantly increased by 75% 
in FAIL compared to CON rats (Table 3.2).  There were also no statistically significant 
differences in M-mode measurements between groups on day 15 (Table 3.3), however 
MCT treated rats tended to have a thicker RV by 7-10% and a more dilated RV 
chamber. 
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Figure 3.5 Representative echocardiographic images of a CON, MCT+BB and FAIL heart 
A End-diastolic B-mode images in the PSAX view.  The RV is visibly dilated in MCT+BB and FAIL rats.  B The RV free wall is hypocontractile and 
thicker in MCT+BB and FAIL rats.  The LV is at the top and the RV on the bottom of each image.  C The parabolic or dome shaped Doppler blood 
flow profile in CON rats changes to triangular or peaked in MCT+BB and FAIL rats with a visible mid-systolic notch indicating early termination of flow.  
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Figure 3.6 Progression of PAH measured by echocardiography 
A Systolic PA pressure (predicted from PAAT) and (B) RV wall thickness increased, whereas (C) cardiac index (cardiac output normalized to body 
surface area) fell over time in FAIL and FAIL+BB rats. Note that measurements on day 23 and day ~31 were not taken from the same FAIL+BB rats, 
however as treatments were identical data are presented as a line graph. Pressure, wall thickness and cardiac index did not change over time in CON 
rats. Between-group differences are omitted for clarity but are detailed in Table 3.1 – 3.6. N=9 CON, 12 FAIL+BB, 7 FAIL rats.  *P<0.05, **P<0.01, 
***P<0.001 vs day 15.  
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The same rats were examined again on the day they went into heart failure (for 
FAIL+BB and FAIL groups) or on the median survival day of FAIL rats (for CON and 
MCT+BB rats).  Representative echo images of a CON, MCT+BB and FAIL rat taken 
on the median or failing day are shown in Figure 3.5.  Viewed in B-mode the RV 
chamber in CON rats appeared as a narrow crescent during diastole with a thin free 
wall, whereas the LV was nearly circular in cross-section and thicker walled.  In 
contrast the geometry of the heart was dramatically altered in MCT+BB and FAIL rats, 
in so far as the RV was severely dilated and hypocontractile with a thicker RV free wall 
and a reduced LV cavity with a ‗D‘ shape appearance due to compression by the 
interventricular septum.  The heart of MCT treated rats appeared to be rotated slightly 
anti-clockwise in the chest when viewed in B-mode.  M-mode analysis confirmed 
dilation and hypertrophy of the RV free wall.  Flow velocity profiles of the pulmonary 
artery were used to predict systolic pressure and RV stroke volume.  The parabolic 
Doppler flow velocity profile in CON rats changed towards a more asymmetric 
triangular shape with a mid-systolic notch in MCT+BB and FAIL rats. 
 
Heart rate was reduced in all MCT treated rats at the failing stage compared to CON, 
but there were no differences in heart rate between metoprolol-treated and placebo 
treated MCT rats.  PAAT was significantly reduced at the failing stage in MCT treated 
compared to CON rats and tended to be reduced in MCT+BB on the median day 
although to a lesser extent (P=0.06) (Table 3.4).  Doppler estimated stroke volume was 
reduced by 44-63% in failing groups compared to CON, but was only reduced by 29% 
in MCT+BB rats on the median day which was not significantly different to CON.  
Cardiac output and cardiac index (cardiac output normalized to body surface area) 
progressively decreased with increasing severity of heart failure (Figure 3.6). 
 
There was a three- to four-fold increase in systolic and diastolic RV chamber area in all 
MCT treated groups at the failing and median time points and fractional area change 
was reduced by about 50% compared to CON (Table 3.6).  LV chamber area was 
reduced in MCT treated groups at the failing stage but not in MCT+BB rats on the 
median day.  The LV chamber perimeter became less circular in cross-section in failing 
groups but was improved in MCT+BB rats and was not significantly different to CON. 
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Heart rate (bpm) 408 ± 7 396 ± 9 407 ± 11
PA acceleration time (ms) 35.7 ± 2.7 32.3 ± 2.2 27.4 ± 1.5
Velocity-time integral (cm) 6.04 ± 0.27 5.47 ± 0.20 5.17 ± 0.27
Peak velocity (m/s) 0.92 ± 0.03 0.79 ± 0.03* 0.86 ± 0.04
Ejection time (ms) 0.13 ± 0.01 0.14 ± 0.01 0.13 ± 0.01
     Systolic Pressure (mmHg) 52.0 ± 4.9 58.1 ± 4.0 67.1 ± 2.7
     Stroke Volume (µL) 129 ± 14 123 ± 10 106 ± 12
     Cardiac Output (mL/min) 53.0 ± 6.1 48.0 ± 4.2 43.2 ± 4.9
     Cardiac Index ( µL/cm
2
) 128.9 ± 14.8 116.3 ± 11.0 108.1 ± 13.4
CON
Data are mean±SEM.  Measurement were recorded 15 days after monocrotaline injection 
prior to the first dose of metoprolol or placebo.  Calculated values are shown in italics.  
MCT+BB and FAIL+BB rats have been combined into a single group at this stage called 
MCT+BB.  PA, pulmonary artery.  N= 9 CON, 12 MCT+BB, 7 FAIL rats. *P<0.05 vs CON.
FAILMCT+BB
Table 3.1 Doppler ultrasound measurements 15 days post-monocrotaline injection 
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Table 3.2 B-mode ultrasound measurements 15 days post-monocrotaline injection 
RV area diastole (cm
2
) 0.08 ± 0.01 0.12 ± 0.01 0.13 ± 0.02
RV area systole (cm
2
) 0.04 ± 0.01 0.06 ± 0.01 0.07 ± 0.01*
     RV area change (%) 51.5 ± 6.0 51.3 ± 5.0 41.3 ± 4.8
LV area diastole (cm
2
) 0.25 ± 0.01 0.25 ± 0.01 0.22 ± 0.02
LV area systole (cm
2
) 0.10 ± 0.02 0.10 ± 0.01 0.07 ± 0.01
     LV area change (%) 62.2 ± 4.1 61.3 ± 2.9 64.4 ± 3.3
     LV circularity (%) 88.4 ± 1.2 86.4 ± 1.6 83.0 ± 2.9
Data are mean±SEM.  Measurement were recorded 15 days after monocrotaline injection 
prior to the first dose of metoprolol or placebo.  Calculated values are shown in italics.  
MCT+BB and FAIL+BB rats have been combined into a single group at this stage called 
MCT+BB.    RV, right ventricle; LV, left ventricle.  N= 9 CON, 12 MCT+BB, 7 FAIL rats.  
*P<0.05 vs CON.
CON MCT+BB FAIL
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RV thickness diastole (mm) 0.68 ± 0.04 0.75 ± 0.05 0.73 ± 0.06
RV thickness systole (mm) 0.81 ± 0.04 0.91 ± 0.06 0.81 ± 0.07
RVID diastole (mm) 2.13 ± 0.24 2.56 ± 0.38 2.74 ± 0.48
RVID systole (mm) 1.22 ± 0.22 1.35 ± 0.26 1.77 ± 0.32
     RV wall shortening (%) 42.9 ± 6.9 50.0 ± 3.3 36.0 ± 5.5
IVS thickness diastole (mm) 1.73 ± 0.09 1.84 ± 0.11 1.82 ± 0.11
IVS thickness systole (mm) 2.21 ± 0.10 2.23 ± 0.13 2.30 ± 0.20
LV thickness diastole (mm) 1.83 ± 0.05 1.91 ± 0.10 1.93 ± 0.09
LV thickness systole (mm) 2.42 ± 0.12 2.75 ± 0.11 2.54 ± 0.18
LVID diastole (mm) 5.55 ± 0.21 5.53 ± 0.16 5.24 ± 0.36
LVID systole (mm) 3.66 ± 0.32 2.97 ± 0.26 2.81 ± 0.28
     LV wall shortening (%) 34.9 ± 4.0 46.0 ± 4.5 46.9 ± 2.6
FAIL
Data are mean±SEM.  Measurement were recorded 15 days after monocrotaline injection 
prior to the first dose of metoprolol or placebo.  Calculated values are shown in italics.  
MCT+BB and FAIL+BB rats have been combined into a single group at this stage called 
MCT+BB.    RV, right ventricle; IVS, interventricular septum; LV, left ventricle; ID, internal 
diameter.  N= 9 CON, 12 MCT+BB, 7 FAIL rats.
MCT+BBCON
Table 3.3 M-mode ultrasound measurements 15 days post-monocrotaline injection 
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Heart rate (bpm) 409 ± 9 340 ± 9** 330 ± 12*** 364 ± 12*
PA acceleration time (ms) 35.9 ± 3.0 26.5 ± 1.8
#
21.5 ± 1.4*** 20.5 ± 1.5***
Velocity-time integral (cm) 5.96 ± 0.19 3.67 ± 0.44** 2.84 ± 0.55*** 2.64 ± 0.41***
Peak velocity (m/s) 1.00 ± 0.03 0.76 ± 0.02* 0.63 ± 0.05*** 0.67 ± 0.08***
Ejection time (ms) 0.12 ± 0.01 0.12 ± 0.01 0.10 ± 0.01 0.08 ± 0.01**
     Systolic Pressure (mmHg) 51.5 ± 5.5 68.7 ± 3.4
$
76.3 ± 3.0** 79.6 ± 2.8***
     Stroke Volume (µL) 140 ± 13 100 ± 13 78 ± 15* 52 ± 9***
     Cardiac Output (mL/min) 57.7 ± 6.4 34.0 ± 4.4* 26.1 ± 5.9** 18.9 ± 3.4***
     Cardiac Index ( µL/cm 2) 129.0 ± 14.1 75.9 ± 8.7* 64.4 ± 14.4** 46.8 ± 8.2***
FAIL+BBCON
Data are mean±SEM.  Measurements were recorded on the day heart failure symptoms developed (Failing columns) 
or on the median survival day of FAIL rats (Median columns).  Calculated values are shown in italics.  PA, pulmonary 
artery.  N= 9 CON, 5 MCT+BB, 7 FAIL+BB, 7 FAIL rats. 
#
P=0.06, 
$
P=0.07, *P<0.05, **P<0.01, ***P<0.001 vs CON.
Median Failing
MCT+BB FAIL
Table 3.4 Doppler ultrasound measurements at the development of heart failure or the 
median survival day 
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RV thickness diastole (mm) 0.72 ± 0.04 1.08 ± 0.06**
††
1.04 ± 0.06**
†††
1.43 ± 0.07***
RV thickness systole (mm) 0.87 ± 0.07 1.40 ± 0.08** 1.24 ± 0.08*
†
1.59 ± 0.10***
RVID diastole (mm) 2.47 ± 0.26 4.68 ± 0.19 4.73 ± 0.46* 5.00 ± 0.26*
RVID systole (mm) 1.43 ± 0.17 4.10 ± 0.22*** 3.69 ± 0.58*** 4.10 ± 0.24***
     RV wall shortening (%) 39.5 ± 7.4 12.4 ± 3.5 26.0 ± 9.2 18.1 ± 1.4
IVS thickness diastole (mm) 1.88 ± 0.14 2.70 ± 0.15** 2.24 ± 0.19 2.16 ± 0.10
IVS thickness systole (mm) 2.35 ± 0.15 3.16 ± 0.18*
a
2.36 ± 0.22 2.46 ± 0.17
LV thickness diastole (mm) 1.98 ± 0.14 2.43 ± 0.18 2.04 ± 0.12 2.00 ± 0.15
LV thickness systole (mm) 2.90 ± 0.20 3.34 ± 0.15 2.52 ± 0.23 2.45 ± 0.19
LVID diastole (mm) 5.55 ± 0.30 5.13 ± 0.27 5.45 ± 0.20 4.93 ± 0.34
LVID systole (mm) 3.02 ± 0.26 3.10 ± 0.40 3.32 ± 0.55 2.98 ± 0.45
     LV wall shortening (%) 46.2 ± 2.3 40.0 ± 6.8 40.9 ± 6.9 39.4 ± 9.2
CON FAIL+BBMCT+BB
Data are mean±SEM.  Measurements were recorded on the day heart failure symptoms developed (Failing columns) 
or on the median survival day of FAIL rats (Median columns).  Calculated values are shown in italics.    RV, right 
ventricle; IVS, interventricular septum; LV, left ventricle; ID, internal diameter.  N= 9 CON, 5 MCT+BB, 7 FAIL+BB, 7 FAIL 
rats.  *P<0.05, **P<0.01, ***P<0.001 vs CON; 
††
P<0.01, 
†††
P<0.001 vs FAIL; 
a
P<0.05 vs [failing] MCT+BB.
Median Failing
FAIL
Table 3.5 M-mode ultrasound measurements at the development of heart failure or the 
median survival day 
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RV area diastole (cm
2
) 0.11 ± 0.01 0.30 ± 0.04** 0.31 ± 0.03*** 0.34 ± 0.04***
RV area systole (cm
2
) 0.05 ± 0.01 0.22 ± 0.02*** 0.23 ± 0.03*** 0.25 ± 0.03***
     RV area change (%) 52.0 ± 3.7 23.9 ± 4.9** 29.8 ± 6.4** 27.4 ± 3.1**
LV area diastole (cm
2
) 0.25 ± 0.02 0.18 ± 0.01 0.13 ± 0.02* 0.16 ± 0.02
LV area systole (cm
2
) 0.09 ± 0.01 0.07 ± 0.01 0.04 ± 0.01** 0.06 ± 0.01
#
     LV area change (%) 61.8 ± 2.6 64.0 ± 2.9 69.9 ± 2.5 61.2 ± 7.4
     LV circularity (%) 87.0 ± 0.9 76.2 ± 4.0
a
61.3 ± 5.3*** 65.0 ± 2.2***
Data are mean±SEM.  Measurements were recorded on the day heart failure symptoms developed (Failing columns) 
or on the median survival day of FAIL rats (Median columns).  Calculated values are shown in italics.  RV, right 
ventricle; LV, left ventricle.  N= 9 CON, 5 MCT+BB, 7 FAIL+BB, 7 FAIL rats.  
#
P=0.05, *P<0.05, **P<0.01, ***P<0.001 vs 
CON; 
a
P<0.05 vs [failing] MCT+BB.
CON FAIL+BB
Failing
MCT+BB FAIL
Median
Table 3.6 B-mode ultrasound measurements at the development of heart failure or the 
median survival day 
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RV wall thickening and chamber dilation were apparent using M-mode analysis of MCT 
treated rats.  This was specific to the RV as there were no changes in LV wall 
thickness, internal diameter or fractional shortening (Table 3.5).  Diastolic RV wall 
thickness was significantly reduced at the median and end stage in MCT+BB rats 
compared to FAIL rats.  The change in RV wall thickness from diastole to systole 
tended to be lower in FAIL (+11%) and FAIL+BB (+19%) compared to CON (+20%) 
and MCT+BB (+30%) although these differences were not statistically significant.  RV 
fractional wall shortening tended to be reduced in MCT treated rats, however due to 
high variability there were no significant differences between groups. 
 
3.3.4 In vivo haemodynamics at the onset of heart failure 
PV analyses were performed in CON, MCT+BB, FAIL+BB and FAIL rats; FAIL+BB rats 
appeared to be particularly vulnerable to dying during the PV procedure from either 
pump failure or heart block.  Increased sensitivity to inhaled anaesthesia and 
ventilation-perfusion mismatch has been reported in rats with heart failure which may 
have been exacerbated by β-blockers (Plante et al., 2006; Balestra et al., 2015).  
Consequently a dataset from only three rats was obtained at the failing stage and 
therefore has not been included in the statistical analysis but is presented in Appendix 
A.  Invasive cardiac pressure-volume measurements were performed and analysed by 
Dr Mark Drinkhill. 
 
The shape of cardiac PV loops in CON rats was fairly triangular with no obvious 
isovolumic contraction and persistent ejection during early relaxation (Figure 3.7).  In 
contrast the shape of FAIL and MCT+BB PV loops was more rectangular with clear 
isovolumic contraction and relaxation phases which tended to result in faster maximal 
rates of pressure development and decay in these rats.  The area enclosed by the 
workloop describes the work performed by the ventricle (stroke work) and tended to be 
greater in MCT+BB compared to CON and be less in FAIL rats compared to CON, but 
was significantly greater in MCT+BB compared to FAIL. 
 
End-systolic pressure in FAIL and MCT+BB rats was more than double that of CON 
(Figure 3.8).  Ejection fraction and stroke volume were significantly reduced in FAIL 
rats compared to CON, and there was a slight but not statistically significant increase in 
both of these measures in MCT+BB rats.  Pulmonary vascular resistance was 
calculated assuming a left atrial pressure of 8 mmHg (Lourenço et al., 2006).  Vascular 
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Figure 3.7 Right ventricle pressure-volume loops 
RV pressure and volume were measured under terminal anaesthesia and cardiac 
work loops constructed.  Traces rotate counter-clockwise during the contraction cycle 
starting from the lower right corner of each loop.  Transient occlusion of the inferior 
vena cava allowed the measurement of load independent parameters at decreasing 
end-diastolic volumes.  The CON recording shows a large stroke volume is achieved 
at low systolic pressure.  Systolic pressure is greatly increased but stroke volume is 
reduced in MCT+BB and FAIL rats.  
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Figure 3.8 In vivo RV pressure-volume measurements 
Pulmonary hypertension and RV dysfunction were evident in MCT+BB and FAIL rats as (A) elevated systolic pressure, (B) reduced ejection fraction 
and (C) depressed stroke volume.  D Pulmonary vascular resistance was elevated and not significantly different between MCT+BB and FAIL rats.  E 
Ventriculo-arterial coupling was assessed using the ratio of ESPVR to Ea, and was significantly depressed in FAIL compared to CON, while MCT+BB 
was intermediate between both groups. F The EDPVR was significantly increased in FAIL rats compared to CON, and was slightly reduced in 
MCT+BB.  Values for individual rats are shown by white circles while the group mean and SEM are shown by the coloured bars.  N=10 CON, 5 
MCT+BB, 7 FAIL rats.  *P<0.05, **P<0.01, ***P<0.001 vs CON.  
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Heart rate (bpm) 366 ± 11 340 ± 12 349 ± 16
End-systolic pressure (mmHg) 39.5 ± 2.7 101.8 ± 9.9* 83.2 ± 5.2*
End-diastolic pressure (mmHg) 4.6 ± 0.7 9.9 ± 2.3* 9.6 ± 0.7*
dP/dt max (mmHg/s) 3165 ± 188 5723 ± 744*** 4360 ± 371
dP/dt min (mmHg/s) -2971 ± 198 -3330 ± 292 -2854 ± 214
Tau (ms) 11.2 ± 0.5 14.7 ± 1.1** 14.0 ± 0.3**
End-systolic volume (µL) 49 ± 6 78 ± 30 52 ± 10
End-diastolic volume (µL) 127 ± 10 133 ± 29 91 ± 19
Stroke volume (µL) 110 ± 10 65 ± 5* 48 ± 10***
Cardiac output (mL.min
-1
) 40.4 ± 3.8 22.2 ± 2.3* 17.1 ± 4.1***
Stroke work (mmHg.µL) 3133 ± 343 4570 ± 467†† 2111 ± 469
Ejection fraction (%) 73.1 ± 3.6 53.3 ± 9.1* 49.2 ± 2.8**
Arterial elastance (Ea) (mmHg/µL) 0.41 ± 0.06 1.62 ± 0.22*** 2.49 ± 0.76***
ESPVR (mmHg/µL) 0.36 ± 0.10 0.75 ± 0.16 0.66 ± 0.21
EDPVR (mmHg/µL) 0.05 ± 0.01 0.09 ± 0.02 0.19 ± 0.06*
ESPVR/Ea 0.93 ± 0.27 0.57 ± 0.20 0.27 ± 0.06*
PVR (mmHg.min.mL
-1
) 0.23 ± 0.04 1.53 ± 0.23*** 2.38 ± 0.83***
Data are mean±SEM.  Measurements in CON and MCT+BB rats were recorded on the median survival 
day of FAIL rats, or in FAIL rats on the day heart failure symptoms developed.  dP/dt max, maximal rate 
of pressure development; dP/dt min, maximal rate of pressure decay; Tau, isovolumic relaxation time; 
Ea, arterial elastance; ESPVR, end-systolic pressure-volume relationship; EDPVR, end-diastolic 
pressure-volume relationship; PVR, pulmonary vascular resistance.  N= 10 CON, 5 MCT+BB, 7 FAIL 
rats.  *P<0.05, **P<0.01, ***P<0.001 vs CON; 
††
P<0.01 vs FAIL.
CON MCT+BB FAIL
Table 3.7 In vivo RV haemodynamic parameters recorded using a transmural 
conductance catheter 
  
120 
 
resistance was significantly elevated in both MCT+BB and FAIL rats, however there 
was no difference between MCT+BB and FAIL rats. 
 
The ESPVR tended to increase in MCT+BB and FAIL rats compared to CON, however 
there was also a large increase in arterial elastance (Ea) in both groups of rats.  This 
resulted in a fall in the ventriculo-arterial coupling (ESPVR/Ea) in FAIL rats which was 
improved in MCT+BB rats.  The load-independent EDPVR was significantly elevated in 
FAIL rats compared to CON indicating reduced ventricle compliance to diastolic filling.  
EDPVR was intermediate in MCT+BB indicating a partial improvement of diastolic 
function.  Other evidence of diastolic dysfunction in FAIL rats was significantly elevated 
end-diastolic pressures and prolonged isovolumic relaxation times (Tau) which were 
elevated to a similar extent in MCT+BB rats (Table 3.7). 
 
3.4 Discussion 
3.4.1 Monocrotaline-induced pulmonary arterial hypertension 
Rats were injected with 60 mg/kg MCT as a minimally-invasive means to induce PAH 
which develops into right-sided heart failure within 4 weeks.  We used a clinically 
relevant humane endpoint which defined the onset of heart failure based on its outward 
functional effects such as lethargy, dyspnoea, sustained weight loss and cold 
extremities.  In the days preceding the onset of heart failure the activity level of rats 
monitored using running wheels is reduced and tachypnoea is apparent (Natali et al., 
2015).  This is consistent with both the New York Heart Association classification of 
heart failure (1994) and the International Classification of Diseases, Ninth Revision 
(ICD-9) Code 428, which define heart failure according to the inability of the heart to 
maintain a sufficient blood supply to meet the metabolic demands of the body resulting 
in an exercise limitation. 
 
FAIL rats all lost weight either suddenly (>10 g lost overnight) or over several days 
before the onset of heart failure indicating the presence of cardiac cachexia.  Cachexia 
is an incompletely understood complication of chronic heart failure associated with 
worse prognosis which may arise due to reduced appetite, altered metabolic state and 
reduced nutrient absorption brought about by neurohormonal imbalance, altered blood 
flow and inflammation (Anker & Sharma, 2002; von Haehling et al., 2007).  The slower 
weight gain in FAIL rats is partly due to lower food intake, however this is not the sole 
cause as CON rats gain weight faster even when their food intake is restricted to that of 
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FAIL counterparts (Lourenço et al., 2006).  Reduced activity and limited cardiac output 
means blood is diverted away from the periphery and towards the vital organs, 
resulting in a cold tail to the touch.  Congestion in the lungs due to accumulation of 
alveolar oedema may also occur and exacerbate dyspnoea.  The arterial O2 saturation 
of MCT rats is lower which suggests oedema or possibly acute lung injury becomes a 
barrier to gas exchange (Ishikawa et al., 1991; Schermuly et al., 2004).   
 
An advantage of the MCT model is the relatively rapid onset of PAH which has been 
shown using echocardiography and continuous telemetry monitoring of PA pressure to 
occur within 2 weeks (Hess et al., 1996; Jones et al., 2002), and it is for this reason we 
chose to start treatment with metoprolol on day 15 as our aim was to treat existing PAH 
rather than prevent the onset of PAH, the former having more clinical relevance.  We 
used non-invasive echocardiography to monitor the change in RV function and systolic 
pressure over time and consistent with previous reports found a tendency for MCT rats 
to have early signs of PAH by day 15 post-MCT injection as shown by decreased 
PAAT and slightly thicker RV free walls.  This is in good agreement with the 
echocardiographic study of Jones et al. (2002) who found significantly reduced PAAT 
by day 15  and a tendency for increased RV wall thickness by day 17. 
 
Functional changes in the hearts of MCT rats were largely confined to the RV, 
consistent with a lack of effects of MCT on the systemic circulation (Schermuly et al., 
2004).  RV weight was significantly increased both in absolute terms and normalized to 
body weight.  There was no direct effect of MCT on LV weight or wall thickness, 
although due to the lower bodyweight and weight loss in MCT rats the LV+S:BW ratio 
tended to increase.  This is consistent with pressure overload being necessary to 
stimulate hypertrophic gene expression in MCT rats (Kögler et al., 2003).  In situations 
where adult body weight fluctuates, such as aging or in this case heart failure, 
normalizing heart weights to tibial length may correlate more closely with myocyte 
hypertrophy (Yin et al., 1982), or alternatively Fulton‘s Index (the RV:LV+S ratio) may 
be used in the case of specifically RV hypertrophy.   
 
Further evidence of RV specific dysfunction was reduced ejection fraction only in the 
RV and not the LV of MCT treated rats.  The function of LV cardiomyocytes and 
trabeculae is generally found to be preserved or sometimes augmented in MCT rats 
(Kögler et al., 2003), however eventually LV systolic pressure falls possibly as a result 
of interventricular interactions and reduced preload (Correia-Pinto et al., 2009).  A fall 
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in systemic pressure can be catastrophic as this reduces the coronary perfusion 
pressure and hence risks myocardial ischaemia.  The flattening of the septum and 
reduced LV circularity results from the decreased interventricular pressure gradient 
which impairs LV filling due to pericardial constraint and thus reduces its force 
generating capacity (Figure 3.5) (Portman et al., 1987).  We did not find evidence of in 
vivo LV dysfunction at any stage of disease, however there was compression and 
reduced LV cavity area in failing rats.  The orientation of the heart of MCT-treated rats 
was rotated anti-clockwise in the chest due to RV hypertrophy and dilatation.  This 
would be detectable as right-axis deviation in the electrical axis of the heart recorded 
on an electrocardiogram. 
 
The cause of death in rats which died suddenly could not be established due to the 
need to intervene at the humane endpoint when animals showed signs of distress.  
However there are reports that AV block is the most prevalent cause of death in 
conscious freely moving MCT rats monitored with telemetry (Liguo et al., 2013), 
although spontaneous ventricular fibrillation leading to death has also been reported 
(Liles et al., 2012; Rey et al., 2012).  This is consistent with sudden death occurring in 
around 20% of PAH patients, whereas RV pump failure is the most common cause, 
accounting for around 30% of deaths (Delcroix & Naeije, 2010).  Some FAIL rats died 
when undergoing the PV procedure which was usually preceded by a progressive fall 
in RV force development suggesting the contractility of the failing RV is an important 
determinant of survival in MCT treated rats. 
 
3.4.2 β-blockers improve survival in pulmonary arterial hypertension 
The key finding of this chapter is that the β1-specific AR blocker metoprolol significantly 
improved survival in rats with pre-exisiting PAH.  The time to onset of heart failure was 
delayed by 35% when daily treatment with 10 mg/kg metoprolol was started on day 15.  
Concomitant with this was an improved functional status of the RV compared to time-
matched FAIL rats.  Using echocardiography it was possible to monitor the progression 
of PAH and RV dysfunction and it was found that while metoprolol slowed the 
deterioration in RV function, at the onset of heart failure RV function was similar in FAIL 
and FAIL+BB rats.  This highlights the importance of the RV as a determinant of 
survival in PAH and justifies further investigation into the causes of contractile 
dysfunction and its subsequent rescue following chronic β-blocker therapy (van de 
Veerdonk et al., 2011). 
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There have been limited investigations of β-blockers in rodent models of PAH which 
have used selective or non-selective blockers in different models of PAH, including 
MCT, PAB and chronic hypoxia.  The most direct comparison to our study is that of 
Perros et al. (2015) who independently have also treated MCT rats with both 10 and 
100 mg/kg/day metoprolol administered by daily subcutaneous injection starting on day 
14 and performing PV analyses on all rats 7 days later on day 21.  As such their MCT 
rats were at a compensated rather than failing stage, however no survival curve was 
established in this study.  Their data is much in agreement with ours as 10 mg/kg 
metoprolol did not affect RV systolic pressure or RV hypertrophy but increased cardiac 
output, whereas in contrast to our study slightly reduced pulmonary vascular 
resistance.  Interestingly none of these changes occurred with a higher dose of 
metoprolol which is in agreement with our findings using 150 mg/kg/day (Appendix A).  
Their main finding was that the third generation β-blocker and vasodilator, nebivolol, a 
highly selective (10x greater than metoprolol) β1 antagonist and β2/3 agonist exerted a 
greater benefit in compensated MCT rats by reducing pulmonary arteriole remodelling 
and vascular resistance through improved endothelial cell function.  However in rats 
studied at 28 days post MCT, when rats are more likely to be in a failing stage, cardiac 
output was not different in nebivolol compared to untreated rats. 
 
Bogaard et al. (2010) found a small improvement in survival in MCT rats treated with a 
higher dose of 150 mg/kg/day metoprolol dissolved in drinking water whereas 15 
mg/kg/day carvedilol (non-selective α1/β1/β2 blocker) delivered by gavage produced a 
greater survival benefit when administered 2 weeks after MCT injection.  The greater 
survival benefit using carvedilol was attributed to reduced muscularization of pulmonary 
arterioles which lowered PA pressure and reduced hypertrophy, in contrast to 
metoprolol which partially improved in vivo RV function but did not affect vascular 
remodelling or systolic pressure.  In humans the recommended equivalent dose of 
metoprolol tartrate is 50 mg per 25 mg carvedilol (Poole-Wilson et al., 2003; Di Lenarda 
et al., 2005), therefore the 10-fold higher dose of metoprolol compared to carvedilol 
reported by Bogaard et al. (2009) may result from inaccuracies in the monitoring of 
drug intake. 
 
de Man et al. (2011) treated MCT rats with 10 mg/kg bisoprolol (selective β1 blocker) 
from day 10 until signs of heart failure were manifest or, in their absence, day 31 and 
found a significant improvement in survival without a regression of RV hypertrophy.  
Similar to our study, RV contractility was improved, as shown by a partial restoration of 
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ventriculo-arterial coupling (ESPVR/Ea), stroke volume and cardiac output, as well as 
improved diastolic function (decreased EDPVR).  Increased phosphorylation of 
myofilament proteins downstream of PKA was reported suggesting resensitization of 
βAR signalling. 
 
Cheng et al. (2012) found improved RV cardiomyocyte contraction and relaxation and 
reduced microtubule proliferation in a cat PAB model treated with propanolol (non-
selective β1/β2 AR blocker), despite no change in RV systolic pressure or RV 
hypertrophy.  However, the effectiveness of β-blockers in other models of RV failure 
has been equivocal, with some studies showing improvement whereas others have not.  
Andersen et al. (2014) found no beneficial in vivo haemodynamic effects of bisoprolol 
in rats with either moderate or severe PAB, although there were also no negative 
consequences.  This discrepancy with our findings may be due to differences between 
models, as PAB causes a sudden and proximal occlusion of the PA whereas MCT 
causes a distal progressive increase in vascular resistance.  Despite similar increases 
in RV systolic pressure MCT rats eventually progress to heart failure whereas PAB rats 
do not (Borgdorff et al., 2013).  Furthermore the stages of disease could be quite 
different, as even severe banding may only reduce cardiac output by 36% without 
significantly reducing the ESVPR/Ea ratio (Andersen et al., 2014), whereas we found 
MCT reduced cardiac output by 58-66% and caused ventriculo-arterial uncoupling 
indicating a more severe heart-failure phenotype. 
 
3.4.2.1 β-blocker dose equivalence 
The US Food and Drug Administration (2002) warns against direct extrapolation of 
doses between animal and human studies according to body weight, and that 
normalizing by body surface area gives a better translation.  Accordingly the human 
equivalent dose (HED) can be calculated by multiplying the animal dose by the ratio of 
animal to human mass per body surface area (Km), where Km is the empirically derived 
mean body weight (kg) divided by body surface area (m2): 
 
                                 
        
       
   
 
We treated rats with a dose of 10 mg/kg/day metoprolol and the Km for rats and adult 
humans is 6 and 37 kg/m2, respectively (Reagan-Shaw et al., 2008).  Thus according to 
FDA recommendations the human equivalent dose we used was 1.62 mg/kg/day which 
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is very similar to the typical clinical dose of metoprolol prescribed in left heart failure: 
150 mg per day, or ~2 mg/kg/day for a 75 kg human. 
 
Comparisons between doses in animals and humans may further be affected by 
differences in the kinetics of uptake and metabolism which influence bioavailability.  
Extensive hepatic and intestinal first-pass metabolism of metoprolol by cytochrome 
CYP2D6 means its bioavailability in rat is around 20% of the oral dose compared to 
40% in humans, and plasma concentrations peak within 30 min in rat compared to 1-2 
h in humans (Darmansjah et al., 1990; Johnson & Burlew, 1996).  Therefore the 
bioavailability of the dose we used is expected to be on the lower end of a clinical dose.  
Administration routes may also affect the outcome, for instance gavage versus 
continuous infusion by osmotic minipump, or immediate versus slow release 
formulations will result in different circulating levels of metoprolol (Darmansjah et al., 
1990).  The pharmacokinetics of metoprolol metabolism are saturable and dose-
independent above oral doses of 2 mg/kg in rat (Yoon et al., 2010), therefore a single 
bolus (as we used) will result in a greater area under curve than an equivalent total 
dose consumed in drinking water over several hours. 
 
Interactions between potential therapies must also be considered as drugs can inhibit 
or compete for breakdown by the same enzymes and therefore remain in circulation for 
longer.  For instance, accumulation of metoprolol due to inhibition of CYP2D6 by the 
anti-arrhythmic drug amiodarone was believed to cause severe systemic hypotension 
in a single case study of a patient with PAH (Fukumoto et al., 2006; Peacock & Ross, 
2010).  The major breakdown pathways of sildenafil are through CYP3A4 and CYP2C9 
whereas metoprolol is extensively metabolised by CYP2D6 (Johnson & Burlew, 1996; 
Wojtczak et al., 2014), making dual therapy with these drugs a possibility in PAH so 
long as care is taken to avoid systemic hypotension.  In contrast, carvedilol is also 
metabolized by CYP3A4 and CYP2C9 suggesting interactions between carvedilol and 
sildenafil could occur if administered simultaneously (Oldham & Clarke, 1997). 
 
Heart rate reduction is a commonly used metric to compare the functional effects of 
different β-blockers which may differ in their pharmacological potency.  The doses of β-
blockers used by Bogaard et al. (2010) were titrated to lower heart rate by 20%, 
whereas a heart rate reduction of 10% was used by de Man et al. (2011).  We found no 
significant difference in resting heart rate under anaesthesia in MCT+BB compared to 
FAIL rats, however heart rate tended to be reduced in both groups anyway possibly 
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due to increased sensitivity to anaesthetic (Benoist et al., 2012).  Heart rate reduction 
is an important but not the sole mechanism through which β-blockers are thought to 
work, for instance Sabbah et al. (2000) found 2 mg/kg/day metoprolol reduced 
apoptosis in a canine model of coronary microembolism without significantly affecting 
heart rate.  Also, Nagatsu et al. (2000) found some improvement in cardiomyocyte 
contractility in a canine model of mitral regurgitation treated with atenolol (specific β1 
blocker) despite bradycardia being prevented using an implanted pacemaker. 
 
3.4.3 Possible mechanisms of improved survival 
Our data indicates the survival benefit conferred by chronic β-blocker treatment is 
independent of afterload reduction as there was no change in systolic pressure or 
pulmonary vascular resistance (Figure 3.8).  This is consistent with the high β1 
selectivity of metoprolol acting on AR found predominantly on the myocardium.  
Consistent with our findings, Perros et al. (2015) and de Man et al. (2011) also found β1 
blockers had no effect on systolic pressure, little effect on pulmonary vascular 
remodelling and no difference in the RV:LV+S ratio in drug treated MCT rats.  However 
in spite of the persisting mechanical load cardiac output was increased in the 
aforementioned studies as well as in the current work.  This suggests the mechanism 
through which β1 blockers improve PAH may be through directly enhancing or 
preserving the contractility of the RV. 
 
The ESPVR is considered an index of contractility as it changes in response to 
inotropic agents which increase the contractility of cardiomyocytes.  ESPVR is 
considered load-independent as it is not influenced by arterial resistance or preload, 
unlike SV and ejection fraction which are highly rate and afterload-dependent.  
However it is sensitive to diastolic stiffening and chamber geometry and therefore does 
not always give an accurate reflection of the contractile state of the heart.  An important 
consideration is whether RV contractility is matched to vascular resistance, as stroke 
work and SV are highly dependent on arterial elastance (Ea).  Burkhoff and Sagawa 
(1986) predicted that maximal stroke work was achieved when the ESPVR/Ea ratio 
was 2.0, but in healthy humans and rats the heart normally operates at a ratio closer to 
1.6 where work efficiency is greater (Starling, 1993; Ruiter et al., 2013).  In FAIL rats 
Ea was significantly increased due to the high vascular resistance and although 
ESPVR also tended to increase this was not sufficient to prevent significant ventriculo-
arterial uncoupling in these rats.  This indicates the contractile capability of the RV is 
severely impaired in FAIL rats.  Interestingly, the ESPVR/Ea ratio was partially restored 
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in MCT+BB rats, indicating enhanced RV contractility may be critical to the 
improvement in cardiac output in these rats.  This was also found by de Man et al. 
(2011) in bisoprolol treated MCT rats, and although they did not study the mechanisms 
in detail, they suggest reduced fibrosis and increased phosphorylation of myofilament 
proteins targeted by PKA may improve the contractile capability of the RV. 
 
Diastolic stiffness was significantly increased in FAIL rats compared to CON but was 
reduced in MCT+BB rats, however the end-diastolic pressure and Tau were still 
significantly elevated in MCT+BB compared to FAIL rats.  Both of these factors are 
highly load dependent and therefore are likely to have been influenced by the larger 
EDV and systolic pressures which were not affected by β-blocker treatment.  The 
steeper EDPVR in FAIL rats may include a slowly cycling crossbridge component 
brought about due to the inability to control cytosolic levels of ADP due to loss of CK 
(see Chapter 6 and Fowler et al. (2015a)), therefore the partial improvement in RV 
compliance may arise due to restoration of the CK system in MCT+BB rats.  Increased 
CK expression was also reported in a rat model of MI treated with bisoprolol either 
early or late after induction of MI (Laser et al., 1996).  The extent to which the CK 
system was affected depended on the delay between MI and the initiation of treatment, 
suggesting early intervention is critical to preventing remodelling. 
 
3.4.4 Echocardiography in pulmonary arterial hypertension 
Echocardiography was a newly available technique at the University of Leeds at the 
start of this study therefore the validity and reproducibility of measurements was 
established.  We found a good linear correlation between PAAT and RV systolic 
pressure which is in agreement with the findings of Dabestani et al. (1987) in humans 
and Jones et al. (2002) in MCT rats.  This relationship occurs due to interference 
between the pulse wave and a reflected wavefront arising due to resistance from 
pulmonary arterioles (Naeije & Torbicki, 1995).  Decreased arterial compliance in PAH 
causes an early collision of wavefronts which briefly increases pressure and decreases 
flow, resulting in a shortening of PAAT and the characteristic mid-systolic notch in the 
Doppler flow-velocity profile in severe PAH (Figure 3.5).  This characteristic feature can 
also be used to discriminate the etiology of disease as PAH has a mid-systolic notch 
whereas thromboembolic pulmonary hypertension does not as the distal arterioles 
have normal compliance in these patients (Nakayama et al., 1997).  The relationship 
between PAAT and systolic pressure in the current study (117.2-1.828[PAAT]) was 
similar to that reported by Kosanovic et al. (2011) (~ 95-1.818[PAAT]) in MCT rats.  
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Our y-intercept was higher, possibly due to the relatively few values with a long PAAT 
and low systolic pressure.  Kitabatake et al. (1983) found the relationship between 
PAAT and pressure was curvilinear and that the logarithm of PAAT vs pressure 
improved the correlation, however using the logarithm (r2 = 0.61) or not (r2 = 0.58) had 
little effect on the goodness of fit as our dataset had minimal skew. 
 
There was a significant correlation between RV wall thickness measured by echo and 
RV:LV+S ratio.  Interestingly there was a significant reduction in diastolic RV wall 
thickness in MCT+BB and FAIL+BB rats compared to FAIL but no significant difference 
in RV:LV+S ratio.  It is possible the improved diastolic compliance in MCT+BB rats 
resulted in a tendency towards increased RV end diastolic volumes (Table 3.5) which 
would tend to stretch and therefore reduce the thickness of the RV measured using 
echo.  In contrast, the reduced compliance in FAIL rats is likely to be due at least in 
part to the RV cardiomyocytes not fully relaxing (see Fowler et al. (2015a) and 
CHAPTER 4 and 6).  Thus the increased wall thickness in FAIL rats may be partly due 
to hypertrophy and also partly due to impaired cardiomyocyte relaxation. 
 
Stroke volume predicted from PA flow measured by echo tended to increase with 
volume measured by invasive cardiac catheterisation, however there was not a 1:1 
relationship.  This does not necessarily mean the Doppler measurement is unreliable, 
as Urboniene et al. (2010) found a good correlation in MCT rats between stroke volume 
measured by MRI and high resolution Doppler echocardiography.  Our Doppler and 
catheter measurements were not taken simultaneously therefore there may have been 
some deterioration in cardiac function between the non-invasive echo examination and 
invasive catheterisation.  Another possible source of error is in the volumes calculated 
using a conductance catheter in the RV which has a more complex geometry and 
anatomy than the LV.  In humans this can be corrected by using multiple ring 
electrodes on the catheter to segment the RV, however the small size of rodent hearts 
precludes this strategy (Champion et al., 2009).  Alternatively volumes can be 
corrected against an independent volume measurement, termed α, such as Doppler 
predicted flow or thermodilution (Pacher et al., 2008; Borgdorff et al., 2013), however 
there are also errors associated with these methods, therefore correcting for α may 
simply compound the errors. 
 
Due to the asymmetric nature of RV contraction neither fractional area change nor wall 
shortening measured in the parasternal short axis are ideal indicators of RV function 
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(Rudski et al., 2010).  This may explain the high variability and lack of significant 
differences between CON and MCT+BB groups, despite fractional RV shortening being 
around half that of CON rats.  Fractional area change in the apical 4 chamber (A4C) 
view or tricuspid annular plane excursion (TAPSE) also measured in A4C, are better 
measures of RV function however accurate assessment of these imaging windows was 
not possible due to the limited resolution of our ultrasound system. 
 
Using echocardiography we were further able to characterise the function of FAIL+BB 
rats at the onset of heart failure (echo data was usable from 7/7 rats) whereas due to a 
lower tolerance to the PV procedure invasive data could only be obtained from 3/7 
FAIL+BB rats.  Thus echocardiography could reduce animal usage.  Our echo findings 
reveal the RV function of FAIL+BB rats at the onset of heart failure is similar to FAIL as 
cardiac index and fractional area change are reduced and systolic pressure is 
increased equally.  This is in agreement with RV function being a key determinant of 
survival in PAH (van Wolferen et al., 2007; Grünig et al., 2013; Courand et al., 2015). 
 
A possible limitation of our findings is that we may have been measuring an acute 
functional improvement in the RV of MCT+BB and FAIL+BB rats due to the time 
between their last dose of metoprolol and the in vivo measurements (>14 h).  
Metoprolol tartrate has a short biological half-life and the majority of a single dose will 
be metabolized during this time (Yoon et al., 2010; Lee et al., 2013).  However a 
measureable reduction in exercise heart rate, which is considered a better indicator of 
β-block than resting heart rate, persists in humans up to 12 h after a single dose of 
metoprolol tartrate despite minimal levels of the drug in the plasma, suggesting even 
low doses exert β-blocking activity (Darmansjah et al., 1990).   
 
Intraobserver reliability was best when measuring PAAT as the correlation coefficient 
was lowest (17%) compared to RV wall thickness (24%) and RV area (56%).  A large 
part of the variability will be due to the level of experience in image analysis, for 
instance experienced clinical echocardiographers may have intraobserver variability as 
low as 7% for PAAT (Dabestani et al., 1987).  A further source of error lies in the 
resolution of our system since at maximum resolution (0.08 mm.pixel-1) variation by 1 
pixel could over or underestimate RV wall thickness by around 10%.  For this reason all 
analyses were performed blinded to the treatment of the rat and the timepoint being 
measured.  Evidence of successful blinding is clearly shown in Figure 3.6, in which 
there is negligible variability in CON parameters between days 15 and 23, but clear 
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early indications of PAH with progressive RV dysfunction over time in FAIL and 
MCT+BB rats. 
 
3.4.5 Conclusions 
The main finding of this work is that the β1-specific AR blocker metoprolol significantly 
improved survival in MCT rats and partially restored RV function in vivo as shown by 
echocardiography and PV analyses.  This is likely to have arisen due to an improved 
functional status of the RV, as when metoprolol-treated rats were allowed to progress 
to heart failure the RV function was similar to placebo treated FAIL rats.  Importantly, 
these functional improvements arose independent of a reduction in pulmonary vascular 
resistance and systolic pressure.  Metoprolol did not appear to have a preventative 
effect on RV hypertrophy indexed by RV:LV+S, perhaps because of the sustained 
mechanical load on the ventricle. 
 
In light of the current findings and previously published preclinical literature, β-blockers 
appear to be safe and may confer benefits in PAH which includes increased survival 
and RV function (Bogaard et al., 2010; de Man et al., 2011).  Non-selective β-blockers 
appear to work primarily through promoting vasodilation through PKG and nitric oxide 
pathways and preventing vascular remodelling thus unloading the RV (de Man et al., 
2011), whether this vasodilating effect would still occur if given in combination with 
traditional therapies in PAH patients in which nitric oxide synthesis is already impaired 
has yet to be investigated (Giaid & Saleh, 1995).  In contrast, selective β1-AR blockers 
appear to preserve RV contractility independent of afterload reduction, possibly by 
reducing apoptosis and increasing angiogenesis and signalling through PKA pathways 
(Bogaard et al., 2010; de Man et al., 2011). 
 
In the past 15 years 9 drugs have been approved by the US Food and Drug 
Administration for use in PAH, all of which target either the endothelin, nitric oxide or 
prostacyclin signalling pathways, however survival is still poor and the efficacy of 
combination therapy with multiple vasodilators on survival has produced mixed results 
suggesting a ceiling has been reached using these treatments (McLaughlin et al., 
2014; Galiè et al., 2015a).  New treatment pathways are therefore needed and on the 
basis of our findings we propose β-blockers could be used as an adjunctive therapy 
alongside conventional afterload reducing treatments, thus targeting two independent 
causes of RV failure: progressive vascular remodelling and RV contractile dysfunction.  
Naturally there are important provisos to this suggestion: 1) interactions between β-
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blockers and conventional therapies would first need to be established in preclinical 
investigations and 2) the efficacy of β-blockers would need to be shown in properly 
monitored clinical trials using a ―start low, go slow‖ approach before wider uptake could 
be considered.  Thus while we were not able to prevent heart failure, which is probably 
only possible by normalizing the mechanical afterload experienced by the RV, by using 
a β1-specific AR blocker whose actions are primarily on the myocardium, we were able 
to significantly increase survival in rats with pre-existing PAH. 
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Chapter 4  Altered energy metabolism in pulmonary artery 
hypertension and rescue by β-blockers 
4.1 Introduction 
The heart is the most energy-consuming organ in the body, cycling through 30 kg of 
ATP per day, equivalent to around 300 mg ATP per heart beat, most of which is used 
to generate the mechanical forces required to pump blood through the vasculature 
(Weiss et al., 2005; Ferrari et al., 2006).  The energy demand of the myocardium is 
proportional to cardiac work, therefore an increase in afterload must be met with an 
increase in energy supply (Khalafbeigui et al., 1979).  In human heart failure 
myocardial levels of high energy phosphates and flux through the CK system are 
reduced and are associated with worsening prognosis (Nascimben et al., 1996; 
Brioschi et al., 2012; Bottomley et al., 2013), leading to the suggestion the failing heart 
is ―energy starved‖ (Ingwall & Weiss, 2004).  Altered mitochondrial energy metabolism 
is thought to play a major role in the pathogenesis of PAH by inducing vascular 
remodelling and impairing energy production in the RV (Paulin & Michelakis, 2014; 
Ryan & Archer, 2014).  Conversely, overexpression of CK-M in mice with LV pressure 
overload improves ejection fraction and SV with increased energy flux through the CK 
system (Gupta et al., 2012).  In this chapter RV O2 supply, energy metabolism and 
energy shuttling from the mitochondria to the cytosol via the mitochondrial CK system 
are investigated in MCT rats. 
 
4.2 Methods 
For detailed methods see Chapter 2. 
 
4.2.1 Animal model 
Rats were injected with MCT or saline as described previously in Chapter 2.  Daily 
treatment with 10 mg/kg/day metoprolol (MCT+BB) was initiated 15 days after MCT 
injection.  Experiments were performed on CON and MCT+BB rats on the median 
survival (±1 day) of FAIL rats, or on FAIL rats on the day heart failure symptoms 
developed. 
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4.2.2 Histology 
Hearts were arrested in diastole using cold (4°C) 0.1 mM EGTA I.S. and dissected in 
EGTA I.S. on ice using a safety razor blade to prevent cutting injury producing 
contracted regions and morphological artefacts in the samples (Gerdes, 2015).  A 
portion of the mid-RV free wall was frozen in OCT and 10 µm thick sections were cut 
using a cryostat.  Sections were stained with picrosirius dye or fluorescein-conjugated 
lectin to identify collagen and capillaries, respectively.  Tissue PO2 was predicted from 
capillary distribution using the model of Al-Shammari et al. (2012) (see Section 
2.4.2.1). 
 
4.2.3 Mitochondrial function 
Electron transport system 
Mitochondrial respiration was measured in saponin permeabilized RV cardiomyocytes 
(isolated according to the methods described in Chapter 2) in the sealed chamber of an 
oxygraph recorder.  Activities of different components of the electron transport system 
were interrogated by the sequential addition of substrates or inhibitors of different 
respiratory complexes (Kuznetsov et al., 2008).  The sequence of additions and a 
typical oxygraph recording are shown in Figure 4.1.  TMPD (0.5 mM)+ascorbate (2 
mM) feed electrons directly into complex IV and the resulting O2 flux corresponds to 
mitochondrial mass, therefore data were normalized to TMPD O2 flux measured at the 
end of the experiment (Larsen et al., 2012).  Flux control ratios (FCR) which are 
independent of cell density and mitochondrial mass were also calculated as the ratio of 
O2 flux to a theoretical maximum uncoupled flux with convergent Complex I+II electron 
flow. 
 
CK-mt coupling to respiration 
The ability of CK-mt to stimulate respiration was investigated by the sequential titration 
of submaximal concentrations of ADP to the oxygraph chambers with or without 
creatine (25 mM).  Data were normalized to basal respiration without ADP and 
maximum respiration in 1 mM ADP and fitted with the Michaelis-Menten equation to 
calculate the apparent Km for ADP and maximum respiration (Vmax). 
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Figure 4.1 Substrate uncoupler inhibitor titration protocol 
Oxygen flux (red line) was measured in saponin permeabilized cells. LEAK respiration was measured in the presence of CI substrates.  Addition of 
ADP initited oxidative phosphorylation (OXPHOS). Succinate addition initiated maximal convergent CI+II OXPHOS. CII activity was measured in the 
presence of rotenone. Residual oxygen consumption (ROX) was measured using Antimycin a. Flux control ratios were calculated normalized to the 
theoretical maximal uncoupled CI+II activity (ETSCI+II). Dashed lines in the trace indicate reoxygenation events.  
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4.3 Results 
4.3.1 Coronary microcirculation 
RV cryosections were stained with fluorescein-conjugated lectin and viewed under an 
epifluorescent microscope to visualise and quantify myocardial capillary supply.  
Brightly stained capillaries were apparent with clear boundaries and a circular lumen.  
Lectin also faintly stained the glycocalyx surrounding myocytes allowing the 
identification of muscle fibre boundaries. 
 
Capillary density (CD) progressively decreased from 2400 capillaries per mm2 in CON 
hearts to 1700 per mm2 in MCT+BB and 1200 per mm2 FAIL.  CD was significantly 
reduced by 49% in FAIL compared to CON, and there was a trend for CD to be lower 
(by 28%) in MCT+BB compared to CON (P=0.06) (Figure 4.2).  Consequently the 
mean area of myocardium supplied by each capillary increased from 427 µm2 in CON 
to 648 µm2 in MCT+BB and 869 µm2 in FAIL.  Myocyte hypertrophy alone could 
account for the reduced capillary density in FAIL rats, therefore the capillary to muscle 
fibre ratio (C:F) was calculated.  The average C:F in CON and MCT+BB rats was 1.21 
and 1.25 respectively, whereas it was around 25% lower in FAIL (0.90), although 
differences between groups were not statistically significant. 
 
Tissue PO2 was predicted from the spatial distribution of capillaries and diffusivity of O2 
in tissue.  The dense and fairly homogeneous distribution of capillaries in CON hearts 
resulted in high levels of tissue oxygenation with relatively few areas of hypoxia (Figure 
4.3).  In contrast the majority of tissue in MCT+BB and FAIL rats was hypoxic due to 
the sparse population of capillaries, although MCT+BB tended to be intermediate in 
oxygenation between CON and FAIL.  The mean tissue PO2 in CON hearts was 13.7 
mmHg, whereas it was 65% lower in MCT+BB (6.2 mmHg) and 82% lower in FAIL (2.5 
mmHg). 
  
136 
 
C O N M C T + B B F A IL
0 .0
0 .5
1 .0
1 .5
C
a
p
il
la
ry
:F
ib
e
r 
ra
ti
o
CON FAILMCT+BBA
B
C D E
C O N M C T + B B F A IL
0
1 0 0 0
2 0 0 0
3 0 0 0
C
a
p
il
la
ri
e
s
 p
e
r 
m
m
2
* * *
P = 0 .0 6
C O N M C T + B B F A IL
0
5 0 0
1 0 0 0
1 5 0 0
C
a
p
il
la
ry
 s
u
p
p
ly
 a
re
a
 (

m
2
)
* * *
*
Figure 4.2 Myocardial capillary supply 
A Representative images of RV sections stained with fluorescein-labelled lectin showing capillaries as bright green spots and muscle fibre 
boundaries.  B Voronoi cells showing supply area of capillaries in (A).  C Capillary density was lower in MCT+BB rats (P=0.06) and FAIL compared to 
CON. D The area of myocardium supplied by each capillary increased in MCT+BB and FAIL compared to CON. E The capillary to muscle fibre ratio 
tended to stay the same in MCT+BB compared to CON but decrease in FAIL, although not significantly so.  N=6 rats in each group. *P<0.05, 
***P<0.001  
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Figure 4.3 Prediction of myocardial tissue oxygenation 
A Heat map showing capillary distribution (white circles) and predicted tissue PO2. Capillary distribution in RV sections was digitised and finite 
element calculations applied to model the spatial profile of tissue PO2.  B Mean tissue PO2 was greatly reduced in MCT+BB and FAIL rats.  C The 
fractional area of myocardium which was hypoxic (PO2 < 0.5 mmHg) was greater in MCT+BB and FAIL rats. N= 6 rats in each group. *P<0.05, 
***P<0.001  
  
138 
 
4.3.2 Myocardial fibrosis 
Myocardial fibrosis was estimated histologically in transverse RV and LV cryosections 
using picrosirius red staining.  Collagen fibres which contain a high proportion of basic 
amino acid residues stain red whereas the cytosol of myocytes is stained yellow by 
picric acid.  Collagen staining was clearly identifiable as punctate points of deep red 
colour in contrast to light yellow muscle fibres (Figure 4.4).  The faintly stained 
perimysial collagen demarcating the muscle fibre boundaries was not included in the 
analysis, also regions containing arterioles (which are strongly stained due to 
perivascular collagen) were avoided during image capture.  The fractional area of 
collagen was not different between CON, FAIL or MCT+BB rats in either the RV or LV.  
Collagen fractional area ranged from a minimum of 1.6% to a maximum of 4.7% in all 
samples. 
 
4.3.3 Mitochondrial mass 
Citrate synthase (CS) is the first enzyme of the TCA cycle and is located exclusively in 
the matrix of mitochondria allowing it to be used as a biomarker of mitochondrial mass 
(Larsen et al., 2012).  CS activity was measured in RV homogenates using a 
colorimetric assay and normalized to protein concentration.  CS activity tended to be 
lower in FAIL and MCT+BB RV compared to CON, by 19% and 20% respectively, 
however the difference between groups was not statistically significant (Figure 4.5).  
CS activity was plotted as a function of HW:BW ratio to see if CS activity was 
associated with the extent of hypertrophy.  The average HW:BW ratio was increased in 
both FAIL and MCT+BB compared to CON (CON 4.02±0.10 mg.g-1, MCT+BB 
5.15±0.27 mg.g-1, FAIL 5.01±12 mg.g-1; P<0.01 vs CON), however there was no 
significant correlation between CS activity and HW:BW ratio (P=0.31). 
 
4.3.4 High-resolution mitochondrial respiration in situ 
Mitochondrial respiration was measured in isolated RV cardiomyocytes in situ by 
selectively permeabilizing the sarcolemma with saponin and supplying exogeneous 
substrates for respiration following a SUIT protocol (Kuznetsov et al., 2008).  Data were 
expressed normalized either to TMPD (as a marker of mitochondrial mass (Larsen et 
al., 2012)) or to an internal reference of maximum and minimum oxygen flux.  Viable 
results were only obtained from 13/26 rats (subsequently found to be due to retention 
of rotenone within the oxygraph chambers) meaning a partial data set from 
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Figure 4.4 Myocardial fibrosis 
A Representative images of RV sections stained with picrosirius dye.  Collagen areas 
are stained red whereas myocardium stains yellow.  The fractional area occupied by 
red staining was used as an index of fibrosis.  B There were no statistical differences in 
collagen fractional area between groups of rats in either the RV or LV.  N=5 CON, 6 
MCT+BB, 6 FAIL RV samples, N=6 CON, 5 MCT+BB, 6 FAIL LV samples.  
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Figure 4.5 Citrate synthase activity 
A Activity of the mitochondrial marker enzyme citrate synthase was not different in RV 
homogenates from different groups of rats.  B  There was no correlation between 
citrate synthase activity and HW:BW (P=0.31).  N= 6 rats per group.  
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only two MCT+BB rats was obtained in the time available.  Therefore only CON and 
FAIL groups were analysed statistically and any P values reported are for comparisons 
between these two groups (t-test); however there were no significant differences 
between CON and FAIL for any parameter measured therefore MCT+BB data has also 
been presented in the figures purely for reference.  Cells from one CON rat produced a 
greater than 15% increase in respiration following addition of Cyt c indicating damage 
to the mitochondrial inner membrane and was therefore excluded from analysis; all 
other cells had <15% increase in respiration indicating viable mitochondria (Kuznetsov 
et al., 2004; Wüst et al., 2012). 
 
Oxidative phosphorylation (OXPHOS) driven by complex I substrates in the presence 
of saturating ADP (OXPHOSCI) tended to be lower in FAIL compared to CON, but 
elevated in MCT+BB compared to CON and FAIL (Figure 4.6A).  The addition of the 
complex II substrate succinate caused a large increase in respiration driven by 
maximal convergent electron flow into the Q-junction (OXPHOSCI+II).  OXPHOSCI+II also 
tended to be lower in FAIL compared to CON, but increased in MCT+BB cells (Figure 
4.6B).  Respiration in the absence of ATP production due to lack of adenylates and 
therefore mainly due to leak of protons back across the inner membrane due to the 
proton pumping action of CI (LEAK) also tended to be decreased in FAIL but increased 
in MCT+BB compared to CON cells (Figure 4.6C).  The coupling of respiration to the 
phosphorylation system was tested by measuring the increase in CI respiration 
following the addition of ADP (acceptor control ratio, ACR).  There was an increase in 
ACR in FAIL, which was nearly double that of CON (P=0.065, t-test); ACR in MCT+BB 
cells was similar to CON (Table 4.1).  Residual O2 consumption (ROX) in the absence 
of electron transport and therefore primarily due to cellular oxidase enzymes was 
similar between all groups.  ROX as a proportion of OXPHOSCI+II was also similar 
between groups. 
 
The protonophore FCCP was added to test for possible limitation of respiration by the 
F1F0-ATP synthase and measure maximal uncoupled capacity of the electron transport 
system with convergent CI+II substrates.  There was no significant difference in 
maximal respiration before (OXPHOSCI+II) and after (ETSCI+II) uncoupling in either CON, 
MCT+BB or FAIL cells (Table 4.1).  Maximal uncoupled respiration tended to be slightly 
lower in FAIL compared to CON, but increased in MCT+BB in relation to both (Figure 
4.7A).  Uncoupled respiration driven by CII (ETSCII) was measured by addition of 
rotenone to inhibit CI; ETSCII was maintained between CON and FAIL and slightly 
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Figure 4.6 Phosphorylating and non-respiratory O2 flux in RV cells 
There were no significant differences between (A) CI driven OXPHOS or (B) maximal OXPHOS through convergent CI+II electron flow.  C Non-
phosphorylating respiration (in the absence of adenylates) tended to be lower in FAIL than CON and MCT+BB cells.  D Residual O2 consumption 
(ROX) was not different between groups.  O2 flux in each condition was normalized to flux with the artificial electron donor TMPD.  RV cells from N= 5 
CON, 2 MCT+BB (excluded from statistical analysis), 6 FAIL rats.  
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Figure 4.7 Uncoupled capacity of the electron transport system 
Uncoupled respiration was measured in RV cells in the presence of FCCP. A Maximal uncoupled respiration with convergent CI and CII substrates 
(ETSCI+II). B Uncoupled respiration driven by CII substrates (ETSCII) was measured in the presence of rotenone. C Uncoupled respiration driven by CI 
was calculated by subtracting ETSCII from ETSCI+II. O2 flux in each condition was normalized to flux with the artificial electron donor TMPD.  RV cells 
from N= 5 CON, 2 MCT+BB (excluded from statistical analysis), 6 FAIL rats.  
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MCT+BB
OXPHOSCI/ETSCI+II 0.27 ± 0.04 0.29 ± 0.04 0.24 ± 0.03
OXPHOSCI+II/ETSCI+II 1.00 ± 0.07 1.00 ± 0.03 0.98 ± 0.06
ETSCI/ETSCI+II 0.33 ± 0.05 0.23 ± 0.04 0.24 ± 0.02
ETSCII/ETSCI+II 0.67 ± 0.05 0.77 ± 0.04 0.76 ± 0.02
ETSCI/ETSCII 0.53 ± 0.13 0.32 ± 0.04 0.30 ± 0.07
LEAK/ETSCI+II 0.04 ± 0.01 0.05 ± 0.01 0.02 ± 0.01
ROX/OXPHOSCI+II 0.03 ± 0.01 0.02 ± 0.01 0.03 ± 0.01
ACR 8.7 ± 1.7 6.3 ± 0.4 18.5 ± 4.0
#
Data are mean±SEM.  For definitions of respiratory states and substrates please see Methods.  
ROX, residual oxygen consumption; ACR, acceptor control ratio.  N= 5 CON, 2 MCT+BB (excluded 
from statistical analysis), 6 FAIL rats. 
#
P=0.065 vs CON
CON FAIL
Table 4.1 Flux control ratios in RV cells 
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increased in MCT+BB.  Uncoupled CI respiration (ETSCI) was calculated by subtracting 
ETSCII from ETSCI+II; ETSCI tended to decrease from CON > MCT+BB > FAIL (Figure 
4.7C). 
 
Internal normalization was achieved by dividing O2 flux under different substrates by 
maximal uncoupled respiration (ETSCI+II) to obtain flux control ratios (FCR).  There were 
no significant differences in any of the FCR between groups (Table 4.1).  The ETSCI 
FCR tended to decrease whereas the ETSCII FCR tended to increase in FAIL 
compared to CON (P=0.105, t-test); similar results were seen in MCT+BB cells.  Thus 
the proportional reliance on CI versus CII respiration tended to shift from 53% in CON 
to 32% in FAIL (P=0.14, t-test); a similar change was seen in MCT+BB cells.  LEAK 
FCR was low in all groups of cells accounting for between 2-5% of maximal respiration.  
The ROX FCR was also low in all groups and contributed 2-3% of O2 flux under 
maximal uncoupled conditions. 
 
4.3.5 CK system 
Total creatine kinase (CK) activity was measured spectrophotometrically in RV tissue 
homogenates.  CK activity decreased by 33% in FAIL and similarly was reduced by 
30% in MCT+BB compared to CON (Figure 4.8).  CK activity in each sample was 
plotted against its corresponding HW:BW ratio to test whether CK activity changed in 
relation to hypertrophy.  There was a significant linear negative correlation between 
HW:BW ratio and CK activity.  We have previously reported decreased expression of 
the mitochondrial CK isoform (CK-mt) in Fowler et al. (2015a) and wanted to test 
whether reduced CK-mt expression was linked to reduced coupling to respiration. 
 
Mitochondrial sensitivity to exogeneous ADP and the functional coupling of CK-mt to 
respiration were assessed in permeabilized cardiomyocytes supplied with NADH-linked 
substrates by the sequential titration of submaximal concentrations of ADP in the 
presence and absence of creatine.  In the absence of creatine there was a progressive 
increase in respiration with each titration of ADP which appeared to plateau close to 1 
mM ADP (Figure 4.9B).  Cells from the same heart were tested simultaneously in a 
second oxygraph chamber with 25 mM creatine.  A greater increase in O2 flux occurred 
in the presence of creatine at lower concentrations of ADP and flux tended to plateau 
between 0.6 and 0.8 mM ADP in CON cells, whereas a smaller leftward shift in the 
curve was seen in MCT+BB and FAIL cells (Figure 4.9A).  Maximum O2 flux (Vmax) was 
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calculated by fitting data with the Michaelis-Menten equation.  Vmax was not significantly 
different between groups, or in the presence or absence of creatine (Table 4.2). 
 
The data was well described by the Michaelis-Menten equation, allowing the apparent 
KmADP to be calculated.  In CON cells in the absence of creatine the high KmADP 
indicated low sensitivity of respiration to exogeneous ADP.  The KmADP without 
creatine was 29% and 57% lower in FAIL and MCT+BB than CON respectively, 
although these differences were not significant.  Creatine significantly reduced the 
KmADP in CON cells whereas there was a non-significant reduction in MCT+BB and 
FAIL (Table 4.2).  The functional coupling or efficiency of CK-mt to stimulate respiration 
was measured as the percentage difference in KmADP in the presence or absence of 
creatine (De Sousa et al., 1999).  The change in KmADP with creatine was greatest in 
CON cells and progressively fell in MCT+BB and FAIL cells, indicating reduced 
coupling of CK-mt to respiration in MCT treated rats (Figure 4.9C).  There was a 
significant negative correlation between percentage change in KmADP and HW:BW 
ratio, indicating that CK-mt coupling decreased when hypertrophy increased (Figure 
4.9D).
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Figure 4.8 Total creatine kinase activity 
A Total CK activity in RV homogenates was significantly reduced in MCT+BB and FAIL 
rats.  B There was a significant negative correlation between CK activity and the 
corresponding HW:BW.  N=6 rats per group.  ***P<0.001 vs CON.  
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Vmax (pmol.s
-1.mL-1) 120 ± 15 145 ± 14 74 ± 3 93 ± 8 305 ± 122 421 ± 165
KmADP (mM) 0.35 ± 0.05 0.14 ± 0.02* 0.20 ± 0.04 0.11 ± 0.02 0.25 ± 0.03 0.18 ± 0.03
Data are mean±SEM. Oxygen consumption was measured in RV cells from the same heart simultaneously in the presence 
or absence of creatine, during titrations of submaximal concentrations of ADP.  Data were fitted with the Michaelis-Menten 
equation to calculate maximal flux (Vmax) and the apparent Km for exogeneous ADP (Km[ADP]).  RV cells from N= 8 CON, 3 
MCT+BB, 5 FAIL rats. *P<0.05 vs CON without creatine.
MCT+BB
+Creatine
FAIL
+Creatine
CON
+Creatine
Table 4.2 Creatine stimulated respiration in mitochondria in situ 
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Figure 4.9 Mitochondrial creatine kinase coupling 
A Average O2 flux of RV cells in the presence (broken lines) and absence (solid lines) of creatine.  Data was normalized to maximum (in 1 mM ADP) 
and minimum (0 mM ADP) OXPHOS respiration.  Creatine caused a leftward shift in the curve indicating increased sensitivity of respiration to 
exogenous ADP.  B Typical oxygraph recording of CON RV cells in the presence (broken lines) and absence (solid line) of creatine.  C There was a 
greater change in the apparent Km for exogeneous ADP in the presence of creatine in CON cells compared to MCT+BB and FAIL cells.  D There was 
a significant negative correlation between change in Km[ADP]  and HW:BW ratio.  Some error bars are smaller than symbols.  RV cells from N=8 
CON, 3 MCT+BB, 5 FAIL rats.  *P<0.05 
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4.4 Discussion 
4.4.1 Microvascular alterations in heart failure 
Myocardial O2 uptake is closely related to cardiac work and systolic wall stress.  Using 
echocardiography we calculated a 140% increase in RV wall stress in FAIL rats due to 
elevated systolic pressures and more dilated ventricles, indicating RV O2 demand will 
also be increased (Benoist et al., 2014).  Wong et al. (2011b) also showed that heart 
rate and systolic pressure are the main determinants of myocardial O2 uptake in 
patients with PAH.  Accordingly, van Wolferen et al. (2008) showed RV coronary 
perfusion is higher in PAH patients on average as a group compared to healthy control 
patients, however within the PAH group mean RV coronary perfusion negatively 
correlated with RV mass, suggesting myocardial perfusion and oxygenation may limit 
function in severe PAH.  β-blockers may be beneficial to an ischaemic RV by reducing 
heart rate and prolonging the diastolic interval as well as promoting angiogenesis which 
will increase perfusion and improve myocardial oxygenation (Ferrari et al., 2006; 
Bogaard et al., 2010). 
 
Hauton et al. (2015) replicated the effect of capillary rarefaction by infusing polystyrene 
microspheres into Langendorff perfused rat hearts which lead to heterogeneous 
regional hypoxia and a fall in the force of contraction.  Using the same model we now 
show similar heterogeneity occurring in the RV of FAIL rats which may impair pump 
function, whereas it was partially improved in MCT+BB rats.  Improved RV oxygenation 
could account for the enhance stroke work in MCT+BB rats compared to FAIL, 
identified in Chapter 3 (Khalafbeigui et al., 1979).  Ischaemia may be a stimulus for 
altered substrate utilisation as carbohydrate oxidation yields a greater energy output 
per litre O2 (21.14 kJ) than fatty acid oxidation (20.04 kJ) suggesting a switch from 
primarily fatty acid oxidation in health to carbohydrate oxidation and glycolysis in failing 
hearts could compensate for reduced oxygenation (Piao et al., 2010).  A further 
consequence of reduced oxygenation could be non-contractile cells which would 
increase the load of the ventricle and reduce mechanical efficiency; a decrease in 
mechanical efficiency has been reported in RV trabeculae from MCT rats which 
correlated with the extent of cardiomyocyte hypertrophy (Wong et al., 2010).  Stretch of 
non-contracting cells may cause another undesirable effect through stretch activated 
ion channels triggering arrhythmias (Kohl et al., 2001); MCT rats have previously been 
shown to exhibit a pro-arrhythmic phenotype (Benoist et al., 2012). 
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Figure 4.2 shows capillary density (CD) decreases in both MCT+BB and FAIL rats 
thereby increasing the area supplied by each capillary.  The partial restoration of 
capillary density in MCT+BB rats could be due in part to a reduction in muscle fibre 
hypertrophy, but also a normalization of the capillary to fibre ratio (CF).  These data are 
in agreement with well conducted studies on CD in healthy versus hypertrophic human 
(3300 vs 2500 mm-2 (Roberts & Wearn, 1941)) and rat ventricle (3400 vs 2900 mm-2 
(Gerdes et al., 1979)).  Reduced CD has previously been reported in the rat MCT and 
PAB models, however in both these cases treatment with bisoprolol did not restore CD 
(de Man et al., 2011; Andersen et al., 2014), whereas in the SuHx rat model metoprolol 
restored CD (Bogaard et al., 2010).  These differences may be due to differential 
effects on the regression of hypertrophy following treatment which profoundly 
influences CD; CF is therefore a better indicator of capillary angiogenesis or 
rarefaction.  CF showed a tendency for a reduction in FAIL rats, whereas it was 
preserved in MCT+BB and CON, suggesting capillary rarefaction may be prevented by 
β-blockers.  Capillary rarefaction may occur due to decreased HIF-1α and VEGF 
expression as well as increased expression of VEGF inhibitors such as p53 (Sano et 
al., 2007), as was found in MCT rats during the transition to decompensated heart 
failure (Redout et al., 2007; Sutendra et al., 2013).   
 
The oxygen diffusion model assumes all parameters remain constant in all samples 
except capillary location, however certain factors could change between CON and FAIL 
which could affect diffusion, for instance mitochondrial density, diffusion through the 
interstitial space and myoglobin concentration.  It is reasonable to assume the first two 
are unchanged as there was no change in mitochondrial mass (citrate synthase 
activity) or fibrosis in FAIL rats which would be expected to promote hypoxic regions by 
increasing O2 extraction proximal to the capillaries and reducing O2 diffusion through 
the interstitial space.  Myoglobin concentration has also been found not to change in 
MCT heart failure (Des Tombe et al., 2002; Mouchaers et al., 2009).  A reduction in 
systemic arterial O2 saturation has been reported in MCT rats which would exaggerate 
myocardial hypoxia (Schermuly et al., 2004). 
 
However, a recently developed technique of estimating mitochondrial PO2 in vivo 
argues against an O2 limitation in MCT heart failure (Mik et al., 2009).  In this method, 
rats are injected with 5-aminolevulinic acid which is a precursor to protoporphyrin IX 
and accumulates in mitochondria.  Protoporphyrin IX is the final precursor to haeme 
and has an oxygen-dependent triplet state which can be populated by blue light and 
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emits red light upon return to the ground state, therefore its lifetime of delayed 
fluorescence depends on O2 concentration (Mik et al., 2008).  Using this method 
Balestra et al. (2015) found no difference in the proportion of mitochondria with low PO2 
(<20 mmHg) in open chest anaesthetised MCT rats (42%) ventilated with room air 
compared to CON (53%), and concluded energy production rather than O2 delivery was 
at fault in MCT rats.  Using a cut-off PO2 of 0.5 mmHg for hypoxic tissue we found the 
area of CON tissue which was hypoxic was 22%, which is the same value reported by 
Hauton et al. (2015) using the same model in healthy rat LV, and similar to the value 
reported by Beard et al. (2003) (~20%) who used a different three-dimensional volume 
simulation.  The data of Balestra et al. (2015) are not necessarily at odds with ours: 
firstly ischaemic regions may not have been adequately perfused with the precursor 
and therefore the results will be skewed towards regions with better flow and higher 
PO2.  Furthermore, as this was measured in vivo, only the subepicardium was 
measured, however Kobayashi et al. (1994) found significant transmural variation in the 
CF in the RV of MCT rats.  Finally, according to their description measurements were 
likely taken from the RV close to the apex where wall stress is lower, whereas our 
measurements were taken from the mid RV free wall where stress is likely to be 
greater and therefore hypertrophy may be greater (Quaife et al., 2006). 
 
Myocardial oxygenation was measured in patients with non-ischaemic dilated 
cardiomyopathy using O2 sensitive MRI by Dass et al. (2015) who found no difference 
in oxygenation despite having lower coronary flow.  However, the same group also 
found oxygenation and coronary perfusion in response to vasodilator stress was 
reduced in patients with hypertrophic cardiomyopathy suggesting the role of myocardial 
oxygenation may differ depending on the disease etiology (Karamitsos et al., 2013). 
 
4.4.2 No evidence of myocardial fibrosis in RV failure 
Given the tendency for reduced myocardial oxygenation, severe pressure overload and 
steeper EDPVR in vivo (Chapter 3), chronic β-adrenergic activation (Seyfarth et al., 
2000; Leineweber et al., 2003), and increased apoptosis and pro-apoptotic enzymes 
reported in this model (Umar et al., 2012), we had reason to expect increased fibrosis 
in the RV of FAIL rats.  However, as this was not the case it suggests proliferation of 
the extracellular matrix is not a leading cause of the steeper EDPVR in FAIL rats. 
 
There is likely to be a temporal discontinuity between cell death and proliferation of the 
extracellular matrix, as was found by Campian et al. (2009) by serially monitoring 
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apoptosis and fibrosis in MCT rats.  Apoptosis increased to a peak around day 22 post-
MCT and then declined, whereas significant fibrosis occurred after day 27.  Increased 
fibrosis and expression of MMP-2 and MMP-9 has also been reported by groups which 
have allowed MCT rats to progress to a point with higher mortality events (Umar et al., 
2012; Kaur et al., 2015; Okumura et al., 2015).  This does not preclude a role for 
collagen in diastolic myocardial stiffness, for instance a higher proportion of collagen 
crosslinking may be more important than total collagen in reducing myocardial 
compliance (Badenhorst et al., 2003; Cingolani et al., 2004).  Also, Ishikawa et al. 
(1992a) found that while total collagen measured by hydroxyproline assay was not 
increased at 4 weeks in MCT rats, there was a shift in collagen isoform from the stiffer 
and more predominant Type I collagen towards the more compliant foetal Type III 
collagen (Medugorac, 1982).  
 
The range of collagen fractional area we found (3-4%) is within a typical range for 
normal myocardium without scarring (e.g. due to myocardial infarction) measured using 
electron microscopy (Page et al., 1971), however many studies report much higher 
collagen content in healthy myocardium.  It is likely this difference is due to the 
inclusion or exclusion of perimysial collagen in the analysis, instead of only the thicker 
punctate or ‗seams‘ of fibrosis (as used in this study).  Inclusion of perivascular fibrosis 
would also dramatically increase the fractional collagen area (c.f. representative 
images in Fig 2C of Umar et al. (2012)).  Conversely, alternative stains such as 
Masson‘s trichrome may produce lower values of fibrosis due to lower sensitivity to thin 
collagen fibres (Whittaker et al., 1994).  It is for these reasons we analysed fibrosis 
blinded to the origin of the samples. 
 
Protein expression of full length caspase-3 was increased in the RV of FAIL and 
MCT+BB rats suggesting they are currently in the midst of apoptosis (R. Norman, 
personal communication).  In the SuHx model in rats both carvedilol and metoprolol 
reduced the number of terminal deoxynucleotidyl transferase dUTP nick end labeling 
(TUNEL) positive cells, indicating fewer cells were undergoing apoptosis, which 
coincided with reduced fibrosis.  In a canine model of coronary microembolism in which 
small coronary vessels are blocked by polystyrene beads resulting in ischaemic heart 
failure, chronic low dose metoprolol (~2 mg/kg/day) significantly reduced apoptosis and 
decreased caspase-3 expression without altering resting heart rate (Sabbah et al., 
2000).  These data suggest a possible mechanism through which β-blockers increase 
survival is by favouring cell survival thus enhancing the contractility of the heart. 
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4.4.3 Preserved mitochondrial mass in RV failure 
At rest the healthy RV extracts about 50% of O2 supplied by the coronary circulation 
but increases extraction during exercise, whereas the LV extracts around 75% O2 at 
rest and relies on increased coronary flow to increase MVO2 (Zong et al., 2005).  
Reduced myocardial perfusion in PAH could be compensated for by an increase in RV 
O2 extraction, as was demonstrated by Wong et al. (2011a) who found it increased to 
75% at rest in NYHA class III PAH patients, suggesting patients may have decreased 
coronary flow reserve and a possible O2 limitation during activity.  Increased 
mitochondrial mass could increase the arterio-venous O2 difference and compensate 
for reduced RV perfusion in PAH, conversely loss of mitochondria could exacerbate RV 
failure by reducing the energy producing capacity of the heart. 
 
There was no difference in CS activity between any of the groups of rats.  CS activity, 
cardiolipin protein expression and Complex IV activity measured respirometrically with 
TMPD+ascorbate, are commonly used as a markers of mitochondrial mass which 
closely correlate with mitochondrial fractional area measured using electron 
microscopy (Larsen et al., 2012).  Mitochondrial mass is usually found not to change 
(Rosca et al., 2008; Lemieux et al., 2011a) or decrease (De Sousa et al., 1999; Stride 
et al., 2013) in human and animal models of heart failure which may reflect the duration 
or severity of disease, but also possibly the method of normalization (Kilbaugh et al., 
2015).  CS enzyme activity can also be depressed independent of a change in 
mitochondrial mass, for instance by oxidative modification, resulting in underestimation 
of mitochondrial mass or respiratory capacity if data are normalized to CS activity 
(Chepelev et al., 2009).  While we did not find a decrease in mitochondrial mass at this 
stage of disease, others have reported decreased PGC-1α mRNA expression in MCT 
rats which could eventually cause a loss of mitochondria and activity of ETS complexes 
(Enache et al., 2013).   
 
4.4.4 Preserved electron-transport system in heart failure 
Gross measures of mitochondrial function such as the acceptor control ratio (ACR) are 
sensitive indicators of coupling between substrate oxidation and ATP synthesis as any 
defect along the electron transport system can reduce the ACR.  We found the ACR 
actually tended to increase in FAIL cells, largely due to decreased LEAK respiration, 
indicating coupling of oxidative phosphorylation was preserved in failing cells.  
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Mitochondrial dysfunction has been found in other models of PAH such as SuHx rats, 
in which the ADP/O2 ratio was reduced in isolated RV mitochondria.  Interestingly this 
was restored by chronic treatment with carvedilol which also promoted the expression 
of genes responsible for mitochondrial biogenesis and maintenance (Drake et al., 
2013).  However, gross measures such as the ACR or ADP/O2 are insensitive to 
opposing changes (e.g. a reduction in LEAK respiration could increase ACR even with 
reduced maximal respiration) furthermore they do not allow identification of the source 
of mitochondrial dysfunction, therefore we employed a substrate uncoupler inhibitor 
titration protocol to interrogate individual components of the electron transport system 
for defects which could impair energy production (Kuznetsov et al., 2008). 
 
Maximal respiration in the presence of both CI+II substrates was slightly but not 
significantly lower in RV cells from FAIL rats compared to CON.  This occurred due to a 
tendency for CI respiration to be lower, whereas CII activity was unchanged in MCT 
rats, resulting in a shift in the relative contribution of CI to respiration from 50% in CON 
rats to 30% in FAIL and MCT+BB rats.  Our results are in accord with those of Daicho 
et al. (2009) who found CI respiration was preserved in MCT rats up to 4 weeks post-
injection, but decreased beyond 4 weeks, whereas CII respiration did not change 
throughout (Daicho et al., 2009).  Leaving our rats beyond the current endpoint may 
have made these changes statistically significant but would also incur an unacceptably 
high mortality rate (c.f. 90% mortality in MCT rats by week 6 (Sutendra et al., 2013)).  
Thus stage-dependent reduction in CI respiration seems to occur in MCT rats due to 
decreased expression of NADH dehydrogenase (Schott et al., 2005). 
 
In healthy human myocardium the phosphorylation system exerts a strong limitation on 
maximal respiration resulting in an OXPHOS/ETS ratio close to 0.5, however in heart 
failure the ratio decreases indicating reduced capacity of the phosphorylation system 
(Lemieux et al., 2011a).  In healthy rat myocardium the phosphorylation system is not 
limiting meaning OXPHOS/ETS is equal to 1.0, as show in Table 4.1, however we 
tested whether this could change in MCT rats by titrating the uncoupler FCCP.  There 
was no increase in respiration with FCCP in any group of rats indicating the 
phosphorylation system does not limit respiration in healthy or failing myocardium in 
rats.  This concords with unchanged protein expression of the F1F0-ATPase in the MCT 
RV found by Redout et al. (2007).  
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A high mitochondrial membrane potential creates a driving force for leak of H+ back 
across the inner membrane resulting in a basal, LEAK, respiration which is non-
phosphorylating and therefore decreases the efficiency of ATP production.  However, 
there was no difference in LEAK respiration in FAIL compared to CON rats in line with 
preserved intactness of the MIM tested by the addition of cytochrome c.  ROS 
production was also not different between groups suggesting mitochondria are not a 
primary source of oxidative stress at this stage in our rats.  Decreased mitochondrial 
ROS production has been reported in MCT rats with compensated hypertrophy, which 
reverses upon the transition to decompensated heart failure (Sutendra et al., 2013).  
Cytosolic oxidase enzymes such as NADPH oxidase and xanthine oxidase are 
increased in heart failure and may contribute substantial amounts of ROS in PAH 
(Redout et al., 2007; Hirsch et al., 2012). 
 
4.4.5 CK energy shuttle in heart failure 
There was a large reduction in total CK activity in FAIL and MCT+BB RV 
homogenates, which is in line with our previous observation that expression of the two 
predominant CK isoforms, CK-M and CK-mt, is reduced in the RV of FAIL rats (Fowler 
et al., 2015a).  However CK activity was not restored or partially increased with β-
blocker treatment which was unexpected considering sarcomere length was partially 
restored in MCT+BB rats.  CK-M and CK-mt protein expression was intermediate in 
MCT+BB compared to FAIL rats (R. Stones, personal communication) suggesting post-
translational inactivation of CK may have occurred. 
 
Changes in expression do not necessarily directly correlate with changes in activity, for 
instance Shen et al. (2005) found in a canine tachypacing model of heart failure, that 
CK-M and CK-mt activity returned to normal after pacing was switched off despite 
protein expression remaining depressed.  The CK catalytic site contains cysteine 
residues sensitive to oxidation which may reversibly (e.g. in the case of S-nitrosation 
(Konorev et al., 1998)) or irreversibly ( e.g. in the case of peroxynitrite (Stachowiak et 
al., 1998; Mihm & Bauer, 2002)) inhibit enzyme activity.  The location of CK-mt within 
mitochondria makes it particularly vulnerable to respiratory ROS (Schlattner et al., 
2006). 
 
β-adrenergic stimulation appears to acutely regulate CK isoform expression, as 
decreased CK-M and increased CK-B mRNA expression occurred in Langendorff 
perfused rat hearts following 3h infusion with 10 nM isoproterenol (Hammerschmidt et 
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al., 2000).  Changes in CK activity and isoenzyme distribution in heart failure can revert 
back to a normal phenotype if the noxious stimulus is removed or attenuated by drug 
therapy.  For instance, reducing the mechanical load on the heart with a ventricle assist 
device restored expression of CK-M and CK-mt in patients with LV failure (Park et al., 
2002), while in a rat model of MI pharmacological treatment with bisoprolol attenuated 
changes in CK-mt and CK-B mRNA expression (Laser et al., 1996).   
 
4.4.6 CK-mt functional coupling in heart failure 
There may not be a direct relationship between the specific activity of an enzyme (a 
product of its abundance and enzymatic activity) and its biological functional activity 
(which arises due to its proximity and interactions with other enzymes or substrates).  
For instance, hypoosmotic treatment of mitochondria releases CK-mt from the MIM and 
abolishes the creatine stimulated increase in respiration, yet as the enzyme remains 
trapped in the intermembrane space its specific activity is unaffected (Kuznetsov et al., 
1989).  Results from the SUIT protocol revealed the machinery of the ETS was largely 
preserved in FAIL cells, however mitochondria are not normally working at maximum 
capacity, therefore the functional consequences of loss of CK-mt protein were 
investigated as this is likely to have a larger impact on mitochondrial submaximal 
respiration at physiological ADP concentrations (~50-100 µM). 
 
There was a smaller change in the apparent Km for ADP with creatine in FAIL 
compared to CON cells and it was intermediate in MCT+BB and interestingly, the 
stimulatory effect of creatine was inversely correlated with RV hypertrophy (Figure 
4.9D).  Reduced CK-mt function has also been reported using a similar protocol in 
human dilated and ischaemic cardiomyopathy (Popovich et al., 1995; Stride et al., 
2013), rat LV pressure overload (De Sousa et al., 1999) and in Syrian cardiomyopathic 
hamsters (Veksler et al., 1988).  Reduced CK-mt activity could make failing hearts less 
responsive to a sudden increase in cardiac work.   
 
The in vivo consequences of reduced CK-mt functional coupling are illustrated by a 
highly significant positive correlation between creatine-stimulated respiration and 
ejection fraction in human systolic heart failure, whereas it negatively correlates with 
end-diastolic pressure (Popovich et al., 1995).  This indicates subcellular changes in 
the CK energy shuttle may affect contraction by limiting energy supply to cytosolic 
ATPases.  Interestingly, in several of these studies the ACR, which is considered a 
sensitive indicator of mitochondrial dysfunction, was not significantly different between 
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healthy and failing conditions (Veksler et al., 1988; De Sousa et al., 1999; Stride et al., 
2013).  This was also a finding of the current work and implies that even if the TCA 
cycle and ETS are preserved in heart failure, reduced phosphocreatine energy 
shuttling may impair energy delivery to the myofilaments and reduce the contractility of 
the heart. 
 
In the absence of creatine there was a tendency for KmADP to be lower in RV cells 
from MCT treated rats indicating increased permeability of the MOM, although this was 
not statistically significant.  Interestingly, increased MOM permeability was also found 
in other circumstances where the CK system is impaired such as LV muscle fibres of 
CK-M-/- (Veksler et al., 1995) and CK-M/mt-/- double knockout mice (Kaasik et al., 
2001), and rats depleted of creatine by β-guanidinopropionic acid feeding (Clark et al., 
1994).  Similarly, during the early development of mice from day 1 up to 3 months old, 
a fall in MOM permeability is inversely correlated with an increase in CK-mt expression 
(Anmann et al., 2014).  Conversely, Roosimaa et al. (2013) found the MOM diffusion 
barrier to ADP was greater in dilated human atrial tissue, however total and CK-mt 
functional activity were unchanged in these samples.  Also, ter Veld et al. (2005) found 
the KmADP of isolated cardiac mitochondria was higher in CK-M/mt
-/- double knockout 
mice but not single knockout mice, which they suggest is an adaptation to higher 
resting levels of ADP; however isolated mitochondria lack the influence of tubulin on 
the VDAC pore and therefore the implications of this in situ where KmADP is much 
higher is unclear.  Therefore increased MOM permeability may be a compensatory 
adaptation to maintain energy production despite the lack of a functioning CK system. 
 
Adenylates cross the MOM through the VDAC whose permeability is determined by the 
open state of the pore which, despite its name, is primary modified by free tubulin 
(Rostovtseva et al., 2008).  Experimentally modifying free and polymerized tubulin 
using colchicine to destabilize, or paclitaxel to polymerize, microtubules leads to a 
decrease or increase, respectively, of MOM permeability (Maldonado et al., 2010).  
Similarly, oxidative muscle fibre types have a low MOM permeability and a high 
proportion of free tubulin whereas glycolytic muscle fibres have a high MOM 
permeability and low proportion of free tubulin (Varikmaa et al., 2014).  The tendency 
for MOM permeability to be increased in MCT treated rats could be due to the 
decreased ratio of free:total β tubulin in FAIL RV cells identified by Stones et al. (2013). 
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The shift in KmADP with creatine is a commonly used method of determining CK-mt 
function, however this protocol has been criticised on the grounds that cytosolic 
ATPases and cytosolic CK could regenerate ADP either through ATP hydrolysis or the 
reverse CK reaction, ATP+Cr→ADP+PCr, which could be sufficient to shift the Km to 
lower values (Callahan & Supinski, 2007; Guzun et al., 2009).  The magnitude of this 
effect has yet to be quantified, however since our solutions lack Ca2+ the activity of the 
main ATPases in cardiomyocytes (SERCA and myosin ATPase) is likely to be relatively 
small.   
 
4.5 Conclusion 
There was a large reduction in capillary density in the RV of FAIL rats leading to 
substantial areas of myocardium poorly supplied with O2, suggesting O2 delivery to the 
myocardium may be limiting in PAH.  The RV of MCT+BB rats may be better 
oxygenated, in part due to less hypertrophy of muscle fibres and also prevention of 
capillary rarefaction.  We found no evidence of a general trend towards mitochondrial 
damage or dysfunction in MCT treated rats, however there was a clear difference in the 
ability of CK-mt to stimulate respiration.  The preserved maximal respiration and 
mitochondrial mass indicates neither reduced mitochondrial availability nor specific 
defects in the machinery of oxidative phosphorylation play a leading role in the 
pathogenesis of MCT heart failure.  Re-instigating blood flow to ischaemic regions may 
awaken ‗hibernating‘ myocardium and restore contractility to the failing RV.  β-blockers 
appear to improve oxygenation through reduction of cardiomyocyte hypertrophy and 
prevention of capillary rarefaction which may contribute to the enhanced RV 
contractility of MCT+BB rats. 
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Chapter 5  Ventricular myocyte contractile function in β-blocker 
treated rats 
5.1 Introduction 
The causes of impaired RV contractility in PAH are likely to be multifactorial; electrical 
remodelling, Ca2+ homeostasis, neurohormonal desensitization, myofilament changes, 
fibrosis, and altered energy metabolism have all been identified as possible 
contributory elements.  Ultimately, the ability of the myocardium to generate force is 
determined by the electrically synchronised cycling of Ca2+ in cardiomyocytes which 
effects actin-myosin crossbridge formation.  Dysfunctional excitation-contraction 
coupling in LV failure is known to profoundly influence the pathophysiology of the 
disease, therefore its role in RV dysfunction in PAH warrants detailed investigation. 
 
In the previous chapters chronic treatment with a low dose of metoprolol was shown to 
significantly improve survival and RV function in vivo in rats with existing PAH and was 
associated with partial restoration of oxygen delivery to the myocardium.  In this 
chapter the intrinsic contractility and Ca2+ handling of RV cardiomyocytes were 
investigated as possible causes of improved RV function and survival in MCT+BB rats.  
In failing RV myocytes deranged Ca2+ handling is shown to coincide with structural 
abnormalities and an inability to cope when stressed.  Ca2+ handling was partially or 
fully restored in RV cells from MCT+BB rats, which improved their ability to contract at 
faster pacing frequencies.  These data provide insight into dysfunctional Ca2+ handling 
in RV myocytes as a cause of poor RV contractility and demonstrate β-blockers 
prevent or reverse these changes.  This provides mechanistic evidence supporting the 
therapeutic potential of β-blockers as a novel treatment for PAH. 
  
5.2 Methods 
5.2.1 Animal model 
Rats were injected with MCT or saline as described previously in Chapter 2.  Daily 
treatment with 10 mg/kg/day metoprolol (MCT+BB) was initiated 15 days after MCT 
injection.  Experiments were performed on CON and MCT+BB rats on the median 
survival (±1 day) of FAIL rats, or on FAIL rats on the day heart failure symptoms 
developed.  RV and LV cardiomyocytes were isolated as described in Chapter 2. 
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5.2.2 Identification of Ca2+ wave initiated ‘action potentials’ 
Cells loaded with Fura-4F-AM were electrically paced at 5 Hz for 1 min, then pacing 
was switched off for 1 min and the number of spontaneous Ca2+ waves counted by 
visually identifying deflections in the Fura-4 ratio recording.  A method was developed 
to categorize waves as propagating (if it travelled through the cell without a global Ca2+ 
transient occurring) or as waves which triggered a global Ca2+ transient and therefore 
an action potential (wave-initiated ‗APs‘); this designation was chosen on the premise 
that a global Ca2+ transient indicated synchronized membrane depolarization and Ca2+ 
channel opening, whereas a propagating wave reflected Ca2+-induced Ca2+-release 
between neighbouring Ca2+ release units (Figure 5.1).  The validity of this method was 
first established by comparing the morphology of Fura-4 recorded Ca2+ waves (which 
lack spatial definition) with Ca2+ waves recorded in Fluo-4 loaded cells.  Spatially 
averaged x-t linescan images of propagating waves showed a slow monophasic 
upstroke and decay.  In contrast, the spatially averaged profile of wave-initiated ‗APs‘ 
produced a biphasic slow initial upstroke followed by a secondary rapid upstroke and 
decay.  These waveforms were also observed in Fura-4 recordings suggesting a 
common cause.  Wave-initiated ‗APs‘ were considered as such if the upstroke velocity 
was ≥50% that of a systolic Ca2+ transient recorded in the same cell.  The fluorescence 
derivative was filtered using a 10 Hz Zero-Phase Lowpass filter (IonWizard, IonOptix, 
Milton, MA) with a width of 21 points to assist identification of wave-initiated ‗APs‘.   
 
5.2.3 Myofilament Ca2+ sensitivity in intact cells 
During late relaxation of unloaded cell shortening there is a dynamic equilibrium 
between cytosolic Ca2+ and lengthening which can be visualised as a linear relationship 
in Ca2+-length plots (Spurgeon et al., 1992).  Sarcomere shortening was recorded in 
Fura-4F-AM (2 µM) loaded cells while cytosolic Ca2+ was monitored according to the 
methods described in Chapter 2.  The Fura-4 recording was interpolated to account for 
the different data recording rates of Fura and sarcomere length (200 vs 250 Hz).  Fura-
4 ratio was plotted against sarcomere length and the slope of the relationship during 
late diastole used as an index of myofilament Ca2+ sensitivity. 
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Figure 5.1 Identification of Ca2+ wave-initiated ‘action potentials’ 
A Example confocal linescan recordings of a propagating Ca2+ wave (upper panel ) and a Ca2+ wave triggering a global Ca2+ transient (lower panel).  
B Upper panel Averaged pixel intensity profiles of the waves in (A).  Wave-initiated ‗APs‘ displayed a distinctive biphasic slow then rapid Ca2+ 
upstroke and decay, in contrast to slow monotonic propagating waves.  Lower panel Similar wave morphologies were identifiable using widefield 
fluoresence recordings of Fura-4 loaded cells .  C The first derivative of the Fura-4 recording was used to categorise waves as wave-initiated ‗APs‘ if 
the upstroke velocity was ≥50% the systolic upstroke velocity (red dashed line), otherwise they were designated as propagating.  
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5.3 Results 
5.3.1 Cell geometry 
Cellular hypertrophy was evident in RV cells from MCT-treated groups, as evidenced 
by increased cell width, width:length ratio and predicted cell volume, but was 
significantly greater in FAIL compared to MCT+BB cells (Figure 5.2).  Cell width was 
9% greater in MCT+BB and 22% greater in FAIL, compared to CON RV cells.  Cell 
length tended to decrease from CON>MCT+BB>FAIL.  Cell length was 2.6% shorter in 
MCT+BB and 7.3% shorter in FAIL, compared to CON RV cells.  This resulted in an 
11% increase in MCT+BB and a 32% increase in FAIL cell width:length ratio, 
compared to CON RV.  Cell volume was predicted from cell length and width and was 
increased by 15% in MCT+BB and 37% in FAIL, compared to CON RV cells. 
 
There were no significant differences between LV cells from CON, MCT+BB or FAIL 
rats in cell width, length, width:length ratio or cell volume.  LV cell length tended to be 
slightly shorter in LV FAIL cells compared to LV MCT+BB by 2.6% but this was not 
significant. 
 
5.3.2 Resting sarcomere length 
SL was measured in quiescent isolated cardiomyocytes.  Resting SL in RV and LV 
cells from CON rats was approximately 1.90 µm.  SL in RV cells from MCT treated rats 
was shorter than in CON rats, though was intermediate between CON and FAIL in 
MCT+BB RV cells (Figure 5.3).  Resting SL in MCT+BB myocytes was 2.5% shorter, 
and FAIL cells 7.5% shorter, compared to CON RV cells.  In LV cells, SL was slightly 
reduced by 1.6% in FAIL and slightly increased by 0.7% in MCT+BB, compared to 
CON, however these differences were not statistically significant.  There was however 
a significant 2.3% decrease in SL in LV FAIL cells compared to MCT+BB cells.  The 
cause and implications of the shorter resting SL will be explored more in Chapter 6. 
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Figure 5.2 Geometry of isolated ventricular cardiomyocytes 
A There was pronounced hypertrophy of RV FAIL cells, shown by increased width, which was attenuated in MCT+BB cells. B Cell length in RV FAIL 
cells decreased in a stepwise manner from CON>MCT+BB>FAIL.  C Cell width:length ratio was increased in MCT+BB and FAIL RV cells compared 
to CON, but reduced in MCT+BB compared to FAIL.  D Cell volume was predicted from cell length and width. Increased cell volume in RV FAIL cells 
was reduced in MCT+BB cells. There were no differences between groups of LV cells in any of these parameters.  N=79 CON, 73 MCT+BB, 70 FAIL 
RV cells, N=64 CON, 64 MCT+BB, 66 FAIL LV cells.  * P<0.05, ** P<0.01, *** P<0.001.  
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Figure 5.3 Resting sarcomere length in isolated RV and LV cells 
There was a stepwise decrease in resting SL in RV cells from MCT+BB and FAIL rats 
compared to CON, but was increased in MCT+BB compared to FAIL.  This did not 
occur in LV cells, where SL was not different between CON and MCT+BB cells, but 
was significantly shorter in LV FAIL compared to MCT+BB.  N=30 cells in each group.  
**P<0.01, ***P<0.001.  
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5.3.3 Transverse tubule system 
The T-tubule network was imaged in di-8-ANEPPS stained RV cells using a confocal 
microscope.  Regular striated T-tubule structures were apparent in CON and MCT+BB 
cells, whereas in FAIL cells the transverse staining was less obvious and appeared 
more disorganised (Figure 5.4).  Power spectrum analysis of fast-Fourier transformed 
intensity profiles across the length of cells revealed reduced regularity (decreased 
power of the first harmonic frequency) of T-tubules in RV FAIL cells, by 65% compared 
to CON and 60% compared to MCT+BB.  T-tubule power was not significantly different 
in CON compared to MCT+BB.  In RV CON and MCT+BB cells, tubules were primarily 
oriented transverse to the long axis of the cell with a much smaller proportion of tubules 
parallel to the long axis of the cell, whereas in RV FAIL cells there were fewer t-tubules 
and more longitudinal tubules compared to CON and MCT+BB.  In RV FAIL cells there 
was a significant reduction in the proportion of T-tubules by 54% and an increase in 
longitudinal tubules by 87%, compared to RV CON.  This decreased the ratio of 
transverse:longitudinal tubules in FAIL RV cells to 1.6, compared to a ratio of 6.4 in 
CON cells and 6.9 in MCT+BB. 
 
5.3.4 Spatiotemporal characteristics of systolic Ca2+ release 
Electrically-evoked Ca2+ transients were recorded in Fluo-4 loaded RV cells using 
confocal line scan.  Time to peak Ca2+ release was measured in the spatially averaged 
fluorescence transient.  The time to peak Ca2+ was significantly slower in FAIL cells 
compared to CON cells by 42% (Figure 5.5B).  Time to peak Ca2+ was 18% slower in 
MCT+BB compared to CON but this was not statistically significant. 
 
Electrical stimulation resulted in a rapid spatially and temporally homogeneous release 
of Ca2+ across the length of the cell in CON and MCT+BB RV cells, whereas FAIL cells 
often had regions of delayed Ca2+ release.  Dyssynchrony was 17% greater in FAIL 
cells compared to CON and 28% greater compared to MCT+BB, but not different 
between CON and MCT+BB cells (Figure 5.5C).  There was greater heterogeneity in 
the time to 50% Ca2+ release in FAIL compared to CON and MCT+BB cells (Figure 
5.5D).  There was a significant positive linear correlation between dyssynchrony index 
and time to peak Ca2+ (P<0.001, Spearman correlation). 
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Figure 5.4 T-tubule organisation in RV cells 
A Upper panel Representative images of RV cells showing the highly structured t-tubule system in CON and MCT+BB cells is lost 
in FAIL cells. Lower panel Skeletonized images of tubules.  B FFT power decreased in RV FAIL cells compared to CON and 
MCT+BB.  C The proportion of t-tubules was lower, and longitudinal tubules higher, in FAIL compared to CON and MCT+BB cells. 
N=30 cells in each group. *** P<0.001  
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Figure 5.5 Spatiotemporal characteristics of systolic Ca2+ release 
A Lower panel Confocal linescan recordings of systolic Ca2+ release in a CON, MCT+BB and FAIL cell.  Regions of delayed Ca2+ release are 
apparent in the FAIL cell.  Upper panel The resulting averaged  Ca2+ transients show the time to peak Ca2+ is delayed in the FAIL cell.  B Time to 
peak Ca2+ was significantly longer in RV FAIL cells than CON.  C The variance in rise of Ca2+ at the start of the transient was greater in FAIL cells 
than CON and MCT+BB. D The standard deviation (SD) in the time to 50% peak Ca2+ was greater in FAIL cells.  E There was a significant positive 
linear relationship between the Dyssynchrony Index and time to peak Ca2+ (P<0.001). N= 46 CON, 43 MCT+BB, 50 FAIL cells.  * P<0.05, ** P<0.01, 
*** P<0.001.  Data was collected by E. Steer and E. Fowler and analysed by E. Fowler.  
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5.3.5 Contraction-frequency relationship 
The unloaded contraction-frequency relationship in RV CON cells displayed an overall 
positive relationship, with fractional shortening at 3-7 Hz being significantly greater than 
at 1 Hz (Figure 5.6A) (P<0.001).  Fractional shortening was also significantly greater at 
5 Hz compared to 3 Hz (P<0.05), but shortening plateaued at 5% of diastolic length 
between 5 and 7 Hz.  In contrast, RV FAIL cell fractional shortening was greater at 1 
Hz compared to CON, but displayed a pronounced negative relationship at faster 
pacing frequencies.  Fractional shortening fell in response to an increase in frequency 
from 3-7 Hz (P<0.05).  Fractional shortening in RV MCT+BB cells at 1 Hz was 
comparable to CON cells, but unlike CON and FAIL cells was stable across the range 
of frequencies and showed neither a positive nor negative response.  Some FAIL (10 
out of 28 cells) and MCT+BB cells (6 out of 28 cells) were unable to maintain stable 
contractions at 7 Hz; the difference in number of cells contracting at 7 Hz was not 
significantly different between FAIL and MCT+BB (P=0.38, Fischer‘s Exact test). 
 
The contractile characteristics of LV CON cells were similar to RV CON; fractional 
shortening increased as pacing frequency increased from 1 to 5 Hz, then did not 
increase further beyond 5 Hz (Figure 5.6B).  LV FAIL fractional shortening was greater 
at 1 and 3 Hz compared to LV CON, but did not change across the range of 
frequencies.  LV MCT+BB cells displayed a slightly positive contraction-frequency 
relationship as shortening was greater at 5 and 7 Hz compared to 1 Hz. 
 
Cytosolic Ca2+ was simultaneously monitored with SL and in general the systolic Ca2+ 
transient amplitude-frequency relationship was similar to the shortening-frequency 
relationship (Figure 5.7A).  Ca2+ release was greater in FAIL cells at 1-5 Hz and in 
MCT+BB cells at 1-3 Hz, compared to CON.  The Ca2+ transient amplitude in MCT+BB 
cells was intermediate between CON and FAIL at all frequencies measured.  Ca2+ 
release in LV cells was greater in FAIL cells at 1-5 Hz compared to CON (Figure 5.7B).  
At most frequencies measured MCT+BB Ca2+ transient amplitude was intermediate 
between CON and FAIL.  Diastolic Ca2+ significantly increased in RV and LV cells at 
faster pacing frequencies, however the main effect of frequency on diastolic Ca2+ was 
not different between groups of RV (P=0.70) or LV cells (P=0.80). 
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Figure 5.6 Shortening-frequency relationship in electrically paced cells 
A Fractional shortening was greater in RV FAIL cells at low pacing frequencies but 
there was a steep monotonic decline when frequency was increased.  Shortening in RV 
CON cells increased with frequency up to 5 Hz then plateaued. MCT+BB RV cell 
shortening was intermediate between CON and FAIL, and showed neither a positive 
nor negative response to frequency. Some FAIL and MCT+BB cells could not entrain to 
stimulation at 7 Hz, therefore the number of surviving cells is annotated on the figure. 
N=30 CON, 28 MCT+BB, 28 FAIL RV cells. B LV cells from CON and MCT+BB rats 
were similar in their positive response to pacing up to 5 Hz, above which there was no 
further increase in shortening.  LV FAIL cell shortening was greater than CON at low 
pacing frequencies, but did not increase with faster pacing.  N=24 CON, 22 MCT+BB, 
22 FAIL LV cells.  * P<0.05, ** P<0.01, *** P<0.001 vs CON, †† P<0.01, ††† P<0.001 vs 
MCT+BB.  
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Figure 5.7 Ca2+ transient-frequency relationship in electrically paced cells 
A Ca2+ transient amplitude was significantly greater in RV FAIL and MCT+BB cells 
compared to CON at low pacing frequencies.  Ca2+ release increased up to 5 Hz in 
CON cells, whereas there was a decline in release in monocrotaline-treated groups 
which was steeper in RV FAIL cells. N=30 CON, 28 MCT+BB, 28 FAIL RV cells. B 
Between 1-5 Hz LV FAIL Ca2+ transient amplitude was greater than CON.  Ca2+ release 
increased in LV CON cells up to 7 Hz, whereas it was stable in MCT+BB between 1-7 
Hz, and in FAIL between 1-5 Hz. N=24 CON, 22 MCT+BB, 22 FAIL cells.  * P<0.05, ** 
P<0.01, *** P<0.001 vs CON.  
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5.3.6 Myofilament Ca2+ sensitivity in intact cells 
Phase-plane loops of Fura-4 fluorescence and corresponding sarcomere shortening 
were plotted to calculate the slope of the Ca2+-length relationship during late relaxation 
as an index of myofilament Ca2+ sensitivity (Figure 5.8).  The slope was not significantly 
different between CON and FAIL RV cells, but was shallower in MCT+BB RV cells 
indicating MCT+BB cells were less Ca2+ sensitive.  A similar trend was observed in 
MCT+BB LV cells compared to CON and FAIL, however between-group differences 
were not significant.  
 
5.3.7 Sarcoplasmic reticulum Ca2+ handling 
SR Ca2+ content was estimated from the amplitude of a caffeine evoked Ca2+ transient 
in cells electrically paced at 5 Hz.  Representative recordings of a caffeine-evoked Ca2+ 
transient in CON, MCT+BB and FAIL cells are shown in Figure 5.9.  The amplitude of 
the Ca2+ transient was similar in the CON and MCT+BB cell, but higher in the FAIL cell.  
The rate at which the cytosolic Ca2+ returned to baseline was also slower in the 
MCT+BB and FAIL cell than the CON cell. 
 
The SR Ca2+ content in RV FAIL cells was 32% greater than CON and 20% greater 
than MCT+BB.  MCT+BB SR content was increased by 10% compared to CON but this 
was not statistically significant.  The rate of decay of the systolic Ca2+ transient was not 
significantly different between any of the groups of RV cells but tended to be faster in 
MCT+BB compared to other groups.  The rate of Ca2+ decay in the presence of 
caffeine (KCAFFEINE) through primarily NCX Ca
2+ efflux, was lower in MCT-treated groups 
of cells compared to CON.  KCAFFEINE was reduced by 23% in MCT+BB and by 19% in 
FAIL, compared to CON cells.  The rate of Ca2+ removal through SERCA (KSERCA) is the 
difference between KSYSTOLIC and KCAFFEINE.  KSERCA was not significantly different 
between any groups of cells but tended to be faster in MCT+BB RV cells. 
 
Fractional SR Ca2+ release was calculated as the amplitude of the electrically 
stimulated Ca2+ transient as a percentage of the caffeine-evoked Ca2+ transient 
amplitude.  In CON cells the systolic Ca2+ transient amplitude was 49% of total 
releasable SR Ca2+.  Fractional Ca2+ release was higher at 58% in MCT+BB cells.  
Fractional release was slightly higher in FAIL cells at 54% compared to CON, however 
this was not statistically significant. 
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Figure 5.8 Intact cell myofilament Ca2+ sensitivity 
A Fura-4 ratio-length trajectory plots of a CON, MCT+BB and FAIL RV cell paced at 1 Hz.  Arrows indicate the anticlockwise direction of travel.  B 
Expanded view of the highlighted region in (A) showing the ‗dynamic equilibrium‘ reached between Ca2+ and length during late relaxation, the slope of 
which indicates myofilament Ca2+ sensitivity.  C The average slope of RV CON and FAIL cells was not different, although in MCT+BB the slope was 
shallower than FAIL indicating reduced sensitivity.  The average slopes did not significantly differ between LV groups, although they tended to follow 
the same general trend as RV cells.  N=17 CON, 24 MCT+BB, 14 FAIL RV cells and N= 20 CON, 16 MCT+BB, 17 FAIL LV cells. * P<0.05.  
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Figure 5.9 Sarcoplasmic reticulum Ca2+ handling in RV cells 
A Representative recordings of SR Ca2+ release during brief caffeine application B SR Ca2+ content was significantly increased in FAIL cells 
compared to CON and MCT+BB. C The rate of Ca2+ decay during electrical stimulation (KSYSTOLIC) was not different between groups.  The rate of 
decay during caffeine  (KCAFFEINE) was significantly slower in MCT+BB and FAIL compared to CON.  SERCA activity (KSERCA) was not different 
between groups.  D SR fractional Ca2+ release was significantly greater in MCT+BB cells compared to CON, and tended to be greater in FAIL though 
this was not statistically significant.  N= 24 CON, 21 MCT+BB, 20 FAIL RV cells.  *P<0.05, ***P<0.001.  
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5.3.8 Spontaneous Ca2+ waves 
Spontaneous Ca2+ waves were counted during 1 min rest which was preceded by 1 
min pacing at 5 Hz.  In CON cells 15/24 cells exhibited ≥ 1 Ca2+ wave, and in both FAIL 
and MCT+BB groups 19/21 cells exhibited ≥ 1 Ca2+ wave.  The proportion of cells 
exhibiting Ca2+ waves was not significantly different between groups.  Of the cells 
which produced at least one wave, the mean number of waves was significantly greater 
in FAIL (9±2 waves.min-1) and MCT+BB (6±1 waves.min-1) compared to CON (2±1 
waves.min-1).  Wave frequency was significantly lower in MCT+BB than FAIL RV cells.  
Resting Fura-4 ratio was not different between groups of cells (CON 0.19±0.01, 
MCT+BB 0.19±0.01, FAIL 0.19±0.01).  There were more wave-initiated ‗APs‘ as a 
proportion of total waves in FAIL and MCT+BB cells compared to CON, but the 
proportion was significantly smaller in MCT+BB compared to FAIL (Figure 5.10). 
 
The velocity of Ca2+ wave propagation was calculated from confocal linescan images of 
Fluo-4 loaded RV cells at 22±1°C in 750 µM Ca2+ Tyrode without intentional SR loading 
and with a short 20 s observation period.  Data for these confocal experiments was 
collected by Emma Steer; analysis was performed by Ewan Fowler.  Wave velocity was 
34% greater in FAIL compared to MCT+BB cells.  There were fewer Ca2+ waves in this 
experiment (1/67 CON cells, 14/72 MCT+BB cells, 17/61 FAIL cells) compared to the 
previously described experiment in Fura-4 loaded cells, therefore the single CON cell 
(velocity 77.5 µm.s-1) was not included in the statistical analysis. 
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Figure 5.10 Spontaneous  Ca2+ release in isolated cells 
A Representative Fura-4 recordings of spontaneous Ca2+ waves during 1 min rest following pacing at 5 Hz.  B Wave frequency was greater in 
MCT+BB and FAIL compared to CON, but was significantly reduced in MCT+BB compared to FAIL.  C The proportion of wave-initiated ‗APs‘ was 
greatest in FAIL, lowest in CON and intermediate in MCT+BB cells.  D Wave velocity was faster in FAIL compared to MCT+BB cells. Data in (D) was 
collected by E. Steer and analysed by E. Fowler.  N= 14 MCT+BB, 17 FAIL RV cells.  *P<0.05, **P<0.01, ***P<0.001.   
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5.4 Discussion 
5.4.1 Hypertrophy 
RV myocytes from FAIL rats had pronounced hypertrophy driven by an increase in cell 
width, in accordance with the elevated systolic pressures in MCT treated rats, but was 
significantly reduced in MCT+BB rats towards CON levels.  The increase in cross-
sectional area likely reflects the increased afterload and wall stress experienced by the 
RV (Benoist et al., 2014).  Resting cell length was actually shorter in MCT treated rats 
and closely corresponded to a reduction in resting sarcomere length.  Horan et al. 
(1981) found a close correlation between RV mass and RV free wall area using the 
postmortem findings of over 1500 patients, suggesting RV dilation, presumably through 
series addition of sarcomeres, is a major cause of RV enlargement in humans.  Our 
rats may have succumbed to their symptoms before there had been sufficient time for 
the RV to dilate.  Mechanotransduction is clearly an important factor in determining cell 
growth in the transverse or longitudinal direction, as cardiomyocytes cultured on 
transformable gel matrices grow longitudinally in response to axial stretch or increase 
cross-sectional area following transverse stretch (Gopalan et al., 2003).  The 
mechanisms through which the cell senses the direction of strain and responds 
accordingly are not fully understood, although myofilament protein interactions between 
titin, telethonin, and cytoskeletal connections with signalling complexes at the 
intercalated disk and sarcolemma are likely to be involved (Knöll et al., 2002; Israeli-
Rosenberg et al., 2015).  Kerckhoffs et al. (2012) have proposed a single law governs 
remodelling either to maintain an optimal sarcomere length or interfilament spacing in 
response to volume or pressure overload respectively. 
 
Activation of adrenergic receptors by catecholamines is also a potent stimulus for 
hypertrophy through the activation of hypertrophic signalling cascades by PKA and 
PKC.  Metoprolol may have reduced signalling through the β1 pathway thus partially 
reducing hypertrophy (Fowler et al., 2015b), but not affected the afterload meaning the 
mechanical stimulus for hypertrophy was still present.  Alternatively, the αAR pathway 
or other circulating factors could be driving hypertrophy; if this were the case LV 
myocytes should also be hypertrophic, however as this did not happen it suggests 
mechanical stress and β1AR activation are the main drivers of hypertrophy.  Kögler et 
al. (2003) reported the mechanical stress of pressure overload resulted in differential 
gene transcription in the RV and LV of MCT rats.  Further reductions in hypertrophy 
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may be possible if metoprolol were given in combination with an afterload lowering 
drug such as sildenafil. 
 
5.4.2 Resting sarcomere length and creatine kinase 
We have previously reported the shorter resting SL in RV FAIL cells occurs through a 
Ca2+-independent mechanism (Fowler et al., 2015a) and found strong evidence 
pointing towards reduced CK-M expression as the cause.  Around 10-30% of CK-M is 
bound to the myofilaments and efficiently removes ADP and regenerates ATP using 
PCr (Ventura-Clapier et al., 1987a; Hornemann et al., 2003); loss of CK-M may impair 
control over cytosolic ADP resulting in slowly cycling rigor-like crossbridges which 
increase cell stiffness.  We now show a partial recovery of resting SL in MCT+BB cells 
towards CON length, implying a partial recovery of the CK system.  This is in accord 
with the partial improvement in the EDPVR found in Chapter 3. 
  
As well as reduced total CK activity, there is reportedly a shift in isoenzyme distribution 
patterns in MCT and LV heart failure towards greater proportional expression of the 
foetal CK-B isoform (Ishikawa et al., 1995).  CK-B is loosely associated with the I-band 
of sarcomeres in complexes of glycolytic enzymes (Kraft et al., 2000), however in 
isolation this is unlikely to account for the increased SL as CK-B in the I-band favours 
PCr and ADP formation, whereas myofilament bound CK-M favours ATP and Cr 
formation and the removal of ADP.  On this basis it is proposed that the increased SL 
in MCT+BB RV cells is due to increased CK-M expression. 
 
5.4.3 Restoration of t-tubule structure 
T-tubule loss, disorganisation and dilation in failing rats is likely due to altered 
expression, localisation, and/or degradation of proteins integral to their formation and 
maintenance such as JP2 and BIN-1 (Wagner et al., 2012).  JP2 protein expression is 
progressively increased during postnatal development coinciding with t-tubule 
proliferation, and downregulated in the transition from compensated hypertrophy to 
decompensated heart failure coinciding with loss of t-tubules (Wei et al., 2010; Xie et 
al., 2012).  This suggests loss of JP2 prevents the sarcolemma attaching to the 
junctional SR therefore resulting in early termination of t-tubule invaginations.  
Preserving JP2 protein levels by transgenic overexpression is protective against 
pressure overload induced hypertrophy (Guo et al., 2014), whereas knockdown of JP2 
results in a dilated cardiomyopathy in neonatal mice (Chen et al., 2013).  Treatment 
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with the afterload lowering drug sildenafil was also found to restore t-tubule structure 
and JP2 expression in MCT rats (Xie et al., 2012).  Microtubule densification in heart 
failure may also play a role in trafficking JP2 from t-tubules to the surface sarcolemma, 
as JP2 redistribution and t-tubule loss can be prevented by colchicine or enhanced by 
paclitaxel (Zhang et al., 2014). 
 
The membrane folding protein BIN-1 is recognised as an important regulator of t-tubule 
formation and also as a scaffolding domain for the localisation of L-type Ca2+ channel 
to t-tubules (Hong et al., 2014).  BIN-1 knockout in mice is perinatal lethal with mice 
developing a hypertrophic cardiomyopathy (Muller et al., 2003), similarly in rat MI and 
pressure overload heart failure BIN-1 expression decreases (Lyon et al., 2012; 
Caldwell et al., 2014) and in human dilated cardiomyopathy  (Hong et al., 2012) which 
may account for the decreased density of transverse and longitudinal tubules in these 
diseases.  We found the t-tubule system was increasingly disorganised in failing cells, 
but in general did not find large areas devoid of tubules as reported by others (e.g. 
Caldwell et al. (2014)).  The proportional increase in longitudinal tubules in failing cells 
is reminiscent of neonatal murine cardiomyocytes which possess primarily longitudinal 
tubules which are not tethered to the junctional SR (Chen et al., 2013).  Interestingly, 
silencing RNA knockdown of JP2 in cultured rat ventricular myocytes also led to a 
reorientation of tubules from transverse to longitudinal, without an overall reduction in 
tubule density (Caldwell et al., 2014), whereas knockdown of BIN-1 reduced density 
without changing orientation (Hong et al., 2014).  On this basis it is possible to 
speculate BIN-1 expression may be unaltered in FAIL rats, whereas JP2 is decreased. 
 
The complete normalization of the transverse-axial tubule system and systolic Ca2+ 
release in MCT+BB rats may be due to increased expression of JP2.  For instance, 
Chen et al. (2012) found chronic metoprolol treatment soon after MI in mice 
ameliorated t-tubule loss through preservation of JP2 expression.  The JPH2 gene has 
a Myocyte enhancing factor-2 (Mef-2) promoter region and Mef-2 is upregulated in the 
RV of rat PAH at the compensated stage, but then sharply declines when the heart 
decompensates, suggesting MCT+BB rats may remain in a compensated disease 
stage for longer (Paulin et al., 2015).  Conversely, mechanically unloading the LV of 
rats with MI increased t-tubule regularity without significantly increasing JP2 expression 
(Ibrahim et al., 2012).  T-tubule signalling microdomains may also be restored as 
protein expression of caveolin-3 thought to be critical in localising β2-AR to t-tubules is 
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fully normalized in MCT+BB rats compared to CON, whereas it is reduced in FAIL (R. 
Norman, personal communication). 
 
5.4.4 Improved synchrony of Ca2+ release 
Loss of t-tubules in failing cells coincided with increasing heterogeneity of Ca2+ release 
which in turn was associated with a slower Ca2+ transient upstroke.  This phenomenon 
has also been identified in large animal models of chronic ischaemia and in failing 
human ventricular cardiomyocytes (Louch et al., 2004; Heinzel et al., 2008).  A slowing 
of the time to peak Ca2+ was reported in intact murine hearts with t-tubule disruption 
due to short hairpin-RNA knockdown of JP2 (Chen et al., 2013).  The net effect of 
dyssynchronous Ca2+ release is a slowing of the velocity and force of muscle 
contraction which slows the rate of pressure development and ejection of blood from 
the ventricle (Louch et al., 2006; Ferrantini et al., 2014).  Orphaning RYR2 on the SR 
from L-type Ca2+ channels on t-tubules is likely to delay Ca2+ release in regions lacking 
T-tubules as Ca2+ must diffuse from neighbouring RYR2 to initiate CICR.  Evidence for 
this comes from detubulation of myocytes using osmotic shock which increases the 
heterogeneity of Ca2+ release and slows the upstroke velocity of the Ca2+ transient 
(Kawai et al., 1999; Louch et al., 2004). 
 
Given that L-type Ca2+ channels and NCX are predominantly located on T-tubules the 
currents carried by these channels may be expected to be reduced in failing cells 
(Despa et al., 2003).  However ICaL density is reportedly preserved in failing MCT rats 
and in LV cells from a rat model of chronic MI, suggesting there may be a redistribution 
of L-type Ca2+ channels from the T-tubule network to the surface sarcolemma (Lee et 
al., 1997; Benoist et al., 2011; Bryant et al., 2015).  A similar redistribution of NCX was 
suggested to occur in rat MI by Gadeberg et al. (2015), however we found Ca2+ 
removal through NCX was lower in failing and MCT+BB cells, possibly due to reduced 
NCX protein expression as found by Xie et al. (2012).  This may contribute to the SR 
Ca2+ overload in FAIL cells, as detubulation with formamide shock also increases SR 
Ca2+ content by reducing Ca2+ removal from the cell (Bovo et al., 2014).   
 
5.4.5 β1 blockers and response to increasing pacing frequency 
Healthy RV myocytes showed a positive Ca2+ transient-frequency relationship which 
peaked at 5 Hz which is in agreement with other studies of rat myocytes under current 
clamp (Dibb et al., 2007).  The inability to cope when challenged by increased demand 
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is a defining characteristic of heart failure and was apparent in FAIL RV cells as a 
steep fall in contractility at faster pacing.  This was closely paralleled by a precipitous 
fall in systolic Ca2+ release in these cells.  In contrast the contractility and Ca2+ release 
of MCT+BB RV cells was better preserved even at the upper range of in vivo heart 
rates in rat.  The preservation of contractile function seemed to occur due to a smaller 
fall in systolic Ca2+ release at higher pacing frequencies, which contrasted with a 
dramatic decline in Ca2+ release in failing cells.  The improved contractility and Ca2+ 
handling in MCT+BB cells was not fully restored to healthy RV function, suggesting 
MCT+BB rats are in a compensated stage of heart failure rather than end-stage heart 
failure.   
 
The Ca2+ transient amplitude was increased in FAIL compared to CON at low pacing 
frequencies which could be due to the prolonged AP in FAIL cells, long diastolic 
interval and reduced NCX efflux excessively loading the SR (Benoist et al., 2012).  
Prolonging the AP duration in healthy rat cardiomyocytes under voltage clamp 
increases the amplitude of the Ca2+ transient by slowing ICaL inactivation thus 
increasing Ca2+ influx to the cell (Bouchard et al., 1995); conversely in SHR rats which 
develop compensated hypertrophy, AP prolongation, and increased Ca2+ transient 
amplitude, shortening the AP to the duration of a healthy cell reduces the Ca2+ transient 
(Brooksby et al., 1993).  The AP duration in FAIL rats shows steep restitution at shorter 
cycle lengths, suggesting reduced Ca2+ entry to the cell may impair Ca2+ release.  The 
cause of the AP duration restitution is not known, although a rate dependent opening of 
ATP-sensitive IKATP channels, possibly due to loss of coupled CK (Crawford et al., 
2002), could shorten the AP and effective refractory period which could promote 
arrhythmias (Uchida et al., 1999).  Reduced activity of SERCA would be an alternative 
explanation as the SR could become depleted and cause a rate dependent increase in 
diastolic Ca2+ (Hasenfuss et al., 1994), however even at 5 Hz SR Ca2+ content was 
elevated in failing RV cells and there was no difference in the rate of rise in diastolic 
Ca2+ with frequency between groups, suggesting the fault lies with Ca2+ release rather 
than uptake.  A possible mechanism for the greater resilience of Ca2+ release across 
pacing frequencies in MCT+BB rats could be a flatter AP duration restitution curve or 
altered phosphorylation status of RyR2 reducing its refractoriness (Poláková et al., 
2015). 
 
In contrast to the profoundly dysfunctional Ca2+ handling in failing RV cells, LV cell 
contractility and Ca2+ release was preserved or augmented in MCT+BB and FAIL rats.  
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A similar finding was reported in the LV of Langendorff perfused MCT hearts (Lamberts 
et al., 2007b) and in isolated LV muscle strips (Kögler et al., 2003).  The LV does not 
experience the elevated afterload encountered by the RV, therefore other factors such 
as circulating catecholamines are likely to affect LV remodelling.  Changes in β1-AR 
expression are more modest compared to the RV, indicating a mechanical stimulus is 
also required to initiate remodelling (Leineweber et al., 2002).  The LV is not free from 
the mechanical effects of PAH however, as interventricular interactions between the 
RV and LV can reduce LV end diastolic dimensions as a result of increased RV 
diastolic pressure and reduced left atrial filling.  For instance in Langendorff perfused 
healthy rat heart, overextending the RV with an indwelling balloon does not impair LV 
developed pressure due to the higher compliance of the RV (Pett & Hauton, 2012), 
whereas in MCT treated rats RV compliance is reduced and an increase in RV volume 
causes a greater increase in LV diastolic pressure (Lamberts et al., 2007b).  Enhanced 
contractility in LV cells in PAH may represent a compensatory mechanism to overcome 
reduced LV preload. 
 
5.4.6 Myofilament Ca2+ sensitivity 
In the current investigation the slope of the Fura-4 ratio-SL relationship was used as an 
index of myofilament sensitivity where the sarcolemma is intact (thus retaining the 
intracellular milieu) and the cell is contracting at 37°C (Spurgeon et al., 1992).  Ca2+ 
sensitivity was unchanged in FAIL compared to CON RV cells, whereas it was 
decreased in MCT+BB cells.  A consequence of this can be seen in the contraction- 
and Ca2+-frequency relationship, in which shortening at 1 Hz is the same in CON and 
MCT+BB RV cells, despite a significantly higher Ca2+ transient in MCT+BB cells.  This 
indicates the enhanced fractional shortening in FAIL and MCT+BB cells at low pacing 
frequencies occurs primarily due to the augmented systolic Ca2+ transient.  Similar 
changes were seen in LV cells although these did not reach statistical significance.  
Neuroendocrine factors do not stimulate the same gene and protein expression 
patterns in the LV compared to the RV in MCT heart failure due to the lack of 
mechanical overload, suggesting the similarity between Ca2+ sensitivity in the RV and 
LV of different groups may be due to altered phosphorylation rather than changes in 
protein expression (Kögler et al., 2003; Schott et al., 2005). 
 
Different methods of measuring Ca2+ sensitivity are available with different advantages 
and disadvantages.  We have previously reported decreased Ca2+ sensitivity in failing 
RV and LV cells measured during tetanic contractions in intact cells at room 
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temperature (Fowler et al., 2015a) which is in conflict with the current findings.  A 
possible methodological reason for this could be elevation of cytosolic Ca2+ in the 
tetanic experiments by thapsigargin activating a Ca2+ dependent kinase, such as 
CaMKII or PKC, resulting in phosphorylation of the myofilaments.  A similar mechanism 
could explain the frequency-dependent decrease in Ca2+ sensitivity reported by 
Lamberts et al. (2007a), who also found PKC-α expression was increased in the RV of 
MCT rats.  The length-dependent increase in myofilament Ca2+ sensitivity is generally 
unaffected by heart failure indicating the Frank-Starling mechanism is preserved (Fan 
et al., 1997; Walker et al., 2011b; Benoist et al., 2014).   
 
5.4.7 Sarcoplasmic reticulum Ca2+ handling 
Altered expression and phosphorylation of PLB is thought to have a key causal role in 
contractile abnormalities in heart failure through modifying SR content and therefore 
contractile force (Sande et al., 2002).  SR Ca2+ content was estimated by briefly 
applying a high concentration of caffeine which opens RyR2 causing rapid depletion of 
SR Ca2+ stores (Varro et al., 1993).  SR load was significantly elevated in FAIL RV 
cells, whereas it was not significantly different in MCT+BB compared to CON cells.  
The fraction of Ca2+ released during electrical stimulation in CON cells was 49% of 
available SR content, which is close to the value of 55% in healthy rat myocytes 
reported by Delbridge et al. (1997).  Fractional release was not different between FAIL 
and CON, but was significantly elevated in MCT+BB.  These data indicate the 
increased systolic Ca2+ transient in FAIL cells occurs due to increased SR load, 
whereas in MCT+BB cells increased fractional release is also a factor. 
 
Our data suggest the increased fractional release in MCT+BB cells might be due to 
increased RyR2 open probability, as SR load was not different to CON and ICaL density 
was previously shown to be unchanged in MCT RV cells (Lee et al., 1997; Benoist et 
al., 2012).  Further support for this is given by the finding of increased Ca2+ spark 
amplitude and spark mediated leak in MCT+BB cells compared to FAIL cells (E. Steer, 
personal communication).  Fractional Ca2+ release decreased from 54% to 37% in a 
ferret aortic banding model of hypertrophy, coinciding with a decrease in SR load by 
20% (Díaz et al., 2004), however an equivalent decrease in fractional release was also 
seen in a rat aortic banding model without a change in SR load or ICaL, highlighting the 
importance of RyR2 open probability (Delbridge et al., 1997). 
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The use of the caffeine-evoked Ca2+ transient amplitude as a surrogate for SR Ca2+ 
content may not be valid if the high cytosolic Ca2+ saturates the Ca2+ indicator.  We 
used the low affinity Fura-4F Ca2+ indicator and saw a clear Ca2+ transient peak in all 
recordings arguing against indicator saturation.  An alternative method would be to 
directly measure and integrate the inward NCX tail current generated during caffeine 
exposure (Varro et al., 1993). 
 
Steady state SR load was increased in FAIL cells without significant changes in 
SERCA activity.  This was somewhat surprising as SERCA2a expression was shown to 
be significantly reduced in failing MCT rats (Reilly et al., 2001; Benoist et al., 2014), 
however in MCT rats with compensated PAH SERCA activity was not depressed 
compared to CON despite SERCA expression negatively correlating with HWːBW, 
suggesting factors other than expression influence its activity.  Expression of PLB 
decreased in failing MCT rats preserving the PLB:SERCA ratio, whereas the ratio of 
phosphorylated Thr17:total PLB actually increased thus relieving its inhibition of SERCA 
(Mattiazzi et al., 2005; Benoist et al., 2014).  NCX activity was decreased in MCT 
treated rats suggesting reduced Ca2+ efflux may further cause accumulation of Ca2+ 
within the SR (Acsai et al., 2007).  These data suggest our rats were taken at the onset 
of heart failure rather than end-stage heart failure. 
 
5.4.8 Diastolic Ca2+ leak 
Ca2+ wave frequency and likelihood of wave-initiated ‗APs‘ was increased in RV cells of 
MCT treated rats and corresponded to the severity of disease.  The increased wave 
frequency in FAIL cells is likely due to increased SR Ca2+ which increases Ca2+ spark 
frequency.  Wave frequency was also increased in MCT+BB cells despite no significant 
change in SR load, suggesting a different mechanism may be responsible in these 
cells.  Elevated cytosolic Ca2+ can be excluded, as resting Fura-4 ratio did not differ 
between groups of cells.  One possible explanation could be increased RYR2 
sensitivity, as Ca2+ spark frequency and fractional Ca2+ release were both increased in 
these cells.   
 
The probability of a wave-initiated ‗AP‘ progressively increased from 
CON<MCT+BB<FAIL.  In FAIL rats the increased SR Ca2+ content will increase the 
amplitude of the Ca2+ wave and therefore the total inward NCX current (Miura et al., 
2011).  Furthermore, the Ca2+ wave velocity was greater in FAIL compared to 
MCT+BB, meaning this current will be discharged more quickly thus causing a larger 
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membrane depolarisation potentially sufficient for sodium channel opening.  Too few 
Ca2+ waves occurred in CON cells at room temperature to analyse statistically, 
however a value of ~70 µm/s is typically reported which is comparable to the velocity of 
MCT+BB waves (Lukyanenko & Györke, 1999).  Shorter distances between Ca2+ 
release units is predicted to highly increase the velocity of waves (Keizer et al., 1998; 
Izu et al., 2006), therefore the shorter SL in FAIL cells compared to MCT+BB cells may 
contribute to the increased wave velocity (this will be explored in more detail in Chapter 
6).  Increased wave velocity was also reported in RV trabeculae of MCT rats which 
correlated with the magnitude of membrane depolarization (Miura et al., 2011).  
Reduced repolarizing currents in heart failure such as IK1 will further increase the 
extent of depolarization during a wave and therefore the likelihood of a wave-initiated 
‗AP‘ (Berlin et al., 1989; Benoist et al., 2011).  Our characterisation of propagating and 
wave-initiated ‗APs‘ hinges upon the morphology of an epifluorescent Ca2+ transient, 
however validation of this method will require simultaneous monitoring of cell 
membrane potential; Fujiwara et al. (2008) showed this phenomenon occurred in 
Langendorff-perfused rat hearts dual loaded with voltage and Ca2+ sensitive dyes 
therefore the reduced likelihood of wave-initiated ‗APs‘ occurring in MCT+BB cells may 
be protective against fatal ventricular arrhythmias.  (Liles et al., 2012) reported a case 
of spontaneous ventricular fibrillation leading to death in a freely moving MCT rat 
implanted with telemetry. 
 
5.5 Conclusions 
RV myocyte contractile function was partially rescued in MCT+BB rats through 
improved excitation-contraction coupling.  A higher resilience when challenged by 
pacing frequency may translate into improved RV function during periods of elevated 
heart rate, such as during exercise, and thus improve the quality of life in PAH.  
Improved diastolic Ca2+ handling with β-blocker treatment may reduce the susceptibility 
of PAH rats and patients to spontaneous ventricular arrhythmias (Delcroix & Naeije, 
2010; Umar et al., 2012). 
 
Importantly these improvements occurred independent of altered pulmonary vascular 
resistance identified in Chapter 3.  Current afterload reducing therapies for PAH such 
as sildenafil do not prevent RV dysfunction when afterload is fixed (Schäfer et al., 
2009; Borgdorff et al., 2012), and no additional morbidity or mortality benefit is accrued 
from combination therapy with different vasodilators suggesting a ceiling has been 
reached in targeting the vasculature alone (McLaughlin et al., 2014).  Our work shows 
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β-blockers may improve survival by restoring EC coupling to failing RV cardiomyocytes 
and therefore represent a potential adjunctive therapy in PAH.  
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Chapter 6  Mechanical and geometric involvement in right 
ventricle function dysfunction 
6.1 Introduction 
The ability of the heart to eject blood is influenced by intrinsic properties of the 
cardiomyocytes (such as the ability to cycle Ca2+ or synthesise ATP) but also the 
loading state which varies depending on venous return and arterial resistance.  The 
majority of data on systolic function in isolated cardiomyocytes is from mechanically 
unloaded cell shortening, however in the heart, myocytes experience a dynamic load 
which changes throughout the cardiac cycle.  How isolated myocytes from failing 
hearts respond to a dynamic load during contraction is not currently known. 
 
The passive properties of the myocardium are a key determinant of cardiac function 
through the Frank-Starling mechanism, which responds to acute changes in end 
diastolic volume on a beat-to-beat basis to preserve stroke volume by modifying the 
force of contraction.  Much of the work on the passive properties of cardiomyocytes has 
been performed in chemically permeabilized cells lacking a working excitation-
contraction coupling system and in which the cytosolic milieu equilibrates with the bulk 
solution.  Consequently, little is known of the diastolic properties of electrically-excitable 
cells and their relation to cardiac function in heart failure.  Defective Ca2+ handling may 
be detrimental to diastolic function, for instance through spontaneous Ca2+ waves 
which can trigger ventricular arrhythmias and sudden death (Heinzel et al., 2011).  
Computer simulations indicate the geometric arrangement of RYR2 in cardiomyocytes 
also has a profound influence on spontaneous Ca2+ waves (Keizer & Smith, 1998; Izu 
et al., 2006). 
 
This chapter details studies that did not involve β-blocker treatment but instead sought 
to extend the work of the laboratory on the mechanisms associated with MCT induced 
RV failure.  Systolic and diastolic function in healthy and failing cardiomyocytes was 
investigated under a variety of mechanical loading conditions.  Under all loading 
conditions myocytes from failing hearts responded worse to increasing demand (pacing 
frequency) compared to healthy cells, which may be associated with impaired energy 
transfer within the cell.  Failing cells are shown to be less compliant and relax more 
slowly, a characteristic of diastolic dysfunction.  Ca2+ waves are shown to exhibit 
sarcomere length-dependence in failing cells.  Studies further implicating CK in RV 
dysfunction are also included.  These findings suggest ventricular myocytes are an 
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important cause of poor cardiac performance in MCT heart failure and therefore should 
be investigated as a potential target for therapy in PAH. 
 
6.2 Methods 
Experiments involving loaded contractions were performed at the Vrijie Universiteit, 
Amsterdam, in 1.8 mM Ca2+ Tyrode using a modified cell isolation procedure.  All other 
experiments were performed in 1 mM Ca2+ Tyrode in cells isolated according to the 
method detailed in Chapter 2. 
 
6.2.1 Modified ventricular myocyte isolation 
We found the suitability of cells for stretch experiments was improved using a cell 
isolation protocol used by the Lederer laboratory (Prosser et al., 2011).  The primary 
difference compared to our standard isolation procedure is the omission of protease 
from the enzyme mix.  Rats were anaesthetised with isoflurane which was confirmed 
by the lack of pedal-withdrawal reflex in response to a toe pinch.  The heart was 
excised and perfused on a Langendorff apparatus with a modified isolation solution 
(digestion buffer, D.B.) containing, in mM: 130 NaCl, 5.4 KCl, 3 Pyruvate, 25 HEPES, 
0.5 MgCl2, 0.33 NaH2PO4, 22 glucose, 0.2 EGTA, pH 7.4 with NaOH.  Perfusion was 
switched to a D.B. without EGTA containing 50 μM Ca2+ and 1.2 mg/mL collagenase 
Type II (activity 270 U/mg, Worthington Biochemical, New Jersey, USA) for 7 min.  The 
RV was coarsely minced then mechanically triturated with a plastic Pasteur pipette for 
3 min in D.B. containing 0.1 mM Ca2+ and 10 mg/mL BSA.  Cells were centrifuged at 50 
g for 1 min and resuspended in three changes of D.B. containing 0.25, 0.5, 1 mM Ca2+. 
 
6.2.2 Isometric contractions in intact myocytes 
RV myocytes were attached to glass fibres connected to a force transducer and piezo 
motor using MyoTak glue.  Isometric contractions were recorded between 1-7 Hz at 
resting cell length.  The end-systolic (ESFLR) and end-diastolic force-length 
relationship (EDFLR) was calculated in cells paced at 1 Hz and stretched in steps of 
2.5, 5, 7.5 and 10 μm, separated by a return to resting length.  The points at end-
diastole and end-systole were fitted with a least squares linear regression to calculate 
the slope of the force-length relationship.  Slopes from different cells were compared 
using an unpaired t-test.  Force was normalised to cell cross-sectional area according 
to the methods described in Section 2.6.1. 
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6.2.3 Physiological work loop style contractions 
Work loops were synchronised to the electrical pacing marks.  A ―preload‖ (10-20% of 
isometric developed force) and ―afterload‖ (70-80% of isometric developed force) was 
chosen for each cell which defined the force the cell was stretched to in diastole, or 
held at by shortening the cell during systole (Figure 6.1).  Feedback from the force 
transducer was processed by an FPGA chip which ran the control algorithm driving the 
piezo motor to shorten the cell when force exceeded the afterload or stretch the cell 
when force dropped below the preload.  A control signal generated by IonWizard 
software was automated such that every contraction had a different preload and 
afterload, allowing the ESFLR and EDFLR to be constructed in < 30 s.  External work 
(µJ) was calculated as Force (µN) X Motor Displacement (µm), using Labchart 7 (AD 
Instruments, Oxford, UK) (Figure 6.2). 
 
Time varying elastance, E(t), is the slope of the line connecting instantaneous points of 
force and length with the intercept of the ESFLR and EDFLR.  E(t) was calculated at 1 
Hz at the initial preload and afterload.  The time to peak elastance and the time 
constant of isometric relaxation, Tau, was calculated from the normalised E(t) (Figure 
6.3) (Suga & Sagawa, 1974). 
 
6.2.4 Myocyte shortening and Ca2+ monitoring 
Cytosolic Ca2+ transients were monitored in cells loaded with the Ca2+ indicator Fura-
4F-AM (2 μM).  Local perfusion of cells with 1 mM Ca2+ Tyrode, Tyrode+blebbistatin 
(10 µM), or Tyrode+caffeine (20 mM) was achieved using an 8-channel pipette with 
temperature control (37±0.5°C).  Cells were paced between 1-7 Hz, or left unpaced for 
1 min to record spontaneous Ca2+ waves. 
 
Blebbistatin is a reversible inhibitor of actin-myosin crossbridge formation and is used 
as a mechanical uncoupler of muscle contractions (Farman et al., 2008).  Blebbistatin 
blocks Pi release from the M•ADP•Pi complex leaving it in a state with low actin affinity 
(Kovács et al., 2004).  Blebbistatin experimental solution (10 μM) was prepared fresh 
each day from an 85.5 mM stock in DMSO (final DMSO <0.1%).  Blebbistatin solutions 
were kept in the dark to prevent photoinactivation (Kolega, 2004; Sakamoto et al., 
2004).
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Figure 6.1 Isometric and force clamp contractions 
Example recording of isometric force generated by a cell contracting at 1 Hz.  At the 
time indicated, work loop control is initiated and the systolic and diastolic force clamped 
at a pre-determined level by dynamically stretching and shortening the cell with a piezo 
motor.  
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Figure 6.2 Reconstruction of work loops in single cells 
A An initial ―preload‖ and ―afterload‖ force was chosen during isometric contractions 
(left). During workloop control a piezo motor shortened the cell when force exceeded 
the afterload or stretched the cell to return force to the preload value (middle).  Plotting 
force against motor displacement allowed cellular work [Work (µJ) = Force (µN) X 
Displacement (µm)] to be calculated from the area inside the loop (right). Upper panels 
show motor displacement, lower panels show force, time and piezo position. B The 
command signal generated by the software to control the piezo was automated to 
progressively vary preload and afterload from the initial values.  
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Figure 6.3 Time-varying elastance in single cells 
A Time varying elastance, E(t), gives a time domain description of contractile function during workloop contractions.  E(t) is the slope of the line (solid 
black lines) connecting points of instantaneous force and length with a length intercept, L0, defined by the intersection of the ESFLR and EDFLR.  The 
slopes of the ESFLR and EDFLR therefore represent the maximum and minimum elastance (broken lines). B E(t) over a contraction cycle plotted as 
a function of time.  The time to peak elastance and time constant of relaxation (tau) were calculated using E(t).  
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1-Fluoro-2,4-dinitrobenzene (DNFB) is a sulfhydryl-modifying irreversible inhibitor of all 
creatine kinase isoforms (Gercken & Schlette, 1968).  Cells were incubated with DNFB 
(20 μM) (from a 20 mM stock in ethanol, final EtOH <0.1%) for 10 min at room 
temperature then resuspended in fresh Tyrode and used immediately. 
 
6.2.5 Exogeneous creatine kinase 
Saponin (0.01 mg/ml) was used to permeabilize myocytes in an intracellular-like 
solution containing, in mM: 130 K+, 30 Na+, 135.7 Cl-, 25 HEPES, 10 PCr, 5.7 Mg2+, 5 
ATP, 0.5 EGTA, 0.01% BSA, pH adjusted to 7.0 with 8N KOH, free Mg2+ was 1 mM 
(Steele & Smith, 1993).  CK-M from bovine heart muscle (Sigma, UK) was included in 
the intracellular-like solution at a concentration of 4.4 mg/ml (total activity 250 U/ml).  
Cells were incubated in intracellular solution with or without exogenous CK for 30 min 
before SL was measured at 20-23°C.  In some experiments the CK substrate PCr was 
omitted from the intracellular solution to test whether exogeneous CK was functionally 
active. 
 
 
6.3 Results 
6.3.1 Mechanical function in response to load and stretch 
6.3.1.1 Physiologically-loaded contractions 
Cellular work (generation of force while shortening) was calculated in CON and FAIL 
RV cells under physiological loading.  There was a tendency for work performed at 
resting length at 1 Hz to be greater in FAIL cells (5.4±0.8 µJ, N=16 cells) compared to 
CON (3.4±0.8 µJ, N=8 cells), however this was not significant (P=0.126).  Increasing 
preload by stretching cells up to 16% significantly increased cellular work by 140% in 
CON and 180% in FAIL cells (Figure 6.4B).  The ESFLR tended to be steeper in FAIL 
than CON (by 21%) and the EDFLR also tended to be steeper (by 17%) however this 
was not statistically significant (Figure 6.4 C+D).  The time course of contraction was 
measured during work loops at resting length according to the concept of time-varying 
elastance.  The time to peak elastance was significantly longer in FAIL cells by 19%.  
The time constant of relaxation was not different in CON or FAIL cells (Figure 6.5). 
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Figure 6.4 Workloop-style contractions in CON and FAIL RV cells 
A The end-systolic (ESFLR) and end-diastolic (EDFLR) force length relationship found using workloop (black loops) and isometric contractions (green 
spikes) were qualitatively similar.  B Increasing preload led to a significant increase in work in both CON and FAIL cells (N= 4 CON, 7 FAIL RV cells, 
P<0.001). C The ESFLR and (D) EDFLR measured using the work loop technique tended to be steeper in FAIL than CON but not significantly so.  
N=6 CON, 7 FAIL RV cells. Experiments were performed in 1.8 mM Ca2+ Tyrode.  
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Figure 6.5 Time-varying elastance in CON and FAIL RV cells 
A Normalized time-varying elastance (E(t)) of a CON and FAIL cell during a work loop 
contraction at 1 Hz.  B The time to peak elastance (E(t)max) was significantly slower in 
FAIL cells.  There was no difference in the time constant of relaxation (Tau) between 
groups. N=6 CON, 7 FAIL RV cells. * P<0.05. Experiments were performed in 1.8 mM 
Ca2+ Tyrode.  
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Feedback-controlled work loop contractions could not be performed as consistently as 
isometric contractions, consequently a full characterisation of cardiomyocyte function 
under dynamic load was not accomplished in the time available.  Work loop failure was 
sometimes caused by an insufficient system response time which is necessary to 
clamp force during contractions at 37°C.  This resulted in an overshoot of force during 
systole and an undershoot during diastole (Figure 6.2A middle panel) which induced a 
rebound overcompensation occasionally triggering resonance in the system.  A LV cell 
dataset could not be collected in the time available during the visit to the Vrijie 
Universiteit, Amsterdam.   
 
Several of the parameters we planned to measure using work loops are conceptually 
and empirically comparable to data obtained from isometric contractions subjected to 
stretch (Nishimura et al., 2004; Iribe et al., 2007).  There was good agreement between 
the ESFLR and EDFLR measured using work loop or isometric contractions (Figure 
6.4A).  Therefore to increase the statistical power the ESFLR and EDFLR were also 
measured by step changes in length under isometric conditions and the results are 
presented below. 
  
6.3.1.2 Systolic and diastolic properties during static stretch 
Progressive stretch of RV cells contracting isometrically at 1 Hz led to an increase in 
end-systolic force.  There was a positive linear ESFLR in both CON and FAIL cells.  
The ESFLR was 97% steeper in RV FAIL cells compared to CON (Figure 6.6 B+C).  
The ESFLR also comprises a diastolic component, therefore the ratio of the ESFLR to 
EDFLR (Frank-Starling Gain index, FSG (Bollensdorff et al., 2011)) was calculated as a 
measure of preload recruitable active force.  FSG was not different differ between CON 
(3.9 ± 0.7) and FAIL (3.7 ± 0.4, P=0.82). 
 
Stretch raised the diastolic force progressively at greater levels of stretch.  This 
relationship could also be described as positive and linear (Figure 6.6).  The slope of 
the EDFLR was 99% greater in RV FAIL compared to CON cells (Figure 6.6 D+E).  For 
consistency with previous reports in normal rats, data are presented as the EDFLR (in 
µN/µm), however RV FAIL cells tended to have a larger cross-sectional area (XSA) 
(FAIL 551±60 μm2, CON 375±29 μm2, P=0.06) consistent with myocyte hypertrophy.  
Additionally, although there was no significant difference in the distance between glass 
fibres at the start of the experiment (CON 95.0±4.9 µm, FAIL 95.6±2.5 µm, P=0.90), we 
tested whether differences in relative stretching could account for the steeper EDFLR  
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Figure 6.6 Systolic and diastolic properties of twitch contractions during stretch 
A Isometric contractions were recorded in myocytes paced at 1 Hz and progressively 
stretched in steps of 2.5 µm.  Cells were returned to resting length between stretches.  
B Mean isometric ESFLR in CON and FAIL cells.  C The slope of the ESFLR was 
significantly steeper in RV FAIL cells compared to CON.  D Mean isometric EDFLR in 
CON and FAIL cells.  E The slope of the EDFLR was also significantly steeper in FAIL 
cells, indicating reduced FAIL cell compliance.  N=8 CON, 13 FAIL cells. *P<0.05. 
Experiments were performed in 1.8 mM Ca2+ Tyrode.  
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Figure 6.7 Paired comparison of loaded and unloaded contractions in single cells 
A Unloaded shortening was greater in FAIL RV cells at low pacing frequencies but declined as frequency increased, whereas CON cell shortening 
increased.  B The isometric tension-frequency relationship was similar but steeper than unloaded contractions measured in the same cells.  C Data in 
(A+B) normalized to contraction at 1 Hz.  N= 8 CON, 13 FAIL RV cells.  *P<0.05, ***P<0.001 vs CON in the same loading condition, #P<0.05 vs CON 
unloaded.  Experiments were performed in 1.8 mM Ca2+ Tyrode.  
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Figure 6.8 Time course of unloaded and isometric contractions 
A+D Representative recordings of unloaded sarcomere shortening and force generation of a CON and FAIL cell. B+E RV FAIL 
cells had a slower time to 50% peak shortening and force than CON.  C+F The time from peak to 50% relengthening was slower 
in RV FAIL than CON cells.  N= 8 RV CON, 13 RV FAIL myocytes. *P<0.05, **P<0.01, ***P<0.001 vs CON. Experiments were 
performed in 1.8 mM Ca2+ Tyrode.  
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in FAIL cells.  The EDFLR was still significantly steeper in FAIL cells after normalizing 
for XSA and percentage length change (CON 0.07±0.01, FAIL 0.13±0.03 mN.mm-2.%-1 
length change, P<0.05).   
 
Developed force at resting length during the inter-stretch intervals was normalized to 
developed force prior to the stretching protocol.  There was no difference in developed 
force during the inter-stretch intervals in either CON (100%, 99.9±2.0%, 100.6±3.3%, 
96.3±3.8%, N=13 cells, P=0.29) or FAIL cells (100%, 101.0±3.6%, 104.1±4.0%, 
95.1±4.3%, N=23 cells, P=0.15) indicating no loss of cell attachment during stretch. 
 
6.3.1.3 Contraction-frequency relationship under load 
The contractile function of RV CON and FAIL cells was measured at low (unloaded 
shortening) and high afterload (isometric contractions) at different pacing frequencies.  
Unloaded fractional shortening in RV CON cells initially decreased from 1 to 2 Hz, but 
as pacing frequency was progressively increased fractional shortening also increased 
(Figure 6.7A).  As a result, in CON cells there was a relative increase in fractional 
shortening by 20% at 7 Hz compared to 1 Hz.  In contrast, every increase in pacing 
frequency led to a decline in fractional shortening in RV FAIL cells.  Fractional 
shortening in FAIL cells began significantly higher than CON cells at 1 and 2 Hz, 
however there was a relative fall in fractional shortening by 32% at 7 Hz compared to 1 
Hz.  As such, fractional shortening at 5 and 7 Hz in both groups was similar.   
 
Isometric contractions were then measured from the same cells and the pacing 
protocol was repeated under load (Figure 6.7B).  The overall shape of the tension-
frequency relationship was very similar to the low afterload condition, however the 
positive and negative inotropic effect of increasing frequency in CON and FAIL cells 
appeared steeper.  As such, the pacing frequency at which the relationships 
intersected occurred earlier, between 2-4 Hz. 
 
The time course of contraction as a function of pacing frequency was investigated in 
both loading conditions.  The time taken for FAIL cells to reach 50% of their maximal 
shortening or force tended to be longer than CON cells at all frequencies (Figure 6.8 
B+E).  In unloaded cells there was an inverse relationship between time to 50% peak 
contraction and pacing frequency, which did not differ between CON and FAIL 
(PINTERACTION = 0.45), whereas under isometric conditions time to 50% peak contraction 
only shortened in FAIL cells (PINTERACTION = 0.015).  The time from peak to 50% 
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relaxation or relengthening was significantly slower in FAIL cells compared to CON at 
nearly all pacing frequencies.  There was also an inverse relationship between 
frequency and time to 50% recovery from isometric or unloaded contraction in CON 
and FAIL cells.  The main effect of loading on time course of contraction and relaxation 
was only significantly different in CON cells in the time to 50% relaxation, where it was 
significantly slower by 7% in isometric compared to unloaded conditions (P=0.019) 
(Figure 6.8 C+F). 
 
6.3.2 Sarcomere length dependence of Ca2+ waves 
Resting SL was significantly shorter by 5.1% in RV FAIL compared to CON cells, 
whereas there was no significant difference between LV FAIL and LV CON (Figure 
6.9A).  The diastolic Fura-4 ratio was measured during this time and was not different 
between CON and FAIL in either RV (RV CON 0.22±0.01 vs RV FAIL 0.22±0.01) or LV 
cells (LV CON 0.23±0.01 vs LV FAIL 0.22±0.01). 
 
CON and FAIL RV cells were paced at 5 Hz followed by 1 min without pacing and the 
number of spontaneous Ca2+ waves recorded during this time (Figure 6.9B).  The 
proportion of RV FAIL cells in which spontaneous Ca2+ waves occurred (0.94) was 
significantly greater than the proportion of RV CON cells (0.53) (P<0.001).  There was 
no significant difference in the proportion of wave-producing LV CON cells (0.73) 
compared to LV FAIL cells (0.61) (P=0.71).  The frequency of waves in cells which 
produced ≥1 wave during the 1 min observation was also significantly greater in RV 
FAIL (9±1 wave.min-1) than RV CON (2±1 wave.min-1), but not different between LV 
FAIL (3±1 wave.min-1) and LV CON (2±1 wave.min-1) (Figure 6.9C). 
 
We investigated a possible SL-dependence of Ca2+ wave frequency in RV cells using 
two approaches to modify resting SL: 1) the actin-myosin crossbridge inhibitor 
blebbistatin, and 2) the irreversible creatine kinase inhibitor DNFB.  We hypothesised 
blebbistatin would lengthen, and DNFB shorten, resting SL and hence decrease and 
increase wave frequency, respectively.  This investigation focused on RV cells from 
CON and FAIL rats as there were no differences in wave frequency between LV CON 
and FAIL cells. 
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Figure 6.9 Sarcomere length and Ca2+ waves in quiescent cells 
A Resting SL was shorter in RV FAIL than CON cells.  SL was not different in LV CON 
and FAIL cells.  B Spontaneous Ca2+ waves were recorded in Fura-4 loaded myocytes 
during 1 min rest following pacing at 5 Hz.  C Wave frequency was greater in RV FAIL 
than CON in cells which produced ≥1 spontaneous wave.  Wave frequency was not 
significantly different in LV FAIL and CON cells.  N= 30 CON, 31 FAIL RV cells, 15 
CON, 18 FAIL LV cells. *P<0.05, ***P<0.001 
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6.3.2.1 Increasing sarcomere length using blebbistatin 
Within a few minutes of switching the local bathing solution from Tyrode (TYR) to 
blebbistatin (BLEB) shortening was effectively abolished in both CON and FAIL cells.  
Systolic Ca2+ transients still occurred, however the amplitude tended to be lower than 
before BLEB.  Ca2+ wave frequency was not different in RV CON cells with or without 
BLEB, however in RV FAIL cells BLEB caused a significant reduction in wave 
frequency by an average of 2 waves.min-1 (Figure 6.11).  Resting SL was significantly 
increased in the presence of BLEB in both CON and FAIL cells, and there was no 
significant difference in the magnitude of lengthening between the two groups.  
Diastolic Fura-4 ratio was not different in TYR or BLEB in CON (TYR 0.22±0.01 vs 
BLEB 0.22±0.01) or FAIL cells (TYR 0.22±0.01 vs BLEB 0.23±0.01). 
 
We were concerned the reduced Ca2+ wave frequency in RV FAIL cells may have been 
due to off-target effects of BLEB on Ca2+ handling.  The experiment was repeated in 
RV FAIL cells, with the additional estimation of SR Ca2+ content using caffeine.  A 
group of RV FAIL cells underwent the same protocol but without BLEB to serve as 
time-matched controls (TYR-only) (Figure 6.12). 
 
BLEB abolished contractions within several minutes and reduced Ca2+ transient 
amplitude to approximately 75% of the amplitude in TYR.  In contrast, contractions and 
Ca2+ transient amplitude were stable throughout the entire experiment in TYR-only 
cells.  In TYR-only cells the resting SL during the second rest period was significantly 
shorter than the first, and in BLEB cells there was no significant change in resting SL.  
There was no significant change in Ca2+ wave frequency in TYR-only cells, and unlike 
Figure 6.10 (without caffeine) there was also no change in wave frequency in BLEB 
cells (Figure 6.13).  SR Ca2+ content was not different between the first and second 
measurement in TYR-only cells, but was significantly reduced by 19% in BLEB cells.  
There were no significant changes in the rates of Ca2+ efflux pathways in either group 
of cells, however there was a trend for Ca2+ removal during caffeine (primarily through 
NCX) to be faster in BLEB (TYR 0.63±0.08 [r.u.].s-1, BLEB 0.86±0.14 [r.u.].s-1, 
p=0.058). 
  
204 
 
6 0  s
re s t re s t
b le b b is ta tin
S a rc o m e re
le ng th
F u ra -4  ra tio 0 .0 5  r .u .
0 .0 5  m
T im e  (m in )
C
a
2
+
 t
ra
n
s
ie
n
t 
a
m
p
li
tu
d
e
(%
 b
a
s
e
li
n
e
)
1 2 3 4 5
0
2 5
5 0
7 5
1 0 0
1 2 5
C O N
F A IL
b le b b is ta tin
a
T im e  (m in )
F
ra
c
ti
o
n
a
l 
s
h
o
rt
e
n
in
g
(%
 b
a
s
e
li
n
e
)
1 2 3 4 5
0
2 5
5 0
7 5
1 0 0
1 2 5
b le b b is ta tin
a
a
a
a
A
B C
Figure 6.10 Blebbistatin abolishes contractions 
A Shortening and Ca2+ transients were recorded in TYR then in BLEB. Resting SL and Ca2+ waves were recorded during 1 min unpaced.  Shortening 
and Ca2+ transients were normalized to pacing in Tyrode.  B BLEB reduced shortening within 2 min, and abolished contractions by 4 min. C Ca2+  
transient amplitude was significantly reduced after 2 min in BLEB compared to TYR in FAIL cells and tended to decrease over time in CON cells.  
N=14 CON, 14 FAIL RV cells.  aP<0.05 vs Min 1  
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Figure 6.11 Longer sarcomere length and fewer Ca2+ waves in blebbistatin 
A BLEB significantly increased resting SL in CON and FAIL cells, however SL remained shorter in FAIL compared to CON.  B BLEB tended to have a 
greater lengthening effect in RV FAIL cells but this was not significantly different to CON (P=0.088).  C Ca2+ wave frequency in RV CON cells was not 
different in BLEB compared to TYR, but was significantly reduced in BLEB compared to TYR in RV FAIL cells.  D The mean change in wave 
frequency (BLEB-TYR) was thus greater in FAIL cells compared to CON cells. N= 14 CON, 15 FAIL RV cells.  *P<0.05, ***P<0.001  
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Figure 6.12 Blebbistatin depresses Ca2+ transient amplitude 
A Effects of blebbistatin on SR Ca2+ handling was investigated in a group of RV FAIL cells using caffeine (20 mM) to estimate SR Ca2+ content in 
Tyrode (TYR) and blebbistatin (BLEB) solutions.  B Contraction was stable throughout the 7 min in TYR, whereas in BLEB there was a sudden and 
complete cessation of contraction.  C Ca2+ transient amplitude was stable over 7 min in TYR, but declined upon switching to BLEB. N=12 RV 
FAIL+BLEB, 9 RV FAIL+TYR cells.  aP<0.05 vs Min 1, bP<0.05 vs Min 3, *P<0.05, ***P<0.001 vs TYR  
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Figure 6.13 Decreased SR content in blebbistatin 
A SL was shorter during the second rest period in TYR, and was not significantly 
different before and after BLEB.  B There was a net reduction in SL during the second 
rest period in both groups of cells, which was not different between groups. C Wave 
frequency was not different in the second rest interval in TYR-only or BLEB cells.  D 
The mean change in wave frequency was not different in TYR-only or BLEB cells.  E 
SR Ca2+  content decreased in BLEB cells compared to TYR-only.  F Ca2+ removal 
during caffeine (primarily though NCX) tended to increase in BLEB.  N= 9 RV 
FAIL+TYR, 12 RV FAIL+BLEB cells. *P<0.05, **P<0.01.  
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6.3.3 Role of CK in Ca2+ handling and mechanical dysfunction in myocytes 
The irreversible creatine kinase inhibitor DNFB was used to shorten resting SL in RV 
CON cells (Fowler et al., 2015a; Sequeira et al., 2015b).  We first attempted to 
replicate the paired study design as in Figure 6.10-6.13 but found cells often became 
arrhythmic and died during DNFB perfusion.  Instead, RV CON cells were pre-
incubated with DNFB (DNFB cells) and compared to RV CON cells without DNFB in 
normal Tyrode (TYR cells) using unpaired statistics. 
 
Resting SL was significantly shorter in DNFB by 14% compared to TYR cells (Figure 
6.14).  There was no significant difference in the proportion of DNFB cells which 
developed Ca2+ waves (0.64) compared to Tyrode cells (0.50) (P=0.51).  In cells 
producing ≥1 Ca2+ wave, the frequency was significantly higher in DNFB compared to 
TYR (TYR 4±1 wave.min-1, DNFB 11±2 wave.min-1).  Diastolic Fura-4 ratio was 
significantly elevated in DNFB (0.29±0.01 r.u.) compared to TYR cells (0.22±0.01 r.u.) 
(P<0.001).  SR Ca2+ content was significantly elevated in DNFB by 63% compared to 
TYR cells.  The rate of systolic Ca2+ decay and efflux due to SERCA removal were not 
different in DNFB or TYR cells, however the rate of Ca2+ removal during caffeine was 
significantly reduced by 39% in DNFB cells. 
 
6.3.3.1 Contraction-frequency relationship with CK inhibition 
The flat or positive contraction-frequency relationship in RV CON cells contrasted with 
the steep negative relationship in RV FAIL and DNFB cells which overlapped (Figure 
6.15).  At 7 Hz both DNFB cells and RV FAIL cell fractional shortening was significantly 
reduced to 44 and 61% respectively, of shortening at 1 Hz.  The Ca2+ transient 
amplitude-frequency relationship measured in Fura-4 loaded cells was also steeply 
negative in DNFB and RV FAIL cells in contrast to an overall positive relationship in RV 
CON.  At 7 Hz the Ca2+ transient amplitude was reduced by 27% and 30% compared to 
1 Hz in DNFB cells and RV FAIL cells, whereas the amplitude in RV CON cells 
increased by 3% compared to 1 Hz. 
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Figure 6.14 Creatine kinase inhibition shortens sarcomere length and 
increases Ca2+ waves 
A RV CON cells were preincubated with TYR or DNFB (20µM) then SL, Ca2+ wave 
frequency and SR Ca2+ content were measured. B Resting SL was shorter in DNFB 
than TYR cells. C In cells producing ≥1 spontaneous Ca2+ wave, frequency was 
greater in DNFB compared to TYR cells.  D SR Ca2+ content was significantly 
elevated in DNFB cells.  E The rate of Ca2+ efflux during caffeine was significantly 
slower in DNFB-treated cells. N= 16 CON+TYR RV cells, 22 CON+DNFB RV cells. 
*P<0.05, ***P<0.001.  
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Figure 6.15 Creatine kinase inhibition reproduces the failing contractile phenotype in CON cells 
A The unloaded contraction-frequency relationship was measured in RV CON, FAIL, and DNFB-treated CON cells.  Contraction was fairly stable in 
CON cells between 1-7 Hz, whereas fractional shortening was significantly reduced in FAIL cells at 5 and 7 Hz compared to CON.  Similar to FAIL 
cells, DNFB-treated CON cells also showed a negative contraction-frequency relationship.  N=23 CON, 28 FAIL, 25 CON+DNFB cells.  B There was 
a fall in systolic Ca2+ transient amplitude measured in Fura-4 loaded FAIL and DNFB-treated CON cells at 5 and 7 Hz. N=28 CON, 30 FAIL, 8 
CON+DNFB.  **P<0.05, ***P<0.001 vs CON. 
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6.3.3.2 Reintroducing CK-M to failing cells 
Resting SL was measured in saponin permeabilized cells incubated in Ca2+-free 
intracellular-like solutions in the presence or absence of exogeneous CK-M and/or PCr.  
Resting SL was significantly shorter in RV FAIL cells incubated with only ATP, PCr, or 
CK compared to RV CON cells incubated with the equivalent solution by 4.1-5.5% 
(Figure 6.16); however SL in RV FAIL cells incubated in CK+PCr solution was not 
significantly different to CON and was significantly longer than RV FAIL cells in the 
other solutions.  There were no differences in resting SL between different solutions in 
CON RV and LV cells, or between any groups of CON and FAIL LV cells.  To 
summarise, RV FAIL resting SL was significantly lengthened only when cells were 
incubated in a solution containing CK and its substrate PCr (Figure 6.16).  
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Figure 6.16 Exogenous creatine kinase lengthens failing sarcomere length 
SL was measured in saponin permeabilized (A) RV or (B) LV cells in intracellular-like 
solution in the absence of both PCr and exogenous CK (ATP); the presence of either 
PCr or CK (+PCr, +CK) or the presence of both (PCr+CK). SL of RV FAIL cells was 
significantly shorter than equivalent CON groups with the exception of the (PCr+CK) 
groups. FAIL RV in the presence of PCr+CK had significantly longer SL than other 
FAIL RV groups (***P<0.001). There were no significant differences between LV 
groups. N = 36 cells in each group. *P<0.05, **P<0.01, ***P<0.001 vs CON in 
equivalent solution.  
  
213 
 
6.4  Discussion 
RV contractile function prognosticates survival in human PAH, for instance RV ejection 
fraction below 25%, reduced stroke volume, and reduced contractile reserve during 
exercise are associated with a 20-40% higher mortality in PAH patients over 4-5 years 
(van Wolferen et al., 2007; Grünig et al., 2013; Courand et al., 2015).  In LV failure the 
incidence and mortality of patients with Heart Failure with reduced Ejection Fraction 
(HFrEF, or systolic heart failure) and Heart Failure with preserved Ejection Fraction 
(HFpEF, or diastolic heart failure) are approximately equal (Bhatia et al., 2006; Owan et 
al., 2006), however in PAH less is known regarding the impact of diastolic dysfunction 
in the pathophysiology of RV failure.  Poor RV diastolic function measured using tissue 
Doppler echocardiography correlated with elevated serum levels of brain natriuretic 
peptide and worse survival in patients with chronic pulmonary thromboembolism or 
PAH (Shiina et al., 2009a; Shiina et al., 2009b), however these measurements are 
difficult to perform in the RV due to its complex geometry and anatomy and are not 
load-independent.  Sudden cardiac death accounts for 20% of mortality in PAH patients 
and spontaneous ventricular fibrillation has also been reported in MCT rats (Delcroix & 
Naeije, 2010; Liles et al., 2012; Umar et al., 2012).  We investigated the contractile 
function of isolated RV myocytes under a variety of loading conditions and the 
geometric influence of SL on spontaneous Ca2+ wave frequency. 
 
6.4.1 Work loop contractions in isolated myocytes 
Forces exerted by, and upon, ventricular myocytes vary throughout the cardiac cycle 
and influence the volume of blood ejected with each contraction.  Shortening and force-
generation are related but distinct indices of contraction, meaning ventricular 
contractility cannot be inferred solely from isometric, auxotonic or isotonic contractions 
of isolated myocytes.  Cellular work is a composite parameter involving shortening 
against an external load, and as such may be more sensitive to changes in function 
and translatable to in vivo cardiac performance. 
 
Cardiac work loops were first characterised by Suga et al. (1973) using open-chested 
dogs as a load-independent means to characterise the contractile state of the heart.  
Since then the concept has been employed to study a hierarchy of complexity, from 
isolated hearts (Suga & Sagawa, 1974), papillary muscles (Wong et al., 2010), 
trabeculae (Han et al., 2012) and most recently isolated cardiomyocytes.  The first 
afterloaded contractions in cardiomyocytes were performed at room temperature in 
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cells from frog ventricle by Parikh et al. (1993) and later in rat ventricle cells at 37°C by 
Yasuda et al. (2001).  The data presented in this thesis are the first recordings of 
cellular work performed by failing ventricular myocytes using feedback-controlled work 
loop contractions at 37°C. 
 
Cellular work by failing RV cells was similar to control cells, which concurs with our 
finding of augmented unloaded and isometric contractions at low frequencies.  This is 
also in agreement with our finding that stroke work in vivo is not different in control and 
failing rats (Chapter 3).  Wong et al. (2010) found papillary muscles from hypertrophic 
MCT rats paced at 5 Hz performed similar amounts of work as those from healthy rats, 
however the O2 cost was higher in MCT rats meaning the failing myocardium was less 
efficient at generating work.  Reduced RV work efficiency was also reported by the 
same group in human PAH patients using positron emission tomography and 15O 
imaging (Wong et al., 2011b).  Possible reasons for the reduced mechanical efficiency 
could be increased ATP turnover required to cycle Ca2+ or increased ROS production 
by intracellular oxidases. 
 
Nishimura et al. (2004) and Iribe et al. (2007) found the ESFLR and EDFLR in isolated 
ventricular myocytes were similar over physiological ranges of stretch whether 
measured by work loop or isometric contractions.  Recently however, Iribe et al. (2014) 
found the ESFLR to be steeper at low afterloads, which we also found.  This may be 
due to shortening inactivation of the thin filament at short SL. 
 
A possible limitation of the work loop method is the use of a rectangular shaped loop 
which is not the normal shape of a pressure-volume loop in a healthy RV which is more 
triangular due to a short isovolumic contraction period and sustained ejection during 
relaxation.  However, in RV failure the PV loop becomes more rectangular and similar 
to LV PV loops (Redington et al., 1988; Redington et al., 1990).  Future work could 
investigate whether intrinsic properties of RV and LV myocytes are better suited to 
these two modes of ejection by modifying the work loop control algorithm. 
 
6.4.1.1 Preserved Frank-Starling mechanism in failing cells 
Increasing the end-diastolic volume of the heart leads to an immediate increase in the 
force of contraction, known as the Frank-Starling mechanism.  We found an increase in 
cellular work in both healthy and failing myocytes when preload was increased, and a 
steeper ESFLR during isometric stretch in failing cells.  The ESFLR in our healthy rat 
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cells (0.1 µN/µm) was less steep than was reported for guineapig LV cells (0.2 µN/µm).  
The reason for this discrepancy may lie in species and regional differences in the force-
length relationship, such as occur between rat and ferret, and from different regions of 
the heart (Cazorla et al., 2000b; Bollensdorff et al., 2011). 
 
The usefulness of the ESFLR is limiting as by definition it is influenced by diastolic 
force.  The ‗Frank-Starling Gain index‘ (FSG), or ratio of ESFLR:EDFLR, has been 
proposed as a measure of preload recruitable active force which, due to being unitless, 
is not influenced by variable cell width or diastolic compliance (Bollensdorff et al., 
2011).  The FSG values of 3.9 in CON and 3.7 in FAIL RV cells calculated by us are 
very similar to the value for rat RV cells (3.6) reported by the proponents of FSG 
(Bollensdorff et al., 2011).  There was no difference in FSG between healthy and failing 
cells suggesting the Frank-Starling mechanism is preserved in failing rats. 
 
A preserved Frank-Starling mechanism was previously found using the carbon fibre 
technique in intact and permeabilized MCT rat myocytes (Benoist et al., 2014).  The 
Frank-Starling mechanism is also generally preserved in LV failure in humans 
(Holubarsch et al., 1996; von Lewinski et al., 2009), in RV trabeculae from failing 
human hearts (Milani-Nejad et al., 2015), and in PAH (Rain et al., 2013), although 
some studies have found it depressed, e.g. in dilated cardiomyopathy (Schwinger et 
al., 1994).  The impaired Frank-Starling mechanism in dilated cardiomyopathies may 
result from proteolytic degradation of titin reducing its ability to narrow myofilament 
lattice spacing (Hein et al., 1994).  This implies the limited ability to increase stroke 
volume in pressure overloaded hearts is most likely not due to intrinsic failure of the 
Frank-Starling mechanism.  Cardiomyocytes are thought to only operate on the 
ascending limb of the force-length curve in vivo (Shiels & White, 2008), therefore the 
high wall stresses resulting from the law of Laplace means cardiomyocytes in a dilated 
ventricle are working towards the isometric end of the force-velocity relationship, and 
as a result the majority of the stress generated goes towards preventing further dilation 
with less going towards ejecting blood.  For this reason preload-reduction with diuretics 
is a first line treatment to reduce volume overload in PAH (Matthews & McLaughlin, 
2008). 
 
6.4.1.2 Reduced compliance of failing cells 
Rain et al. (2013) measured RV compliance in vivo and in chemically skinned muscle 
fibres from PAH patients and ascribed the increased stiffness of both to a combination 
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of reduced phosphorylation of the giant protein titin and increased fibrosis.  They found 
no evidence of residual crossbridge activity as myofilament Ca2+ sensitivity was 
unchanged and 2,3-BDM did not affect the passive stiffness of chemically skinned 
fibres.  In contrast, we have shown evidence that loss of CK from the myofilaments in 
rat PAH shortens SL likely due to accumulation of ADP causing rigor-like crossbridges 
(Figure 6.16 and Fowler et al. (2015a)).  This same mechanism was proposed by 
Mulieri et al. (2002) to explain prolonged crossbridge attachment time in skinned fibres 
from human failing hearts, and by Yoshikawa et al. (2013) to explain increased 
transverse stiffness of cardiomyocytes in isoproterenol-induced heart failure in rats.  
Nishimura et al. (2005) showed the passive stiffness of normal cardiomyocytes to axial 
stretch (which contain a smaller proportion of Ca2+-independent crossbridges) could be 
reduced by uncoupling with 2,3-BDM, therefore we believe the same mechanism may 
be responsible for the increased stiffness to stretch in isolated FAIL cells and therefore 
potentially the failing RV.  A possible reason for the differences between our study and 
Rain et al. (2013) may be their use of chemically skinned myocytes, whereas we used 
membrane-intact cells which may better retain their cytosolic constituents. 
 
Future work could investigate the contribution of crossbridges and passive elements to 
stiffness in MCT cells using 2,3-BDM, as no reports have been published on the role of 
titin in MCT diastolic dysfunction.  Changes in titin were not investigated in this thesis, 
however as rats primarily express the shorter N2B isoform, whereas humans also 
express the longer, more compliant N2BA isoform, any changes would likely be though 
altered phosphorylation or oxidative crosslinking of sulfhydryl groups in the Ig domain 
(Cazorla et al., 2000a; Grutzner et al., 2009; Zile et al., 2015).   
 
We did not find a change in collagen volume fraction in our MCT rats (Chapter 4).  At 
physiologically-relevant degrees of stretch, titin and actin-myosin crossbridges are 
thought to be the main determinants of stiffness, whereas collagen becomes 
increasingly important when end-diastolic volumes are very large, such as when the 
heart decompensates (Chung & Granzier, 2011).  This suggests RV myocytes 
themselves may be an important source of passive stiffness in the failing heart, and 
therefore treatments which improve cellular energetics may improve diastolic function. 
 
The EDFLR we measured in healthy rat RV cells (0.03 µN/µm) was similar to the 
compliance of guinea pig LV cells (0.02 µN/µm) reported by Iribe et al. (2007).  The 
present finding contrasts with recent work from this laboratory which found no 
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difference in passive tension in intact RV FAIL myocytes stretched using the carbon 
fibre technique (Benoist et al., 2014).  Korstjens et al. (2002) found a tendency for 
passive stiffness in RV trabeculae to be greater in rats injected with 44 mg/kg MCT, 
however this difference was not significant.  The greater magnitude of stretch 
achievable using MyoTak combined with a high sensitivity force transducer may have 
helped identify sub-microNewton differences in diastolic forces in our MCT RV cells. 
 
Stones et al. (2013) reported increased microtubule proliferation in the MCT model 
which was reported to decreased the compliance of RV cells in a cat PAB model (Zile 
et al., 1999).  Under normal circumstances microtubules have a minimal contribution to 
stiffness in response to longitudinal stretch (Granzier & Irving, 1995), however they do 
seem to play an important role in shear stress (Nishimura et al., 2005).  Microtubule 
proliferation may have an important role in vivo where myocytes are in a three 
dimensional organisation in the ventricle wall and subject to different types of stresses.   
 
6.4.2 Contraction-frequency relationship differs under load in failing and 
healthy myocytes 
Our finding of enhanced or unchanged contractility in failing cells at low pacing 
frequencies has also been reported in isolated hearts and trabeculae from rat MCT 
(Lamberts et al., 2007a; Lamberts et al., 2007b) and cat pulmonary artery banding 
(Quaile et al., 2007).  In these studies, a negative force-frequency relationship was 
found in the failing RV which is likely due to the steeply negative Ca2+-frequency 
relationship (Chapter 5).   
 
Direct comparisons between tension developed by single cells, trabeculae and 
papillary muscles is complicated by factors such as attachment method, system 
compliance, variable geometry, extracellular volume, as well as paracrine and 
endocrine influences.  Consequently the peak tension reported in trabeculae and 
papillary muscle studies can be as much as an order of magnitude higher than for 
single myocytes (Alvarez et al., 1999).  Conversely variable collagen content, 
particularly in heart failure, will influence the force of contraction in trabeculae and 
papillary muscle which is not an issue with isolated cells.  Our data from single cells 
measured at resting length are comparable to the peak forces measured at resting 
length in isometrically contracting rat (2 mN.mm-2) and rabbit myocytes (5.4 mN.mm-2) 
(Bluhm et al., 1995; Yasuda et al., 2001).  Shearing due to sarcomere shortening of the 
unattached surfaces of the cell, or compliance in the MyoTak, may lower the measured 
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force of contraction.  This problem was elegantly and intricately tackled by Iribe et al. 
(2014) by attaching cells both top and bottom to carbon fibres to increase the surface 
area for attachment which increased the detachment force.  We did not aim to record 
maximum twitch forces, however isometric forces in excess of 6.50 µN were recorded 
in the current investigation which is higher than the maximum previously reported (5.72 
µN) (Nishimura et al., 2004).  Inaccuracies measuring cell width and the assumption of 
a constant cell width:depth ratio in pathological conditions may also lead to over- or 
underestimation of cell cross-sectional area (Wang & Gerdes, 1999; Natali et al., 
2002).   
 
Changes in force with frequency were exaggerated compared to unloaded shortening, 
which was also found in failing and non-failing muscle strips and isolated cells from 
human heart failure (Brixius et al., 2001).  Only using unloaded cell shortening might 
lead one to conclude failing RV myocyte contractility at 5 Hz (a typical resting heart rate 
for a rat) was unchanged or enhanced, whereas if isometric force was measured 
contractility would clearly be depressed.  This highlights the need for complementary 
functional measurements ideally across different levels of structural complexity. 
 
The slopes of the unloaded shortening-frequency relationship were less steep than in 
Fura-4 loaded cells described in Chapter 5.  The buffering effect of Ca2+ indicators will 
be non-linear under non-saturating conditions, therefore the relative buffering in failing 
cells at lower pacing frequencies (where Ca2+ transients are large) will be less than in 
control cells with smaller Ca2+ transients.  The opposite effects of pacing frequency on 
Ca2+ transient amplitude in control and failing cells will exaggerate the effect of pacing 
on contraction.   
 
6.4.3 Load-dependence of time course of contraction 
The time to 50% peak contraction tended to be longer in failing cells, however this was 
less apparent at faster pacing frequencies.  The rate of force development and 
shortening depends on synchronous Ca2+ entry through L-type Ca2+ channels in T-
tubules during depolarisation.  Loss of T-tubules in failing cells identified in Chapter 5 
slowed the Ca2+ transient upstroke and hence is likely to contribute to the slower rate of 
isometric force development in these cells (Ferrantini et al., 2014).  The adult rat 
myocardium primarily expresses α-MHC however in heart failure there is a shift 
towards the fetal β-MHC (Ishikawa et al., 1992b; Korstjens et al., 2002).  β-MHC has a 
lower ATPase activity and higher ADP affinity than α-MHC resulting in slower 
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crossbridge turnover and slower contraction velocity (Chung et al., 2014).  This may be 
exacerbated by the loss of CK described previously which could increase cytosolic 
ADP and slow the rate of crossbridge cycling (Sequeira et al., 2015a). 
 
The cytoskeleton imposes a viscous brake on shortening (Yamamoto et al., 1998) and 
was investigated by Zile et al. (1998) and (1999), using a cat pulmonary artery banding 
model.  They found the viscous dampening of RV cells embedded in an agarose matrix 
was increased and isotonic shortening velocity of papillary muscles was reduced by 
PAB, coinciding with increased β-tubulin expression in PAB muscles.  Microtubule 
depolymerization with colchicine restored the velocity of shortening and normalized the 
viscous dampening in cells.  Proliferation of microtubules in failing RV MCT cells was 
also found by Stones et al. (2013), however depolymerization did not normalize cell 
shortening velocity.  A possible explanation for these discrepant findings could lie in 
microtubules playing a greater role in modulating shear stress which will be important 
in a three dimensional papillary muscle or gel matrix, but less so when shortening in a 
single axis (Nishimura et al., 2005). 
 
The timecourse of activation and relaxation in myocytes usually shows clear load-
dependency, with force development faster and relaxation slower in isometric 
compared to isotonic conditions (Yasuda et al., 2003; Iribe et al., 2007; Iribe et al., 
2014).  Myocyte shortening decreases the affinity of TnC for Ca2+, whereas under 
isometric conditions myofilament affinity for Ca2+ remains high.  Conversely, isometric 
stretch was shown to decrease the rate of force development and crossbridge cycling 
rate in intact human RV trabeculae, presumably due to crossbridges remaining in a 
high affinity bound state for longer (Milani-Nejad et al., 2015).  Shortening cells also 
contract against an internal load with both an elastic and a viscous component, the 
latter of which depends on shortening velocity.  We found the time to relaxation was 
slower in CON cells under isometric compared to isotonic conditions as we expected, 
however the time to relaxation was not different in loaded or unloaded FAIL cells, and 
the time to 50% peak contraction was not different in different loading conditions in 
either group of cells.  The analysis of instantaneous elastance also revealed a delayed 
time to peak elastance in failing cells, however there was no difference in the rate of 
relaxation using this method. 
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6.4.4 Ca2+ waves depend on resting sarcomere length 
Umar et al. (2012) and Benoist et al. (2011) reported isolated hearts from MCT rats 
were more susceptible to spontaneous or pacing induced ventricular fibrillation, and 
there is a report of spontaneous ventricular fibrillation leading to the death of a 
conscious MCT rat implanted with telemetry (Liles et al., 2012).  We found increased 
frequency of Ca2+ waves in failing RV cells, which could be a trigger for ventricular 
arrhythmias.  We have already identified elevated SR Ca2+ content as a possible 
mechanism behind increased Ca2+ waves in failing cells in Chapter 5 (Venetucci et al., 
2007).  We also investigated a hypothesized link between RyR2 spacing and Ca2+ 
waves (Keizer et al., 1998; Izu et al., 2006).  Sarcomere length was used as a proxy for 
RyR2 spacing as it has been shown to be preserved despite loss of t-tubules in heart 
failure (Heinzel et al., 2008; Lenaerts et al., 2009).  The shorter SL in FAIL cells is 
expected to result in a smaller barrier for Ca2+ spark diffusion between RyR2 on 
neighbouring junctional SR and hence profoundly increase the probability of Ca2+ wave 
initiation. 
 
6.4.4.1 Increasing sarcomere length with blebbistatin 
decreases waves 
When resting SL was increased by blebbistatin there was a significant reduction in Ca2+ 
wave frequency as hypothesised, however there was also a reduction in Ca2+ transient 
amplitude due to reduced SR content.  Fortuitously, a side-effect of measuring SR 
content was a reduction in SL probably due to a residual myofilament Ca2+ sensitising 
effect of caffeine.  Following caffeine application blebbistatin no longer increased SL or 
reduced wave frequency.  Therefore it can be said that after the same duration of 60-
120 s exposure to blebbistatin (i.e. under equivalent SR Ca2+ loads) but with different 
resting SL, wave frequency only decreased when slack SL increased.  This supports 
the predictions of Izu et al. (2006).  Our results may be applicable in other cases of 
heart failure where resting SL is also shorter, such as diabetic and troponin-mutation 
related cardiomyopathies (Tardiff et al., 1999; Flagg et al., 2009).  Conversely, Prosser 
et al. (2011) found mechanically stretching rat myocytes from 1.84 to 1.99 µm had the 
opposite effect and increased Ca2+ wave frequency, particularly in mdx dystrophic 
mouse ventricular myocytes.  However this occurred due to stretch-induced 
cytoskeletal activation of NADPH oxidase 2 which generates reactive oxygen species 
sensitising RyR2 and promoting Ca2+ leak.  This would not occur in our experiment due 
to passive rather than active lengthening. 
  
221 
 
 
Blebbistatin was chosen as it uncouples actin and myosin and lengthens resting SL, 
but reportedly has no effect on ICaL or Ca
2+ transient morphology (Dou et al., 2007; 
Fedorov et al., 2007; Farman et al., 2008).  We found blebbistatin significantly altered 
Ca2+ transient amplitude and SR content, possibly through promoting Ca2+ efflux from 
the cell.  This was not due to rundown of the cells, as time matched control cells in 
normal Tyrode maintained normal contractions, Ca2+ transients and SR content.  This 
discrepancy with the literature could be due to species differences in sensitivity to 
blebbistatin, for instance our data show contractions were <15% and <5% of initial 
amplitude after 1 and 3 min of blebbistatin, whereas after 5 min in the same 
concentration of blebbistatin mouse ventricular myocytes contracted ~20% of initial 
amplitude (Dou et al., 2007).  Alternatively, the higher concentration of blebbistatin 
used in this study (10 µM vs 0.5 µM) (Farman et al., 2008), use of different Ca2+ 
indicators (Fedorov et al., 2007), or a direct consequence of changes in heart failure 
(Venkataraman et al., 2013) may account for the differences between reports. 
 
Blebbistatin is the drug of choice in electrophysiological optical mapping studies 
compared to 2,3-BDM or cytochalasin D which have well known effects on Ca2+ 
handling and electrophysiology of the heart (Adams et al., 1998; Howarth et al., 1998; 
Fedorov et al., 2007; Lou et al., 2012).  However, blebbistatin too was reported to alter 
action potential morphology in a rabbit optical mapping study (Brack et al., 2013), 
increase spontaneous activity in rat atrium preparation (Kanlop & Sakai, 2010), and 
decrease the susceptibility to ventricular fibrillation in troponin T mutant mice with 
elevated myofilament Ca2+ sensitivity (Baudenbacher et al., 2008).  Further work 
should characterise the effects of blebbistatin on Ca2+ handling in relation to its use as 
a mechanical uncoupler in cardiac electrophysiology investigations. 
 
The sarcomere lengthening effect of blebbistatin was less than we found using 2,3-
BDM (see Fowler et al. (2015a)), which was surprising considering both work by 
blocking Pi release from the M•ADP•Pi complex.  Blebbistatin binds with high affinity 
and irreversibly to the large 50 kDa cleft in the motor domain of myosin keeping it in an 
open state and preventing the power stroke (Allingham et al., 2005; Farman et al., 
2008), whereas 2,3-BDM binds with low affinity.  Blebbistatin may therefore stabilize 
the accumulation of weak AM•ADP•Pi crossbridges whereas 2,3-BDM prevents the 
powerstroke but can also dissociate and allow actin and myosin to dissociate.  An 
alternative inhibitor with a different mode of action may be useful in dissecting whether 
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this is the case; N-benzyl-p-toluene sulphonamide (BTS) is another small molecule 
inhibitor which reversibly binds the same hydrophobic pocket as blebbistatin preventing 
Pi release and also reduces actin affinity in fast skeletal muscle myosin of rabbit and 
frog (Cheung et al., 2002; Shaw et al., 2003), and is 100x less potent in rat cardiac 
muscle meaning it may cause fewer weakly bound crossbridges. 
 
6.4.4.2 Shortening sarcomere length with DNFB increases 
waves 
The CK inhibitor DNFB shortened SL and promoted Ca2+ waves in healthy cells.  CK 
inhibition results in a ‗rigor-like‘ state of contracture in healthy myocytes due to local 
accumulation of  ADP which slows crossbridge detachment and cycling (Sequeira et 
al., 2015a).  This is the same mechanism we believe is responsible for the shorter 
resting sarcomere length and steeper EDFLR in failing RV cells due to reduced CK 
expression (Fowler et al., 2015a).  Definitive conclusions on the importance of SL in 
this situation cannot be made as CK inhibition also impacted Ca2+ handling, increasing 
cytosolic and SR Ca2+. 
 
SERCA requires the highest free energy of ATP hydrolysis (~59 kJ/mol) to function 
normally compared to all other ATPases and therefore should be very sensitive to 
changes in ΔGATP resulting from CK inhibition (Shannon & Bers, 1997; Tian et al., 
1998).  It was therefore surprising to find SERCA activity unchanged and SR content 
elevated in DNFB-treated cells.  A different CK inhibitor, iodoacetamide, was reported 
to cause no change in Ca2+ transient amplitude but slow the rate of Ca2+ decay and 
raise diastolic Ca2+ in rat ventricular myocytes (Ren et al., 2009; Sequeira et al., 
2015b). 
 
Inhibition of CK coupled with Na+/K+-ATPase could raise [Na+]i and promote Ca
2+ 
retention or influx into the cell via NCX (Blum et al., 1991).  Alternatively, increased 
leak of Ca2+ from the SR could occur due to direct modification of sulfhydryl groups on 
RyR2 by DNFB (Hadad et al., 1999).  The elevated cytosolic Ca2+ may reduce the 
trans-SR Ca2+ gradient thereby lowering the free energy required for SERCA pump 
function, and cause CaMKII activation and phosphorylation of PLB thus reducing 
SERCA inhibition.  Alternatively, glycolytic enzymes functionally coupled with SERCA 
may be sufficient to maintain Ca2+ uptake activity without a functioning CK system (Xu 
et al., 1995).  In a rat aortic banding model of congestive heart failure, De Sousa et al. 
(1999) showed a reduced efficiency of CK, but preserved ability of glycolytic enzymes, 
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to load the SR with Ca2+.  In MCT rats there is an overall shift towards greater 
glycolysis which may partially compensate for reduced energy flux through CK (Piao et 
al., 2010). 
 
Acute inhibition of CK caused a negative contraction- and Ca2+ transient-frequency 
relationship, reminiscent of failing RV cells which have reduced CK protein expression.  
More complete metabolic inhibition with cyanide, iodoacetate and 2,3-deoxyglucose 
results in a gradual decline in contraction and Ca2+ transient in cells contracting at 1 Hz 
(Lancaster & Harrison, 1998) likely due to shortening of the AP by activation of IKATP 
(Nichols & Lederer, 1990).  Metabolic acidosis could decrease myofilament sensitivity 
by influencing  TnC Ca2+ binding which would reduce contraction (Orchard & Kentish, 
1990); metabolic acidosis has also been reported in a rat MI model (Kemi et al., 2006).  
This suggests alternative energy sources were sufficient to maintain contraction at low 
demand in our DNFB cells, but not at higher demand.  CK inhibition with iodoacetamide 
was also found to impair contractile reserve in Langendorff-perfused hearts and cause 
systolic and diastolic dysfunction when infused directly into the coronary arteries of pigs 
(Hamman et al., 1995; Korinek et al., 2004).  In contrast, cardiac overexpression of CK-
M in mice with aortic banding pressure overload increased flux through CK, improved 
the inotropic response to adrenergic challenge by dobutamine and improved survival 
(Gupta et al., 2012).  In human left heart failure, low energy flux through CK was 
associated with worsening prognosis (Bottomley et al., 2013), whereas inhibition of the 
ROS-producing enzyme xanthine oxidase with allopurinol increased flux through CK 
and improved cardiac work efficiency (Cappola et al., 2001; Hirsch et al., 2012).  These 
data suggest reduced energy flux through the CK system be an important mediator of 
contractile dysfunction in both RV and LV failure and would thus make an ideal 
therapeutic target.   
 
6.4.1 Exogenous CK lengthens the shorter failing sarcomere length 
Work from the laboratories of Renée Ventura-Clapier and Theo Wallimann 
demonstrated dynamic binding of CK-M to the myofilaments of Triton skinned muscle 
fibres which was functionally equivalent to the native enzyme (Ventura-Clapier et al., 
1987b; Kraft et al., 1995).  Exchange of fluorescently labelled CK-M with non-
fluorescent CK-M takes 7-10 min to fully equilibrate, however in the absence of 
exogeneous enzyme CK-M stays firmly bound for several hours indicating a high 
affinity association with myomesin (Kraft et al., 1995).  Incubating saponin 
permeabilized FAIL RV cells in a solution containing CK and PCr restored resting SL to 
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CON length, whereas if either CK or PCr was absent there was no change.  This 
shows loss of CK-M activity from the myofilaments may allow local ADP to accumulate 
which would slow crossbridge detachment and result in a ‗rigor-like‘ state of 
contraction. 
 
It is not clear from this experiment whether loss or inactivation of CK is responsible, as 
the additional CK could attach to free binding sites or replace damaged CK.  We 
reported a loss of CK-M protein in the RV of MCT rats which could mean there were 
more free binding sites (Fowler et al., 2015a), however the high affinity of CK-M for the 
myomesin suggests it is unlikely there are unoccupied binding sites (Kraft et al., 1995).  
Alternatively CK-M was shown to be vulnerable to oxidative inactivation by peroxynitrite 
in a MI model of heart failure in rat (Mihm & Bauer, 2002).  If this were the case, and 
provided the modification was reversible, then antioxidants or reducing agents should 
improve CK activity.  (Hirsch et al., 2012) showed the xanthine oxidase inhibitor 
allopurinol increased flux through the CK reaction, lowered ADP and increased the free 
energy of ATP hydrolysis in human patients with non-ischaemic cardiomyopathy.  In a 
similar patient population, Cappola et al. (2001) further showed this resulted in 
increased cardiac work efficiency.  This suggests rescue of inactivated CK may be a 
feasible and beneficial therapeutic strategy to improve energetic derangement in heart 
failure. 
 
6.5 Conclusion 
RV contractile function is a primary prognostic indicator in PAH and also in left heart 
failure.  We have identified systolic and diastolic dysfunction occurring in isolated RV 
myocytes from MCT rats suggesting they are a major source of dysfunction in the 
failing RV.  Aspects of the failing phenotype, such as the negative contraction-
frequency relationship, could be induced in healthy cells by inhibiting energy transfer 
through the creatine kinase pathway.  Reduced energy transfer through the creatine 
kinase system and impaired cardiac reserve are predictors of mortality in left heart 
failure (Bottomley et al., 2013), suggesting this may be a common feature of heart 
failure and a possible therapeutic target.  Manipulating resting sarcomere length with 
blebbistatin in failing cells reduced the incidence of spontaneous Ca2+ waves (Izu et al., 
2006).  These data show energetic dysfunction is a key contributor to both systolic and 
diastolic dysfunction and may further promote a pro-arrhythmogenic phenotype; 
restoring energy flux through the creatine kinase system either by increasing 
expression or activity could be beneficial to RV function in PAH. 
  
225 
 
Chapter 7  General discussion, conclusions and future 
perspectives 
7.1 Introduction 
This research investigated the controversial hypothesis that β1-blockers confer a 
benefit to survival and RV function in PAH.  This contradicts current PAH treatment 
guidelines and a study of the acute effects of non-selective β-blockers in PAH 
(Provencher et al., 2006b; Galiè et al., 2015b), but is supported by a small number of 
preclinical studies (Bogaard et al., 2010; de Man et al., 2011) and retrospective clinical 
studies (So et al., 2012; Thenappan et al., 2014; Bandyopadhyay et al., 2015).  The 
MCT model was used to induce severe PAH leading to RV failure in rats, and a regime 
was developed of chronic treatment with the β1-selective AR blocker metoprolol.  
MCT+BB rats survived for significantly longer than placebo treated FAIL rats which 
appeared to be due to preserved RV function.  The mechanisms contributing to RV 
dysfunction in FAIL and subsequent rescue in MCT+BB rats were investigated at the in 
vivo, tissue, single cell and molecular levels, with particular attention paid to the role of 
excitation-contraction coupling and metabolic derangement.  The importance of altered 
energy metabolism in contractile dysfunction of FAIL hearts was a recurring theme and 
it is tempting to speculate some of the beneficial effects of metoprolol may have arisen 
due to reduced energy expenditure.  This final chapter will summarize some of the key 
findings of this work, their possible role in RV dysfunction in PAH, new areas of 
research which may follow on as a result, and the potential clinical implications of this 
study.  Table 7.1 highlights some of the changes which occurred in the RV of FAIL rats 
and whether or not this was improved in MCT+BB rats. 
 
7.2 Survival and functional benefit of β1 AR blockade in PAH 
A β-blocker treatment regime was successfully developed which increased the survival 
of MCT treated rats by around 30%.  Treatment with metoprolol was initiated once PAH 
was already present (see Chapter 3 and Jones et al. (2002)) as this more closely 
replicates the clinical situation in which PAH is often diagnosed late into the condition.  
The function of MCT+BB rats was assessed at two stages: the first was around the 
time placebo treated FAIL rats would normally develop heart failure thus allowing a 
comparison of function at temporally equivalent points, and the second was on the day 
heart failure symptoms developed.  Using this approach we determined metoprolol 
slowed the deterioration of RV function but did not prevent it. 
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Repeated monitoring of in vivo RV function was made possible by establishing and 
validating echocardiography as a technique, which had not previously been available to 
the Cardiac Research group at the University of Leeds.  Invasive right heart 
catheterisation was used alongside echocardiography to measure pulmonary vascular 
resistance and to characterise RV function using load-independent parameters of 
contractility.  Early trends towards PAH were identified by day 15 in MCT treated rats 
using Doppler ultrasound to predict RV systolic pressure, in agreement with previous 
studies (Jones et al., 2002).  This progressed over the following days into severe PAH 
in both FAIL and MCT+BB rats.  Increased systolic pressures were compensated for by 
increased RV wall thickness and weight measured post mortem in FAIL rats, which 
were slightly reduced in MCT+BB rats.  This was reflected by increased width of single 
RV cells which was greatest in FAIL and reduced in MCT+BB.  Resting RV cell length 
progressively shortened with increasing disease severity, indicating that at this stage 
hypertrophy is primarily concentric and driven by high systolic pressure (Tamura et al., 
1998). 
 
The RV in FAIL rats was hypocontractile as shown by reduced ejection fraction and 
decreased cardiac output, whereas in MCT+BB rats cardiac output was intermediate 
between CON and FAIL due to a partial improvement in stroke volume.  This occurred 
despite there being no change in RV systolic pressure or pulmonary vascular 
resistance, indicating RV contractility in MCT+BB rats was enhanced as shown by a 
partial normalization of ventriculo-arterial coupling.  Poor RV systolic function was 
reflected at the level of single RV cells: the rate of force development and Ca2+ release 
was slower in FAIL cells than CON, likely due to spatially and temporally 
dyssynchronized systolic Ca2+ release which was associated with a disorganized t-
tubule system.  In contrast, Ca2+ release kinetics were restored in MCT+BB cells 
coinciding with complete normalization of t-tubule structures.  Unloaded shortening and 
Ca2+ transient amplitude were initially greater in FAIL RV cells at low pacing 
frequencies, however when challenged by increasing pacing up to 7 Hz there was a 
steep fall in both Ca2+ and contraction.  In contrast, CON cell contractility and Ca2+ 
transient amplitude increased with frequency, whereas in MCT+BB cells the 
relationship was intermediate between CON and FAIL.  This indicates MCT+BB rats 
may be better able to cope when stressed, for instance during exercise.  The SR of 
FAIL RV cells was overloaded, possibly due to decreased Ca2+ efflux from the cell via 
  
227 
 
NCX or a prolonged AP (Benoist et al., 2012), whereas SR content and NCX activity 
were partially restored towards CON levels in MCT+BB cells. 
 
In contrast to the large changes identified in RV function in vivo and in vitro, there were 
usually minor or no differences in LV structure and function.  There was no change in 
LV wall thickness which concurred with no change in cellular hypertrophy in the LV of 
any group, indicating the combination of pressure overload and catecholamines are 
required for a maximal hypertrophic response (Kögler et al., 2003).  LV ejection fraction 
measured by echo was normal in all treatment groups, however in MCT-treated groups 
the septum bulged into the LV reducing its cavity size and thus preload.  Isolated LV 
cells from FAIL and MCT+BB rats tended to show enhanced contractility and larger 
Ca2+ transients across the range of pacing frequencies suggesting the LV may have 
adapted to reduced filling by augmenting its contractility. 
 
These data indicated metoprolol was primarily acting through direct protective effects 
on the RV myocardium rather than afterload reduction.  Metoprolol delayed the 
progression of RV dysfunction and eventual failure although it did not prevent it, as RV 
function was similar in placebo and metoprolol treated rats at the point of failure.  This 
is in agreement with clinical data highlighting the prognostic importance of RV function 
in PAH (van de Veerdonk et al., 2011), and shows β1AR blockers represent a viable 
therapeutic option to target the failing RV. 
 
7.3 Role of creatine kinase in the failing phenotype 
Diastolic function was severely impaired in FAIL rats as indexed by the load-
independent EDPVR, whereas there was a partial improvement in MCT+BB rats.  
There was no change in fibrosis in the RV or LV of any group of rats measured using 
histology, suggesting collagen is not the primary source of ventricle stiffness in MCT 
rats.  Diastolic dysfunction was present at the level of single FAIL RV cells which had a 
shorter resting SL, steeper EDFLR when stretched and slower rate of relaxation 
despite no dramatic changes in the rate of Ca2+ removal or myofilament Ca2+ 
sensitivity.  This indicated mechanisms other than Ca2+ handling were responsible for 
impaired diastolic function.  MCT treated rats had depressed total CK activity measured 
in RV homogenates, which concurs with reduced CK-M and CK-mt protein expression 
we reported in Fowler et al. (2015a).  SL was shorter in FAIL than CON cells.  The SL 
in CON cells was shorter following CK inhibition with DNFB, conversely incubating 
permeabilized FAIL RV cells with exogeneous CK and PCr restored SL.  Inhibiting CK 
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in healthy cells caused a steep negative contraction- and Ca2+ transient amplitude 
frequency relationship remarkably similar to FAIL cells, suggesting the reduced CK 
activity may have pleiotropic effects on contraction.  These data support the hypothesis 
that loss of CK in the failing RV cardiomyocytes slows crossbridge cycling and 
increases diastolic stiffness, but is partially restored in MCT+BB rats which 
corresponds to improved ventricle compliance. 
 
7.4 Tissue hypoxia and metabolism in the failing RV 
Using histology it was shown that the average area of RV myocardium supplied by 
each capillary was greater in MCT+BB and FAIL rats, although this may have occurred 
for different reasons: muscle fibre hypertrophy increased the diffusion distance from 
capillaries to the fibre cores in MCT+BB rats.  This also occurred in FAIL rats as well as 
an additional trend for capillary rarefaction.  Finite element calculations were used to 
predict myocardial PO2 from capillary distribution which showed the majority of FAIL 
RV myocardium was hypoxic, whereas there was a partial improvement in tissue PO2 
in MCT+BB rats. 
 
Mitochondrial mass was estimated by citrate synthase activity in RV homogenates, 
however this did not account for differences in survival or function as activity did not 
change between different treatment groups.  Maximal respiration and individual 
activities of mitochondrial respiratory complexes were measured functionally in situ by 
supplying saponin permeabilized RV cells with different substrates and inhibitors, 
however none of the measured parameters differed between CON and FAIL, indicating 
the ETS was preserved at this stage of disease.  In contrast the ability of the CK 
system to stimulate submaximal respiration was greatly reduced in FAIL, and to a 
lesser extent in MCT+BB, suggesting the hypertrophic myocardium may be less able to 
respond to a sudden increase in energy demand. 
 
These data indicate O2 availability, rather than loss of mitochondria or specific defects 
in the ETS, may limit oxidative ATP production in FAIL rats.  Accordingly RV coronary 
perfusion was found to be inversely related to RV hypertrophy in human PAH (van 
Wolferen et al., 2008).  The improved myocardial oxygenation in MCT+BB rats may 
have contributed to the increased stroke work of the RV compared to FAIL rats 
(Khalafbeigui et al., 1979).  A further possible benefit could be reduced apoptosis, 
which may account for the significant reduction in cellular hypertrophy despite modest 
reductions in ventricular weight if there were more, but smaller, cardiomyocytes.   
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7.5 Proposed mechanism of protection by metoprolol 
Identifying the cellular pathways responsible for the improvements in MCT+BB rats 
requires characterisation of molecular signalling events which was outwith the scope of 
this thesis but is work currently ongoing at the University of Leeds.  It is however 
possible to speculate, based on the observed changes in cellular structure and 
function, where metoprolol may be exerting its influence: 
 
Table 7.1 shows Ca2+ handling was subject to the greatest detrimental changes in 
function in FAIL cells and was also most likely to improve following metoprolol 
treatment, thus indicating a critical role in the pathophysiology of failing hearts (Figure 
7.1A).  Improved Ca2+ handling in MCT+BB cells may stem from preserved T-tubule 
structure due to increased expression of JP2, with or without increased BIN-1 
expression (Figure 7.1B).  This would tether T-tubules to the junctional SR preserving 
Ca2+ release kinetics and maintaining normal trans-sarcolemmal ion exchange.  This 
would help prevent Ca2+ overload and reduce arrhythmogenic Ca2+ waves and 
activation of Ca2+-dependent kinases (e.g. CaMKII), phosphatases (e.g. calcineurin) 
and proteases (e.g. calpain).  Thus amelioration of the disruption to Ca2+ signalling may 
prevent excessive hypertrophy either directly by influencing gene transcription, or 
indirectly by prevention of apoptosis. 
 
The specificity of metoprolol to β1 receptors confined its actions primarily to the 
myocardium and did not alter pulmonary vascular resistance, therefore the remaining 
RV hypertrophy is likely attributable to mechanical stresses relayed to the nucleus via 
the cytoskeleton rather than circulating factors, as there was no detectable LV 
hypertrophy in any group.  Reduced hypertrophy would enhance mitochondrial O2 
availability by reducing O2 demand and facilitating delivery from capillaries.  Improved 
O2 availability could decrease the reliance on inefficient glycolysis as a source of 
energy (Piao et al., 2010).  Hepatic glycogenolysis is primarily promoted by β2 
receptors whereas lipolysis is mostly under the control of β1AR (Arinze & Kawai, 1983).  
Koch et al. (1981) showed lipid, but not carbohydrate, mobilization was blunted by 
metoprolol during exercise in hypertensive patients, therefore β-blockers may result in 
an unfavourable blood lipid and glycaemic profile by increasing blood glucose levels 
and depressing fat utilization. Thus altered metabolism and reduced daily energy 
expenditure could account for slower weight loss in MCT+BB rats (Sharma et al., 
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2001).  Preservation of the CK energy shuttle would improve energy delivery to 
cytosolic ATPases and speed crossbridge kinetics thus improving diastolic function. 
 
Metoprolol preserved β1AR expression which would improve the ability of the RV to 
cope during periods of increased demand (R. Norman, personal communication); 
prevention of agonist binding and receptor phosphorylation may have prevented 
desensitization.  The inverse agonism by metoprolol may also be clinically relevant as 
this provides additional survival benefits in severe heart failure independent of β1AR 
desensitization (Harding et al., 2001). 
 
7.6 Sarcomere length-dependence of Ca2+ waves 
We tested whether the shorter SL in RV FAIL cells increased Ca2+ wave frequency.  
There was a progressive increase in wave frequency from CON to MCT+BB to FAIL.  
When CK was inhibited by DNFB in CON cells the resting SL decreased and wave 
frequency increased, however off-target effects such as raised cytosolic and SR Ca2+ 
also occurred which were likely to influence wave frequency.  Lengthening SL in FAIL 
RV cells with the crossbridge uncoupler blebbistatin reduced wave frequency, but also 
decreased SR Ca2+ load.  Wave frequency was unchanged when blebbistatin failed to 
lengthen SL due to prior exposure of the cell to caffeine despite an identical duration 
exposure to blebbistatin (i.e. under equivalent SR Ca2+ loads).  The velocity of waves 
also increased from MCT+BB to FAIL.  This data supports an inverse relationship 
between SL and wave frequency, as proposed by Keizer and Smith (1998) and Chen-
Izu et al. (2006).  This may contribute to the greater proportion of waves triggering a 
global Ca2+ transient in FAIL RV cells, and therefore the risk of ventricular arrhythmias 
as a result of delayed afterdepolarizations. 
 
7.7 Future directions 
β-blockers could be incorporated into a therapeutic regime for PAH as an adjunctive 
therapy alongside traditional vasodilators which would target both the cause of PAH 
(excessive vasoconstriction and vascular remodelling) and the ultimate cause of death 
in the majority of patients (RV failure) (Delcroix & Naeije, 2010).  Unintended drug 
interactions have contributed to the reluctance to use β-blockers in PAH in the past 
(Peacock & Ross, 2010), therefore it will be critical to firstly identify possible 
interactions between β-blockers and existing therapies, and also whether there is an 
additive effect on function and/or survival.  A possible combination could be metoprolol 
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and sildenafil as these are metabolised by separate enzymes and are unlikely to cause 
systemic hypotension.  This could be tested experimentally with a clinically relevant 
dose of sildenafil, such as used by Schermuly et al. (2004) in MCT rats from day 14 
onwards, which slightly improves survival and significantly lowers pulmonary vascular 
resistance, without directly improving RV function (Andersen et al., 2008). 
 
Currently the effect of metoprolol on apoptosis in MCT+BB rats is mostly speculative 
although preliminary data indicates upregulation of caspase-3 in the RV of FAIL rats 
(R. Norman, personal communication).  There is precedent for reduced apoptosis 
occurring with low dose metoprolol (2 mg/kg/day) in a canine coronary microembolism 
model of heart failure.  Apoptosis occurs within a relatively narrow window of time and 
ideally complementary techniques which identify different steps in the apoptosis 
pathway should be used.  A histological method to detect apoptotic signalling in nuclei, 
such as TUNEL staining or an enzyme assay using a fluorogenic substrate specific for 
the cleaved and activated form of caspase-3 such as Ac-DMQD-AMC, would be useful 
additions to this work and would provide further insight into the myocardium-specific 
effects of metoprolol (Kaur et al., 2015). 
 
Although not presented in this thesis, ex vivo passive pressure-volume measurements 
were recorded in Langendorff-perfused FAIL hearts to explore the effect loss of CK 
activity had on the diastolic properties of the RV.  Using an inflatable PVC balloon 
connected to a pressure transducer we showed inhibiting CK increased the passive 
stiffness of the LV (these results are presented in Appendix B and Sequeira et al. 
(2015b)).  Unfortunately, at low pressures the balloon conformed poorly to the complex 
RV geometry precluding accurate volume measurements (Suga & Sagawa, 1979; Goto 
et al., 1988), therefore we could not measure stiffness using this method in FAIL 
hearts.  Using a working RV configuration may circumvent the problem of RV 
geometry. 
 
No studies to date have investigated titin in MCT PAH, although there is data showing 
hypophosphorylation of titin in the RV of human PAH (Rain et al., 2013).  We have 
clearly shown crossbridges play an important role in diastolic dysfunction in FAIL cells, 
however even 40 mM 2,3-BDM did not completely restore resting SL to CON length 
(Fowler et al., 2015a), suggesting some additional non-crossbridge component may be 
present.  Rats with a mutant giant isoform of titin (3.8 MDa) have been described which 
display reduced passive stiffness (Greaser et al., 2008) and consequently shown 
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longer resting sarcomere length in skeletal muscle fibres (Greaser & Pleitner, 2014) 
and isolated cardiomyocytes (M. Helmes, personal communication), however I am 
unaware of any cases of the resting sarcomere length being shortened as a result of 
titin.  Degradation of titin by proteases MMP-2 and Ca2+ activated calpain have been 
reported in human dilated cardiomyopathy which could reduce the resting SL and 
impair recoil during early diastole (Hein et al., 1994). 
 
We present the first empirical evidence of the SL-dependence of Ca2+ waves which 
was hypothesised over 15 years ago (Keizer et al., 1998; Chen-Izu et al., 2006).  Wave 
frequency was also measured in a small number of cells subjected to isometric stretch 
to different SL in the presence of the antioxidant n-acetylcysteine (20 mM) (to 
counteract NADPH oxidase induced Ca2+ waves (Prosser et al., 2011)), however time 
constraints of the laboratory visit to Amsterdam prevented collection of a complete 
dataset.  Further work could build on these findings, perhaps by using saponin skinned 
cells to avoid the confounding influence of cytosolic Ca2+ or ROS induced Ca2+ leak on 
wave frequency.  It should be possible to stretch saponin permeabilized cells using 
MyoTak which could open up new opportunities in studying the interaction between 
contraction and SR and mitochondrial function.  Confocal analysis of wave velocity 
would add further support to our conclusions if wave velocity was negatively associated 
with SL. 
 
Whether the change in SL is physiologically relevant ultimately depends on whether it 
also differs in vivo, however accurate measurement of SL in contracting hearts 
presents huge technical challenges and is therefore still somewhat elusive.  Diastolic 
SL measured in situ in di-ANEPPS loaded mouse hearts ranges from 1.95 to 2.3 µm 
when intraventricular pressure is increased from 0 to 40 mmHg (Bub et al., 2010; 
Nance et al., 2015), however these may be overestimated due to oedema and use of 
Ca2+-free buffers.  Inspection of the images in Xie et al. (2012), who used the same 
method as above, appears to show a severity-dependent decrease in SL in situ in the 
RV of arrested MCT hearts.  Recently, Aguirre et al. (2014) measured the in vivo SL of 
beating mouse LV and found it to be closer to 1.90 µm in diastole and 1.75 µm at end 
systole, presumably reflecting the contribution of Ca2+ activated crossbridges during 
diastole due to the high murine heart rate.  This suggests crossbridge activation during 
diastole prevents excessive stretch and allows the heart to continually work on the 
ascending limb of the length-tension relationship.  This could also mean the heart is 
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susceptible to SL-dependent Ca2+ wave initiation, as Ca2+ waves are known to occur in 
Langendorff-perfused hearts (Kaneko et al., 2000). 
 
We found a tendency for FAIL cells to have increased sensitivity to exogeneous ADP, 
similar to findings in rats with developing or deficient CK systems (Clark et al., 1994; 
Anmann et al., 2014).  The MOM presents the greatest diffusion barrier for exogeneous 
ADP to mitochondria (Guzun et al., 2009) due to the VDAC pore which in turn is 
regulated by free tubulin (Rostovtseva et al., 2008).  Stones et al. (2013) found 
free:total tubulin was reduced in the MCT RV suggesting this may be modifying 
mitochondrial permeability.  It would be interesting to know whether this is indeed the 
cause, perhaps by using colchicine or paclitaxel to increase or decrease free tubulin, 
respectively as greater VDAC opening will increase respiratory flux and therefore ROS 
production potentially leading to mitochondrial damage (Maldonado et al., 2015).  
Microtubules are also thought to be influential in internalizing and desensitizing β1AR 
and are increased primarily in the pressure-overloaded RV rather than LV in the cat 
PAB model (Sato et al., 1997), therefore it would be interesting to know whether this is 
responsible for the greater loss of β1AR in the RV compared to LV of MCT rats 
(Seyfarth et al., 2000; Leineweber et al., 2003). 
 
7.8 Clinical perspectives 
The European Society of Cardiology guidelines on pulmonary hypertension 
consistently emphasise improvements in RV function and regression of remodelling as 
of utmost importance as treatment goals (McLaughlin et al., 2013; Galiè et al., 2015b), 
therefore it is astonishing that there are currently no therapies which specifically target 
the RV.  Our work shows a salutary effect of metoprolol in PAH which acted primarily 
through direct effects on the RV and provides insight into potential mechanisms 
underlying improved RV function.  We show what is true for the left is also true for right: 
namely that β-blockers do not represent a ―cure‖ for heart failure but improve survival 
and slow the deterioration of function and remodelling which is critically important for 
quality of life and prognosis (Bristow, 2000; van de Veerdonk et al., 2011). 
 
Our data add to a small but growing number of preclinical studies demonstrating 
improved survival and/or RV function with selective and non-selective β-blockers 
(Bogaard et al., 2010; de Man et al., 2011; Perros et al., 2015), and the next step 
clearly is translating this into small closely monitored clinical trials in human PAH.  
Such trials in NYHA class II and III PAH patients are currently underway in the 
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Netherlands and Virginia (Grinnan et al., 2014; Van Campen et al., 2014).  In these 
single arm or crossover-design studies of 6-18 patients currently receiving PAH-
specific therapy, adjunctive therapy with bisoprolol and carvedilol has generated 
promising results: after 3-6 months of treatment RV ejection fraction and stroke volume 
both increased with a trend towards improve exercise capacity.  Importantly all patients 
tolerated β-blockers when they were introduced at a low dose and gradually uptitrated, 
as per recommendations (Bristow & Quaife, 2015).  What is now needed is a larger 
scale clinical trial of β-blockers which is appropriately powered to detect persistent 
benefits over a longer period of time and with RV function as a primary endpoint.  It is 
hoped our work will advance the understanding of the pathophysiology of RV failure in 
PAH and draw attention to the benefit of RV targeted therapies. 
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Table 7.1 Summary of changes in structure and function with metoprolol 
treatment 
MCT+BB FAIL MCT+BB vs FAIL P<0.05?
Survival ↓ ↓↓ YES
Heart rate ↓↓ ↓ NO
RV:BW ↑↑↑ ↑↑↑ NO
LV:BW ─ ─ NO
RV:LV+S ↑↑↑ ↑↑↑ NO
Systolic pressure ↑ ↑ NO
Diastolic pressure ↑ ↑ NO
Wall thickness ↑↑ ↑↑↑ YES
Ejection fraction ↓ ↓↓ NO
Stroke volume ↓ ↓↓↓ NO
Cardiac output ↓ ↓↓↓ NO
EDPVR ─ ↑ NO
ESPVR/Ea ─ ↓ NO
PVR ↑↑↑ ↑↑↑ NO
Capillary density ↓ ↓↓↓ NO
Tissue hypoxia ─ ↑ NO
Fibrosis ─ ─ NO
Mitochondrial mass ─ ─ NO
ETS capacity ─ ─ NO
Reactive oxygen species ─ ─ NO
Total CK activity ↓↓↓ ↓↓↓ NO
CK-mt activity ─ ↓ NO
CK-mt expression1 ↓ ↓↓ NO
CK-M expression1 ↓ ↓↓ NO
Cellular hypertrophy ↑ ↑↑↑ YES
Sarcomere length ↓↓ ↓↓↓ YES
T-tubule organisation ─ ↓↓↓ YES
Ca2+ release kinetics ─ ↓ YES
Contraction: low pacing ─ ↑↑↑ YES
response to faster pacing flat
steep 
negative
YES
Ca2+ transient: low pacing ↑↑ ↑↑↑ NO
response to faster pacing negative
steep 
negative
NO
SR content ─ ↑↑↑ YES
Myofilament sensitivity ─ ─ YES
Spontaneous waves ↑↑ ↑↑↑ YES
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Arrows indicate direction of change relative to CON and the level of significance; single arrow P<0.05, 
double arrow P<0.01, triple arrow P<0.001 vs CON. 1R. Stones, personal communication.  
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Figure 7.1 Postulated mechanisms underlying improved function with metoprolol 
A Severe Ca2+ handling abnormalities underpinned the pathophysiology of FAIL cells.  Loss of T-tubules orphans RYR2 on the junctional SR slowing 
the rise time of the Ca2+ transient and force development.   Reduced NCX activity leads to Ca2+ overload, spontaneous Ca2+ waves, and activation of 
Ca2+-dependent transcription pathways.  Increased pulmonary afterload initiates hypertrophic remodelling and parallel sarcomere addition.   
Increased O2 diffusion distance between capillaries and muscle fibre cores produces a compromised metabolic state, which is compounded by 
reduced CK function in mitochondria and at the myofilaments slowing crossbridge turnover.  Chronic activation of β1 receptors initiates pro-
hypertrophic and pro-apoptotic pathways and causes desensitization and internalization of receptors.  B Metoprolol greatly improved Ca2+ handling 
and restored T-tubule structure, perhaps through preserved JP2 expression.  Increased NCX activity prevents Ca2+ overload and associated Ca2+ 
waves.  Hypertrophy is partially reduced improving myocardial oxygenation, however persistent elevated pulmonary vascular resistance means 
hypertrophy is not completely avoided.  Energy transfer around the cell is improved due to restored CK expression which aids crossbridge turnover 
and diastolic function.  Metoprolol-treated cells retain β1 receptor density thereby preserving the capacity for PKA-dependent phosphorylation of 
intracellular targets when the level of β-blockade is overcome during periods of increased sympathetic activity.  
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Appendix A 
 
We attempted to replicate the treatment regime described by Bogaard et al. (2010), 
using a dose of 150 mg/kg/day metoprolol dissolved in drinking water.  Despite 
extensive time and effort, we found no survival or functional benefit from using this 
supra-physiological dose (approximately equivalent to around 1.8 g metoprolol per day 
in humans (see Section 3.4.2.1 for discussion)).  The concentration was tailored to 
each cage of rats according to their daily water consumption over the preceding 14 
days, and ranged from 0.84 - 1.99 mg/mL, the average concentration was 1.33 mg/mL.  
Daily water intake remained fairly stable in CON and FAIL rats throughout the 
monitoring period (Figure 8.A).  In contrast, water intake in MCT+BB150 rats dropped 
suddenly when metoprolol was introduced to the drinking water, and continued to fall 
for the remaining study time.  The same reduction in fluid intake was also seen in 3 rats 
which began β-blocker treatment on day 21.  As such, the calculated daily dose of 
metoprolol consumed in the drinking water varied between 28-94 mg/kg, or 18-63% of 
the target dose. 
 
A possible reason for these discrepant findings in relation to Bogaard et al. (2010) is 
that the actual daily dose of metoprolol consumed differed greatly from the target dose 
(calculated based on water consumption).  This is consistent with the findings of 
Prabhu et al. (2000) and Cherng et al. (1994) who found 2 mg/mL metoprolol in 
drinking water resulted in a variable intake between 71-157 mg/kg/day in Wistar and 
Sprague-Dawley rats with MI.  Indeed, Yaoita et al. (2002) stopped treating rats with MI 
with 270 mg/kg/day metoprolol administered by gavage due to a higher rate of 
mortality.  Water intake was not reported by Bogaard et al. (2010) therefore the actual 
daily dose of metoprolol consumed in that study is unknown, but is likely to be much 
lower than claimed. 
 
Consistent with our finding in MCT+BB rats there was no change in PVR in FAIL+BB150 
rats, however interestingly there was a trend for the EDPVR to be improved relative to 
FAIL rats (P=0.07) (Figure 8.).  This suggests a key effect of β-blockers may 
lie in their positive effect on diastolic function. 
  
240 
 
Figure 8.1 No survival benefit with high dose metoprolol 
A Fluid intake was monitored before and after addition of metoprolol to drinking water at a concentration equivalent to 150 mg/kg/day. Water intake 
remained stable throughout the monitoring period in CON and FAIL, however when metoprolol was added (arrow) the daily water intake dropped 
suddenly and continued to fall. B  Dose adherence was calculated based on the daily water intake.  A target dose of 150 mg/kg metoprolol was not 
sustained due to taste aversion. C The median survival of FAIL+BB150 rats (day 24) was not significantly different to placebo treated FAIL (day 23), 
but tended to be worse than FAIL+BB10 (P=0.05). N=12 CON, 9 FAIL, 21 FAIL+150mg/kg Met rats 
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Figure 8.2 Organ weights following high dose metoprolol 
A Organ weights, B ventricle weights, C organ ratios, and D ventricle ratios in CON (N=8), FAIL (N=10) and FAIL+BB150 (N=18) rats.  
  
242 
 
C
O
N
F
A
IL
+
B
B
1
0
F
A
IL
+
B
B
1
5
0
F
A
IL
0
1 0 0
2 0 0
3 0 0
4 0 0
5 0 0
H
e
a
rt
 r
a
te
 (
b
p
m
)
* * *
*
* *
C
O
N
F
A
IL
+
B
B
1
0
F
A
IL
+
B
B
1
5
0
F
A
IL
0
5 0
1 0 0
1 5 0
2 0 0
P
re
s
s
u
re
 (
m
m
H
g
)
E n d -s y s to lic  p re s s u re
* *
* * *
* * *
C
O
N
F
A
IL
+
B
B
1
0
F
A
IL
+
B
B
1
5
0
F
A
IL
0
2 0
4 0
6 0
8 0
1 0 0
E
je
c
ti
o
n
 F
ra
c
ti
o
n
 (
%
)
E je c tio n  F ra c tio n
*
C
O
N
F
A
IL
+
B
B
1
0
F
A
IL
+
B
B
1
5
0
F
A
IL
-5 0 0 0
-4 0 0 0
-3 0 0 0
-2 0 0 0
-1 0 0 0
0
d
P
/d
t 
(m
m
H
g
.s
-1
)
d P /d t m in
C
O
N
F
A
IL
+
B
B
1
0
F
A
IL
+
B
B
1
5
0
F
A
IL
0
2 0 0 0
4 0 0 0
6 0 0 0
d
P
/d
t 
(m
m
H
g
.s
-1
)
d P /d t m a x
*
C
O
N
F
A
IL
+
B
B
1
0
F
A
IL
+
B
B
1
5
0
F
A
IL
0
5
1 0
1 5
2 0
2 5
P
re
s
s
u
re
 (
m
m
H
g
)
E n d -d ia s to lic  p re s s u re
*
*
  
243 
 
C
O
N
F
A
IL
+
B
B
1
0
F
A
IL
+
B
B
1
5
0
F
A
IL
0
5 0
1 0 0
1 5 0
2 0 0
V
o
lu
m
e
 (

L
)
S tro k e  v o lu m e
* *
C
O
N
F
A
IL
+
B
B
1
0
F
A
IL
+
B
B
1
5
0
F
A
IL
0
2 0 0 0 0
4 0 0 0 0
6 0 0 0 0
8 0 0 0 0
V
o
lu
m
e
 (

L
.m
in
-1
)
C a rd ia c  o u tp u t
* *
* * *
C
O
N
F
A
IL
+
B
B
1
0
F
A
IL
+
B
B
1
5
0
F
A
IL
0
5 0 0 0
1 0 0 0 0
1 5 0 0 0
S
tr
o
k
e
 W
o
rk
 (
m
m
H
g
. 
L
)
S tro k e  w o rk
C
O
N
F
A
IL
+
B
B
1
0
F
A
IL
+
B
B
1
5
0
F
A
IL
0 .0
0 .5
1 .0
1 .5
2 .0
S
lo
p
e
 (
m
m
H
g
. 
L
-1
)
E S P V R
C
O
N
F
A
IL
+
B
B
1
0
F
A
IL
+
B
B
1
5
0
F
A
IL
0
2
4
6
8
S
lo
p
e
 (
m
m
H
g
. 
L
-1
)
A rte r ia l e la s ta n c e  (E a )
* *
C
O
N
F
A
IL
+
B
B
1
0
F
A
IL
+
B
B
1
5
0
F
A
IL
0
1
2
3
4
R
a
ti
o
E S P V R /E a
  
244 
 
C
O
N
F
A
IL
+
B
B
1
0
F
A
IL
+
B
B
1
5
0
F
A
IL
0
2
4
6
8
P
V
R
 (
m
m
H
g
.m
in
.m
L
-1
)
P u lm o n a ry  v a s c u la r  re s is ta n ce
*
C
O
N
F
A
IL
+
B
B
1
0
F
A
IL
+
B
B
1
5
0
F
A
IL
0 .0
0 .1
0 .2
0 .3
0 .4
0 .5
S
lo
p
e
 (
m
m
H
g
. 
L
-1
)
E D P V R
*
P = 0 .0 7
C
O
N
F
A
IL
+
B
B
1
0
F
A
IL
+
B
B
1
5
0
F
A
IL
0
5 0
1 0 0
1 5 0
2 0 0
V
o
lu
m
e
 (

L
)
E n d -s y s to lic  v o lu m e
C
O
N
F
A
IL
+
B
B
1
0
F
A
IL
+
B
B
1
5
0
F
A
IL
0
5 0
1 0 0
1 5 0
2 0 0
2 5 0
V
o
lu
m
e
 (

L
)
E n d -d ia s to lic  v o lu m e
C
O
N
F
A
IL
+
B
B
1
0
F
A
IL
+
B
B
1
5
0
F
A
IL
0
1 0
2 0
3 0
T
a
u
 (
m
s
e
c
)
Is o v o lu m ic  re la x a tio n
Figure 8.3 RV PV measurements in high dose metoprolol rats at onset of heart failure 
MCT-treated rats were treated with either Ribena placebo, 10 mg/kg/day metoprolol (FAIL+BB10), or 150 mg/kg/day metoprolol (FAIL+BB150) and RV 
function assessed on the day heart failure symptoms developed.  
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Table 8.1 Doppler ultrasound measurements in high dose metoprolol rats at 
the onset of heart failure 
Heart rate (bpm) 409 ± 9 317 ± 15*** 364 ± 12
PA acceleration time (ms) 35.9 ± 3.0 22.4 ± 2.1** 20.5 ± 1.5***
Velocity-time integral (cm) 5.96 ± 0.19 2.25 ± 0.27*** 2.64 ± 0.41***
Peak velocity (m/s) 1.00 ± 0.03 0.57 ± 0.06*** 0.67 ± 0.08***
Ejection time (ms) 0.12 ± 0.01 0.09 ± 0.01** 0.08 ± 0.01**
     Systolic Pressure (mmHg) 51.5 ± 5.5 78.58 ± 5.08** 79.6 ± 2.8***
     Stroke Volume (µL) 140 ± 13 55 ± 9*** 52 ± 9***
     Cardiac Output (mL/min) 57.7 ± 6.4 16.9 ± 3.0*** 18.9 ± 3.4***
     Cardiac Index ( µL/cm 2) 129.0 ± 14.1 44.7 ± 8.0* 46.8 ± 8.2*
FAILFAIL+BB150
Data are mean±SEM.  Measurements were recorded on the day heart failure symptoms developed 
(Failing columns) or on the median survival day of FAIL rats for CON.  Calculated values are shown 
in italics.  PA, pulmonary artery.  N= 9 CON, 9 FAIL+BB150, 7 FAIL.  *P<0.05, **P<0.01, ***P<0.001 vs 
CON.
CON
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Table 8.2 M-mode ultrasound measurements in high dose metoprolol rats at 
the onset of heart failure  
RV thickness diastole (mm) 0.72 ± 0.04 1.21 ± 0.05*** 1.43 ± 0.07***
RV thickness systole (mm) 0.87 ± 0.07 1.48 ± 0.07*** 1.59 ± 0.10***
RV internal diameter diastole (mm) 2.47 ± 0.26 5.42 ± 0.36* 5.00 ± 0.26*
RV internal diameter systole (mm) 1.43 ± 0.17 4.30 ± 0.23*** 4.10 ± 0.24***
     RV wall shortening (%) 39.5 ± 7.4 19.6 ± 3.4 18.1 ± 1.4
IVS thickness diastole (mm) 1.88 ± 0.14 2.17 ± 0.09 2.16 ± 0.10
IVS thickness systole (mm) 2.35 ± 0.15 2.41 ± 0.10 2.46 ± 0.17
LV thickness diastole (mm) 1.98 ± 0.14 2.11 ± 0.10 2.00 ± 0.15
LV thickness systole (mm) 2.90 ± 0.20 2.74 ± 0.13 2.45 ± 0.19
LV internal diameter diastole (mm) 5.55 ± 0.30 4.98 ± 0.33 4.93 ± 0.34
LV internal diameter systole (mm) 3.02 ± 0.26 3.40 ± 0.38 2.98 ± 0.45
     LV wall shortening (%) 46.2 ± 2.3 32.6 ± 5.2 39.4 ± 9.2
CON
Data are mean±SEM.  Measurements were recorded on the day heart failure symptoms developed 
(Failing columns) or on the median survival day of FAIL rats for CON.  Calculated values are shown 
in italics.  RV, right ventricle; IVS, interventricular septum; LV, left ventricle.  N= 9 CON, 9 FAIL+BB 150, 
7 FAIL rats.  *P<0.05, **P<0.01, ***P<0.001 vs CON
FAIL+BB150 FAIL
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Table 8.3 B-mode ultrasound measurements in high dose metoprolol rats at 
the onset of heart failure 
RV area diastole (cm
2
) 0.11 ± 0.01 0.33 ± 0.03*** 0.34 ± 0.04***
RV area systole (cm
2
) 0.05 ± 0.01 0.24 ± 0.03*** 0.25 ± 0.03***
     RV area change (%) 52.0 ± 3.7 25.4 ± 3.9*** 27.4 ± 3.1**
LV area diastole (cm
2
) 0.25 ± 0.02 0.13 ± 0.01* 0.16 ± 0.02
LV area systole (cm
2
) 0.09 ± 0.01 0.05 ± 0.01** 0.06 ± 0.01
#
     LV area change (%) 61.8 ± 2.6 59.2 ± 3.9 61.2 ± 7.4
     LV systolic circularity (%) 87.0 ± 0.9 69.3 ± 3.6** 65.0 ± 2.2***
CON FAILFAIL+BB150
Data are mean±SEM.  Measurements were recorded on the day heart failure symptoms developed 
(Failing columns) or on the median survival day of FAIL rats for CON.  Calculated values are shown 
in italics.  RV, right ventricle; LV, left ventricle.  N= 9 CON, 9 FAIL+BB150, 7 FAIL rats.  *P<0.05, 
**P<0.01, ***P<0.001 vs CON, 
#
P=0.06 vs CON
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Figure 9.1 Passive LV pressure volume relationship 
A fluid-filled balloon was passed into the LV of a Langendorff-perfused heart through 
the left atrium.  Volume was controlled with a micropump dispensing at 400 μL.min-1 
and pressure recorded continuously via a side port connected to a pressure 
transducer.  The heart was arrested in diastole by perfusing 0 mM Ca2+ solution (0Ca) 
then balloon volume was adjusted in cycles to produce passive pressure-volume (PV) 
curves between 0-30 mmHg.  Measurements were taken during inflation of the balloon. 
Measurements were taken after 60 min perfusion with 0Ca (N=6 hearts) or 20 µM 
BAPTA-AM (N=5 hearts).  PV measurements were repeated following 30 min perfusion 
with DNFB (20 µM).  In an additional two hearts , instead of DNFB a low dose of 
caffeine (200 µM) was used.  A Mean PV relationships in different solutions (error bars 
are omitted for clarity) B Mean slopes of PV curves.  DNFB significantly steepened the 
PV curve, however when intracellular Ca2+ was buffered there was no change in PV 
slope.  Caffeine slightly reduced LV compliance but less so than DNFB.  These data 
show elevated ADP in combination with diastolic Ca2+ significantly increases passive 
ventricle stiffness. 
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